,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,1332,1,1,,49699016,36462,Inactive,,,,,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
1,1376,1,2,,49681767,36462,Inactive,15608158.0,886069.0,,IC50,Inhibitors of Mycobacterial Glucosamine-1-phosphate acetyl transferase (GlmU),Confirmatory,,
2,1385,2,2,,49681767,36462,Inactive,49168602.0,5888.0,,,Homologous recombination - Rad 51,Screening,,
3,1422,1,1,,49681767,36462,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
4,1465,1,1,,49681767,36462,Inactive,,,,EC50,"Screen for small molecule probes relevant to Friedreich's ataxia, Single Dose and Dose Response",Confirmatory,,
5,1511,1,3,,49681767,36462,Inactive,487738.0,3757.0,,,Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents,Screening,,
6,1529,1,1,,49681767,36462,Inactive,42794767.0,4215.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase3 Wildtype",Screening,,
7,1530,1,1,,49681767,36462,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase 2 mutant",Screening,,
8,1531,1,1,,49681767,36462,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 binding to MEK Kinase 2 Wildtype",Screening,,
9,1532,1,1,,49681767,36462,Inactive,,,,,Rml C and D inhibition 384-well mixture HTS,Screening,,
10,1554,1,1,,49681767,36462,Inactive,,,,,MLPCN Ras selective lethality-BJeLR viability,Screening,,
11,1621,1,2,,49681767,36462,Inactive,,,,IC50,A Cell Based Assay for the Identification of Lead Compounds with Anti-Viral Activity Against West Nile Virus,Confirmatory,,
12,1626,1,2,,49681767,36462,Inactive,,,,IC50,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
13,1662,1,2,,49681767,36462,Inactive,15675770.0,901648.0,,,MLPCN Streptokinase Expression Inhibition,Screening,,
14,1663,1,2,,49681767,36462,Inactive,,,,,MLPCN Platelet Activation -Dense Granule Release,Screening,,
15,1672,1,3,,49681767,36462,Inactive,6680530.0,16518.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1,Screening,,
16,1813,1,2,,49681767,36462,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - inhibitors,Screening,,
17,1814,1,2,,49681767,36462,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - activators,Screening,,
18,1832,2,1,,49681767,36462,Inactive,55976631.0,178296.0,,,MLPCN maternal gene expression-MEX-5 TCR-2 binding assay-Primary Screen,Screening,,
19,1850,2,1,,49681767,36462,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella typhi,Confirmatory,,
20,1863,2,1,,49681767,36462,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium,Confirmatory,,
21,1875,2,1,,49681767,36462,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Polyadenylation,Screening,,
22,1885,2,1,,49681767,36462,Inactive,,,,,Luminescence Cell-Based/Microorganism Primary HTS to Identify Inhibitors of T.Cruzi Replication,Screening,,
23,1899,1,3,,49681767,36462,Inactive,83779224.0,,,,TR-FRET-based primary biochemical high-throughput screening assay to identify inhibitors of Hepatitis C Virus (HCV) core protein dimerization,Screening,,
24,1903,2,3,,49681767,36462,Inactive,297591903.0,29031019.0,,IC50,Identification of SV40 T antigen inhibitors: A route to novel anti-viral reagents,Confirmatory,,
25,1906,1,3,,49681767,36462,Inactive,55958172.0,,,,QFRET-based counterscreen for PFM18AAP inhibitors: biochemical high throughput screening assay to identify inhibitors of the Cathepsin L proteinase (CTSL1).,Screening,,
26,1910,1,2,,49681767,36462,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Transcriptional Activators of Hypoxia-Inducible Factor Pathway,Screening,,
27,1947,1,2,,49681767,36462,Inactive,21595511.0,226016.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the serine hydrolase family member Fam108B.,Screening,,
28,1950,1,3,,49681767,36462,Inactive,23893623.0,3783709.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the Epstein-Barr virus nuclear antigen 1 (EBNA-1).,Screening,,
29,1956,1,1,,49681767,36462,Inactive,,,,Conc @ Max Fold Increase,A high-throughput screen to identify small molecule compounds that augment HSV replication,Confirmatory,,
30,1962,1,2,,49681767,36462,Inactive,68476498.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of tRNA 2'-phosphotransferase (TPT1).,Screening,,
31,1974,1,2,,49681767,36462,Inactive,4758484.0,9446.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the oxidoreductase glutathione S-transferase omega 1(GSTO1).,Screening,,
32,1987,1,2,,49681767,36462,Inactive,37589898.0,5536.0,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase 5 (PP5).,Screening,,
33,2016,1,3,,49681767,36462,Inactive,1302091.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ MEP2_MLPCN.,Screening,,
34,2023,1,3,,49681767,36462,Inactive,486173.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ LAP4_MLPCN.,Screening,,
35,2025,1,3,,49681767,36462,Inactive,536029.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ RPL19A_MLPCN.,Screening,,
36,2029,1,3,,49681767,36462,Inactive,171229.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ CIT2_MLPCN.,Screening,,
37,2052,2,1,,49681767,36462,Inactive,124486680.0,16408.0,,,HTS for developing T Cell Immune Modulators,Screening,,
38,2057,1,2,,49681767,36462,Inactive,78070770.0,4170.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide.,Screening,,
39,2066,1,4,,49681767,36462,Inactive,85666113.0,850333.0,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ AGP1_MLPCN.,Screening,,
40,2094,1,2,,49681767,36462,Inactive,67463988.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
41,2094,1,2,,49681767,36462,Inactive,67463989.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
42,2094,1,2,,49681767,36462,Inactive,166202459.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
43,2097,1,2,,49681767,36462,Inactive,21361340.0,2932.0,,,Cell-Free Homogeneous Primary HTS to Identify Inhibitors of GSK3beta Activity,Screening,,
44,2098,1,1,,49681767,36462,Inactive,62740231.0,15499.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Heat Shock Factor 1 (HSF1).,Screening,,
45,2099,1,1,,49681767,36462,Inactive,,,,,Fluorescence Biochemical Primary HTS to Identify Inhibitors of GASC-1 Activity,Screening,,
46,2129,1,2,,49681767,36462,Inactive,510901.0,598.0,,,"Primary biochemical high throughput screening assay to identify inhibitors of BCL2-related protein, long isoform (BCLXL).",Screening,,
47,2130,1,3,,49681767,36462,Inactive,7706645.0,51400.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase Methylesterase 1 (PME-1).,Screening,,
48,2156,2,2,,49681767,36462,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels,Screening,,
49,2174,1,3,,49681767,36462,Inactive,5453722.0,10434.0,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 1 (LYPLA1).,Screening,,
50,2177,1,3,,49681767,36462,Inactive,4581413.0,,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 2 (LYPLA2).,Screening,,
51,2216,1,3,,49681767,36462,Inactive,,,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the RanGTP-Importin-beta complex,Screening,,
52,2221,1,2,,49681767,36462,Inactive,15609874.0,888371.0,,,Fluorescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of RecA Intein Splicing Activity,Screening,,
53,2227,1,2,,49681767,36462,Inactive,2935630.0,22066.0,,,Primary cell-based high-throughput screening assay for identification of compounds that allosterically potentiate transient receptor potential cation channel C4 (TRPC4),Screening,,
54,2234,1,2,,49681767,36462,Inactive,82503229.0,3783744.0,,,"Counterscreen for inhibitors of EBNA-1: fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of the Epstein-Barr virus-encoded protein, ZTA.",Screening,,
55,2235,1,2,,49681767,36462,Inactive,56790945.0,5499.0,,,Counterscreen for inhibitors of PP5: fluorescence-based biochemical high throughput primary assay to identify inhibitors of Protein Phosphatase 1 (PP1).,Screening,,
56,2237,1,2,,49681767,36462,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that activate transient receptor potential cation channel C4 (TRPC4).,Screening,,
57,2239,1,2,,49681767,36462,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels,Screening,,
58,2240,1,1,,85788790,36462,Inactive,38156699.0,4286.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of MITF,Screening,,
59,2241,1,1,,85788790,36462,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1,Screening,,
60,2247,1,2,,49681767,36462,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that inhibit transient receptor potential cation channel C4 (TRPC4).,Screening,,
61,2275,1,1,,85788790,36462,Inactive,,,,,Luminescence Cell-Based Primary HTS to Measure Viability of BJeLR cells,Screening,,
62,2280,2,3,,49681767,36462,Inactive,17507875.0,172532.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of GLD-1 protein - TGE RNA interaction.,Screening,,
63,2300,1,3,,49681767,36462,Inactive,216409728.0,10002.0,,,"TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).",Screening,,
64,2313,1,1,,85788790,36462,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of the Sonic Hedgehog Signaling Pathway,Screening,,
65,2322,1,1,,85788790,36462,Inactive,,,,,Luminescence Homogenous Primary HTS to Identify Inhibitors of STK33 Activity,Screening,,
66,2330,1,1,,85788790,36462,Active,12830367.0,65975.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of STK33,Screening,,
67,2380,1,2,,49681767,36462,Inactive,,,,,uHTS identification of small molecules that induce b-cell replication in the MIN-6 cell line,Screening,,
68,2391,1,1,,49681767,36462,Inactive,,,,IC50,A Cell Based HTS Approach for the Discovery of New Inhibitors of Respiratory syncytial virus (RSV),Confirmatory,,
69,2435,1,2,,49681767,36462,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).,Screening,,
70,2445,1,2,,49681767,36462,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify potentiators of Oxytocin Receptor (OXTR),Screening,,
71,2462,1,1,,49681767,36462,Inactive,20336315.0,10018.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
72,2462,1,1,,49681767,36462,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
73,2520,1,4,,49681767,36462,Inactive,4885057.0,187.0,,,uHTS identification of small molecule agonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
74,2521,1,3,,49681767,36462,Inactive,4885057.0,187.0,,,uHTS identification of small molecule antagonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
75,2524,1,2,,49681767,36462,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of activators of human intestinal alkaline phosphatase,Screening,,
76,2540,1,2,,49681767,36462,Inactive,262118306.0,123228.0,,,HTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 8 (SENP8),Screening,,
77,2544,1,2,,49681767,36462,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of inhibitors of human intestinal alkaline phosphatase,Screening,,
78,2550,1,3,,49681767,36462,Inactive,160333370.0,22068.0,,,High throughput screening of activators of transient receptor potential cation channel C6 (TRPC6),Screening,,
79,2553,1,2,,49681767,36462,Inactive,160333370.0,22068.0,,,High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6),Screening,,
80,2557,1,3,,49681767,36462,Inactive,67191027.0,3676.0,,,HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library,Screening,,
81,2563,1,1,,49681767,36462,Inactive,6323930.0,855317.0,,,Fluorescence Cell-Free Homogenous Primary HTS  to Identify Inhibitors of the Ras-converting Enzyme,Screening,,
82,2599,1,2,,49681767,36462,Inactive,6166485.0,26054.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 6 (SENP6),Screening,,
83,2606,1,2,,49681767,36462,Inactive,15610807.0,885176.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the membrane-associated serine protease Rv3671c in M.tuberculosis,Screening,,
84,2629,1,1,,49681767,36462,Inactive,139472804.0,4961527.0,,,Fluorescence Polarization Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the LANA Histone H2A/H2B Interaction,Screening,,
85,2642,1,2,,49681767,36462,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels,Screening,,
86,2648,1,2,,49681767,36462,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels,Screening,,
87,2650,2,1,,49681767,36462,Inactive,49574532.0,2931.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha,Screening,,
88,2661,1,1,,49681767,36462,Inactive,23943882.0,65975.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of Serine/Threonine  Kinase 33  Activity,Screening,,
89,2690,1,2,,49681767,36462,Inactive,,,,,A yeast HTS for caloric restriction mimetics that inhibit age-related superoxide,Screening,,
90,2716,1,1,,49681767,36462,Inactive,,,,,Luminescence  Microorganism Primary HTS to Identify Inhibitors of the SUMOylation Pathway Using a Temperature Sensitive Growth Reversal Mutant Mot1-301,Screening,,
91,2717,1,2,,49681767,36462,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Cancer Stem Cells,Screening,,
92,2718,1,1,,49681767,36462,Inactive,13128862.0,8841.0,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3,Screening,,
93,2751,2,2,,49681767,36462,Inactive,153217451.0,9581.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL),Screening,,
94,2796,1,4,,49681767,36462,Inactive,4502003.0,196.0,,,Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR),Screening,,
95,2797,1,2,,49681767,36462,Inactive,4502331.0,552.0,,,Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R),Screening,,
96,2805,2,2,,49681767,36462,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of activators of mouse intestinal alkaline phosphatase,Screening,,
97,2806,2,2,,49681767,36462,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of inhibitors of mouse intestinal alkaline phosphatase,Screening,,
98,2825,1,2,,49681767,36462,Inactive,219518789.0,114548.0,,,uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast,Screening,,
99,7222,6,2,,104234176,36462,Active,,,0.53,IC50,Growth inhibition against human 5637 cell lines,Confirmatory,15189040.0,
100,7900,4,5,,104234176,36462,Active,,,0.591,IC50,In vivo antiproliferative activity against A431 cell line,Confirmatory,15084135.0,
101,8459,5,1,,104234176,36462,Active,,,1.9,ED50,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,Confirmatory,12419378.0,
102,8471,8,1,,104234176,36462,Unspecified,,,1950.0,ED50,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,Confirmatory,10395485.0,
103,8624,6,2,,104234176,36462,Active,,,8.0,GI50,In vitro cytotoxic activity against renal (A 498) cancer cell line.,Confirmatory,10465531.0,
104,8677,4,5,,104234176,36462,Active,,,0.664,IC50,In vivo antiproliferative activity against A549 cell line,Confirmatory,15084135.0,
105,8681,6,2,,104234176,36462,Active,,,0.16,IC50,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),Confirmatory,10780913.0,
106,8817,6,2,,104234176,36462,Unspecified,,,,,Cytotoxic activity against human A-427 lung tumor cell line,Other,15149673.0,
107,8821,6,2,,104234176,36462,Unspecified,,,,,Cytotoxic activity of compound against A-427 lung human tumor cell line,Other,12459024.0,
108,8835,5,1,,104234176,36462,Unspecified,,,,,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,Other,8389875.0,
109,8866,3,4,,104234176,36462,Unspecified,,,,,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",Other,15084135.0,
110,8893,3,4,,104234176,36462,Unspecified,,,,,Synergism with indomethacin in A549 cells,Other,15012986.0,
111,8894,3,4,,104234176,36462,Unspecified,,,,,Synergism with sulindac in A549 cells,Other,15012986.0,
112,8895,4,4,,104234176,36462,Inconclusive,,,,,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,Other,15012986.0,
113,9039,4,4,,104234176,36462,Active,,,0.17,IC50,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,Confirmatory,14980682.0,
114,9244,5,2,,104234176,36462,Active,,,6.30957,GI50,GI values against A549 cells (lung cancer),Confirmatory,11311065.0,
115,9253,6,2,,104234176,36462,Unspecified,,,,,Growth inhibition of A549 (human lung carcinoma) cell line.,Other,2002477.0,
116,9856,5,1,,104234176,36462,Unspecified,,,,,Inhibition of growth of renal cancer ACHN cell line,Other,8389875.0,
117,10037,5,3,,104234176,36462,Active,,,0.8709600000000001,GI50,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,Confirmatory,,
118,10184,6,2,,104234176,36462,Unspecified,,,65.0,IC50,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,Confirmatory,11844671.0,
119,15769,3,3,,104234176,36462,Unspecified,,,,,Tested for the highest concentration at which toxicity was not observed or the concentration which provided the highest number of net grain counts,Other,7932571.0,
120,19468,3,3,,104234176,36462,Unspecified,,,,,Partition coefficient (logP),Other,12699389.0,
121,23271,4,4,,104234176,36462,Unspecified,,,,,Partition coefficient (logD7.4),Other,2362268.0,
122,23743,7,2,,104234176,36462,Unspecified,,,,,Water solubility of the compound,Other,9804687.0,
123,31127,6,2,,104234176,36462,Unspecified,,,100.0,IC50,Tested for cytotoxicity against Doxo resistant A2780 type ADR5000 cell line expressing MDR-1 (++) gene,Confirmatory,11844671.0,
124,32547,6,2,,104234176,36462,Unspecified,,,,,Cytotoxic activity against human AZ-521 stomach tumor cell line,Other,15149673.0,
125,32550,6,2,,104234176,36462,Unspecified,,,,,Cytotoxic activity of compound against AZ-521 stomach human tumor cell line,Other,12459024.0,
126,39120,6,2,,104234176,36462,Active,,,0.32,IC50,"Cytotoxic activity against solid tumor, B16 (murine melanoma) concentration of agent required to reduce cell viability by 50%",Confirmatory,10377219.0,
127,39262,5,2,,104234176,36462,Active,,,,,"Cytotoxic activity against solid tumor, B16 (murine melanoma) concentration of agent required to reduce cell viability by 90%",Other,10377219.0,
128,42573,8,1,,104234176,36462,Unspecified,,,2200.0,ED50,The compound was tested for tumor cell growth inhibitory activity against human renal cancer(CAKI-1) cell line,Confirmatory,10395485.0,
129,42742,5,2,,104234176,36462,Active,,,6.30957,GI50,GI values against CAKI-1 cells(renal carcinoma),Confirmatory,11311065.0,
130,43374,8,2,,104234176,36462,Unspecified,,,,,Cytotoxicity was assessed using human leukemic cell line CCRF-CEM,Other,11170627.0,
131,43376,3,4,,104234176,36462,Unspecified,,,,,Relative potency in comparison to etoposide,Other,11170627.0,
132,43725,6,2,,104234176,36462,Active,,,0.002,IC50,Tested for the inhibitory activity against CCRF CEM T- cell leukemia cells,Confirmatory,7932571.0,
133,44201,3,4,,104234176,36462,Unspecified,,,,,Effect on cross resistance of CCRF-CEM cells resistant to vincristine expressed as log of ratio of molar concentration of compound inducing 50% growth inhibition in resistant to sensitive cells,Other,2362268.0,
134,44603,6,3,,104234176,36462,Unspecified,,,,,Cytotoxic activity against human C-33A cervix tumor cell line,Other,15149673.0,
135,45215,6,2,,104234176,36462,Active,,,0.35,IC50,"Cytotoxic activity against solid tumor, CHO (Chinese hamster ovaric carcinoma) concentration of agent required to reduce cell viability by 50%",Confirmatory,10377219.0,
136,45239,5,2,,104234176,36462,Active,,,,,"Cytotoxic activity against solid tumor, CHO (Chinese hamster ovaric carcinoma) concentration of agent required to reduce cell viability by 90%",Other,10377219.0,
137,46279,6,2,,104234176,36462,Active,,,18.1,GI50,In vitro cytotoxicity against human colon cancer COLO 205 cell line,Confirmatory,9871772.0,
138,46475,5,1,,104234176,36462,Unspecified,,,,,Inhibition of growth of colon carcinoma COLO 2-1 cell line,Other,8389875.0,
139,46483,5,1,,104234176,36462,Unspecified,,,,,Inhibition of growth of colon carcinoma COLO 320DM,Other,8389875.0,
140,51931,6,2,,104234176,36462,Active,,,0.14,IC50,Tested for the cytotoxicity against the repair deficient xrs-6 chinese hamster ovary cell line,Confirmatory,7525959.0,
141,52060,3,3,,104234176,36462,Unspecified,,,,,Effect on cellular protein DNA complex formation(%) at 10 uM in comparison with etoposide,Other,1312600.0,
142,52061,3,3,,104234176,36462,Unspecified,,,,,Effect on cellular protein DNA complex formation(%) at 10 uM in comparison with etoposide,Other,1312601.0,
143,52062,3,3,,104234176,36462,Unspecified,,,,,Compound was tested for the % complex formation of cellular protein -DNA complex at a concentration of 10 uM,Other,1662724.0,
144,52064,3,3,,104234176,36462,Unspecified,,,,,Inhibition of cellular protein-DNA complex formation at 10 uM,Other,2167985.0,
145,53289,3,8,,104234176,36462,Unspecified,,,,,Percent inhibition of DNA topoisomerase II at 100 uM concentration in calf thymus,Other,,
146,53290,3,8,,104234176,36462,Unspecified,,,,,Percent inhibition of DNA topoisomerase II at 250 uM concentration in calf thymus,Other,,
147,53291,3,8,,104234176,36462,Unspecified,,,,,Percent inhibition of DNA topoisomerase II at 50 uM concentration in calf thymus,Other,,
148,53294,4,8,,104234176,36462,Unspecified,,,,,Compound was tested for DNA Topoisomerase II mediated cleavage of DNA; Each + indicates 2 to 4 fold increase,Other,,
149,53297,3,7,,104234176,36462,Unspecified,,,,,Double strand DNA breakage reflecting stabilization of DNA topoisomerase II intermediate by the compound expressed in terms of ng of DNA/unit of enzyme/mM of drug,Other,,
150,53301,8,1,,104234176,36462,Unspecified,,,50.0,ID50,Evaluated for inhibitory activity against DNA topoisomerase II,Confirmatory,2158562.0,
151,53302,3,7,,104234176,36462,Unspecified,,,,,Inhibition of DNA topoisomerase II at 100 uM.,Other,2158562.0,
152,53303,3,3,,104234176,36462,Unspecified,,,,,Percent of cellular protein-DNA complex formation at concentration of 20 uM,Other,8295216.0,
153,53304,3,3,,104234176,36462,Unspecified,,,,,Percentage inhibition of cellular protein-DNA complex formation,Other,8120864.0,
154,53956,3,4,,104234176,36462,Unspecified,,,,,Synergism with indomethacin in DLKP cells,Other,15012986.0,
155,54072,3,4,,104234176,36462,Unspecified,,,,,Synergism with sulindac in DLKP cells,Other,15012986.0,
156,54073,3,4,,104234176,36462,Unspecified,,,,,Synergism with tolmedin in DLKP cells,Other,15012986.0,
157,54437,9,3,,104234176,36462,Unspecified,,,70.0,EC50,Inhibition of calf thymus DNA/ethidium bromide complex formation.,Confirmatory,,
158,54923,6,5,,104234176,36462,Unspecified,,,50.0,IC50,Inhibition of human cytochrome P450 3A4,Confirmatory,12699389.0,
159,55595,6,2,,104234176,36462,Active,,,0.38,IC50,Growth inhibition against human DAN-G cell lines,Confirmatory,15189040.0,
160,55802,6,2,,104234176,36462,Active,,,1.3,IC50,Antiproliferative activity against human DU145 prostate cell line,Confirmatory,10498216.0,
161,56699,6,5,,104234176,36462,Inactive,,,,,In vitro inhibition of DNA topoisomerase I activity (ATP-independent DNA relaxation) at a concentration of 50 uM; no activity,Other,,
162,57050,3,8,,104234176,36462,Unspecified,,,,,In vitro inhibition of DNA topoisomerase II activity (DNA unknotting) at a concentration of 50 uM,Other,,
163,57053,9,2,,104234176,36462,Unspecified,,,56.0,EC50,Concentration of compound at which inhibitory activity detected against DNA topoisomerase II,Confirmatory,9804687.0,
164,57057,3,7,,104234176,36462,Unspecified,,,,,Inhibition of human DNA Topoisomerase II mediated DNA cleavage through the stabilization of transient DAN/topoisomerase II cleavage complex,Other,15084135.0,
165,57061,3,7,,104234176,36462,Unspecified,,,,,Percentage of intracellular covalent DNA-topoisomerase II complexes formed,Other,12014968.0,
166,57065,9,1,,104234176,36462,Unspecified,,,,,Tested for the inhibition of DNA topoisomerase II,Other,,
167,57193,7,1,,104234176,36462,Unspecified,,,,,The compound was tested for inhibitory activity against human DNA topoisomerase-2.,Other,10395485.0,
168,57197,6,4,,104234176,36462,Unspecified,,,,,Inhibitory activity in a DNA cleavage assay using HeLa DNA topoisomerase II yielding its effective concentration,Other,12459024.0,
169,57199,5,4,,104234176,36462,Unspecified,,,,,In vitro inhibition of partially purified human ovarian carcinoma topoisomerase II of kDNA decatenation,Other,7473578.0,
170,57200,8,1,,104234176,36462,Unspecified,,,50.0,ID50,Evaluated for the inhibition of human DNA Topoisomerase II,Confirmatory,1312600.0,
171,57201,8,1,,104234176,36462,Unspecified,13959709.0,7153.0,50.0,ID50,Inhibition of human DNA Topoisomerase II,Confirmatory,1312601.0,
172,57201,8,1,,104234176,36462,Unspecified,20141946.0,7155.0,50.0,ID50,Inhibition of human DNA Topoisomerase II,Confirmatory,1312601.0,
173,57204,8,1,,104234176,36462,Unspecified,,,50.0,ID50,Inhibition of human DNA topoisomerase II,Confirmatory,1662724.0,
174,57205,8,1,,104234176,36462,Unspecified,,,50.0,ID50,Inhibitory activity against human DNA topoisomerase II,Confirmatory,2167985.0,
175,57206,3,7,,104234176,36462,Unspecified,,,,,Compound was tested for inhibition against human DNA topoisomerase II,Other,2537424.0,
176,57216,3,7,,104234176,36462,Unspecified,,,,,Compound was tested for percentage inhibition against DNA topoisomerase II,Other,3016271.0,
177,57217,3,7,,104234176,36462,Unspecified,,,,,Compound was tested in vitro for inhibitory effect on DNA topoisomerase II activity at a concentration of 100 uM; Evidence inhibition,Other,9873631.0,
178,57221,3,7,,104234176,36462,Inactive,,,,,Compound was tested in vitro for inhibitory effect on DNA topoisomerase II activity at a concentration of 12.5 uM; No inhibition,Other,9873631.0,
179,57222,3,7,,104234176,36462,Inactive,,,,,Compound was tested in vitro for inhibitory effect on DNA topoisomerase II activity at a concentration of 25 uM; No inhibition,Other,9873631.0,
180,57224,3,7,,104234176,36462,Inactive,,,,,Compound was tested in vitro for inhibitory effect on DNA topoisomerase II activity at a concentration of 3.2 uM; No inhibition,Other,9873631.0,
181,57225,3,7,,104234176,36462,Unspecified,,,,,Compound was tested in vitro for inhibitory effect on DNA topoisomerase II activity at a concentration of 50 uM; Slight inhibition,Other,9873631.0,
182,57227,3,7,,104234176,36462,Inactive,,,,,Compound was tested in vitro for inhibitory effect on DNA topoisomerase II activity at a concentration of 6.3 uM; No inhibition,Other,9873631.0,
183,57383,3,8,,104234176,36462,Unspecified,,,,,In vitro inhibition of human DNA topoisomerase II activity.,Other,15177438.0,
184,57541,4,5,,104234176,36462,Active,,,3.6672,IC50,Inhibitory concentration required for cytotoxicity in DOX-resistant (DOX/R) cells,Confirmatory,,
185,57731,6,2,,104234176,36462,Active,,,2.0,GI50,In vitro cytotoxic activity against prostate (DU-145) cancer cell line.,Confirmatory,10465531.0,
186,57885,4,5,,104234176,36462,Active,,,2.3733,IC50,In vivo antiproliferative activity against DU-145 cell line,Confirmatory,15084135.0,
187,57902,5,3,,104234176,36462,Active,,,0.85114,GI50,Tested for the in vitro cytotoxicity against DU-145 prostate cancer cell line,Confirmatory,,
188,67104,3,4,,104234176,36462,Unspecified,,,,,Percent colony reduction in cell growth in EBV-positive nasopharyngeal cell lines (D98/HR1) after administration of 3.0 ug/mL dose,Other,6685770.0,
189,67107,3,5,,104234176,36462,Unspecified,,,,,EBV-positive nasopharyngeal cells (D98/HR1) survived at concentration of 3.0 ug/mL of compound,Other,6685770.0,
190,67504,5,1,,104234176,36462,Unspecified,,,,,Inhibition of growth of hepatoma HLE cell line,Other,8389875.0,
191,68776,6,2,,104234176,36462,Active,,,0.74,IC50,Inhibitory activity against F460pv8/eto cell line using MTT assay,Confirmatory,10780913.0,
192,71086,5,2,,104234176,36462,Inconclusive,,,,,In vitro antibacterial activity of compound towards Escherichia coli NIHJ JC-2; NT = Not tested,Other,15149673.0,
193,72415,6,2,,104234176,36462,Unspecified,,,,,Cytotoxic activity of compound against G-361 melanoma human tumor cell line,Other,12459024.0,
194,72429,5,1,,104234176,36462,Unspecified,,,,,Inhibition of growth of renal cancer G-402 cell line,Other,8389875.0,
195,73177,6,2,,104234176,36462,Active,,,4.0,IC50,Cytotoxic effect against GLC4 (human small cell lung carcinoma cell line) using the microculture tetrazolium (MTT) assay based on 2 hr incubation,Confirmatory,7783142.0,
196,73178,6,2,,104234176,36462,Active,,,0.82,IC50,Cytotoxic effect against GLC4 (human small cell lung carcinoma cell line) using the microculture tetrazolium (MTT) assay based on continuous incubation,Confirmatory,7783142.0,
197,73179,6,2,,104234176,36462,Unspecified,,,76.0,IC50,Inhibitory activity against GLIOMA#108 cell line,Confirmatory,9554873.0,
198,73180,6,2,,104234176,36462,Unspecified,,,62.0,IC50,Inhibitory activity against GLIOMA#112 cell line,Confirmatory,9554873.0,
199,78419,6,2,,104234176,36462,Active,,,0.39,IC50,Inhibitory activity against H460pv8 cell line using MTT assay,Confirmatory,10780913.0,
200,78451,6,3,,104234176,36462,Unspecified,,,,,Tested for in vitro cytotoxicity against HCT116 cells,Other,,
201,78724,6,2,,104234176,36462,Active,,,0.9,GI50,In vitro cytotoxic activity against lung (H 522) cancer cell line.,Confirmatory,10465531.0,
202,78823,8,1,,104234176,36462,Unspecified,,,5000.0,ED50,The compound was tested for tumor cell growth inhibitory activity against human ileocecal carcinoma (HCT-8) cell line,Confirmatory,10395485.0,
203,79005,6,3,,104234176,36462,Unspecified,,,,,Compound was evaluated for in vitro cytotoxicity against HCT/VP35 cells,Other,,
204,79771,6,2,,104234176,36462,Active,,,3.46,GI50,In vitro cytotoxicity against human colon cancer HCC 2998 cell line,Confirmatory,9871772.0,
205,79797,5,3,,104234176,36462,Active,,,18.197,GI50,Tested for the in vitro cytotoxicity against HCC2998 colon cancer cell lines,Confirmatory,,
206,80089,8,1,,104234176,36462,Active,,,8.64,ED50,Inhibitory activity against human cytomegalovirus (HCMV) in HEL cells,Confirmatory,11311065.0,
207,80114,8,1,,104234176,36462,Active,,,1.03,ID50,Inhibitory activity against human cytomegalovirus (HCMV),Confirmatory,11311065.0,
208,80250,6,2,,104234176,36462,Active,,,6.16,GI50,In vitro cytotoxicity against human colon cancer HCT 116 cell line,Confirmatory,9871772.0,
209,80554,6,3,,104234176,36462,Unspecified,,,,,Compound was tested for its in vitro cytotoxicity in HCT116 cell line after 72 hours,Other,,
210,80555,5,3,,104234176,36462,Unspecified,,,,,Compound was tested for its in vitro cytotoxicity in HCT-VP35 cell line after 72 hours,Other,,
211,80680,6,2,,104234176,36462,Active,,,2.5,IC50,Cytotoxicity against HCT116 cells.,Confirmatory,7473578.0,
212,80703,6,2,,104234176,36462,Active,,,2.5,IC50,Tested for the cytotoxicity to inhibit replication assay against the human colon tumor cell line HCT116,Confirmatory,7525959.0,
213,80965,6,1,,104234176,36462,Active,,,0.025,IC50,Compound was tested for its anticancer activity against HL-60 cells.,Confirmatory,,
214,81321,6,2,,104234176,36462,Unspecified,,,,,Cytotoxic activity against human HMV-2 melanoma tumor cell line,Other,15149673.0,
215,81456,6,2,,104234176,36462,Active,,,1.2,IC50,Cytotoxic activity against human promyelocytic leukemia HL-60 concentration of agent required to reduce cell viability by 50%,Confirmatory,10377219.0,
216,81487,6,2,,104234176,36462,Active,,,0.36700000000000005,IC50,Relative cytotoxicity against human promyelocytic leukemia(HL-60) cells,Confirmatory,10377219.0,
217,81490,6,3,,104234176,36462,Active,,,0.025,IC50,Tested for the cytostatic activity as inhibitory concentration against leukemia HL-60 cells,Confirmatory,,
218,81639,5,2,,104234176,36462,Active,,,,,Cytotoxic activity against human promyelocytic leukemia HL-60 concentration of agent required to reduce cell viability by 90%,Other,10377219.0,
219,81644,5,2,,104234176,36462,Active,,,,,Relative cytotoxicity against human promyelocytic leukemia(HL-60) cells,Other,10377219.0,
220,82503,6,2,,104234176,36462,Unspecified,,,,,Cytotoxic activity against human tumor HL-60 leukemia cells,Other,15056007.0,
221,82976,8,1,,104234176,36462,Active,,,0.45,AC50,In vitro concentration required to induce apoptosis in HL60 cells,Confirmatory,12877593.0,
222,82982,6,2,,104234176,36462,Active,,,0.12300000000000001,IC50,In vitro inhibitory concentration against proliferation of HL60 cells,Confirmatory,12877593.0,
223,82994,8,2,,104234176,36462,Unspecified,,,,,Cytotoxicity was assessed using adriamycin-resistant human leukemic cell line HL60/ADR,Other,11170627.0,
224,83006,4,4,,104234176,36462,Unspecified,,,,,Resistance factor was determined using the ratio of (IC50) of drug resistance cells/drug sensitive cells in HL60/ADR cell line,Other,11170627.0,
225,83009,8,2,,104234176,36462,Unspecified,,,,,Cytotoxicity was assessed using drug-sensitive human leukemic cell line HL60/S,Other,11170627.0,
226,83123,8,2,,104234176,36462,Unspecified,,,,,Cytotoxicity was assessed using vincristine-resistant human leukemic cell line HL60/Vinc,Other,11170627.0,
227,83131,4,4,,104234176,36462,Unspecified,,,,,Resistance factor was determined using the ratio of (IC50) of drug resistance cells/drug sensitive cells in HL60/Vinc cell line,Other,11170627.0,
228,83137,8,1,,104234176,36462,Active,,,15.0,AC50,In vitro concentration required to induce apoptosis in HL60R cells,Confirmatory,12877593.0,
229,83140,6,2,,104234176,36462,Active,,,6.5,IC50,In vitro inhibitory concentration against proliferation of HL60R cells,Confirmatory,12877593.0,
230,83141,6,2,,104234176,36462,Active,,,0.5,IC50,In vitro inhibitory concentration against proliferation of HL60R cells along with 5 (uM) verapamil,Confirmatory,12877593.0,
231,83144,5,1,,104234176,36462,Unspecified,,,,,Inhibition of growth of hepatoma HLF cell line,Other,8389875.0,
232,83615,4,4,,104234176,36462,Active,,,1.7,IC50,In vitro cytotoxicity against the HT-29 (human colon carcinoma) neoplastic cell line,Confirmatory,14980682.0,
233,83626,4,5,,104234176,36462,Active,,,2.3667,IC50,In vivo antiproliferative activity against HT-29 cell line,Confirmatory,15084135.0,
234,83762,6,2,,104234176,36462,Active,,,10.0,IC50,Tested for cytotoxicity against Colon carcinoma type HT-29 cell line expressing MDR-1 (-) gene; 35% of cells were affected,Confirmatory,11844671.0,
235,83969,6,2,,104234176,36462,Unspecified,,,,,Cytotoxic activity of compound against HT-29 colon human tumor cell line,Other,12459024.0,
236,84091,6,2,,104234176,36462,Unspecified,,,,,Growth inhibition of HT-29 (human colon adenocarcinoma) cell line.,Other,2002477.0,
237,84434,6,2,,104234176,36462,Active,,,0.2,IC50,Antiproliferative activity against human HT-29 colon cell line,Confirmatory,10498216.0,
238,85223,6,2,,104234176,36462,Active,,,8.0,GI50,In vitro cytotoxicity against human breast cancer Hs 578.T cell line,Confirmatory,9871772.0,
239,85442,6,2,,104234176,36462,Active,,,15.13,GI50,In vitro cytotoxicity against human colon cancer HT 29 cell line,Confirmatory,9871772.0,
240,86826,7,1,,104234176,36462,Active,,,,,Concentration required to inhibit S phase and G2/M phase in HeLa cells,Other,15026047.0,
241,86841,6,2,,104234176,36462,Active,,,40.0,GI50,Growth inhibitory concentration of compound was determined against HeLa cells by alamar blue assay,Confirmatory,15026047.0,
242,90120,6,2,,104234176,36462,Active,,,0.99,IC50,Relative cytotoxicity against human bone marrow samples,Confirmatory,10377219.0,
243,90122,5,2,,104234176,36462,Active,,,,,Relative cytotoxicity against human bone marrow samples,Other,10377219.0,
244,91033,6,2,,104234176,36462,Unspecified,,,,,Cytotoxic activity against human tumor Hs 746.T stomach cells,Other,15056007.0,
245,91215,2,4,,104234176,36462,Active,,,,,Antitumor activity administered ip was determined in human model; Active,Other,,
246,91481,4,7,,104234176,36462,Unspecified,,,,,Binding constant against human serum albumin (HSA),Other,11728183.0,
247,91784,4,5,,104234176,36462,Active,,,0.5767,IC50,Inhibitory concentration required for cytotoxicity in J774.2 murine macrophage-like cells,Confirmatory,,
248,91916,4,5,,104234176,36462,Active,,,0.16,IC50,Inhibitory concentration against Human Jurkat leukemia (JLC) cell proliferation,Confirmatory,9207945.0,
249,91973,5,2,,104234176,36462,Unspecified,,,83.1764,GI50,Tested for in vitro inhibitory activity against drug concentration causing 50% cell growth inhibition in 56 human tumor cell lines derived from leukemia; log10 GI50,Confirmatory,8182704.0,
250,92120,5,2,,104234176,36462,Unspecified,,,83.1764,GI50,Inhibition of human tumor cell growth,Confirmatory,8120864.0,
251,93381,9,5,,104234176,36462,Unspecified,82312013.0,,100.0,IC50,Compound concentration required to reduce HIV-1 Integrase 3'-processing activity by 50%,Confirmatory,9767632.0,
252,93625,4,5,,104234176,36462,Active,,,0.9845,IC50,In vivo antiproliferative activity against IGROV1 cell line,Confirmatory,15084135.0,
253,93836,5,3,,104234176,36462,Active,,,0.19952999999999999,GI50,GI values against KB cells (nasopharyngeal carcinoma),Confirmatory,11311065.0,
254,93861,4,5,,104234176,36462,Active,,,0.5665,IC50,In vivo antiproliferative activity against KB-3-1 cell line,Confirmatory,15084135.0,
255,93913,3,6,,104234176,36462,Unspecified,,,,,The number of mice survived for 30 days,Other,8389875.0,
256,94008,3,4,,104234176,36462,Unspecified,,,,,Compound was evaluated for cytotoxicity against KB-7d cells at 10 uM concentration; NMD = not markedly different from control.,Other,15125972.0,
257,94009,8,1,,104234176,36462,Active,,,11.0,ED50,Effective dose required for inhibition of KB-7d cell replication after 3 days of continuous treatment,Confirmatory,15125972.0,
258,94012,3,4,,104234176,36462,Unspecified,,,,,Lethal dose against KB-7d cells when treated for 30 min; NMD = not markedly different from control.,Other,15125972.0,
259,94015,8,1,,104234176,36462,Unspecified,,,23800.0,ED50,The compound was tested for tumor cell growth inhibitory activity against human KB-7d cell line resistant to etoposide,Confirmatory,10395485.0,
260,94019,5,1,,104234176,36462,Active,,,18.0,ID50,"50% reduction in the number of KB 7D (topoisomerase II, aMDR) resistant variant",Confirmatory,8120864.0,
261,94022,2,5,,104234176,36462,Inconclusive,,,,,Tested for the cytotoxicity against KB-7d cells; ID50/LD50 = 25/Not tested,Other,,
262,94175,8,1,,104234176,36462,Active,,,0.2,ID50,Cytotoxicity against KB-ATCC cell lines after a 3-day incubation,Confirmatory,8295216.0,
263,94327,8,1,,104234176,36462,Unspecified,,,30600.0,ED50,The compound was tested for tumor cell growth inhibitory activity against human KB-vin20c cell line resistant to vincristine,Confirmatory,10395485.0,
264,94329,5,1,,104234176,36462,Active,,,2.3,ID50,50% reduction in the number of KB V20C resistant variant,Confirmatory,8120864.0,
265,94331,6,2,,104234176,36462,Active,,,23.8,IC50,Growth inhibitory activity (antiproliferative) against KB/7d cell lines,Confirmatory,8691469.0,
266,94355,6,2,,104234176,36462,Unspecified,,,50.0,IC50,Antiproliferative activity against drug-resistant tumor cell line KB7D.,Confirmatory,10411476.0,
267,94356,6,2,,104234176,36462,Unspecified,,,20.0,IC50,Concentration required to reduce proliferation of KB subclones passaged in the presence of etoposide 7 uM (KB7D) cell line by 50% as determined by the MTT method,Confirmatory,14761187.0,
268,94357,6,2,,104234176,36462,Active,,,2.4,IC50,Concentration required to reduce proliferation of KB subclones passaged in the presence of vincristine 0.02 uM (KB7D) cell line by 50% as determined by the MTT method,Confirmatory,14761187.0,
269,94498,6,2,,104234176,36462,Active,,,1.3,IC50,Antiproliferative activity against drug-resistant tumor cell line KBCamp.,Confirmatory,10411476.0,
270,94501,6,2,,104234176,36462,Active,,,26.2,IC50,Antiproliferative activity against drug-resistant tumor cell line KBMDR.,Confirmatory,10411476.0,
271,94502,6,2,,104234176,36462,Unspecified,,,20.0,IC50,Concentration required to reduce proliferation of KB subclones passaged in the presence of doxorubicin 0.09 uM (KBMDR) cell line by 50% as determined by the MTT method,Confirmatory,14761187.0,
272,94510,6,2,,104234176,36462,Unspecified,,,50.0,IC50,Antiproliferative activity against drug-resistant tumor cell line KBV20C.,Confirmatory,10411476.0,
273,94511,6,2,,104234176,36462,Active,,,0.8,IC50,Concentration required to reduce proliferation of KB human nasopharyngeal carcinoma (KBWT) cell line by 50% as determined by the MTT method,Confirmatory,14761187.0,
274,94686,6,2,,104234176,36462,Active,,,5.62,GI50,In vitro cytotoxicity against human colon cancer KM 12 cell line,Confirmatory,9871772.0,
275,95012,6,2,,104234176,36462,Active,,,0.7,IC50,Growth inhibition against human KYSE-150 cell lines,Confirmatory,15189040.0,
276,95016,6,2,,104234176,36462,Active,,,0.41,IC50,Growth inhibition against human KYSE-520 cell lines,Confirmatory,15189040.0,
277,95019,6,2,,104234176,36462,Active,,,0.79,IC50,Growth inhibition against human KYSE-70 cell lines,Confirmatory,15189040.0,
278,95455,4,4,,104234176,36462,Active,,,0.16,IC50,Growth inhibitory activity against human Jurkat leukemia cell line (JLC),Confirmatory,12620081.0,
279,95460,3,5,,104234176,36462,Unspecified,,,,,Percent of Jurkat-Vec cells killed after 72 hr of 2.5 uM of compound administration,Other,15115387.0,
280,95462,3,5,,104234176,36462,Unspecified,,,,,Percent of Jurkat-Vec cells killed after 72 hr of 10 uM of compound administration,Other,15115387.0,
281,95463,3,5,,104234176,36462,Unspecified,,,,,Percent of Jurkat-Vec cells killed after 72 hr of 2.5 uM of compound administration,Other,15115387.0,
282,95495,3,5,,104234176,36462,Unspecified,,,,,Tested for the cellular protein DNA complex formation in KB cells at concentration of 25 uM,Other,,
283,95496,3,5,,104234176,36462,Unspecified,,,,,Tested for the cellular protein DNA complex formation in KB cells at the concentration of 2.5 uM,Other,,
284,95500,6,2,,104234176,36462,Active,,,0.1,CC50,Compound concentration required to reduce the exponential growth of KB cells by 50%,Confirmatory,9767632.0,
285,95504,3,5,,104234176,36462,Unspecified,,,,,In vitro cellular protein-DNA complex formation at a concentration of 50 uM,Other,,
286,95508,3,5,,104234176,36462,Unspecified,,,,,In vitro topoisomerase II -DNA complex formation at a concentration of 50 uM,Other,,
287,95512,3,4,,104234176,36462,Unspecified,,,,,Compound was evaluated for cytotoxicity against KB cells at 10 uM concentration,Other,15125972.0,
288,95665,8,1,,104234176,36462,Unspecified,,,200.0,ED50,The compound was tested for tumor cell growth inhibitory activity against human nasopharynx carcinoma(KB) cell line.,Confirmatory,10395485.0,
289,95674,6,2,,104234176,36462,Active,,,1.45,IC50,Antiproliferative activity against drug-resistant tumor cell line KBwt.,Confirmatory,10411476.0,
290,95826,6,2,,104234176,36462,Unspecified,,,,,Cytotoxic activity against human KB nasopha tumor cell line,Other,15149673.0,
291,95840,6,2,,104234176,36462,Active,,,0.16399999999999998,IC50,Growth inhibitory activity (antiproliferative) against KB cell lines,Confirmatory,8691469.0,
292,96013,5,1,,104234176,36462,Active,,,0.32,ID50,50% reduction in the number of KB ATCC cells,Confirmatory,8120864.0,
293,96014,8,1,,104234176,36462,Active,,,0.2,ID50,Cytotoxicity against KB cells after a 3 day incubation,Confirmatory,8120864.0,
294,96032,8,1,,104234176,36462,Unspecified,,,50.0,LD50,Lethal dose against KB cells when treated for 30 min,Confirmatory,15125972.0,
295,96033,8,1,,104234176,36462,Active,,,20.0,LD50,The compound was tested for cytotoxic activity against KB cell line by clonogenic cell survival assay.,Confirmatory,10395485.0,
296,96036,2,5,,104234176,36462,Unspecified,,,,,Tested for the cytotoxicity against KB cells; ID50/LD50 = 0.20/3,Other,,
297,96044,3,5,,104234176,36462,Unspecified,,,,,Cellular protein-DNA complex breaking activity against KB cells labeled with tritiated thymidine.,Other,10395485.0,
298,96160,4,5,,104234176,36462,Active,,,0.5222,IC50,In vivo antiproliferative activity against K-562 cell line,Confirmatory,15084135.0,
299,96193,5,1,,104234176,36462,Unspecified,,,,,Compound was tested for in vitro cytotoxicity in KB cells after 3 days of incubation,Other,2537424.0,
300,96213,3,4,,104234176,36462,Unspecified,,,,,Fold increase in protein-linked DNA breaks (PLDB) with respect to untreated controls.,Other,9767632.0,
301,96219,6,2,,104234176,36462,Unspecified,,,20.0,IC50,Compound concentration required to reduce the cell proliferation of Wild type and Drug- resistant KB subclones passaged in the presence of doxorubicin 0.09 uM by 50%,Confirmatory,12431048.0,
302,96220,6,2,,104234176,36462,Active,,,0.6,IC50,Compound concentration required to reduce the cell proliferation of Wild type and Drug- resistant human nasopharyngeal carcinoma KB cells by 50%,Confirmatory,12431048.0,
303,96221,6,2,,104234176,36462,Unspecified,,,20.0,IC50,Compound concentration required to reduce the cell proliferation of Wild type and drug-resistant KB subclones passaged in the presence of etoposide 7 uM by 50%,Confirmatory,12431048.0,
304,96350,6,2,,104234176,36462,Active,,,0.2,IC50,Concentration required for 50% reduction in KB cell number after 3-day incubation,Confirmatory,1312600.0,
305,96351,6,2,,104234176,36462,Active,,,0.2,IC50,Concentration required for 50% reduction in KB cell number after 3-day incubation,Confirmatory,1312601.0,
306,96363,6,2,,104234176,36462,Active,,,6.2,IC50,Effect on the proliferation wild-type and drug-resistant KB subclones passaged uM,Confirmatory,12431048.0,
307,96388,8,1,,104234176,36462,Active,,,0.2,ID50,50% reduction in KB cell number after a 3-day incubation.,Confirmatory,1662724.0,
308,96389,8,1,,104234176,36462,Active,,,0.2,ID50,Concentration for 50% reduction in cell number after 3-day incubation,Confirmatory,2167985.0,
309,96390,8,1,,104234176,36462,Active,,,0.2,ID50,In vitro cytotoxicity against KB cells after a 3-day incubation.,Confirmatory,2158562.0,
310,96482,3,4,,104234176,36462,Unspecified,,,,,Antitumor activity in vivo expressed as the percentage increase in life span at the dose of 10 (mg/kg/day),Other,8389875.0,
311,96725,3,4,,104234176,36462,Unspecified,,,,,Percent of L1210 cells accumulated in G2+M phase of cell cycle at 0.5 uM compound concentration,Other,11128630.0,
312,98006,6,2,,104234176,36462,Active,,,0.23,IC50,Antiproliferative activity was evaluated against murine L1210 leukemia cell line,Confirmatory,11128630.0,
313,98032,5,1,,104234176,36462,Unspecified,,,,,Compound was tested for its antitumor activity and the cytotoxicity against L1210 lymphoid leukemia screen,Other,3820231.0,
314,98180,3,4,,104234176,36462,Unspecified,,,,,Percent of L1210 cells in the G2+M phase of the cell cycle at a compound concentration of 2.5 uM,Other,15084135.0,
315,98726,6,2,,104234176,36462,Active,,,0.2,IC50,In vitro cytotoxic activity against murine L1210 leukemia cells.,Confirmatory,9804687.0,
316,98890,4,5,,104234176,36462,Active,,,0.2014,IC50,In vivo antiproliferative activity against L1210 cell line,Confirmatory,15084135.0,
317,98907,6,2,,104234176,36462,Active,,,0.8340000000000001,IC50,Inhibitory activity against L1210 cell line,Confirmatory,14592517.0,
318,98925,6,2,,104234176,36462,Active,,,0.83,IC50,Inhibitory concentration required to reduce 50 percent L1210 cell growth,Confirmatory,15084135.0,
319,99873,3,5,,104234176,36462,Unspecified,,,,,In vitro cytotoxic activity tested in mouse leukemia L1210 cells at a dose of 0.5 ug/mL,Other,7131486.0,
320,99874,3,5,,104234176,36462,Unspecified,,,,,In vitro cytotoxic activity tested in mouse leukemia L1210 cells at a dose of 5.0 ug/mL,Other,7131486.0,
321,99875,3,5,,104234176,36462,Unspecified,,,,,In vitro cytotoxic activity tested in mouse leukemia L1210 cells at a dose of 50.0 ug/mL,Other,7131486.0,
322,99980,8,2,,104234176,36462,Inconclusive,,,,,Compound was tested for growth inhibition against human LCLC-103H cell lines; nd denotes not determined,Other,15189040.0,
323,100239,4,5,,104234176,36462,Active,,,0.18,IC50,Inhibitory concentration against Murine Lewis lung carcinoma (LLC) cell proliferation,Confirmatory,9207945.0,
324,101620,6,2,,104234176,36462,Active,,,0.6,IC50,"Inhibitory activity against MDA-468 cell line using MTT assay (ER-, amplified EGFR, mutant p53)",Confirmatory,10780913.0,
325,101652,6,2,,104234176,36462,Active,,,2.0,GI50,In vitro cytotoxicity against human breast cancer MDA-MB 231 cell line,Confirmatory,9871772.0,
326,101653,6,2,,104234176,36462,Active,,,0.9,GI50,In vitro cytotoxicity against human breast cancer MDA-MB 435 cell line,Confirmatory,9871772.0,
327,101817,4,5,,104234176,36462,Active,,,0.6,IC50,In vivo antiproliferative activity against MDA-MB-231 cell line,Confirmatory,15084135.0,
328,102037,6,2,,104234176,36462,Active,,,2.3,IC50,"Cytotoxic activity against solid tumor, LoVo, (human colon adenocarcinoma) concentration of agent required to reduce cell viability by 50%",Confirmatory,10377219.0,
329,102190,5,2,,104234176,36462,Active,,,,,"Cytotoxic activity against solid tumor, LoVo, (human colon adenocarcinoma) concentration of agent required to reduce cell viability by 90%",Other,10377219.0,
330,103000,6,2,,104234176,36462,Active,,,0.01,GI50,In vitro cytotoxic activity against melanoma (M 14) cancer cell line.,Confirmatory,10465531.0,
331,103073,6,2,,104234176,36462,Active,,,0.085,IC50,"Inhibitory activity against MCF-7 wt cell line using MTT assay (ER+,pgR+,wildtype p53)",Confirmatory,10780913.0,
332,103107,3,4,,104234176,36462,Unspecified,,,,,Antitumor activity in vivo expressed as the percentage increase in life span at the dose of 12 (mg/kg/day); (p<0.001),Other,8389875.0,
333,103108,3,4,,104234176,36462,Unspecified,,,,,Antitumor activity in vivo expressed as the percentage increase in life span at the dose of 2.32 (mg/kg/day); (p<0.005),Other,8389875.0,
334,103109,3,4,,104234176,36462,Unspecified,,,,,Antitumor activity in vivo expressed as the percentage increase in life span at the dose of 21 (mg/kg/day); (p<0.005),Other,8389875.0,
335,103110,3,4,,104234176,36462,Unspecified,,,,,Antitumor activity in vivo expressed as the percentage increase in life span at the dose of 4 (mg/kg/day); (p<0.001),Other,8389875.0,
336,103111,3,4,,104234176,36462,Unspecified,,,,,Antitumor activity in vivo expressed as the percentage increase in life span at the dose of 7 (mg/kg/day); (p<0.001),Other,8389875.0,
337,103152,5,3,,104234176,36462,Active,,,0.81283,GI50,Tested for the in vitro cytotoxicity against M-14 melanoma,Confirmatory,,
338,103278,3,5,,104234176,36462,Unspecified,,,,,Mean body weight change at the dose of 12 (mg/kg/day),Other,8389875.0,
339,103279,3,5,,104234176,36462,Unspecified,,,,,Mean body weight change at the dose of 2.3 (mg/kg/day),Other,8389875.0,
340,103280,3,5,,104234176,36462,Unspecified,,,,,Mean body weight change at the dose of 21 (mg/kg/day),Other,8389875.0,
341,103281,3,5,,104234176,36462,Unspecified,,,,,Mean body weight change at the dose of 4 (mg/kg/day),Other,8389875.0,
342,103282,3,5,,104234176,36462,Unspecified,,,,,Mean body weight change at the dose of 7 (mg/kg/day),Other,8389875.0,
343,103294,4,4,,104234176,36462,Active,,,0.18,IC50,Growth inhibitory activity against murine Lewis lung carcinoma cell line,Confirmatory,12620081.0,
344,103365,6,2,,104234176,36462,Active,,,25.0,GI50,Compound was evaluated for in vitro cytotoxicity data against human breast cancer MCF-7 ADR cell line,Confirmatory,9871772.0,
345,103441,6,2,,104234176,36462,Unspecified,,,100.0,IC50,Antiproliferative activity against human MCF-7 breast cell line,Confirmatory,10498216.0,
346,103450,6,2,,104234176,36462,Active,,,1.1,IC50,"Cytotoxic activity against solid tumor LLC(Lewis lung carcinoma), concentration of agent required to reduce cell viability by 50%",Confirmatory,10377219.0,
347,103452,5,2,,104234176,36462,Active,,,,,"Cytotoxic activity against solid tumor LLC(Lewis lung carcinoma), concentration of agent required to reduce cell viability by 90%",Other,10377219.0,
348,103594,5,3,,104234176,36462,Active,,,4.3651599999999995,GI50,Tested for the in vitro cytotoxicity against MCF-7 breast cancer cell line,Confirmatory,,
349,103730,8,1,,104234176,36462,Unspecified,,,5000.0,ED50,The compound was tested for tumor cell growth inhibitory activity against human breast cancer (MCF-7) cell line.,Confirmatory,10395485.0,
350,103762,6,3,,104234176,36462,Active,,,25.0,GI50,In vitro cytotoxic activity against ADR resistant breast cancer (MCF-7-ADR) cell line.,Confirmatory,10465531.0,
351,103907,6,2,,104234176,36462,Active,,,0.54,IC50,Growth inhibition against human MCF-7 cell lines,Confirmatory,15189040.0,
352,103947,5,3,,104234176,36462,Unspecified,,,67.0,IC50,Antiproliferative activity measured against MCF-7-mdr cells.,Confirmatory,9876111.0,
353,104131,6,2,,104234176,36462,Active,,,0.15,IC50,"Inhibitory activity against MDA-231 cell line using MTT assay (ER-,EGFR+,mutant p53)",Confirmatory,10780913.0,
354,105115,6,1,,104234176,36462,Active,,,0.038,IC50,Compound was tested for its anticancer activity against human T-lymphocytic leukemia MOLT-4 cells.,Confirmatory,,
355,105226,6,2,,104234176,36462,Active,,,0.01,GI50,In vitro cytotoxicity against human breast cancer MDA-N cell line,Confirmatory,9871772.0,
356,105494,5,3,,104234176,36462,Active,,,1.02329,GI50,Tested for the in vitro cytotoxicity against MOLT-4 leukemia cell line,Confirmatory,,
357,105666,6,2,,104234176,36462,Active,,,7.55,IC50,Tested for cytotoxicity against VP 16 resistant Molt3 type MOVP-3 cell line expressing MDR-1 (++) gene,Confirmatory,11844671.0,
358,106311,4,4,,104234176,36462,Active,,,0.85,IC50,In vitro cytotoxicity against MEL-28 (human malign melanoma) neoplastic cell line,Confirmatory,14980682.0,
359,106581,6,2,,104234176,36462,Active,,,0.08,CC50,Compound concentration required to reduce the exponential growth of MT-4 cells by 50%,Confirmatory,9767632.0,
360,106871,6,2,,104234176,36462,Unspecified,,,,,Cytotoxic activity against human MKN45 stomach tumor cell line,Other,15149673.0,
361,108229,3,3,,104234176,36462,Unspecified,,,,,"Drug related lethality is percent animals in treated groups dying prior to first tumor related death in untreated groups measured in BDF1 mice after ip administration at 16 mg/kg dose days 3,7,11 after tumor challenge",Other,2002471.0,
362,108235,3,3,,104234176,36462,Unspecified,,,,,"Drug related lethality is percent animals in treated groups dying prior to first tumor related death in untreated groups measured in BDF1 mice after ip administration at 32 mg/kg dose days 3,7,11 after tumor challenge",Other,2002471.0,
363,108242,3,3,,104234176,36462,Unspecified,,,,,"Drug related lethality is percent animals in treated groups dying prior to first tumor related death in untreated groups measured in BDF1 mice after ip administration at 8 mg/kg dose days 3,7,11 after tumor challenge",Other,2002471.0,
364,108378,3,3,,104234176,36462,Unspecified,,,,,"In vivo activity measured against 3LL metastasis in BDF1 mice after ip administration at 16 mg/kg dose, dosing on days 3,7,11 after tumor challenge",Other,2002471.0,
365,108383,3,3,,104234176,36462,Unspecified,,,,,"In vivo activity measured against 3LL metastasis in BDF1 mice after ip administration at 32 mg/kg dose, dosing on days 3,7,11 after tumor challenge",Other,2002471.0,
366,108389,3,3,,104234176,36462,Unspecified,,,,,"In vivo activity measured against 3LL metastasis in BDF1 mice after ip administration at 8 mg/kg dose, dosing on days 3,7,11 after tumor challenge",Other,2002471.0,
367,108697,3,3,,104234176,36462,Unspecified,,,,,"The compound (10mg/kg, ip) was tested for change in average weight of BDF2 mice bearing E0771 mammary adenocarcinoma",Other,7650675.0,
368,108698,3,4,,104234176,36462,Unspecified,,,,,"The compound (10 mg/kg, ip) was tested for change in average weight of BDF2 mice bearing Lewis lung carcinoma.",Other,7650675.0,
369,108708,3,4,,104234176,36462,Unspecified,,,,,"The compound,(10 mg/kg, ip) was tested for change in average weight of BDF2 mice bearing B-16 melanoma.",Other,7650675.0,
370,109538,2,4,,104234176,36462,Active,,,,,"Antitumor activity administered ip, po was determined in murine model; Active",Other,,
371,109967,5,2,,104234176,36462,Unspecified,,,,,Compound was tested in vivo for antitumor activity against murine lewis lung cancer and the ratio of the body weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 5.0 mg/kg i.p. (day10); 19.3/17.0,Other,10509925.0,
372,110116,5,2,,104234176,36462,Unspecified,,,,,Ratio of the body weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 3.0 mg/kg i.p. (day7); 20.9/26.1,Other,10509925.0,
373,110117,5,2,,104234176,36462,Unspecified,,,,,Ratio of the body weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 3.0 mg/kg i.p. (day7); 21.3/21.4,Other,10509925.0,
374,110118,5,2,,104234176,36462,Unspecified,,,,,Ratio of the body weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 3.0 mg/kg i.p. (day7); 21.4/23.5,Other,10509925.0,
375,110130,5,2,,104234176,36462,Unspecified,,,,,Ratio of the body weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 5.0 mg/kg i.p. (day10); 20.2/19.7,Other,10509925.0,
376,110789,3,3,,104234176,36462,Unspecified,,,,,Number of mice(with Colon 38 tumors) cured after treatment of 45 mg/kg/day dose given as 3 times in a day for 4 days out of 5 mice,Other,12620081.0,
377,114253,6,1,,104234176,36462,Unspecified,,,,,In vivo antitumor activity against subcutaneous Colon 38 tumors in mice determined as delay in growth after 45 mg/kg/day dose given as 3 times in a day for 4 days,Other,12620081.0,
378,114888,4,3,,104234176,36462,Unspecified,,,,,In vivo inhibitory activity against murine S-180 sarcoma at a dose of 3.0 mg/kg (day 7),Other,10509925.0,
379,114894,4,3,,104234176,36462,Unspecified,,,,,In vivo inhibitory activity against murine lewis lung cancer at a dose of 5.0 mg/kg i.p. (day10),Other,10509925.0,
380,115126,2,4,,104234176,36462,Unspecified,,,,,"In vivo antitumor activity was measured as maximum tolerated dose in BDF1 male mice implanted with murine pancreatic adenocarcinoma (Panc 03) at dose schedule qd 4,6,8,10,12,14,16 administered iv",Other,,
381,115704,4,2,,104234176,36462,Unspecified,,,,,Compound was tested in vivo for antitumor activity against murine S-180 sarcoma and the ratio of the number of mice at the initial stage and the final stage of the experiment was reported at a dose of 3.0 mg/kg (day 7) administered i.p.; 10/10,Other,10509925.0,
382,115981,3,4,,104234176,36462,Unspecified,,,,,In vivo antitumor activity against the B16 melanoma cell line expressed as percent increase in life span at 10 mg/kg dose,Other,2821258.0,
383,115984,3,4,,104234176,36462,Unspecified,,,,,In vivo antitumor activity against the B16 melanoma cell line expressed as percent increase in life span at 8 mg/kg dose,Other,2821258.0,
384,115990,3,4,,104234176,36462,Unspecified,,,,,In vivo antitumor activity against the L1210 leukemia cell line expressed as percent increase in life span at 4 mg/kg dose,Other,2821258.0,
385,115991,3,4,,104234176,36462,Unspecified,,,,,In vivo antitumor activity against the L1210 leukemia cell line expressed as percent increase in life span at 8 mg/kg dose,Other,2821258.0,
386,115994,4,3,,104234176,36462,Unspecified,,,,,In vivo antitumor activity against the M5076 reticulum cell sarcoma expressed as percent increase in life span at 32 mg/kg dose,Other,2821258.0,
387,116433,3,4,,104234176,36462,Unspecified,,,,,Percent increase in life span (ILS) was measured on P388 cells which were inoculated intraperitoneally in CD2F1 mice at 16 mg/kg,Other,2821258.0,
388,116805,3,3,,104234176,36462,Unspecified,,,,,Percent increase in life span of mouse leukemia L1210 system at a dose of 30 mg/kg,Other,7131486.0,
389,116807,5,2,,104234176,36462,Unspecified,,,,,Percent increase in life span of mouse leukemia L1210 system at a dose of 45 mg/kg; Two long term survivors were observed,Other,7131486.0,
390,116808,3,3,,104234176,36462,Unspecified,,,,,Percent increase in life span of mouse leukemia L1210 system at a dose of 60 mg/kg,Other,7131486.0,
391,117393,3,3,,104234176,36462,Unspecified,,,,,Compound was evaluated for long-term survivors scored at day 60; 6/42,Other,15084135.0,
392,117640,3,4,,104234176,36462,Inactive,,,,,In vivo activity against iv transplanted AML Leukemia 1498 tumors of mice; Not active,Other,11356111.0,
393,118555,3,5,,104234176,36462,Unspecified,,,,,In vivo antitumor activity against the B16 melanoma cell line determined as number of cured out of the number tested at 10 mg/kg dose ( out of 10 mice),Other,2821258.0,
394,118556,3,5,,104234176,36462,Unspecified,,,,,In vivo antitumor activity against the B16 melanoma cell line determined as number of cured out of the number tested at at 8 mg/kg dose ( out of 6 mice),Other,2821258.0,
395,118557,3,5,,104234176,36462,Unspecified,,,,,In vivo antitumor activity against the L1210 leukemia cell line determined as number of cured out of the number tested at 8 mg/kg dose ( out of 8 mice),Other,2821258.0,
396,118558,3,5,,104234176,36462,Unspecified,,,,,In vivo antitumor activity against the L1210 leukemia cell line determined as number of cured out of the number tested at at 4 mg/kg dose ( out of 10 mice),Other,2821258.0,
397,118559,3,4,,104234176,36462,Unspecified,,,,,P388 activity determined as number of cured out of the number tested in 6 CD2F1 mice,Other,2821258.0,
398,120024,4,3,,104234176,36462,Unspecified,,,,,Average tumor volume of the B-16 melanoma,Other,7650675.0,
399,120025,3,3,,104234176,36462,Unspecified,,,,,Average tumor volume of the E0771 mammary adenocarcinoma,Other,7650675.0,
400,120027,4,3,,104234176,36462,Unspecified,,,,,Average tumor volume of the Lewis lung carcinoma,Other,7650675.0,
401,120414,4,3,,104234176,36462,Unspecified,,,,,Ratio of median survival time of treated mice (T) to that of median survival time of controls (C) in mice infected with p388 cells (in vivo) at a dose of 0.78 mg/kg,Other,15056007.0,
402,120415,4,3,,104234176,36462,Unspecified,,,,,Ratio of median survival time of treated mice (T) to that of median survival time of controls (C) in mice infected with p388 cells (in vivo) at a dose of 1.56 mg/kg,Other,15056007.0,
403,120548,4,3,,104234176,36462,Unspecified,,,,,Ratio of median survival time of treated mice (T) to that of median survival time of controls (C) in mice infected with p388 cells (in vivo) at a dose of 12.5 mg/kg,Other,15056007.0,
404,120549,4,3,,104234176,36462,Unspecified,,,,,Ratio of median survival time of treated mice (T) to that of median survival time of controls (C) in mice infected with p388 cells (in vivo) at a dose of 25 mg/kg,Other,15056007.0,
405,120550,4,3,,104234176,36462,Unspecified,,,,,Ratio of median survival time of treated mice (T) to that of median survival time of controls (C) in mice infected with p388 cells (in vivo) at a dose of 3.13 mg/kg,Other,15056007.0,
406,120551,3,3,,104234176,36462,Unspecified,,,,,Ratio of median survival time of treated mice (T) to that of median survival time of controls (C) in mice infected with p388 cells (in vivo) at a dose of 50 mg/kg,Other,15056007.0,
407,120552,4,3,,104234176,36462,Unspecified,,,,,Ratio of median survival time of treated mice (T) to that of median survival time of controls (C) in mice infected with p388 cells (in vivo) at a dose of 6.25 mg/kg,Other,15056007.0,
408,121081,2,4,,104234176,36462,Unspecified,,,,,Tested for tumor growth inhibition in mice,Other,,
409,121808,3,3,,104234176,36462,Unspecified,,,,,In vivo antitumor activity against murine P388 leukemia measured as median survival of treated mice to that of control (T/C) at a dose of 12.5 mg/kg,Other,15149673.0,
410,121809,3,3,,104234176,36462,Unspecified,,,,,In vivo antitumor activity against murine P388 leukemia measured as median survival of treated mice to that of control (T/C) at a dose of 3.13 mg/kg,Other,15149673.0,
411,121810,3,3,,104234176,36462,Unspecified,,,,,In vivo antitumor activity against murine P388 leukemia measured as median survival of treated mice to that of control (T/C) at a dose of 50 mg/kg,Other,15149673.0,
412,121969,2,4,,104234176,36462,Unspecified,,,,,In vivo antitumor activity was observed in mice at a dose of 96 mg/kg administered intravenously,Other,,
413,122271,2,4,,104234176,36462,Unspecified,,,,,"In vivo antitumor activity was measured as tumor growth inhibition in BDF1 male mice implanted with murine pancreatic adenocarcinoma (Panc 03) at dose schedule qd 4,6,8,10,12,14,16 administered iv",Other,,
414,122590,3,3,,104234176,36462,Unspecified,,,,,In vivo activity against transplanted colon-26 tumors of mice,Other,11356111.0,
415,123720,3,3,,104234176,36462,Unspecified,,,,,Ratio of the tumor weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 3.0 mg/kg (day 7),Other,10509925.0,
416,123721,4,3,,104234176,36462,Unspecified,,,,,Ratio of the tumor weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 3.0 mg/kg (day 7),Other,10509925.0,
417,123842,4,3,,104234176,36462,Unspecified,,,,,Ratio of the tumor weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 5.0 mg/kg i.p. (day10),Other,10509925.0,
418,124254,3,3,,104234176,36462,Unspecified,,,,,In vivo activity against iv transplanted Leukemia L1210 tumors of mice,Other,11356111.0,
419,124255,3,3,,104234176,36462,Unspecified,,,,,In vivo activity against transplanted Mam-16/C tumors of mice,Other,11356111.0,
420,124256,3,3,,104234176,36462,Unspecified,,,,,In vivo activity against transplanted Mam-16/C/ Taxol tumors of mice,Other,11356111.0,
421,124257,3,3,,104234176,36462,Unspecified,,,,,In vivo activity against transplanted Mam-16/C/Adr tumors of mice,Other,11356111.0,
422,124259,3,3,,104234176,36462,Unspecified,,,,,In vivo activity against transplanted Mam-17 tumors of mice,Other,11356111.0,
423,124260,3,3,,104234176,36462,Unspecified,,,,,In vivo activity against transplanted Mam-17/Adr tumors of mice,Other,11356111.0,
424,124261,3,3,,104234176,36462,Unspecified,,,,,In vivo activity against transplanted Mel-B16 tumors of mice,Other,11356111.0,
425,124262,3,3,,104234176,36462,Unspecified,,,,,In vivo activity against transplanted Panc-02 tumors of mice,Other,11356111.0,
426,124263,3,3,,104234176,36462,Unspecified,,,,,In vivo activity against transplanted Panc-03 tumors of mice,Other,11356111.0,
427,124264,3,3,,104234176,36462,Unspecified,,,,,In vivo activity against transplanted Squam lung-LC12 tumors of mice,Other,11356111.0,
428,124266,3,3,,104234176,36462,Unspecified,,,,,In vivo activity against transplanted colon-38 tumors of mice,Other,11356111.0,
429,124267,3,3,,104234176,36462,Unspecified,,,,,In vivo activity against transplanted colon-51 tumors of mice,Other,11356111.0,
430,125181,6,2,,104234176,36462,Active,,,0.065,IC50,Tested for cytotoxicity against parental T-cell leukemia type Molt 3 cell line expressing MDR-1 (-) gene,Confirmatory,11844671.0,
431,130329,2,4,,104234176,36462,Unspecified,,,,,"Tested for the increased life span (ILS) in murine leukemia model (in which P388 administered intraperitoneally), at a concentration of 180 mg/kg",Other,,
432,130330,3,5,,104234176,36462,Unspecified,,,,,The compound was tested for antitumor activity against (P388/0) Leukemia cells in mice. with a dosage of 10.0 mg/Kg/dose. activity is expressed as %ILS.,Other,10395485.0,
433,130331,3,5,,104234176,36462,Unspecified,,,,,The compound was tested for antitumor activity against (P388/0) Leukemia cells in mice. with a dosage of 27.0 mg/kg/dose. activity is expressed as %ILS.,Other,10395485.0,
434,130332,3,5,,104234176,36462,Unspecified,,,,,The compound was tested for antitumor activity against (P388/0) Leukemia cells in mice. with a dosage of 40.0 mg/Kg/dose. activity is expressed as %ILS.,Other,10395485.0,
435,132801,7,2,,104234176,36462,Unspecified,,,,,compound was tested in vivo for inhibition of P388 murine leukemia cells after iv / ip administration.,Other,9804687.0,
436,133404,3,4,,104234176,36462,Unspecified,,,,,Antitumor activity against Lewis lung carcinoma (LLC) cells transplanted s.c. into the auxiliary region of the BDF1 mice at a formulable dose of 0.06 mmol/kg/day,Other,12419378.0,
437,133759,2,4,,104234176,36462,Unspecified,,,,,In vivo antitumor activity was measured as the maximum dose tolerated by murine when administered intravenously,Other,,
438,133781,3,3,,104234176,36462,Unspecified,,,,,Evaluated in vivo for maximum tolerated dose (MTD/16) using MXT mouse mammary adenocarcinoma model ( ineffective),Other,12036363.0,
439,133785,3,3,,104234176,36462,Unspecified,,,,,Evaluated in vivo for maximum tolerated dose (MTD/8) using MXT mouse mammary adenocarcinoma model ( highly toxic),Other,12036363.0,
440,133786,3,3,,104234176,36462,Unspecified,,,,,Evaluated in vivo for maximum tolerated dose (MTD/2) using MXT mouse mammary adenocarcinoma model,Other,12036363.0,
441,133908,3,3,,104234176,36462,Unspecified,,,,,Evaluated in vivo for maximum tolerated dose (MTD/4) using MXT mouse mammary adenocarcinoma model,Other,12036363.0,
442,135412,3,3,,104234176,36462,Inconclusive,,,,,Number of long time survivors (mice alive/total) when administered intraperitoneally at dose 120 mg/kg; No data,Other,2738876.0,
443,136066,3,4,,104234176,36462,Unspecified,,,,,percent T / C values (total / control) against P388 murine leukemia cells at 160 mg/kg dose,Other,9804687.0,
444,137400,3,3,,104234176,36462,Unspecified,,,,,Percent median survival time (T/C) of mice when administered intraperitoneally at dose 120 mg/kg,Other,2738876.0,
445,138958,4,3,,104234176,36462,Unspecified,,,,,The compound was tested for antitumor activity against Subcutaneous Mammary Tumor MCF-7 cells. with a dosage of 10.0 mg/Kg/dose. activity is expressed as tumor free survival; 0/8,Other,10395485.0,
446,138959,4,3,,104234176,36462,Unspecified,,,,,The compound was tested for antitumor activity against Subcutaneous Mammary Tumor MCF-7 cells. with a dosage of 27.0 mg/Kg/dose. activity is expressed as tumor free survival; 0/8,Other,10395485.0,
447,138960,4,3,,104234176,36462,Unspecified,,,,,The compound was tested for antitumor activity against Subcutaneous Mammary Tumor MCF-7 cells. with a dosage of 40.0 mg/Kg/dose. activity is expressed as tumor free survival; 0/8,Other,10395485.0,
448,139581,3,5,,104234176,36462,Unspecified,,,,,The compound was tested for antitumor activity against (P388/0) Leukemia cells in mice. with a dosage of 10.0 mg/Kg/dose. activity is expressed as net log change in tumor burden.,Other,10395485.0,
449,139582,3,5,,104234176,36462,Unspecified,,,,,The compound was tested for antitumor activity against (P388/0) Leukemia cells in mice. with a dosage of 27.0 mg/Kg/dose. activity is expressed as net log change in tumor burden.,Other,10395485.0,
450,139583,3,5,,104234176,36462,Unspecified,,,,,The compound was tested for antitumor activity against (P388/0) Leukemia cells in mice. with a dosage of 40.0 mg/Kg/dose. activity is expressed as net log change in tumor burden.,Other,10395485.0,
451,140084,3,5,,104234176,36462,Unspecified,,,,,The compound was tested for antitumor activity against (P388/0) Leukemia cells in mice. with a dosage of 10.0 mg/Kg/dose. activity is expressed as median day of death.,Other,10395485.0,
452,140085,3,5,,104234176,36462,Unspecified,,,,,The compound was tested for antitumor activity against (P388/0) Leukemia cells in mice. with a dosage of 27.0 mg/Kg/dose. activity is expressed as median day of death.,Other,10395485.0,
453,140086,3,5,,104234176,36462,Unspecified,,,,,The compound was tested for antitumor activity against (P388/0) Leukemia cells in mice. with a dosage of 40.0 mg/Kg/dose,Other,10395485.0,
454,140087,3,5,,104234176,36462,Unspecified,,,,,The compound was tested for antitumor activity against Subcutaneous Mammary Tumor MCF-7 cells. with a dosage of 27.0 mg/Kg/dose. activity is expressed as days to tumor doubling.,Other,10395485.0,
455,140088,3,5,,104234176,36462,Unspecified,,,,,The compound was tested for antitumor activity against Subcutaneous Mammary Tumor MCF-7 cells. with a dosage of 40.0 mg/Kg/dose. activity is expressed as days to tumor doubling.,Other,10395485.0,
456,140232,4,3,,104234176,36462,Unspecified,,,,,The compound was tested for antitumor activity against Subcutaneous Mammary Tumor MCF-7 cells. with a dosage of 10.0 mg/Kg/dose. activity is expressed as nonspecific deaths/total; 8/8,Other,10395485.0,
457,140233,4,3,,104234176,36462,Unspecified,,,,,The compound was tested for antitumor activity against Subcutaneous Mammary Tumor MCF-7 cells. with a dosage of 27.0 mg/Kg/dose. activity is expressed as nonspecific deaths/total; 0/8,Other,10395485.0,
458,140234,4,3,,104234176,36462,Unspecified,,,,,The compound was tested for antitumor activity against Subcutaneous Mammary Tumor MCF-7 cells. with a dosage of 40.0 mg/Kg/dose. activity is expressed as nonspecific deaths/total; 2/8,Other,10395485.0,
459,143042,6,2,,104234176,36462,Active,,,0.1,IC50,Inhibitory activity against NCI-H460 cell line using MTT assay,Confirmatory,10780913.0,
460,143043,6,2,,104234176,36462,Active,,,0.1,IC50,Inhibitory activity against NCI-H460 cell line using MTT assay(Wild type p53),Confirmatory,10780913.0,
461,143360,6,2,,104234176,36462,Active,,,0.08,IC50,Inhibitory activity against NCI-H647 cell line using MTT assay(mutant p53),Confirmatory,10780913.0,
462,143363,4,5,,104234176,36462,Active,,,1.1922,IC50,In vivo antiproliferative activity against NCI-H69 cell line,Confirmatory,15084135.0,
463,144936,6,2,,104234176,36462,Active,,,0.24,IC50,Inhibitory activity against NCI-H226 cell line using MTT assay(mutant p53),Confirmatory,10780913.0,
464,145068,5,3,,104234176,36462,Active,,,8.317639999999999,GI50,Tested for the in vitro cytotoxicity against NCI-H23 non-small cell lung cancer cell line,Confirmatory,,
465,145200,6,2,,104234176,36462,Active,,,1.59,IC50,Inhibitory activity against NCI-H322 cell line using MTT assay(mutant p53),Confirmatory,10780913.0,
466,145206,6,2,,104234176,36462,Active,,,1.5,IC50,Inhibitory activity against NCI-H358 cell line using MTT assay(mutant p53),Confirmatory,10780913.0,
467,145779,5,3,,104234176,36462,Active,,,16.5959,GI50,"Tested for the in vitro cytotoxicity against OVCAR-8 ovarian cancer cell lines,",Confirmatory,,
468,150503,6,2,,104234176,36462,Active,,,0.24,IC50,Cytotoxic activity against murine lymphocytic leukemia P388 concentration of agent required to reduce cell viability by 50%,Confirmatory,10377219.0,
469,150507,6,2,,104234176,36462,Active,,,0.01,IC50,Cytotoxicity against P388 leukemia,Confirmatory,8389875.0,
470,150529,6,3,,104234176,36462,Active,,,0.3,IC50,In vitro cytotoxicity against P388 mouse leukemia cells,Confirmatory,,
471,150535,6,2,,104234176,36462,Unspecified,,,,,In vitro cytotoxicity was measured towards murine lymphocytic leukemia P388 cells,Other,15149673.0,
472,150536,6,3,,104234176,36462,Active,,,0.12,IC50,In vitro cytotoxicity was determined by quantitating P388 murine leukemia cells on a Coulter Counter following a 48 hour exposure of cells to the test compound,Confirmatory,,
473,150539,6,3,,104234176,36462,Active,,,0.3,IC50,In vitro cytotoxicity was evaluated following 1 hour transient exposure of P388 mouse leukemia cells to the compound,Confirmatory,,
474,150658,4,5,,104234176,36462,Active,,,0.0298,IC50,In vivo antiproliferative activity against P388 cell line,Confirmatory,15084135.0,
475,150670,4,5,,104234176,36462,Active,,,0.025,IC50,Inhibitory concentration to reduce cell number to 50% of Murine P388 leukemia cell culture,Confirmatory,9207945.0,
476,150690,5,2,,104234176,36462,Active,,,,,Cytotoxic activity against murine lymphocytic leukemia P388 concentration of agent required to reduce cell viability by 90%,Other,10377219.0,
477,150751,7,1,,104234176,36462,Unspecified,,,,,Inhibition of P-glycoprotein using ATPase in MDR1 membranes,Other,12699389.0,
478,150752,6,3,,104234176,36462,Unspecified,,,50.0,IC50,"Inhibition of P-glycoprotein, human L-MDR1 expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay",Confirmatory,12699389.0,
479,150753,6,3,,104234176,36462,Unspecified,,,50.0,IC50,"Inhibition of P-glycoprotein, mouse L-mdr1a expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay",Confirmatory,12699389.0,
480,150754,6,3,,104234176,36462,Unspecified,,,50.0,IC50,"Inhibition of P-glycoprotein, mouse L-mdr1b expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay",Confirmatory,12699389.0,
481,150755,6,3,,104234176,36462,Unspecified,,,50.0,IC50,Inhibition of P-glycoprotein using calcein-AM assay transfected in porcine PBCEC,Confirmatory,12699389.0,
482,150756,3,7,,104234176,36462,Unspecified,,,,,Inhibition of P-gp was determined using rhodamine-assay in human CaCo-2 cells,Other,12699389.0,
483,152257,5,1,,104234176,36462,Unspecified,,,,,Compound was tested for its antitumor activity and the cytotoxicity against P-388 lymphocytic leukemia screen,Other,3820231.0,
484,152273,4,4,,104234176,36462,Active,,,0.17,IC50,In vitro cytotoxicity against the P-388 (from DBA/2 mouse) neoplastic cell line,Confirmatory,14980682.0,
485,152358,5,2,,104234176,36462,Unspecified,,,63.0957,GI50,Tested for in vitro inhibitory activity against drug concentration causing 50% cell growth inhibition in P388/ADR cell lines; log10 GI50,Confirmatory,8182704.0,
486,153066,3,5,,104234176,36462,Unspecified,,,,,Compound was tested for % increase in life span of P388 tumor,Other,,
487,153068,2,5,,104234176,36462,Unspecified,,,,,Compound was tested for % increase in life span of adriamycin resistant P388 tumor,Other,,
488,153338,7,2,,104234176,36462,Unspecified,,,,,Cytotoxic activity against murine P388 leukemia cells,Other,15056007.0,
489,153339,4,4,,104234176,36462,Active,,,0.15,IC50,Growth inhibitory activity against murine P388 leukemia cells,Confirmatory,12620081.0,
490,153376,6,2,,104234176,36462,Unspecified,,,,,Growth inhibition of P388-D1 (murine leukemia) cell line.,Other,2002477.0,
491,153667,7,2,,104234176,36462,Unspecified,,,,,Cytotoxic activity of compound against Murine P388 Leukemia,Other,12459024.0,
492,153670,6,2,,104234176,36462,Active,,,0.3,IC50,In vitro cytotoxicity against P388 murine leukemia cells in culture in a clonogenic assay after 1 hour exposure to drug,Confirmatory,8410993.0,
493,154014,3,4,,104234176,36462,Unspecified,,,,,Increased life span at the P388 dose of 2.3 (mg/kg/day),Other,8389875.0,
494,154015,3,4,,104234176,36462,Unspecified,,,,,Increased life span at the P388 dose of 4 (mg/kg/day),Other,8389875.0,
495,154016,3,4,,104234176,36462,Unspecified,,,,,Increased life span at the P388 dose of 7 (mg/kg/day),Other,8389875.0,
496,154412,3,4,,104234176,36462,Unspecified,,,,,In vitro antitumor activity of compound against P388 leukemia cells at a dose of 12.5 mg/kg,Other,12459024.0,
497,154413,3,4,,104234176,36462,Unspecified,,,,,In vitro antitumor activity of compound against P388 leukemia cells at a dose of 3.13 mg/kg,Other,12459024.0,
498,154414,3,4,,104234176,36462,Unspecified,,,,,In vitro antitumor activity of compound against P388 leukemia cells at a dose of 50 mg/kg,Other,12459024.0,
499,154473,6,2,,104234176,36462,Unspecified,,,180.0,IC50,Inhibitory activity against PAM cell line,Confirmatory,9554873.0,
500,154474,6,2,,104234176,36462,Unspecified,,,136.0,IC50,Inhibitory activity against PAM-RAS cell line,Confirmatory,9554873.0,
501,154605,6,2,,104234176,36462,Unspecified,,,,,Cytotoxic activity against human tumor PANC-1 pancreas cells,Other,15056007.0,
502,154812,3,4,,104234176,36462,Unspecified,,,,,"Antitumor activity against P388 leukemia at dose range of 6.25-100 mg/kg on day 1, activity expressed as maximum tolerated dose",Other,15084135.0,
503,156017,5,4,,104234176,36462,Active,,,2.3,IC50,Antiproliferative activity measured against PC-3 human prostate adenocarcinoma,Confirmatory,9876111.0,
504,156479,5,1,,104234176,36462,Unspecified,,,,,Inhibition of growth of lung non-small cell carcinoma PC-7 cell line,Other,8389875.0,
505,166683,5,1,,104234176,36462,Unspecified,,,,,Inhibition of growth of lung small cell carcinoma RERF-LC-MA cell line,Other,8389875.0,
506,167236,6,2,,104234176,36462,Active,,,0.22,IC50,Growth inhibition against human RT-112 cell lines,Confirmatory,15189040.0,
507,167238,6,2,,104234176,36462,Active,,,1.33,IC50,Growth inhibition against human RT-4 cell lines,Confirmatory,15189040.0,
508,188438,3,3,,104234176,36462,Unspecified,,,,,Nuclear count minus the highest cytoplasmic count determined in rat hepatocytes for each cell,Other,7932571.0,
509,200419,5,1,,104234176,36462,Unspecified,,,,,Inhibition of growth of lung small cell carcinoma SBC-3 cell line,Other,8389875.0,
510,200422,6,2,,104234176,36462,Unspecified,,,,,Cytotoxic activity against human tumor SBC-3 lung cells,Other,15056007.0,
511,200620,6,2,,104234176,36462,Active,,,0.5,IC50,Cytotoxicity against human small-cell lung cancer (SCLC),Confirmatory,8258835.0,
512,200624,6,2,,104234176,36462,Active,,,1.3,IC50,Cytotoxicity against human SCLC cells resistant to cisplatin (SCLC/CDDP),Confirmatory,8258835.0,
513,200759,6,2,,104234176,36462,Unspecified,,,,,Cytotoxic activity of compound against SCaBER bladder squamous human tumor cell line,Other,12459024.0,
514,200760,6,2,,104234176,36462,Unspecified,,,,,Cytotoxic activity against human tumor SCaBER bladder cells,Other,15056007.0,
515,201129,5,3,,104234176,36462,Active,,,10.0,GI50,Tested for the in vitro cytotoxicity against SF-295 CNS tumor cell lines,Confirmatory,,
516,201614,6,2,,104234176,36462,Active,,,0.15,IC50,Growth inhibition against human SISO cell lines,Confirmatory,15189040.0,
517,201686,6,2,,104234176,36462,Unspecified,,,90.0,GI50,In vitro cytotoxic activity against colon (SW 620) cancer cell line.,Confirmatory,10465531.0,
518,202042,6,2,,104234176,36462,Unspecified,,,50.0,IC50,Tested for cytotoxicity against Colon adenocarcinoma resistant type SW480 cell line expressing MDR-1 (+) gene; ~50% cells affected by drug,Confirmatory,11844671.0,
519,202343,4,5,,104234176,36462,Active,,,0.275,IC50,In vivo antiproliferative activity against SK-N-MC cell line,Confirmatory,15084135.0,
520,202499,6,3,,104234176,36462,Unspecified,,,,,Cytotoxic activity against human tumor SK-OV-3 ovary cells,Other,15056007.0,
521,202652,6,3,,104234176,36462,Unspecified,,,,,Cytotoxic activity of compound against SK-OV-3 ovary human tumor cell line,Other,12459024.0,
522,202655,6,2,,104234176,36462,Active,,,0.01,GI50,In vitro cytotoxic activity against Ovarian (SK-OV3) cell line.,Confirmatory,10465531.0,
523,202679,6,2,,104234176,36462,Active,,,0.3,IC50,"Inhibitory activity against SKBR-3 cell line using MTT assay (ER-amplified erB2,mutant p53)",Confirmatory,10780913.0,
524,202842,6,2,,104234176,36462,Active,,,4.9,IC50,Antiproliferative activity against human SKOV-3 ovarian cell line,Confirmatory,10498216.0,
525,206617,5,2,,104234176,36462,Inconclusive,,,,,In vitro antibacterial activity towards Staphylococcus aureus 209 JC-1; NT = Not tested,Other,15149673.0,
526,208685,6,2,,104234176,36462,Active,,,0.16,IC50,"Inhibitory activity against T47D cell line using MTT assay (ER+,mutant p53)",Confirmatory,10780913.0,
527,209032,6,2,,104234176,36462,Active,,,0.09,IC50,Compound was tested for growth inhibition against human h-TERTRPE1 cell lines,Confirmatory,15189040.0,
528,210155,8,2,,104234176,36462,Unspecified,,,59.2,IC50,Inhibition of DNA topoisomerase II from rat liver measured as 50% reduction in the amount of minicircle DNA relative to the control,Confirmatory,8389875.0,
529,210945,8,2,,104234176,36462,Unspecified,,,,,Inhibition of topoisomerase I,Other,8246238.0,
530,211122,5,3,,104234176,36462,Unspecified,,,,,Effect of dose dependent inhibition of TOPO II-catalyzed kDNA decatenation in vitro,Other,7525959.0,
531,211127,8,2,,104234176,36462,Active,,,,,Inhibition of topoisomerase II,Other,8246238.0,
532,211128,3,7,,104234176,36462,Unspecified,,,,,Relative potency to cause 90% of topoisomerase II-mediated cleavage of liner 8.4-kb YEPG DNA,Other,7932571.0,
533,211285,5,4,,104234176,36462,Unspecified,,,,,Inhibition of commercially obtained pure Drosophila Topoisomerase II in catalytic DNA unwinding.,Other,7473578.0,
534,211290,9,2,,104234176,36462,Active,,,0.81,EC50,Compound was tested for topoisomerase II inhibition in purified HeLa cells by SDS/K+ precipitation method,Confirmatory,,
535,211291,9,3,,104234176,36462,Active,,,0.81,EC50,Inhibitory activity against HeLa cell Topoisomerase II,Confirmatory,,
536,211292,9,1,,104234176,36462,Active,,,0.81,EC50,Tested for inhibition of topoisomerase II isolated from HeLa cells by DNA-cleavage assay,Confirmatory,8410993.0,
537,211293,9,2,,104234176,36462,Active,,,0.81,EC50,Tested for inhibitory activity against Topoisomerase II isolated from HeLa cells by using SDS-K+ precipitation method,Confirmatory,,
538,211299,8,1,,104234176,36462,Unspecified,,,50.0,ID50,Inhibition of human DNA topoisomerase II,Confirmatory,8120864.0,
539,211300,8,1,,104234176,36462,Unspecified,,,50.0,ID50,Inhibition of human DNA topoisomerase II activity,Confirmatory,8295216.0,
540,211306,9,2,,104234176,36462,Active,,,38.0,IC50,In vitro activity against mammalian topoisomerase II measured as ATP-dependent unknotting of P4 DNA compared to enzyme and DNA control,Confirmatory,9599244.0,
541,211316,3,4,,104234176,36462,Unspecified,,,,,Stimulation of in vitro Topoisomerase II-Linked DNA Complex Formation and Interference with Etoposide-Induced Cleavage at concentration 100 uM,Other,8691469.0,
542,211318,3,4,,104234176,36462,Unspecified,,,,,Stimulation of in vitro Topoisomerase II-Linked DNA Complex Formation and Interference with Etoposide-Induced Cleavage at concentration 1 uM,Other,8691469.0,
543,211320,3,4,,104234176,36462,Unspecified,,,,,Stimulation of in vitro Topoisomerase II-Linked DNA Complex Formation and Interference with Etoposide-Induced Cleavage at concentration 50 uM,Other,8691469.0,
544,211458,3,6,,104234176,36462,Unspecified,,,,,Compound tested for ability to form a cellular covalent topoisomerase II-DNA complex.,Other,8691468.0,
545,214003,9,5,,104234176,36462,Unspecified,75053726.0,,60.0,IC50,Drug concentration needed to produce a 50% reduction of bovine brain tubulin polymerization relative to the control,Confirmatory,8389875.0,
546,214003,9,5,,104234176,36462,Unspecified,75053735.0,,60.0,IC50,Drug concentration needed to produce a 50% reduction of bovine brain tubulin polymerization relative to the control,Confirmatory,8389875.0,
547,214003,9,5,,104234176,36462,Unspecified,118573906.0,281555.0,60.0,IC50,Drug concentration needed to produce a 50% reduction of bovine brain tubulin polymerization relative to the control,Confirmatory,8389875.0,
548,214504,8,2,,104234176,36462,Inconclusive,,,,,in vitro inhibitory activity against tubulin polymerization; Not tested,Other,9804687.0,
549,214549,8,4,,104234176,36462,Inactive,,,,,In vitro inhibition of mammalian tubulin polymerization by 50%; Inactive,Other,9599244.0,
550,216262,4,5,,104234176,36462,Active,,,2.1333,IC50,Inhibitory concentration required for cytotoxicity in hydroxyrubicin-resistant (WP159/R) cells,Confirmatory,,
551,216583,6,2,,104234176,36462,Unspecified,,,,,Cytotoxic activity against human WiDr colon tumor cell line,Other,15149673.0,
552,217165,6,2,,104234176,36462,Active,,,15.5,IC50,Tested for cytotoxicity against T-lymphoblastoide VC resistant type VCR 100 cell line expressing MDR-1 (+) gene,Confirmatory,11844671.0,
553,219914,6,2,,104234176,36462,Active,,,0.14,IC50,Cytotoxicity against CHO cell line xrs6,Confirmatory,7473578.0,
554,220076,6,2,,104234176,36462,Active,,,1.32,IC50,Compound was tested for growth inhibition against human YAPC cell lines,Confirmatory,15189040.0,
555,220406,6,2,,104234176,36462,Active,,,0.24,IC50,"Inhibitory activity against ZR-75-1 cell line using MTT assay (ER+,pgr+,mutant p53)",Confirmatory,10780913.0,
556,221176,3,4,,104234176,36462,Unspecified,,,,,Percentage inhibition of tumor growth at the lewis lung dose of 12 (mg/kg/ day); (p<0.01),Other,8389875.0,
557,221180,3,4,,104234176,36462,Unspecified,,,,,Percentage inhibition of tumor growth at the lewis lung dose of 7 (mg/kg/day); (p<0.05),Other,8389875.0,
558,221633,3,3,,104234176,36462,Unspecified,,,,,Cellular protein-DNA complex formation at 10 uM.,Other,2158562.0,
559,227090,3,3,,104234176,36462,Unspecified,,,,,Ratio of inhibitory concentration of Human Jurkat leukemia A (JLA) and Human Jurkat leukemia C (JLC),Other,9207945.0,
560,227091,3,3,,104234176,36462,Unspecified,,,,,Ratio of inhibitory concentration of Human Jurkat leukemia D (JLD) and Human Jurkat leukemia C (JLC),Other,9207945.0,
561,227366,3,4,,104234176,36462,Unspecified,,,,,DNA intercalating activity was determined; Each (+) indicates 1 to 2 -fold increase,Other,,
562,227573,3,3,,104234176,36462,Unspecified,,,,,Relative resistance is the ratio of IC50 values of drug with JTV-519 to that without the reversing agent,Other,15012986.0,
563,227752,5,2,,104234176,36462,Inconclusive,,,,,Concentration required to reduce ethidium bromide fluorescence to 50% of control in presence of calf thymus DNA; Not determined,Other,7525959.0,
564,228429,9,3,,104234176,36462,Active,,,0.81,EC50,Inhibitory activity in a cell-free assay of DNA cleavage mediated by purified HeLa cell topoisomerase II.,Confirmatory,,
565,229286,3,4,,104234176,36462,Unspecified,,,,,Ratio of IC50 of HCT-VP35 to IC50 of HCT116.,Other,,
566,230161,6,1,,104234176,36462,Unspecified,,,,,The differential toxicity ratio was defined as IC50(KB/7d)/IC50(KB),Other,8691469.0,
567,231477,3,4,,104234176,36462,Unspecified,,,,,Ratio between IC50 value of DOX/R and WP159/R was determined,Other,,
568,231951,3,3,,104234176,36462,Unspecified,,,,,Ratio of cytotoxicity of compound towards bone marrow sample and to that of HL-60 was determined as IC50BM/IC50HL,Other,10377219.0,
569,231952,3,3,,104234176,36462,Unspecified,,,,,Ratio of cytotoxicity of compound towards bone marrow sample and to that of HL-60 was determined as IC50BM/IC90HL,Other,10377219.0,
570,231953,3,3,,104234176,36462,Unspecified,,,,,Ratio of cytotoxicity of compound towards bone marrow sample and to that of HL-60 was determined as IC90BM/IC90HL,Other,10377219.0,
571,232174,3,4,,104234176,36462,Unspecified,,,,,Ratio of growth inhibitory activity against human Jurkat leukemia cell line (JLA- resistant to amsacrine) to that of Jurkat leukemia cell line,Other,12620081.0,
572,232175,3,4,,104234176,36462,Unspecified,,,,,Ratio of growth inhibitory activity against human Jurkat leukemia cell line (JLD- resistant to doxorubicin) to that of Jurkat leukemia cell line,Other,12620081.0,
573,232294,3,3,,104234176,36462,Unspecified,,,,,Differential cytotoxicity was determined from the ratio between BR1(IC50) and xrs-6 (IC50),Other,7525959.0,
574,232336,3,3,,104234176,36462,Unspecified,,,,,Ratio of BR1 IC50 to xrs-6 IC50,Other,7473578.0,
575,232420,3,4,,104234176,36462,Unspecified,,,,,Ratio of inhibition of HCT116 to that of inhibition of HCT/VP 35 cells,Other,,
576,233327,5,3,,104234176,36462,Active,,,9.77237,GI50,"Average in vitro cytotoxicity was calculated from all cell lines tested,",Confirmatory,,
577,233331,5,3,,104234176,36462,Unspecified,,,524.807,LC50,Average in vitro cytotoxicity was calculated from all cell lines tested,Confirmatory,,
578,233340,5,3,,104234176,36462,Unspecified,,,77.6247,TGI,"Average in vitro cytotoxicity was calculated from all cell lines tested, activity expressed as average log TGI50.",Confirmatory,,
579,234593,4,4,,104234176,36462,Unspecified,,,,,Median survival time of treated animals/median survival time of control animals,Other,15084135.0,
580,234594,3,3,,104234176,36462,Unspecified,,,,,Median survival time of treated animals/median survival time of control animals; ranges from 122-131,Other,15084135.0,
581,235455,3,3,,104234176,36462,Unspecified,,,,,Selectivity index (ED50/ID50) value of the compound,Other,11311065.0,
582,240778,9,5,,104234176,36462,Unspecified,13959709.0,7153.0,50.4,IC50,Inhibitory concentration against human DNA topoisomerase II,Confirmatory,15914002.0,
583,240778,9,5,,104234176,36462,Unspecified,20141946.0,7155.0,50.4,IC50,Inhibitory concentration against human DNA topoisomerase II,Confirmatory,15914002.0,
584,243343,3,10,,104234176,36462,Unspecified,13959709.0,7153.0,,,Percentage of protein-linked DNA breaks in KB cells by [3H]thymidine incorporation,Other,15456257.0,
585,243343,3,10,,104234176,36462,Unspecified,20141946.0,7155.0,,,Percentage of protein-linked DNA breaks in KB cells by [3H]thymidine incorporation,Other,15456257.0,
586,243353,3,10,,104234176,36462,Unspecified,13959709.0,7153.0,,,Percentage of protein-linked DNA breaks in KB cells by [3H]thymidine incorporation at 5 ug/mL,Other,15456257.0,
587,243353,3,10,,104234176,36462,Unspecified,20141946.0,7155.0,,,Percentage of protein-linked DNA breaks in KB cells by [3H]thymidine incorporation at 5 ug/mL,Other,15456257.0,
588,243422,3,10,,104234176,36462,Unspecified,116241312.0,1576.0,,,log (1/Km) value for human liver microsome cytochrome P450 3A4,Other,15990295.0,
589,243964,4,9,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of human DNA topoisomerase II alpha as percent linear DNA after treatment with 20 ug/mL,Other,15658872.0,
590,245714,4,4,,104234176,36462,Unspecified,,,,,Maximum tolerated dose value on day 1 against mouse P388 leukemia cells,Other,15658872.0,
591,245716,4,4,,104234176,36462,Unspecified,,,,,"Maximum tolerated dose after treatment on days 14, 21, and 28 against mouse A549 non-small-cell lung carcinoma",Other,15658872.0,
592,245765,4,3,,104234176,36462,Unspecified,,,,,Percent median survival time to that of control in mice on day 1,Other,15658872.0,
593,245766,4,3,,104234176,36462,Unspecified,,,,,"Percent median survival time to that of control in mice on days 14,21 and 28",Other,15658872.0,
594,246834,8,1,,104234176,36462,Active,,,3.39,ED50,Effective dose on human lung carcinoma (A549) cells,Confirmatory,15914002.0,
595,246861,8,1,,104234176,36462,Active,,,10.6,ED50,Dose required for reduction in human lung A549 cancer cells after 3 days incubation,Confirmatory,15456257.0,
596,246868,8,1,,104234176,36462,Unspecified,,,62.2,ED50,Dose required for reduction in human breast MCF-7 cancer cells after 3 day incubation,Confirmatory,15456257.0,
597,246872,8,1,,104234176,36462,Unspecified,,,100.0,ED50,Dose required for reduction in human renal CAKI-1 cancer cells after 3 days incubation,Confirmatory,15456257.0,
598,246873,8,1,,104234176,36462,Unspecified,,,100.0,ED50,Dose required for reduction in human prostate PC-3 cancer cells after 3 days incubation,Confirmatory,15456257.0,
599,246876,8,1,,104234176,36462,Unspecified,,,62.9,ED50,Dose required for reduction in human ileocecal HCT-8 cancer cells after 3 day incubation,Confirmatory,15456257.0,
600,246879,8,1,,104234176,36462,Active,,,0.15,ED50,Dose required to cause reduction in human ovarian 1A9 cancer cells after 3 days incubation,Confirmatory,15456257.0,
601,246895,8,1,,104234176,36462,Unspecified,,,73.6,ED50,Dose required for reduction in human glioblastoma U-87-MG cancer cells after 3 days incubation,Confirmatory,15456257.0,
602,246904,10,1,,104234176,36462,Unspecified,,,,ED50,Dose required to cause reduction in human nasopharyngeal KB cancer cells after 3 days incubation,Confirmatory,15456257.0,
603,246921,5,1,,104234176,36462,Unspecified,,,,,Dose required to cause reduction in human nasopharyngeal KB-7d cancer cells after 3 days incubation,Other,15456257.0,
604,246980,8,1,,104234176,36462,Unspecified,,,5.0,ED50,Dose required for reduction in paclitaxel resistant human ovarian 1A9-PTX10 cancer cells after 3 days incubation,Confirmatory,15456257.0,
605,246990,8,1,,104234176,36462,Active,,,7.0,ED50,Dose required for reduction in camptothecin resistant human nasopharyngeal KB cancer cells after 3 days incubation,Confirmatory,15456257.0,
606,246991,8,1,,104234176,36462,Active,,,17.2,ED50,Dose required for reduction in etoposide resistant human nasopharyngeal KB-7d cancer cells after 3 days incubation,Confirmatory,15456257.0,
607,247002,8,1,,104234176,36462,Unspecified,,,100.0,ED50,Dose required for reduction in vincristine resistant human nasopharyngeal KB-VIN cancer cells after 3 days incubation,Confirmatory,15456257.0,
608,247816,6,2,,104234176,36462,Active,,,0.83,IC50,Inhibition of L1210 cell proliferation in cytotoxic assay,Confirmatory,15658872.0,
609,248698,6,2,,104234176,36462,Active,,,1.06,IC50,Concentration required for inhibiting proliferation of human lung tumor cell line A549 after 72 hr of incubation was determined,Confirmatory,15482917.0,
610,248748,6,2,,104234176,36462,Active,,,1.45,IC50,Concentration required for inhibiting proliferation of human colon tumor cell line HCT-15 after 72 hr of incubation was determined,Confirmatory,15482917.0,
611,248782,6,2,,104234176,36462,Active,,,3.46,IC50,Concentration required for inhibiting proliferation of human ovarian tumor cell line SK-OV-3 after 72 hr of incubation was determined,Confirmatory,15482917.0,
612,248816,6,2,,104234176,36462,Active,,,3.14,IC50,Concentration required for inhibiting proliferation of human brain tumor cell line XF 498 by 50% after 72 hr of incubation was determined,Confirmatory,15482917.0,
613,248851,6,2,,104234176,36462,Active,,,4.13,IC50,Concentration required for inhibiting proliferation of human melanoma tumor cell line SK-MEL-2 by 50% after 72 hr of incubation was determined,Confirmatory,15482917.0,
614,250691,3,5,,104234176,36462,Unspecified,,,,,Percentage of L1210 cells in the G2M phase after treatment with compound at 2.5 uM concentration expressed as cell cycle effect,Other,15658872.0,
615,253085,3,4,,104234176,36462,Unspecified,,,,,Ratio of ED50 for KB-7d cells to that of KB cells,Other,15456257.0,
616,264545,9,1,,104234176,36462,Inconclusive,12644118.0,7150.0,,,Inhibition of topoisomerase 1 DNA cleavage activity,Other,16686539.0,
617,264546,9,1,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of topoisomerase 2 DNA cleavage activity,Other,16686539.0,
618,264546,9,1,,104234176,36462,Unspecified,20141946.0,7155.0,,,Inhibition of topoisomerase 2 DNA cleavage activity,Other,16686539.0,
619,264547,8,1,,104234176,36462,Active,,,4.5,IC50,Antiproliferative activity against human HCT15 cell line,Confirmatory,16686539.0,
620,264548,8,1,,104234176,36462,Active,,,6.6,IC50,Antiproliferative activity against human HT29 cell line,Confirmatory,16686539.0,
621,264549,8,1,,104234176,36462,Active,,,7.8,IC50,Antiproliferative activity against human PC3 cell line,Confirmatory,16686539.0,
622,264550,8,1,,104234176,36462,Active,,,0.2,IC50,Antiproliferative activity against mouse CT26 cell line,Confirmatory,16686539.0,
623,264551,8,1,,104234176,36462,Active,,,2.9,IC50,Antiproliferative activity against mouse Renca cell line,Confirmatory,16686539.0,
624,266313,3,9,,104234176,36462,Active,13959709.0,7153.0,,,Induction of topoisomerase 2 alpha-mediated DNA cleavage at 100 uM,Other,16759114.0,
625,277217,6,2,,104234176,36462,Active,,,0.3,IC50,Cytotoxicity against human HL60 cell line by MTT assay,Confirmatory,17243725.0,
626,277218,6,2,,104234176,36462,Active,,,0.1,IC50,Cytotoxicity against human KATO3 cell line by MTT assay,Confirmatory,17243725.0,
627,277219,6,2,,104234176,36462,Active,,,20.9,IC50,Cytotoxicity against human A549 cell line by MTT assay,Confirmatory,17243725.0,
628,283901,3,3,,104234176,36462,Unspecified,,,,,Inhibition of human recombinant topoisomerase 2-mediated KDNA decatenation activity at 200 uM relative to control,Other,17035025.0,
629,283902,6,2,,104234176,36462,Unspecified,,,78.4,IC50,Inhibition of human recombinant topoisomerase 2-mediated KDNA decatenation activity,Confirmatory,17035025.0,
630,286402,6,2,,104234176,36462,Active,,,0.32,IC50,Growth inhibition of K562 cells by XTT assay after 5 days,Confirmatory,17411092.0,
631,286412,3,10,,104234176,36462,Unspecified,13959709.0,7153.0,,,Induction of human recombinant topoisomerase 2-DNA complexes in K562 cells assessed as integrated green fluorescence at 10 uM after 2 hrs by TARDIS assay,Other,17411092.0,
632,286437,3,10,,104234176,36462,Unspecified,20141946.0,7155.0,,,Induction of human recombinant topoisomerase 2beta-DNA complex in K562 cells assessed as integrated fluorescence at 10 uM after 2 hrs by TARDIS assay,Other,17411092.0,
633,286441,3,10,,104234176,36462,Unspecified,13959709.0,7153.0,,,Induction of human recombinant topoisomerase 2-DNA complexes in K562 cells assessed as integrated green fluorescence at 10 times their IC50 after 2 hrs by TARDIS assay,Other,17411092.0,
634,286442,3,10,,104234176,36462,Unspecified,13959709.0,7153.0,,,Induction of human recombinant topoisomerase 2-DNA complexes in K562 cells assessed as integrated green fluorescence at 10 times their IC50 after 8 hrs by TARDIS assay,Other,17411092.0,
635,286443,3,10,,104234176,36462,Unspecified,13959709.0,7153.0,,,Induction of human recombinant topoisomerase 2-DNA complexes in K562 cells assessed as integrated green fluorescence at 10 times their IC50 after 24 hrs by TARDIS assay,Other,17411092.0,
636,288637,6,2,,104234176,36462,Active,,,0.32,IC50,Cytotoxicity against human A549 cells after 48 hrs by SRB method,Confirmatory,17493824.0,
637,288638,6,2,,104234176,36462,Active,,,1.72,IC50,Cytotoxicity against human SKOV3 cells after 48 hrs by SRB method,Confirmatory,17493824.0,
638,288639,6,2,,104234176,36462,Active,,,0.3,IC50,Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB method,Confirmatory,17493824.0,
639,288640,6,2,,104234176,36462,Active,,,2.43,IC50,Cytotoxicity against human HCT15 cells after 48 hrs by SRB method,Confirmatory,17493824.0,
640,288682,3,4,,104234176,36462,Active,,,,,Induction of apoptosis in HeLa cells assessed as PARP1 ceavage at 100 uM,Other,17497841.0,
641,291927,6,2,,104234176,36462,Active,,,1.4,IC50,Cytotoxicity against human A549 cells by SRB microtiter plate assay,Confirmatory,17585747.0,
642,291928,6,2,,104234176,36462,Active,,,4.8,IC50,Cytotoxicity against human KB cells by SRB microtiter plate assay,Confirmatory,17585747.0,
643,291929,6,2,,104234176,36462,Active,,,2.4,IC50,Cytotoxicity against human DU145 cells by SRB microtiter plate assay,Confirmatory,17585747.0,
644,291930,6,3,,104234176,36462,Active,,,3.1,IC50,Cytotoxicity against human ZR751cells by SRB microtiter plate assay,Confirmatory,17585747.0,
645,291931,6,3,,104234176,36462,Unspecified,,,10.0,IC50,Cytotoxicity against multidrug resistant human KB-Vin cells by SRB microtiter plate assay,Confirmatory,17585747.0,
646,293470,6,2,,104234176,36462,Active,,,1.16,IC50,Cytotoxicity against human A549 cells by SRB assay,Confirmatory,17194596.0,
647,293471,6,3,,104234176,36462,Active,,,0.23,IC50,Cytotoxicity against human SNU638 cells by SRB assay,Confirmatory,17194596.0,
648,293472,6,2,,104234176,36462,Active,,,1.87,IC50,Cytotoxicity against human HCT116 cells by SRB assay,Confirmatory,17194596.0,
649,293473,6,2,,104234176,36462,Active,,,0.25,IC50,Cytotoxicity against human HT1080 cells by SRB assay,Confirmatory,17194596.0,
650,293474,6,2,,104234176,36462,Active,,,0.37,IC50,Cytotoxicity against human HL60 cells by SRB assay,Confirmatory,17194596.0,
651,293475,6,2,,104234176,36462,Active,,,4.28,IC50,Cytotoxicity against human SK-OV-3 cells by SRB assay,Confirmatory,17194596.0,
652,293476,6,2,,104234176,36462,Active,,,5.72,IC50,Cytotoxicity against human SK-MEL-2 cells by SRB assay,Confirmatory,17194596.0,
653,293477,6,2,,104234176,36462,Active,,,3.48,IC50,Cytotoxicity against human XF498 cells by SRB assay,Confirmatory,17194596.0,
654,293478,3,3,,104234176,36462,Unspecified,,,,,Inhibition of human topoisomerase 2-mediated KDNA decatenation activity at 200 uM after 10 mins relative to control,Other,17194596.0,
655,293482,6,2,,104234176,36462,Unspecified,,,78.4,IC50,Inhibition of human topoisomerase 2 at 5 uM,Confirmatory,17194596.0,
656,294461,6,2,,104234176,36462,Active,,,3.2,IC50,Cytotoxic activity against human MCF7 cells after 48 hrs by MTT reduction assay,Confirmatory,17316916.0,
657,296516,6,2,,104234176,36462,Active,,,0.2,IC50,Growth inhibition of human H460 cells by MTT assay,Confirmatory,17482821.0,
658,296517,6,2,,104234176,36462,Active,,,2.9,IC50,Growth inhibition of human HeLa cells by MTT assay,Confirmatory,17482821.0,
659,296518,6,2,,104234176,36462,Active,,,15.4,IC50,Growth inhibition of human MiaPaCa2 cells by MTT assay,Confirmatory,17482821.0,
660,296519,6,2,,104234176,36462,Active,,,20.0,IC50,Growth inhibition of human SW620 cells by MTT assay,Confirmatory,17482821.0,
661,296520,6,2,,104234176,36462,Unspecified,,,50.0,IC50,Growth inhibition of human MCF7 cells by MTT assay,Confirmatory,17482821.0,
662,296521,6,2,,104234176,36462,Inconclusive,,,,IC50,Growth inhibition of human WI38 cells by MTT assay,Confirmatory,17482821.0,
663,297862,3,3,,104234176,36462,Active,,,,,Inhibition of human recombinant topoisomerase 2,Other,17705462.0,
664,298655,3,4,,104234176,36462,Unspecified,,,,,Antiproliferative activity against HeLa cells assessed as cell viability at 5 uM after 48 hrs by MTT assay relative to control,Other,17894480.0,
665,298656,3,4,,104234176,36462,Unspecified,,,,,Antiproliferative activity against human MCF7/AZ cells assessed as cell viability at 5 uM after 48 hrs by MTT assay relative to control,Other,17894480.0,
666,298657,3,4,,104234176,36462,Unspecified,,,,,Antiproliferative activity against human Jurkat cells assessed as cell viability at 5 uM after 48 hrs by MTT assay,Other,17894480.0,
667,298658,3,4,,104234176,36462,Unspecified,,,,,Induction of apoptosis in Jurkat cells assessed as cell viability at 5 uM after 48 hrs by flow cytometry Annexin-V/propidium iodide assay,Other,17894480.0,
668,298659,6,2,,104234176,36462,Active,,,8.0,GI50,Growth inhibition of HeLa cells after 48 hrs by MTT assay,Confirmatory,17894480.0,
669,298661,3,4,,104234176,36462,Unspecified,,,,,Antiproliferative activity against HeLa cells assessed as cell viability at 50 uM after 48 hrs by MTT assay,Other,17894480.0,
670,298662,3,4,,104234176,36462,Unspecified,,,,,Antiproliferative activity against human MCF7/AZ cells assessed as cell viability at 50 uM after 48 hrs by MTT assay,Other,17894480.0,
671,298663,3,4,,104234176,36462,Unspecified,,,,,Antiproliferative activity against human Jurkat cells assessed as cell viability at 50 uM after 48 hrs by MTT assay,Other,17894480.0,
672,298664,3,4,,104234176,36462,Unspecified,,,,,Induction of apoptosis in Jurkat cells assessed as cell viability at 50 uM after 48 hrs by flow cytometry Annexin-V/propidium iodide assay,Other,17894480.0,
673,298670,3,4,,104234176,36462,Inactive,,,,,Effect on apoptosis in Jurkat cells assessed as DNA laddering after 24 hrs at 1 uM,Other,17894480.0,
674,298672,3,4,,104234176,36462,Inactive,,,,,Induction of apoptosis in human whole blood lymphocytes after 24 hrs by flow cytometric Annexin-V/propidium iodide assay,Other,17894480.0,
675,298673,3,4,,104234176,36462,Active,,,,,Induction of apoptosis in Jurkat cells after 24 hrs by flow cytometric Annexin-V/propidium iodide assay,Other,17894480.0,
676,302080,4,3,,104234176,36462,Active,,,0.315,IC50,Inhibition of cell growth in human HL20 cells after 48 hrs by MTT assay,Confirmatory,17889547.0,
677,302865,6,3,,104234176,36462,Inconclusive,,,,IC50,Antitumor activity against human Hep2 cells after 72 hrs by MTT assay,Confirmatory,17935309.0,
678,302866,6,2,,104234176,36462,Active,,,3.0,IC50,Antitumor activity against human HeLa cells after 72 hrs by MTT assay,Confirmatory,17935309.0,
679,302867,6,2,,104234176,36462,Active,,,15.0,IC50,Antitumor activity against human MiaPaCa2 cells after 72 hrs by MTT assay,Confirmatory,17935309.0,
680,302868,6,2,,104234176,36462,Active,,,20.0,IC50,Antitumor activity against human SW620 cells after 72 hrs by MTT assay,Confirmatory,17935309.0,
681,302869,6,2,,104234176,36462,Unspecified,,,50.0,IC50,Antitumor activity against human MCF7 cells after 72 hrs by MTT assay,Confirmatory,17935309.0,
682,302870,6,2,,104234176,36462,Inconclusive,,,,IC50,Antiproliferative activity against human WI39 fibroblast after 72 hrs by MTT assay,Confirmatory,17935309.0,
683,305850,3,4,,104234176,36462,Unspecified,,,,,Cytotoxicity against human HeLa cells assessed as viability at 5 uM after 48 hrs by MTT method relative to control,Other,17188868.0,
684,305851,3,4,,104234176,36462,Unspecified,,,,,Cytotoxicity against human MCF7AZ cells assessed as viability at 5 uM after 48 hrs by MTT method relative to control,Other,17188868.0,
685,305852,3,4,,104234176,36462,Unspecified,,,,,Cytotoxicity against human Jurkat cells assessed as viability at 5 uM after 48 hrs by MTT method relative to control,Other,17188868.0,
686,305853,3,4,,104234176,36462,Unspecified,,,,,Cytotoxicity against human MCF7AZ cells assessed as viability at 50 uM after 48 hrs by MTT method relative to control,Other,17188868.0,
687,305855,3,4,,104234176,36462,Unspecified,,,,,Induction of apoptosis in human Jurkat cells at 50 uM by flow cytometric annexin-V/propidium iodide assay,Other,17188868.0,
688,305857,3,4,,104234176,36462,Unspecified,,,,,Induction of apoptosis in human Jurkat cells at 50 uM after 48 hrs by flow cytometric annexin-V/propidium iodide assay,Other,17188868.0,
689,307098,6,2,,104234176,36462,Active,,,1.7,IC50,Cytotoxicity against human HCT116 cells by XTT assay,Confirmatory,17368022.0,
690,307099,6,2,,104234176,36462,Active,,,35.6,IC50,Cytotoxicity against human MCF7 cells by XTT assay,Confirmatory,17368022.0,
691,307100,6,3,,104234176,36462,Active,,,13.6,IC50,Cytotoxicity against human MDA-MB468 cells by XTT assay,Confirmatory,17368022.0,
692,307362,3,4,,104234176,36462,Unspecified,,,,,Anticancer activity against human A549 cells at 1 nM after 12 hrs,Other,17428660.0,
693,307552,6,2,,104234176,36462,Active,,,3.1,IC50,Cytotoxicity against human K562 cells after 72 hrs by MTT assay,Confirmatory,17459529.0,
694,307553,6,3,,104234176,36462,Active,,,0.9,IC50,Cytotoxicity against human BV173 cells after 72 hrs by MTT assay,Confirmatory,17459529.0,
695,307555,3,4,,104234176,36462,Active,,,,,Induction of apoptosis in BV173 cells assessed as DNA fragmentation at 0.25 uM after 24hrs,Other,17459529.0,
696,311105,6,2,,104234176,36462,Unspecified,,,,,Cytotoxicity against human A549 cells after 2 days,Other,17629328.0,
697,311106,6,2,,104234176,36462,Unspecified,,,,,Cytotoxicity against human MCF7 cells after 2 days,Other,17629328.0,
698,311248,6,2,,104234176,36462,Unspecified,,,,,Cytotoxicity against human A549 cells,Other,17672504.0,
699,311249,6,2,,104234176,36462,Unspecified,,,,,Cytotoxicity against human MCF7 cells,Other,17672504.0,
700,312292,6,2,,104234176,36462,Active,,,0.32,IC50,Cytotoxicity against human K562 cells after 5 days by XTT assay,Confirmatory,18076140.0,
701,314052,5,3,,104234176,36462,Inconclusive,,,,,Inhibition of calf thymus topoisomerase 1 assessed as relaxation of supercoiled DNA pBR322 at 2 uM relative to etoposide,Other,18178085.0,
702,314053,5,3,,104234176,36462,Inconclusive,,,,,Inhibition of calf thymus topoisomerase 1 assessed as relaxation of supercoiled DNA pBR322 at 20 uM relative to etoposide,Other,18178085.0,
703,314054,5,8,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of human topoisomerase 2alpha assessed as relaxation of supercoiled DNA pBR322 at 2 uM relative to etoposide,Other,18178085.0,
704,314055,5,8,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of human topoisomerase 2alpha assessed as relaxation of supercoiled DNA pBR322 at 10 uM relative to etoposide,Other,18178085.0,
705,314056,6,2,,104234176,36462,Active,,,29.79,IC50,Cytotoxicity against human DU145 cells,Confirmatory,18178085.0,
706,314057,6,2,,104234176,36462,Active,,,15.11,IC50,Cytotoxicity against human HCT116 cells,Confirmatory,18178085.0,
707,314058,6,2,,104234176,36462,Active,,,18.24,IC50,Cytotoxicity against human HeLa cells,Confirmatory,18178085.0,
708,314059,6,3,,104234176,36462,Active,,,16.25,IC50,Cytotoxicity against human MDA-MB-231 cells,Confirmatory,18178085.0,
709,314060,6,2,,104234176,36462,Active,,,1.44,IC50,Cytotoxicity against human HL60 cells,Confirmatory,18178085.0,
710,318911,6,2,,104234176,36462,Active,,,3.9,IC50,Cytotoxicity against human MRC5 cells after 72 hrs by MTT assay,Confirmatory,18299197.0,
711,318912,6,2,,104234176,36462,Active,,,0.36,IC50,Antitumor against human AGS cells after 72 hrs by MTT assay,Confirmatory,18299197.0,
712,318913,6,3,,104234176,36462,Active,,,2.5,IC50,Antitumor against human SK-MES1 cells after 72 hrs by MTT assay,Confirmatory,18299197.0,
713,318914,6,2,,104234176,36462,Active,,,2.8,IC50,Antitumor against human J82 cells after 72 hrs by MTT assay,Confirmatory,18299197.0,
714,318915,6,2,,104234176,36462,Active,,,0.8,IC50,Antitumor against human HL60 cells after 72 hrs by MTT assay,Confirmatory,18299197.0,
715,320437,5,3,,104234176,36462,Active,,,0.14,GI50,Cytotoxicity against human HL60 cells after 48 hrs by MTT assay,Confirmatory,17962028.0,
716,320438,5,3,,104234176,36462,Active,,,5.98,GI50,Cytotoxicity against DNA topoisomerase-2 deficient human HL60/MX2 cells by MTT assay,Confirmatory,17962028.0,
717,320439,3,3,,104234176,36462,Unspecified,,,,,Ratio of GI50 for human HL60/MX2 cells to GI50 for human HL60 cells,Other,17962028.0,
718,324407,3,4,,104234176,36462,Unspecified,,,,,Induction of light chain 3-GFP level in human H4 cells at 4.3 uM after 24 hrs by high throughput fluorescence microscopy relative to control,Other,18024584.0,
719,324459,3,4,,104234176,36462,Unspecified,,,,,Increase in light chain 3-GFP+ autophagosome vesicle number per cell in human H4 cells at 4.3 uM after 24 hrs by high throughput fluorescence microscopy relative to control,Other,18024584.0,
720,324511,3,4,,104234176,36462,Unspecified,,,,,Increase in light chain 3-GFP+ autophagosome vesicle area per cell in human H4 cells at 4.3 uM after 24 hrs by high throughput fluorescence microscopy relative to control,Other,18024584.0,
721,324563,3,4,,104234176,36462,Unspecified,,,,,Increase in light chain 3-GFP+ autophagosome vesicle intensity per cell in human H4 cells at 4.3 uM after 24 hrs by high throughput fluorescence microscopy relative to control,Other,18024584.0,
722,326626,6,2,,104234176,36462,Active,,,35.6,IC50,Cytotoxicity against human MCF7 cells by XTT assay,Confirmatory,18093835.0,
723,327214,6,3,,104234176,36462,Active,,,8.7,GI50,Cytotoxicity against human H520 cells after 72 hrs by Cell Titer 96 Aqueous Non-Radioactive assay,Confirmatory,18321710.0,
724,327215,6,2,,104234176,36462,Unspecified,,,55.6,GI50,Cytotoxicity against human MCF7 cells after 72 hrs by Cell Titer 96 Aqueous Non-Radioactive assay,Confirmatory,18321710.0,
725,327216,6,2,,104234176,36462,Active,,,11.1,GI50,Cytotoxicity against human PC3 cells after 72 hrs by Cell Titer 96 Aqueous Non-Radioactive assay,Confirmatory,18321710.0,
726,327574,6,2,,104234176,36462,Active,,,1.16,IC50,Cytotoxicity against human A549 cells after 3 days by SRB assay,Confirmatory,18321715.0,
727,327575,6,2,,104234176,36462,Active,,,4.28,IC50,Cytotoxicity against human SKOV3 cells after 3 days by SRB assay,Confirmatory,18321715.0,
728,327576,6,2,,104234176,36462,Active,,,5.72,IC50,Cytotoxicity against human SK-MEL-2 cells after 3 days by SRB assay,Confirmatory,18321715.0,
729,327577,6,2,,104234176,36462,Active,,,3.48,IC50,Cytotoxicity against human XF498 cells after 3 days by SRB assay,Confirmatory,18321715.0,
730,327578,6,2,,104234176,36462,Active,,,2.8,IC50,Cytotoxicity against human HCT15 cells after 3 days by SRB assay,Confirmatory,18321715.0,
731,327579,6,3,,104234176,36462,Active,,,0.23,IC50,Cytotoxicity against human SNU638 cells after 3 days by SRB assay,Confirmatory,18321715.0,
732,327580,6,2,,104234176,36462,Active,,,0.25,IC50,Cytotoxicity against human HT1080 cells after 3 days by SRB assay,Confirmatory,18321715.0,
733,327581,6,2,,104234176,36462,Active,,,0.37,IC50,Cytotoxicity against human HL60 cells after 3 days by SRB assay,Confirmatory,18321715.0,
734,327582,9,5,,104234176,36462,Unspecified,13959709.0,7153.0,92.9,IC50,Inhibition of human recombinant topoisomerase 2 by decatenation assay,Confirmatory,18321715.0,
735,331346,6,2,,104234176,36462,Active,,,13.5,GI50,Growth inhibition of human NCI-H520 cells,Confirmatory,18502124.0,
736,331347,6,2,,104234176,36462,Active,,,12.5,GI50,Growth inhibition of human PC3 cells,Confirmatory,18502124.0,
737,331348,3,4,,104234176,36462,Unspecified,,,,,Cytotoxicity against human NCI-H520 cells assessed as cell survival at 10 uM relative to control,Other,18502124.0,
738,331349,3,4,,104234176,36462,Unspecified,,,,,Cytotoxicity against human NCI-H520 cells assessed as cell survival at 50 uM relative to control,Other,18502124.0,
739,331350,3,4,,104234176,36462,Unspecified,,,,,Cytotoxicity against human NCI-H520 cells assessed as cell survival at 100 uM relative to control,Other,18502124.0,
740,331351,3,4,,104234176,36462,Unspecified,,,,,Cytotoxicity against human PC3 cells assessed as cell survival at 10 uM relative to control,Other,18502124.0,
741,331352,3,4,,104234176,36462,Unspecified,,,,,Cytotoxicity against human PC3 cells assessed as cell survival at 50 uM relative to control,Other,18502124.0,
742,331353,3,4,,104234176,36462,Unspecified,,,,,Cytotoxicity against human PC3 cells assessed as cell survival at 100 uM relative to control,Other,18502124.0,
743,332297,6,2,,104234176,36462,Unspecified,,,,,Cytotoxicity against human HL60 cells after 72 hrs by MTT assay,Other,11908966.0,
744,332298,7,3,,104234176,36462,Unspecified,,,,,Cytotoxicity against human HSC2 cells by MTT assay,Other,11908966.0,
745,332299,7,2,,104234176,36462,Unspecified,,,,,Cytotoxicity against HGF by MTT assay,Other,11908966.0,
746,333385,6,2,,104234176,36462,Unspecified,,,,,Cytotoxicity against human HL60 cells after 72 hrs by MTT assay,Other,15497941.0,
747,333386,6,3,,104234176,36462,Unspecified,,,,,Cytotoxicity against human HSC2 cells after 24 hrs by MTT assay,Other,15497941.0,
748,333825,6,3,,104234176,36462,Active,,,41.0,IC50,Cytotoxicity against human HSC2 cells assessed as cell viability after 24 hrs,Confirmatory,15620262.0,
749,334307,5,4,,104234176,36462,Unspecified,,,,,Inhibition of human DNA topoisomerase 2 at 200 uM,Other,2849640.0,
750,334309,3,4,,104234176,36462,Unspecified,,,,,Inhibition of human DNA topoisomerase 2 at 400 uM,Other,2849640.0,
751,334310,5,1,,104234176,36462,Unspecified,,,,,Cytotoxicity against human KB cells,Other,2849640.0,
752,335666,8,1,,104234176,36462,Active,,,0.2,ID50,Cytotoxicity against human KB cells assessed as reduction in cell number after 3 days,Confirmatory,1331331.0,
753,335667,8,1,,104234176,36462,Unspecified,13959709.0,7153.0,50.0,ID50,Inhibition of human DNA topoisomerase 2,Confirmatory,1331331.0,
754,335669,3,9,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of strand rejoining activity of human DNA topoisomerase 2 assessed as protein-DNA complex formation at 10 uM by cell-based assay,Other,1331331.0,
755,335670,3,5,,104234176,36462,Unspecified,,,,,Ratio of cytotoxicity for normally oxygenated mouse EMT6 cells over hypoxic mouse EMT6 cells,Other,1331331.0,
756,335970,5,1,,104234176,36462,Unspecified,,,,,Cytotoxicity against human KB cells,Other,2095375.0,
757,335972,5,1,,104234176,36462,Unspecified,,,,,Cytotoxicity against mouse P388 cells,Other,2095375.0,
758,335973,5,1,,104234176,36462,Unspecified,,,,,Cytotoxicity against mouse L1210 cells,Other,2095375.0,
759,336179,6,2,,104234176,36462,Unspecified,,,,,Cytotoxicity against human HL60 cells after 72 hrs by MTT assay,Other,12398536.0,
760,336180,6,2,,104234176,36462,Unspecified,,,,,Cytotoxicity against human HL60 cells after 72 hrs by MTT assay,Other,12398537.0,
761,336181,6,3,,104234176,36462,Unspecified,,,,,Cytotoxicity against human HSC2 cells after 24 hrs by MTT assay,Other,12398537.0,
762,338804,5,1,,104234176,36462,Unspecified,,,,,Cytotoxicity against mouse EAT cells after 4 days by trypan blue assay,Other,1602298.0,
763,338805,5,1,,104234176,36462,Unspecified,,,,,Cytotoxicity against human HeLa cells after 4 days by trypan blue assay,Other,1602298.0,
764,343351,6,2,,104234176,36462,Active,,,0.5,IC50,Cytotoxicity against mouse L1210 ATCC CCL 219 cells after 48 hrs by MTT assay,Confirmatory,18558490.0,
765,343352,6,2,,104234176,36462,Inconclusive,,,,IC50,Cytotoxicity against CHO cells after 48 hrs by MTT assay,Confirmatory,18558490.0,
766,343353,6,2,,104234176,36462,Inconclusive,,,,IC50,Cytotoxicity against polyamine transport-deficient mutant CHO cells after 48 hrs by MTT assay,Confirmatory,18558490.0,
767,343354,6,3,,104234176,36462,Active,,,4.0,IC50,Cytotoxicity against mouse 3LL CRL 1642 cells after 48 hrs by MTT assay,Confirmatory,18558490.0,
768,343355,6,2,,104234176,36462,Active,,,1.5,IC50,Cytotoxicity against human DU145 ATCC HTB 81 cells after 72 hrs by MTT assay,Confirmatory,18558490.0,
769,343356,6,2,,104234176,36462,Active,,,12.2,IC50,Cytotoxicity against human MCF7 ATCC HTB 22 cells after 72 hrs by MTT assay,Confirmatory,18558490.0,
770,343357,6,2,,104234176,36462,Active,,,4.9,IC50,Cytotoxicity against human K562 ATCC CCL 243 cells after 72 hrs by MTT assay,Confirmatory,18558490.0,
771,343358,6,2,,104234176,36462,Active,,,0.5,IC50,Cytotoxicity against human U251 RCB 0641 cells after 72 hrs by MTT assay,Confirmatory,18558490.0,
772,343371,3,4,,104234176,36462,Unspecified,,,,,Induction of apoptosis in mouse L1210 ATCC CCL 219 cells assessed as fragmented cell nuclei at 1.7 uM after 24 hrs by Hoechst 33342 staining,Other,18558490.0,
773,343372,3,4,,104234176,36462,Unspecified,,,,,Induction of apoptosis in mouse L1210 ATCC CCL 219 cells assessed as fragmented cell nuclei at 1.7 uM after 48 hrs by Hoechst 33342 staining,Other,18558490.0,
774,343379,3,4,,104234176,36462,Unspecified,,,,,Induction of apoptosis in mouse L1210 ATCC CCL 219 cells assessed as increase in caspase 3 activity at 1.7 uM after 48 hrs relative to control,Other,18558490.0,
775,351328,6,3,,104234176,36462,Active,,,0.21,GI50,Antiproliferative activity against human MESSA cells by SRB assay,Confirmatory,19394218.0,
776,351329,6,2,,104234176,36462,Active,,,9.72,GI50,Antiproliferative activity against multidrug resistant human MES-SA/Dx5 cells by SRB assay,Confirmatory,19394218.0,
777,351330,6,2,,104234176,36462,Active,,,1.25,GI50,Antiproliferative activity against human HCT15 cells by SRB assay,Confirmatory,19394218.0,
778,351331,6,2,,104234176,36462,Active,,,10.02,GI50,Antiproliferative activity against multidrug resistant human HCT15/CLO2 cells by SRB assay,Confirmatory,19394218.0,
779,351578,6,2,,104234176,36462,Active,,,1.2,IC50,Cytotoxicity against human Jurkat cells after 72 hrs by MTT assay,Confirmatory,19394829.0,
780,351579,6,2,,104234176,36462,Active,,,10.9,IC50,Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay,Confirmatory,19394829.0,
781,351580,6,2,,104234176,36462,Active,,,21.2,IC50,Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay,Confirmatory,19394829.0,
782,351581,6,2,,104234176,36462,Active,,,3.9,IC50,Cytotoxicity against human HeLa cells after 72 hrs by MTT assay,Confirmatory,19394829.0,
783,351582,6,2,,104234176,36462,Active,,,1.1,IC50,Cytotoxicity against human CCRF-CEM cells after 72 hrs by MTT assay,Confirmatory,19394829.0,
784,351583,6,2,,104234176,36462,Active,,,14.3,IC50,Cytotoxicity against human A549 cells after 72 hrs by MTT assay,Confirmatory,19394829.0,
785,354537,9,1,,104234176,36462,Active,,,0.12,LC50,Cytotoxicity against rat C6 cells after 3 days treated 4 hrs before db-cAMP challenge by MTT assay,Confirmatory,8988604.0,
786,354541,9,1,,104234176,36462,Unspecified,,,680.0,EC50,Inhibition of tubulin polymerization in rat C6 cells after 4 hrs,Confirmatory,8988604.0,
787,354543,3,4,,104234176,36462,Inactive,,,,,Cytotoxicity against rat C6 cells assessed as cell release at 50 ug/mL to 2.5 mg/mL after 5 hrs by MTT assay in absence of db-cAMP,Other,8988604.0,
788,354834,6,2,,104234176,36462,Active,,,0.16,IC50,Cytotoxicity against human HL60 cells after 5 days by MTT assay,Confirmatory,8778240.0,
789,354835,6,3,,104234176,36462,Active,,,6.7,IC50,Cytotoxicity against human BGC cells after 5 days by MTT assay,Confirmatory,8778240.0,
790,354836,6,2,,104234176,36462,Active,,,6.4,IC50,Cytotoxicity against human HCT8 cells after 5 days by MTT assay,Confirmatory,8778240.0,
791,354837,6,3,,104234176,36462,Active,,,1.9,IC50,Cytotoxicity against human Bel7402 cells after 5 days by MTT assay,Confirmatory,8778240.0,
792,355592,3,9,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of human DNA topoisomerase 2 assessed as bacteriophage P4 DNA unknotting at 100 uM after 30 mins by agarose gel electrophoresis,Other,2550587.0,
793,355593,8,1,,104234176,36462,Unspecified,13959709.0,7153.0,50.0,ID50,Inhibition of human DNA topoisomerase 2 assessed as bacteriophage P4 DNA unknotting after 30 mins by agarose gel electrophoresis,Confirmatory,2550587.0,
794,355594,5,1,,104234176,36462,Unspecified,,,,,Cytotoxicity against human KB cells assessed as reduction in cell number after 3 days by crystal violet staining,Other,2550587.0,
795,355595,4,7,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of DNA topoisomerase 2 in human KB cells assessed as enzyme-[methyl-3H]thymidine-labeled DNA complex formation at 10 uM after 1 hr by K-SDS precipitation assay,Other,2550587.0,
796,355596,3,9,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of DNA topoisomerase 2 in human KB cells assessed as enzyme-[methyl-3H]thymidine-labeled DNA complex formation at 5 uM after 1 hr by K-SDS precipitation assay,Other,2550587.0,
797,356061,6,3,,104234176,36462,Unspecified,,,,,Cytotoxicity against human HSC2 cells by MTT assay,Other,12828488.0,
798,356062,6,2,,104234176,36462,Unspecified,,,,,Cytotoxicity against human HPC by MTT assay,Other,12828488.0,
799,356991,3,4,,104234176,36462,Unspecified,,,,,Selectivity for human KB-7d cells to human KB cells,Other,11473423.0,
800,356992,3,4,,104234176,36462,Unspecified,,,,,Selectivity for human KB-VCR cells to human KB cells,Other,11473423.0,
801,356993,3,4,,104234176,36462,Unspecified,,,,,Selectivity for human KB-CPT cells to human KB cells,Other,11473423.0,
802,357305,5,1,,104234176,36462,Unspecified,,,,,Cytotoxicity against human A549 cells after 72 hrs,Other,11520215.0,
803,357306,5,1,,104234176,36462,Unspecified,,,,,Cytotoxicity against human HCT116 cells after 72 hrs,Other,11520215.0,
804,357340,6,2,,104234176,36462,Unspecified,,,,,Cytotoxicity against human HL60 cells after 72 hrs by MTT assay,Other,11520229.0,
805,357392,6,2,,104234176,36462,Active,,,,IC50,Inhibition of 2-amino-4-(4-heptyloxyphenyl)-2-methylbutanol-resistant human Jurkat SBR1 mutant cells proliferation after 18 hrs by MTT assay,Confirmatory,17400555.0,
806,357393,6,2,,104234176,36462,Active,,,,IC50,Inhibition of 2-amino-4-(4-heptyloxyphenyl)-2-methylbutanol-resistant human Jurkat SBR2 mutant cells proliferation after 18 hrs by MTT assay,Confirmatory,17400555.0,
807,357394,6,2,,104234176,36462,Active,,,,IC50,Inhibition of human 2-amino-4-(4-heptyloxyphenyl)-2-methylbutanol-resistant human Jurkat SBR3 mutant cells proliferation after 18 hrs by MTT assay,Confirmatory,17400555.0,
808,357971,3,9,,104234176,36462,Inactive,13959709.0,7153.0,,,Inhibition of human topoisomerase 2 p170alpha assessed as relaxation of lambda ZAPII plasmid Bluescript KS+ DNA at 100 uM by SDS electrophoresis,Other,11678653.0,
809,357974,3,9,,104234176,36462,Active,13959709.0,7153.0,,,Inhibition of human topoisomerase 2 p170alpha assessed as retardation of supercoiled lambda ZAPII plasmid Bluescript KS+ DNA migration at 50 uM after 60 mins by electrophoretic mobility shift assay,Other,11678653.0,
810,358555,7,2,,104234176,36462,Active,,,0.025,IC50,Cytotoxicity against human HL60 cells after 72 hrs by MTT assay,Confirmatory,11170674.0,
811,358918,9,5,,104234176,36462,Unspecified,13959709.0,7153.0,50.0,IC50,Inhibition of human 1 unit topoisomerase 2alpha catalytic activity assessed as relaxation of 198 ng supercoiled pBR322 DNA by agarose gel electrophoresis,Confirmatory,11754608.0,
812,361410,9,5,,104234176,36462,Unspecified,13959709.0,7153.0,75.7,IC50,Inhibition of human DNA topoisomerase 2alpha,Confirmatory,12444693.0,
813,365928,6,2,,104234176,36462,Active,,,49.6,IC50,Cytotoxicity against human SK-Hep1 cells by MTT assay,Confirmatory,18637688.0,
814,366731,6,2,,104234176,36462,Active,,,0.2,IC50,Cytotoxicity against human HL60 cells by SRB assay,Confirmatory,18651771.0,
815,377684,6,3,,104234176,36462,Active,,,0.79,IC50,Cytotoxicity against human LAMA-84 cells after 72 hrs by MTT assay,Confirmatory,16872135.0,
816,377685,6,3,,104234176,36462,Active,,,1.87,IC50,Cytotoxicity against human K-562 cells after 72 hrs by MTT assay,Confirmatory,16872135.0,
817,377686,6,3,,104234176,36462,Active,,,0.82,IC50,Cytotoxicity against human SKW3 cells after 72 hrs by MTT assay,Confirmatory,16872135.0,
818,378053,6,2,,104234176,36462,Active,,,10.5,IC50,Cytotoxicity against human HL-60 cells after 72 hrs by MTT assay,Confirmatory,16933865.0,
819,378351,6,2,,104234176,36462,Unspecified,,,,,Cytotoxicity against human HL-60 cells after 72 hrs by MTT assay,Other,9917320.0,
820,379025,8,1,,104234176,36462,Inconclusive,,,,ED50,Cytotoxicity against mouse P388 cells after 72 hrs by MTT assay,Confirmatory,16441087.0,
821,379026,8,1,,104234176,36462,Active,,,3.76,ED50,Cytotoxicity against human A549 cells after 72 hrs by MTT assay,Confirmatory,16441087.0,
822,379232,6,3,,104234176,36462,Active,,,24.0,IC50,Cytotoxicity against human HSC2 cells after 24 hrs by MTT assay,Confirmatory,17125230.0,
823,379233,6,2,,104234176,36462,Active,,,2.0,IC50,Cytotoxicity against human KB cells after 72 hrs,Confirmatory,17125231.0,
824,379385,9,1,,104234176,36462,Unspecified,,,,IC50,Cytotoxicity against human HCT116 cells after 72 hrs by MTS reduction assay,Confirmatory,16441091.0,
825,379731,6,2,,104234176,36462,Active,,,0.21,IC50,Antiproliferative effect against human HL60 cells after 69 hrs,Confirmatory,16499324.0,
826,379732,3,4,,104234176,36462,Unspecified,,,,,Growth inhibition of human HL60 cells at 20 uM after 69 hrs,Other,16499324.0,
827,379733,6,2,,104234176,36462,Active,,,0.19,IC50,Antiproliferative effect against human MCF7 cells after 72 hrs by MTT assay,Confirmatory,16499324.0,
828,379734,3,4,,104234176,36462,Unspecified,,,,,Growth inhibition of human MCF7 cells at 20 uM after 72 hrs by MTT assay,Other,16499324.0,
829,379735,6,2,,104234176,36462,Active,,,3.6,IC50,Antiproliferative effect against human HeLa cells after 69 hrs by MTT assay,Confirmatory,16499324.0,
830,379736,3,4,,104234176,36462,Unspecified,,,,,Growth inhibition of human HeLa cells at 20 uM after 69 hrs by MTT assay,Other,16499324.0,
831,381214,6,2,,104234176,36462,Unspecified,,,,,Cytotoxicity against human HL-60 cells after 72 hrs by MTT assay,Other,10514313.0,
832,381673,6,2,,104234176,36462,Active,,,2.9,IC50,Cytotoxicity against human HeLa cells after 48 hrs by MTT assay,Confirmatory,18258438.0,
833,382073,3,7,,104234176,36462,Active,,,,,Inhibition of topoisomerase 2alpha-mediated pBR322 DNA relaxation activity at 100 uM by gel electrophoresis,Other,18258442.0,
834,384124,6,2,,104234176,36462,Unspecified,,,,,Cytotoxicity against human U937 cells after 2 days by MTT assay,Other,17689837.0,
835,384945,9,5,,104234176,36462,Unspecified,3915902.0,,210.0,Kd,Binding affinity to HPV1a recombinant E2 protein by surface plasmon resonance method,Confirmatory,18396405.0,
836,384953,3,10,,104234176,36462,Unspecified,3915902.0,,,,Inhibition of HPV1a E2-E7 protein interaction at 250 uM assessed as rate of E2 binding to E7 protein by surface plasmon resonance method,Other,18396405.0,
837,386623,4,8,,104234176,36462,Unspecified,313104181.0,6580.0,,,Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy,Other,18788725.0,
838,386866,6,2,,104234176,36462,Active,,,3.85,IC50,Cytotoxicity against human DU145 cells by sulforhodamine B assay,Confirmatory,17988764.0,
839,386867,6,2,,104234176,36462,Active,,,17.4,IC50,Cytotoxicity against human PC-3 cells by sulforhodamine B assay,Confirmatory,17988764.0,
840,386868,6,2,,104234176,36462,Active,,,13.3,IC50,Cytotoxicity against human SF295 cells by sulforhodamine B assay,Confirmatory,17988764.0,
841,386869,6,2,,104234176,36462,Active,,,1.48,IC50,Cytotoxicity against human HCT-15 cells by sulforhodamine B assay,Confirmatory,17988764.0,
842,386870,6,3,,104234176,36462,Active,,,2.42,IC50,Cytotoxicity against human 502713 cells by sulforhodamine B assay,Confirmatory,17988764.0,
843,386871,6,3,,104234176,36462,Active,,,2.15,IC50,Cytotoxicity against human HEP2 cells by sulforhodamine B assay,Confirmatory,17988764.0,
844,386872,6,2,,104234176,36462,Active,,,5.62,IC50,Cytotoxicity against human A549 cells by sulforhodamine B assay,Confirmatory,17988764.0,
845,387635,6,2,,104234176,36462,Active,,,9.98,IC50,Cytotoxicity against human A549 cells assessed as reduction of cell growth by SRB method,Confirmatory,18782668.0,
846,387636,6,2,,104234176,36462,Active,,,14.2,IC50,Cytotoxicity against human KB cells assessed as reduction of cell growth by SRB method,Confirmatory,18782668.0,
847,387637,6,3,,104234176,36462,Inactive,,,,IC50,Cytotoxicity against drug-resistant human KB-VIN cells assessed as reduction of cell growth by SRB method,Confirmatory,18782668.0,
848,388883,3,9,,104234176,36462,Inactive,13959709.0,7153.0,,,Inhibition of human topoisomerase 2 alpha-mediated bacterial plasmid DNA relaxation assessed as pRYG negative supercoiled form at 100 uM,Other,18816045.0,
849,388884,3,9,,104234176,36462,Active,13959709.0,7153.0,,,Inhibition of human topoisomerase 2 alpha-mediated bacterial plasmid DNA relaxation assessed as pRYG negative supercoiled form added 100 uM after relaxation,Other,18816045.0,
850,388885,3,3,,104234176,36462,Inactive,,,,,DNA intercalative activity assessed retardation in migration of negatively supercoiled small circular Escherichia coli pBSKS in agarose gel electrophoresis at 100 uM,Other,18816045.0,
851,389027,6,2,,104234176,36462,Active,,,3.9,IC50,Cytotoxicity against human MRC5 cells after 3 days by MTT assay,Confirmatory,19013074.0,
852,389028,6,2,,104234176,36462,Active,,,0.36,IC50,Cytotoxicity against human AGS cells after 3 days by MTT assay,Confirmatory,19013074.0,
853,389029,6,2,,104234176,36462,Active,,,2.5,IC50,Cytotoxicity against human SK-MES-1 cells after 3 days by MTT assay,Confirmatory,19013074.0,
854,389030,6,2,,104234176,36462,Active,,,2.8,IC50,Cytotoxicity against human J82 cells after 3 days by MTT assay,Confirmatory,19013074.0,
855,389031,6,2,,104234176,36462,Active,,,0.8,IC50,Cytotoxicity against human HL-60 cells after 3 days by MTT assay,Confirmatory,19013074.0,
856,390356,3,4,,104234176,36462,Unspecified,,,,,Cell cycle arrest in human HL-60 cells assessed as accumulation at G2-M phase at 30 uM after 48 hrs by flow cytometry,Other,19053514.0,
857,390357,3,4,,104234176,36462,Unspecified,,,,,Cell cycle arrest in human HL-60 cells assessed as accumulation at S phase at 30 uM after 48 hrs by flow cytometry,Other,19053514.0,
858,390358,3,4,,104234176,36462,Unspecified,,,,,Cell cycle arrest in human HL-60 cells assessed as accumulation at G0/G1 phase at 30 uM after 48 hrs by flow cytometry,Other,19053514.0,
859,390359,3,4,,104234176,36462,Unspecified,,,,,Cell cycle arrest in human HL-60 cells assessed as accumulation at sub G0/G1 phase at 30 uM after 48 hrs by flow cytometry,Other,19053514.0,
860,390360,6,2,,104234176,36462,Active,,,5.9,IC50,Cytotoxicity against human A549 cells after 72 hrs by MTT assay,Confirmatory,19053514.0,
861,390361,6,2,,104234176,36462,Unspecified,,,30.0,IC50,Cytotoxicity against human SK-MEL-1 cells after 72 hrs by MTT assay,Confirmatory,19053514.0,
862,390362,6,2,,104234176,36462,Active,,,0.92,IC50,Cytotoxicity against human U937 cells after 72 hrs by MTT assay,Confirmatory,19053514.0,
863,390363,6,2,,104234176,36462,Active,,,0.25,IC50,Cytotoxicity against human HL-60 cells after 72 hrs by MTT assay,Confirmatory,19053514.0,
864,396069,8,1,,104234176,36462,Active,,,0.4,AC50,Induction of apoptosis in human HL60 cells after 48 hrs,Confirmatory,18339455.0,
865,396070,8,1,,104234176,36462,Unspecified,,,400.0,AC50,Induction of apoptosis in multidrug resistant human HL60 cells after 48 hrs,Confirmatory,18339455.0,
866,397804,6,2,,104234176,36462,Active,,,0.5,IC50,Cytotoxicity against human A549 cells by MTT assay,Confirmatory,11473438.0,
867,397805,6,2,,104234176,36462,Active,,,5.4,IC50,Cytotoxicity against human HL60 cells by MTT assay,Confirmatory,11473438.0,
868,397806,6,2,,104234176,36462,Active,,,12.3,IC50,Cytotoxicity against human MCF7 cells by MTT assay,Confirmatory,11473438.0,
869,397807,6,2,,104234176,36462,Active,,,0.1,IC50,Cytotoxicity against mouse P388 cells by MTT assay,Confirmatory,11473438.0,
870,398900,6,2,,104234176,36462,Unspecified,,,,,Cytotoxicity against human KB cells,Other,9214732.0,
871,398903,7,2,,104234176,36462,Unspecified,,,,,Cytotoxicity against mouse P388 cells,Other,9214732.0,
872,399010,4,4,,104234176,36462,Active,,,9.9525,IC50,Cytotoxicity against human TK10 cells after 48 hrs by SRB assay,Confirmatory,16309315.0,
873,399011,4,4,,104234176,36462,Active,,,0.8775,IC50,Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay,Confirmatory,16309315.0,
874,399012,4,4,,104234176,36462,Active,,,1.13,IC50,Cytotoxicity against human UACC62 cells after 48 hrs by SRB assay,Confirmatory,16309315.0,
875,399023,3,10,,104234176,36462,Active,20141946.0,7155.0,,,Inhibition of topoisomerase 2beta in human K562 cells assessed as cleavage of supercoiled pRYG DNA at 10 uM after 2 hrs by TARDIS assay,Other,16309315.0,
876,399177,6,2,,104234176,36462,Active,,,0.2,IC50,Cytotoxicity against human HL60 cells by MTT assay,Confirmatory,14738377.0,
877,399509,6,2,,104234176,36462,Active,,,1.1,IC50,Cytotoxicity against human KB cells after 72 hrs by methylene blue assay,Confirmatory,14738395.0,
878,399510,6,2,,104234176,36462,Active,,,2.3,IC50,Cytotoxicity against human HT-29 cells after 72 hrs by methylene blue assay,Confirmatory,14738395.0,
879,399598,3,9,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of human DNA topoisomerase 2 assessed as DNA cleavage at 50 uM,Other,14987069.0,
880,399600,5,2,,104234176,36462,Active,,,1.02329,GI50,Cytotoxicity against human MOLT4 cells,Confirmatory,14987069.0,
881,399601,7,1,,104234176,36462,Active,,,4.3651599999999995,GI50,Cytotoxicity against human MCF7 cells,Confirmatory,14987069.0,
882,399602,8,1,,104234176,36462,Active,,,,ID50,Cytotoxicity against human KB cells,Confirmatory,14987069.0,
883,399603,7,1,,104234176,36462,Unspecified,,,,,Inhibition of topoisomerase 2,Other,14987069.0,
884,399604,4,5,,104234176,36462,Unspecified,,,,,Inhibition of topoisomerase 2 assessed as DNA cleavage at 12.5 uM,Other,14987069.0,
885,402037,6,2,,104234176,36462,Active,,,40.0,IC50,Inhibition of human recombinant DNA topoisomerase-2,Confirmatory,15974606.0,
886,402038,9,5,,104234176,36462,Unspecified,12644118.0,7150.0,1000.0,IC50,Inhibition of human recombinant DNA topoisomerase1,Confirmatory,15974606.0,
887,402039,6,2,,104234176,36462,Unspecified,,,150.0,IC50,Cytotoxicity against human HL60 cells by MTT assay,Confirmatory,15974606.0,
888,402299,6,2,,104234176,36462,Active,,,25.0,IC50,Cytotoxicity against human HL60 cells after 24 hrs by MTT assay,Confirmatory,15974617.0,
889,403680,5,1,,104234176,36462,Unspecified,,,,,Cytotoxicity against human A549 cells by SRB method,Other,16252909.0,
890,403681,5,1,,104234176,36462,Unspecified,,,,,Cytotoxicity against human SKOV3 cells by SRB method,Other,16252909.0,
891,403682,5,1,,104234176,36462,Unspecified,,,,,Cytotoxicity against human SK-MEL-2 cells by SRB method,Other,16252909.0,
892,403683,5,1,,104234176,36462,Unspecified,,,,,Cytotoxicity against human XF498 cells by SRB method,Other,16252909.0,
893,403684,5,1,,104234176,36462,Unspecified,,,,,Cytotoxicity against human HCT15 cells by SRB method,Other,16252909.0,
894,403984,3,3,,104234176,36462,Unspecified,,,,,"Therapeutic index, ratio of MTC for human primary amnion cells to lowest drug level causing inhibition of HSV1",Other,9834179.0,
895,404065,9,1,,104234176,36462,Unspecified,,,,,Antiviral activity against HSV1 infected in human primary amnion cells assessed as inhibition of virus-induced pathogenic effect,Other,9834179.0,
896,404066,7,1,,104234176,36462,Unspecified,,,,,Cytotoxicity against human primary amnion cells assessed as morphological changes by microscopic examination,Other,9834179.0,
897,404304,3,10,,104234176,36462,Unspecified,308153583.0,1244.0,,,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,Other,18457386.0,
898,404699,6,2,,104234176,36462,Active,,,0.486,IC50,Cytotoxicity against human mitoxantrone-sensitive HL60 cells after 72 hrs,Confirmatory,18507368.0,
899,404700,6,3,,104234176,36462,Active,,,48.5,IC50,Cytotoxicity against mitoxantrone-resistant human HL60/MX2 cells after 72 hrs,Confirmatory,18507368.0,
900,404701,3,3,,104234176,36462,Unspecified,,,,,"Resistant index, ratio of IC50 for mitoxantrone-resistant human HL60/MX2 cells to IC50 for mitoxantrone-sensitive human HL60 cells",Other,18507368.0,
901,404815,4,4,,104234176,36462,Active,,,0.315,IC50,Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay,Confirmatory,18513974.0,
902,404820,3,4,,104234176,36462,Unspecified,,,,,Induction of apoptosis in human HL60 cells assessed as increase in caspase 3 activation at 2.0 uM after 24 hrs,Other,18513974.0,
903,405959,6,2,,104234176,36462,Active,,,0.2,IC50,Cytotoxicity against human HL60 cells after 72 hrs by MTT assay,Confirmatory,18507472.0,
904,408557,6,2,,104234176,36462,Active,,,0.54,IC50,Antiproliferative activity against human 5637 cells after 96 hrs by crystal violet assay,Confirmatory,18434163.0,
905,408558,6,2,,104234176,36462,Active,,,0.13,IC50,Antiproliferative activity against human A427 cells after 96 hrs by crystal violet assay,Confirmatory,18434163.0,
906,408559,6,3,,104234176,36462,Active,,,0.94,IC50,Antiproliferative activity against human KYSE70 cells after 96 hrs by crystal violet assay,Confirmatory,18434163.0,
907,408560,6,2,,104234176,36462,Active,,,0.5,IC50,Antiproliferative activity against human MCF7 cells after 96 hrs by crystal violet assay,Confirmatory,18434163.0,
908,408909,6,2,,104234176,36462,Active,,,1.25,IC50,Antiproliferative activity against human MT4 cells after 96 hrs by MTT assay,Confirmatory,19053767.0,
909,408910,6,2,,104234176,36462,Active,,,2.5,IC50,Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay,Confirmatory,19053767.0,
910,408911,6,2,,104234176,36462,Active,,,1.2,IC50,Antiproliferative activity against human CCRF-CEM cells after 96 hrs by MTT assay,Confirmatory,19053767.0,
911,408912,6,2,,104234176,36462,Active,,,0.1,IC50,Antiproliferative activity against human CCRF-SB cells after 96 hrs by MTT assay,Confirmatory,19053767.0,
912,408913,6,2,,104234176,36462,Active,,,1.0,IC50,Antiproliferative activity against human MCF7 cells after 96 hrs by MTT assay,Confirmatory,19053767.0,
913,408914,6,2,,104234176,36462,Active,,,3.0,IC50,Antiproliferative activity against human HeLa cells after 96 hrs by MTT assay,Confirmatory,19053767.0,
914,408915,6,2,,104234176,36462,Active,,,2.15,IC50,Antiproliferative activity against human ACHN cells after 96 hrs by MTT assay,Confirmatory,19053767.0,
915,408916,6,2,,104234176,36462,Active,,,3.25,IC50,Antiproliferative activity against human SF-268 cells after 96 hrs by MTT assay,Confirmatory,19053767.0,
916,408917,6,2,,104234176,36462,Active,,,3.45,IC50,Antiproliferative activity against human XF498 cells after 96 hrs by MTT assay,Confirmatory,19053767.0,
917,408918,6,2,,104234176,36462,Active,,,3.9,IC50,Antiproliferative activity against human MRC5 cells after 96 hrs by MTT assay,Confirmatory,19053767.0,
918,408920,3,7,,104234176,36462,Unspecified,,,,,Inhibition of DNA topoisomerase 1-mediated supercoiled pBR322 DNA relaxation at 5 to 10 uM by agarose gel electrophoresis,Other,19053767.0,
919,409953,3,9,,104234176,36462,Inactive,341940599.0,17161.0,,,Inhibition of mouse liver MAOA,Other,18834112.0,
920,409954,4,9,,104234176,36462,Inactive,341940599.0,17161.0,,,Inhibition of mouse brain MAOA,Other,18834112.0,
921,409955,3,9,,104234176,36462,Inactive,341940629.0,109731.0,,,Inhibition of mouse liver MAOB,Other,18834112.0,
922,409956,4,9,,104234176,36462,Inactive,341940629.0,109731.0,,,Inhibition of mouse brain MAOB,Other,18834112.0,
923,410970,6,2,,104234176,36462,Active,,,2.16,IC50,Cytotoxicity against human THP1 cells by MTT assay,Confirmatory,19036584.0,
924,410971,6,2,,104234176,36462,Active,,,1.83,IC50,Cytotoxicity against human HL60 cells by MTT assay,Confirmatory,19036584.0,
925,410972,6,2,,104234176,36462,Active,,,3.92,IC50,Cytotoxicity against human A375 cells by MTT assay,Confirmatory,19036584.0,
926,410973,6,2,,104234176,36462,Active,,,9.51,IC50,Cytotoxicity against human A549 cells by MTT assay,Confirmatory,19036584.0,
927,412960,8,1,,104234176,36462,Active,,,1.1,IC50,Growth inhibition of human KB cells after 72 hrs by methylene blue dye assay,Confirmatory,19053773.0,
928,412961,8,1,,104234176,36462,Active,,,23.0,IC50,Growth inhibition of human Pgp170 overexpressing multidrug resistant-KB-VIN10 cells after 72 hrs by methylene blue dye assay,Confirmatory,19053773.0,
929,412965,8,1,,104234176,36462,Active,,,3.5,IC50,Growth inhibition of human Pgp170 overexpressing multidrug resistant-KB-TAX50 cells after 72 hrs by methylene blue dye assay,Confirmatory,19053773.0,
930,412966,8,1,,104234176,36462,Unspecified,,,54.0,IC50,Growth inhibition of human KB-7D cells overexpressing multidrug resistant associated protein after 72 hrs by methylene blue dye assay,Confirmatory,19053773.0,
931,416059,6,2,,104234176,36462,Active,,,0.42,IC50,Antiproliferative activity against human KB cells after 48 hrs by MTT assay,Confirmatory,18514972.0,
932,416060,6,2,,104234176,36462,Active,,,1.27,IC50,Antiproliferative activity against human K562 cells after 48 hrs by MTT assay,Confirmatory,18514972.0,
933,416061,6,3,,104234176,36462,Active,,,13.0,IC50,Antiproliferative activity against human L02 cells after 48 hrs by MTT assay,Confirmatory,18514972.0,
934,416363,6,2,,104234176,36462,Active,,,3.3,IC50,Cytotoxicity against human HL60 cells after 48 hrs by MTT assay,Confirmatory,19251420.0,
935,416970,3,4,,104234176,36462,Unspecified,,,,,Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay,Other,19271734.0,
936,416977,3,4,,104234176,36462,Active,,,,,Induction of DNA fragmentation in human HL60 cells at 25 uM after 48 hrs by ethidium bromide based gel electrophoresis,Other,19271734.0,
937,419086,6,2,,104234176,36462,Active,,,3.9,IC50,Cytotoxicity against human MRC5 cells after 72 hrs by MTT assay,Confirmatory,19269832.0,
938,419087,6,2,,104234176,36462,Active,,,0.36,IC50,Cytotoxicity against human AGS cells after 72 hrs by MTT assay,Confirmatory,19269832.0,
939,419088,6,3,,104234176,36462,Active,,,2.5,IC50,Cytotoxicity against human SKMES1 cells after 72 hrs by MTT assay,Confirmatory,19269832.0,
940,419089,6,2,,104234176,36462,Active,,,2.8,IC50,Cytotoxicity against human J82 cells after 72 hrs by MTT assay,Confirmatory,19269832.0,
941,419643,7,2,,104234176,36462,Unspecified,,,,,Antiproliferative activity against human THP1 cells after 48 hrs by MTT assay,Other,19410455.0,
942,419644,7,2,,104234176,36462,Unspecified,,,,,Antiproliferative activity against human U937 cells after 48 hrs by MTT assay,Other,19410455.0,
943,419645,7,2,,104234176,36462,Unspecified,,,,,Antiproliferative activity against human A375 cells after 48 hrs by MTT assay,Other,19410455.0,
944,422506,6,3,,104234176,36462,Active,,,1.3,IC50,Cytotoxicity against human NB4 cells after 48 hrs by WST-8 assay,Confirmatory,19072209.0,
945,422507,6,2,,104234176,36462,Active,,,1.7,IC50,Cytotoxicity against human A549 cells after 48 hrs by WST-8 assay,Confirmatory,19072209.0,
946,422508,6,4,,104234176,36462,Active,,,1.7,IC50,Cytotoxicity against human SH-SY5Y cells after 48 hrs by WST-8 assay,Confirmatory,19072209.0,
947,422509,6,2,,104234176,36462,Active,,,13.6,IC50,Cytotoxicity against human PC3 cells after 48 hrs by WST-8 assay,Confirmatory,19072209.0,
948,422510,6,2,,104234176,36462,Active,,,7.6,IC50,Cytotoxicity against human MCF7 cells after 48 hrs by WST-8 assay,Confirmatory,19072209.0,
949,423006,6,2,,104234176,36462,Active,,,1.2,IC50,Cytotoxicity against human A549 cells after 48 hrs,Confirmatory,19115839.0,
950,423007,6,2,,104234176,36462,Active,,,27.0,IC50,Cytotoxicity against human DLD1 cells after 48 hrs,Confirmatory,19115839.0,
951,423008,6,2,,104234176,36462,Active,,,0.7,IC50,Cytotoxicity against human MCF7 cells after 48 hrs,Confirmatory,19115839.0,
952,423009,6,2,,104234176,36462,Active,,,1.7,IC50,Cytotoxicity against human PC3 cells after 48 hrs,Confirmatory,19115839.0,
953,423010,6,3,,104234176,36462,Active,,,34.0,IC50,Cytotoxicity against human WS1 cells after 48 hrs,Confirmatory,19115839.0,
954,426700,6,2,,104234176,36462,Active,,,0.73,GI50,Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay,Confirmatory,19572549.0,
955,426930,6,3,,104234176,36462,Active,,,1.3,IC50,Cytotoxicity against human NB4 cells after 48 hrs by SRB method,Confirmatory,19425589.0,
956,426931,6,2,,104234176,36462,Active,,,1.7,IC50,Cytotoxicity against human A549 cells after 48 hrs by SRB method,Confirmatory,19425589.0,
957,426932,6,4,,104234176,36462,Active,,,1.7,IC50,Cytotoxicity against human SH-SY5Y cells after 48 hrs by SRB method,Confirmatory,19425589.0,
958,426933,6,2,,104234176,36462,Active,,,13.6,IC50,Cytotoxicity against human PC3 cells after 48 hrs by SRB method,Confirmatory,19425589.0,
959,426934,6,2,,104234176,36462,Active,,,7.6,IC50,Cytotoxicity against human MCF7 cells after 48 hrs by SRB method,Confirmatory,19425589.0,
960,429971,7,2,,104234176,36462,Unspecified,,,,,Cytotoxicity against human HL60 cells after 72 hrs by MTT assay,Other,19449879.0,
961,432102,6,2,,104234176,36462,Active,,,3.93,IC50,Cytotoxicity against human MRC5 cells after 3 days by MTT assay,Confirmatory,19419803.0,
962,432103,6,2,,104234176,36462,Active,,,0.36,IC50,Cytotoxicity against human AGS cells after 3 days by MTT assay,Confirmatory,19419803.0,
963,432104,6,2,,104234176,36462,Active,,,2.5,IC50,Cytotoxicity against human J82 cells after 3 days by MTT assay,Confirmatory,19419803.0,
964,432105,6,3,,104234176,36462,Active,,,2.8,IC50,Cytotoxicity against human SKMES1 cells after 3 days by MTT assay,Confirmatory,19419803.0,
965,432106,6,2,,104234176,36462,Active,,,0.8,IC50,Cytotoxicity against human HL60 cells after 3 days by MTT assay,Confirmatory,19419803.0,
966,434820,3,9,,104234176,36462,Active,13959709.0,7153.0,,,Inhibition of human topoisomerase 2-mediated DNA relaxation assessed as double stranded break form by agarose gel electrophoresis,Other,19386396.0,
967,434955,1,2,,49681767,36462,Inactive,,,,IC90,Screen to Identify Novel Compounds That Sensitize Mycobacterium Tuberculosis to Beta-lactam Antibiotics,Confirmatory,,
968,434959,1,1,,85788790,36462,Inactive,,,,,Fluorescence Cell-Based Primary HTS to Measure Inhibition of Y box Binding Protein 1 Expression,Screening,,
969,434962,1,2,,49681767,36462,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify inhibitors of insulin-degrading enzyme (IDE),Screening,,
970,434973,1,3,,49681767,36462,Inactive,120538355.0,57337.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 7 (SENP7),Screening,,
971,434989,1,1,,49681767,36462,Inactive,222080095.0,3061.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
972,435003,1,3,,49681767,36462,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of T-cell specific antigen receptor-induced NF-kB activation,Screening,,
973,435005,1,1,,49681767,36462,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Beta Cell Apoptosis.,Screening,,
974,435022,2,2,,49681767,36462,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of B-cell specific antigen receptor-induced NF-kB activation,Screening,,
975,435030,1,2,,49681767,36462,Inactive,15645703.0,899625.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
976,435030,1,2,,49681767,36462,Inactive,15646160.0,899738.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
977,436291,5,2,,104234176,36462,Active,,,1.25,IC50,Cytotoxicity against human KB cells after 72 hrs by MTT assay,Confirmatory,18844422.0,
978,436292,5,2,,104234176,36462,Active,,,8.37,IC50,Cytotoxicity against human A549 cells after 72 hrs by MTT assay,Confirmatory,18844422.0,
979,440896,5,2,,104234176,36462,Active,,,2.16,IC50,Cytotoxicity against human HL60 cells by MTT assay,Confirmatory,19782567.0,
980,440897,5,2,,104234176,36462,Active,,,1.83,IC50,Cytotoxicity against human THP1 cells by MTT assay,Confirmatory,19782567.0,
981,440898,5,2,,104234176,36462,Active,,,3.92,IC50,Cytotoxicity against human A375 cells by MTT assay,Confirmatory,19782567.0,
982,440899,5,2,,104234176,36462,Active,,,9.51,IC50,Cytotoxicity against human A549 cells by MTT assay,Confirmatory,19782567.0,
983,444050,7,1,,104234176,36462,Unspecified,,,,,Fraction unbound in human plasma,Other,20070106.0,
984,444051,6,2,,104234176,36462,Unspecified,,,,,Total clearance in human,Other,20070106.0,
985,444052,6,2,,104234176,36462,Unspecified,,,,,Hepatic clearance in human,Other,20070106.0,
986,444053,6,2,,104234176,36462,Unspecified,,,,,Renal clearance in human,Other,20070106.0,
987,444054,6,1,,104234176,36462,Unspecified,,,,,Oral bioavailability in human,Other,20070106.0,
988,444055,3,3,,104234176,36462,Unspecified,,,,,Fraction absorbed in human,Other,20070106.0,
989,444056,3,3,,104234176,36462,Unspecified,,,,,Fraction escaping gut-wall elimination in human,Other,20070106.0,
990,444057,3,3,,104234176,36462,Unspecified,,,,,Fraction escaping hepatic elimination in human,Other,20070106.0,
991,444058,6,2,,104234176,36462,Unspecified,,,,,Volume of distribution at steady state in human,Other,20070106.0,
992,449728,1,2,,49681767,36462,Inactive,,,,,Counterscreen for inhibitors of AddAB: absorbance-based bacterial cell-based high throughput screening assay to identify inhibitors of bacterial viability,Screening,,
993,449739,1,2,,49681767,36462,Inactive,53832009.0,8912.0,,,Inhibitors of Cav3 T-type Calcium Channels: Primary Screen,Screening,,
994,449762,1,2,,49681767,36462,Inconclusive,,,,IC50,High Throughput Screening Assay used to Identify Novel Compounds that Inhibit Mycobacterium Tuberculosis in 7H9 Media,Confirmatory,,
995,449763,1,3,,49681767,36462,Inactive,,,,,uHTS identification of small molecule activators of the apoptotic arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
996,449768,1,1,,49681767,36462,Inactive,7108463.0,6531.0,,,High Throughput Screening for Cocaine Antagonists: Primary Screen,Screening,,
997,452678,3,9,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of human topoisomerase 2 alpha-mediated relaxation of supercoiled pBR322 DNA at 20 uM after 30 mins by agarose gel electrophoresis,Other,19954977.0,
998,452679,3,9,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of human topoisomerase 2 alpha-mediated relaxation of supercoiled pBR322 DNA at 100 uM after 30 mins by agarose gel electrophoresis,Other,19954977.0,
999,452680,5,2,,104234176,36462,Active,,,21.07,IC50,Cytotoxicity against human DU145 cells after 3 days,Confirmatory,19954977.0,
1000,452681,5,2,,104234176,36462,Active,,,18.01,IC50,Cytotoxicity against human MCF7 cells after 3 days,Confirmatory,19954977.0,
1001,452682,5,2,,104234176,36462,Active,,,17.92,IC50,Cytotoxicity against human HCT116 cells after 3 days,Confirmatory,19954977.0,
1002,452683,5,2,,104234176,36462,Active,,,16.85,IC50,Cytotoxicity against human MDA-MB-231 cells after 3 days,Confirmatory,19954977.0,
1003,452684,5,2,,104234176,36462,Active,,,8.43,IC50,Cytotoxicity against human HeLa cells after 3 days,Confirmatory,19954977.0,
1004,453794,4,8,,104234176,36462,Active,13959709.0,7153.0,,,Inhibition of human topoisomerase 2alpha-mediated relaxation of double-stranded pRYG DNA at 100 uM by agarose gel electrophoresis,Other,19783445.0,
1005,453795,3,3,,104234176,36462,Inactive,,,,,Induction of DNA intercalation in pRYG DNA at 100 uM by agarose gel electrophoresis,Other,19783445.0,
1006,453796,4,3,,104234176,36462,Inactive,,,,,Inhibition of Xanthomonas vasicola XhoI assessed as pBSKS cleavage at 100 uM by endonuclease assay,Other,19783445.0,
1007,454057,3,4,,104234176,36462,Unspecified,,,,,Cytotoxicity against human DU145 cells at 10 uM by MTT assay,Other,19800803.0,
1008,454060,5,2,,104234176,36462,Active,,,14.39,IC50,Cytotoxicity against human HCT116 cells after 4 days,Confirmatory,19800803.0,
1009,456249,3,9,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of human DNA topoisomerase 2alpha-mediated relaxation of supercoiled pBR322 DNA at 100 uM after 30 mins by agarose gel electrophoresis,Other,19939682.0,
1010,456250,3,9,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of human DNA topoisomerase 2alpha-mediated relaxation of supercoiled pBR322 DNA at 20 uM after 30 mins by agarose gel electrophoresis,Other,19939682.0,
1011,456251,5,2,,104234176,36462,Active,,,1.89,IC50,Cytotoxicity against human MCF7 cells after 4 days by ELISA reader assay,Confirmatory,19939682.0,
1012,456252,5,2,,104234176,36462,Active,,,1.3,IC50,Cytotoxicity against human DU145 cells after 4 days by ELISA reader assay,Confirmatory,19939682.0,
1013,456253,5,2,,104234176,36462,Active,,,1.09,IC50,Cytotoxicity against human HCT15 cells after 4 days by ELISA reader assay,Confirmatory,19939682.0,
1014,456254,5,2,,104234176,36462,Active,,,2.41,IC50,Cytotoxicity against human K562 cells after 4 days by ELISA reader assay,Confirmatory,19939682.0,
1015,456255,5,2,,104234176,36462,Active,,,1.29,IC50,Cytotoxicity against human HeLa cells after 4 days by ELISA reader assay,Confirmatory,19939682.0,
1016,456874,5,2,,104234176,36462,Active,,,0.29,IC50,Cytotoxicity against human A549 cells after 48 hrs,Confirmatory,20053564.0,
1017,456875,5,2,,104234176,36462,Active,,,0.42,IC50,Cytotoxicity against human HL60 cells after 48 hrs,Confirmatory,20053564.0,
1018,456876,5,3,,104234176,36462,Active,,,0.14,IC50,Cytotoxicity against human RPMI8226 cells after 48 hrs,Confirmatory,20053564.0,
1019,456877,5,2,,104234176,36462,Active,,,43.89,IC50,Antioxidant activity in Sprague-Dawley rat liver assessed as inhibition of malonaldehyde,Confirmatory,20053564.0,
1020,456878,5,2,,104234176,36462,Active,,,23.77,IC50,Antioxidant activity in Sprague-Dawley rat kidney assessed as inhibition of malonaldehyde,Confirmatory,20053564.0,
1021,456879,5,2,,104234176,36462,Active,,,40.67,IC50,Antioxidant activity in Sprague-Dawley rat heart assessed as inhibition of malonaldehyde,Confirmatory,20053564.0,
1022,456880,5,2,,104234176,36462,Active,,,0.68,IC50,"Octanol-water partition coefficient, log P of the compound",Confirmatory,20053564.0,
1023,460538,5,2,,104234176,36462,Active,,,0.47,IC50,Cytotoxicity against human HeLa cells after 48 hrs by MTT assay,Confirmatory,20093033.0,
1024,460539,5,2,,104234176,36462,Active,,,1.42,IC50,Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay,Confirmatory,20093033.0,
1025,460540,5,2,,104234176,36462,Active,,,1.63,IC50,Cytotoxicity against human DU145 cells after 48 hrs by MTT assay,Confirmatory,20093033.0,
1026,460541,5,2,,104234176,36462,Active,,,2.87,IC50,Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay,Confirmatory,20093033.0,
1027,460542,5,2,,104234176,36462,Active,,,0.97,IC50,Cytotoxicity against human HL60 cells after 48 hrs by MTT assay,Confirmatory,20093033.0,
1028,460545,3,9,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of human recombinant DNA topoisomerase 2alpha -mediated pBR322 DNA relaxation at 100 uM by gel electrophoresis,Other,20093033.0,
1029,460546,3,9,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of human recombinant DNA topoisomerase 2alpha -mediated pBR322 DNA relaxation at 20 uM by gel electrophoresis,Other,20093033.0,
1030,461008,4,9,,104234176,36462,Inactive,13959709.0,7153.0,,,Inhibition of DNA topoisomerase 2alpha in human K562 cells assessed as protein-DNA covalent complex formation under UV irradiation at 25 uM by scintillation counting,Other,20006518.0,
1031,461009,5,2,,104234176,36462,Active,,,0.42,IC50,Cytotoxicity against human K562 cells after 72 hrs by MTS assay,Confirmatory,20006518.0,
1032,461011,8,5,,104234176,36462,Unspecified,13959709.0,7153.0,56.0,IC50,Inhibition of human DNA topoisomerase 2alpha-mediated decatenation of kinetoplast plasmid DNA by fluorescent plate reader,Confirmatory,20006518.0,
1033,461014,4,6,,104234176,36462,Active,,,,,Inhibition of DNA topoisomerase 2alpha-mediated pBR322 DNA cleavage at 100 uM by SDS-PAGE,Other,20006518.0,
1034,461015,4,9,,104234176,36462,Active,13959709.0,7153.0,,,Inhibition of DNA topoisomerase 2alpha in human K562 cells assessed as protein-DNA covalent complex formation at 50 uM by scintillation counting,Other,20006518.0,
1035,461017,4,8,,104234176,36462,Active,13959709.0,7153.0,,,Inhibition of DNA topoisomerase 2alpha in human K-VP.5 cells assessed as decrease in protein-DNA covalent complex formation at 50 uM by scintillation counting,Other,20006518.0,
1036,461020,4,6,,104234176,36462,Inactive,,,,,Inhibition of DNA topoisomerase 2alpha-mediated pBR322 DNA cleavage at 20 uM by SDS-PAGE,Other,20006518.0,
1037,462322,3,4,,104234176,36462,Unspecified,,,,,Cytotoxicity against human MCF7 cells in presence of 10% fetal bovine serum,Other,20188578.0,
1038,462325,3,9,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of human recombinant DNA topoisomerase 2 assessed as inhibition of relaxation of supercoiled pBR322 DNA at 100 uM by agarose gel electrophoresis,Other,20188578.0,
1039,462326,3,9,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of human recombinant DNA topoisomerase 2 assessed as inhibition of relaxation of supercoiled pBR322 DNA at 20 uM by agarose gel electrophoresis,Other,20188578.0,
1040,462327,5,2,,104234176,36462,Active,,,1.57,IC50,Cytotoxicity against human HeLa cells in presence of 10% fetal bovine serum,Confirmatory,20188578.0,
1041,462328,5,2,,104234176,36462,Active,,,2.45,IC50,Cytotoxicity against human DU145 cells in presence of 10% fetal bovine serum,Confirmatory,20188578.0,
1042,462329,5,2,,104234176,36462,Active,,,1.29,IC50,Cytotoxicity against human HCT15 cells in presence of 10% fetal bovine serum,Confirmatory,20188578.0,
1043,462330,5,2,,104234176,36462,Active,,,2.84,IC50,Cytotoxicity against human K562 cells in presence of 10% fetal bovine serum,Confirmatory,20188578.0,
1044,463079,1,2,,49681767,36462,Inactive,,,,,Fluorescence-based counterscreen for orexin 1 receptor (OX1R) antagonists: cell-based assay to identify antagonists of the parental CHO cell line,Screening,,
1045,463082,1,1,,49681767,36462,Inactive,270133071.0,7941.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH),Screening,,
1046,463104,1,2,,49681767,36462,Inactive,,,,,uHTS identification of small molecule activators of the adaptive arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
1047,463111,1,1,,49681767,36462,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate regulator of G-protein signaling 4 (RGS4),Screening,,
1048,463141,1,2,,49681767,36462,Inactive,14790119.0,836.0,,,Absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-3,Screening,,
1049,463165,1,1,,49681767,36462,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit regulator of   G-protein signaling 4 (RGS4),Screening,,
1050,463190,1,2,,49681767,36462,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10-1 yeast via a luminescent assay,Screening,,
1051,463195,1,2,,49681767,36462,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10 yeast via a luminescent assay,Screening,,
1052,463210,1,2,,49681767,36462,Inactive,55960760.0,,,,Counterscreen for procaspase-3 activators: absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-7,Screening,,
1053,463212,1,1,,49681767,36462,Inactive,285814664.0,855751.0,,,uHTS identification of small molecule inhibitors of tim23-1 yeast via a luminescent assay,Screening,,
1054,463755,5,2,,104234176,36462,Active,,,1.1,EC50,Cytotoxicity against human KB cells,Confirmatory,20102168.0,
1055,465654,6,2,,104234176,36462,Unspecified,,,,,Cytotoxicity against human A549 cells after 72 hrs by SRB assay,Other,20073490.0,
1056,465655,6,2,,104234176,36462,Unspecified,,,,,Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay,Other,20073490.0,
1057,465656,6,2,,104234176,36462,Unspecified,,,,,Cytotoxicity against human KB cells after 72 hrs by SRB assay,Other,20073490.0,
1058,465657,6,3,,104234176,36462,Unspecified,,,,,Cytotoxicity against human vincristine resistant KBVIN cells after 72 hrs by SRB assay,Other,20073490.0,
1059,467758,5,2,,104234176,36462,Active,,,2.15,IC50,Cytotoxicity against human HeLa cells by MTT assay,Confirmatory,19836231.0,
1060,467759,5,2,,104234176,36462,Active,,,6.32,IC50,Cytotoxicity against human HT-29 cells by MTT assay,Confirmatory,19836231.0,
1061,467760,5,2,,104234176,36462,Active,,,5.16,IC50,Cytotoxicity against human DU145 cells by MTT assay,Confirmatory,19836231.0,
1062,467761,5,2,,104234176,36462,Active,,,3.5,IC50,Cytotoxicity against human MDA-MB-231 cells by MTT assay,Confirmatory,19836231.0,
1063,467762,5,2,,104234176,36462,Active,,,0.93,IC50,Cytotoxicity against human HL60 cells by MTT assay,Confirmatory,19836231.0,
1064,467763,4,8,,104234176,36462,Inconclusive,12644118.0,7150.0,,,Inhibition of human topoisomerase 1 at 20 uM,Other,19836231.0,
1065,467764,4,8,,104234176,36462,Inconclusive,12644118.0,7150.0,,,Inhibition of human topoisomerase 1 at 100 uM,Other,19836231.0,
1066,467765,4,8,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of human topoisomerase 2 at 20 uM,Other,19836231.0,
1067,467766,4,8,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of human topoisomerase 2 at 100 uM,Other,19836231.0,
1068,468207,5,2,,104234176,36462,Active,,,0.28,IC50,Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay,Confirmatory,19919064.0,
1069,468209,5,2,,104234176,36462,Active,,,0.55,IC50,Cytotoxicity against human HaCaT cells after 72 hrs by MTT assay,Confirmatory,19919064.0,
1070,468978,5,2,,104234176,36462,Active,,,0.63,IC50,Cytotoxicity against human A549 cells after 24 hrs by SRB assay,Confirmatory,19769341.0,
1071,468979,5,2,,104234176,36462,Active,,,0.042,IC50,Cytotoxicity against human HL60 cells after 72 hrs by MTT assay,Confirmatory,19769341.0,
1072,470655,5,2,,104234176,36462,Active,,,0.05,IC50,Cytotoxicity against mouse P388 cells after 24 hrs by SRB assay,Confirmatory,19685913.0,
1073,470656,5,2,,104234176,36462,Active,,,0.042,IC50,Cytotoxicity against human HL60 cells after 24 hrs by SRB assay,Confirmatory,19685913.0,
1074,470657,5,2,,104234176,36462,Active,,,0.63,IC50,Cytotoxicity against human A549 cells after 72 hrs by MTT assay,Confirmatory,19685913.0,
1075,470658,5,3,,104234176,36462,Active,,,1.03,IC50,Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay,Confirmatory,19685913.0,
1076,470667,4,6,,104234176,36462,Inconclusive,,,,,Inhibition of topoisomerase 1 catalytic activity assessed as relaxation of supercoiled plasmid DNA at 100 uM after 30 mins by agarose gel electrophoresis,Other,19691293.0,
1077,470668,4,6,,104234176,36462,Active,,,,,Inhibition of topoisomerase 2 alpha catalytic activity assessed as decatenation of kinetoplast DNA at 100 uM after 15 mins by agarose gel electrophoresis,Other,19691293.0,
1078,470669,5,2,,104234176,36462,Active,,,1.3,IC50,Antiproliferative activity against human SW948 cells after 3 days by XTT assay,Confirmatory,19691293.0,
1079,470670,5,2,,104234176,36462,Active,,,1.7,IC50,Antiproliferative activity against human HCT116 cells after 3 days by XTT assay,Confirmatory,19691293.0,
1080,470671,5,2,,104234176,36462,Inconclusive,,,,IC50,Antiproliferative activity against human MDA-MB-231 cells after 3 days by MTT assay,Confirmatory,19691293.0,
1081,470733,5,3,,104234176,36462,Active,,,1.2,IC50,Cytotoxicity against human HONE1 cells after 72 hrs by methylene blue dye assay,Confirmatory,19785430.0,
1082,470734,5,2,,104234176,36462,Active,,,1.3,IC50,Cytotoxicity against human KB cells after 72 hrs by methylene blue dye assay,Confirmatory,19785430.0,
1083,470735,5,2,,104234176,36462,Active,,,2.3,IC50,Cytotoxicity against human HT-29 cells after 72 hrs by methylene blue dye assay,Confirmatory,19785430.0,
1084,471077,5,3,,104234176,36462,Active,,,5.1,IC50,Cytotoxicity against human HuCCa1 cells,Confirmatory,19788270.0,
1085,471078,5,2,,104234176,36462,Active,,,0.5,IC50,Cytotoxicity against human KB cells,Confirmatory,19788270.0,
1086,471079,5,2,,104234176,36462,Active,,,0.4,IC50,Cytotoxicity against human HeLa cells,Confirmatory,19788270.0,
1087,471080,5,2,,104234176,36462,Active,,,0.3,IC50,Cytotoxicity against human MDA-MB-231 cells,Confirmatory,19788270.0,
1088,471081,5,2,,104234176,36462,Active,,,0.1,IC50,Cytotoxicity against human T47D cells,Confirmatory,19788270.0,
1089,471082,5,2,,104234176,36462,Active,,,46.0,IC50,Cytotoxicity against human adriamycin resistant H69 cells,Confirmatory,19788270.0,
1090,474870,5,2,,104234176,36462,Active,,,4.1,IC50,Growth inhibition of human HepG2 cells after 72 hrs by sulforhodamine B assay,Confirmatory,20346660.0,
1091,475883,3,4,,104234176,36462,Active,,,0.145,IC50,Cytotoxicity against human U87MG cells after 48 hrs by [3H]thymidine incorporation assay,Confirmatory,20210346.0,
1092,475884,3,4,,104234176,36462,Active,,,0.062,IC50,Cytotoxicity against human SKHEP1 cells after 48 hrs by [3H]thymidine incorporation assay,Confirmatory,20210346.0,
1093,475885,3,4,,104234176,36462,Active,,,0.09,IC50,Cytotoxicity against human NCI-H460 cells after 48 hrs by [3H]thymidine incorporation assay,Confirmatory,20210346.0,
1094,475888,3,3,,104234176,36462,Unspecified,,,,,Cell cycle arrest in human U87MG cells assessed as accumulation at G0/G1 phase at 3 uM after 24 hrs by flow cytometry,Other,20210346.0,
1095,475892,3,3,,104234176,36462,Unspecified,,,,,Cell cycle arrest in human U87MG cells assessed as accumulation at S phase at 3 uM after 24 hrs by flow cytometry,Other,20210346.0,
1096,475896,3,3,,104234176,36462,Unspecified,,,,,Cell cycle arrest in human U87MG cells assessed as accumulation at G2/M phase at 3 uM after 24 hrs by flow cytometry,Other,20210346.0,
1097,475898,3,5,,104234176,36462,Unspecified,,,,,Drug uptake in perfused mouse brain assessed as blood-brain transfer coefficient,Other,20210346.0,
1098,476929,3,3,,104234176,36462,Unspecified,,,,,Human intestinal absorption in po dosed human,Other,20022146.0,
1099,477032,5,2,,104234176,36462,Active,,,0.83,IC50,Cytotoxicity against human A549 cells after 48 hrs by MTT assay,Confirmatory,20071056.0,
1100,477033,5,3,,104234176,36462,Active,,,0.7,IC50,Cytotoxicity against human RPMI8226 cells after 72 hrs by CCK8 method,Confirmatory,20071056.0,
1101,477034,5,2,,104234176,36462,Active,,,0.18,IC50,Cytotoxicity against human HL60 cells after 72 hrs by CCK8 method,Confirmatory,20071056.0,
1102,477035,5,2,,104234176,36462,Unspecified,,,64.63,IC50,Antioxidant activity in Sprague-Dawley rat kidney assessed as lipid peroxidation by thiobarbituric acid assay,Confirmatory,20071056.0,
1103,477036,5,2,,104234176,36462,Active,,,46.38,IC50,Antioxidant activity in Sprague-Dawley rat liver assessed as lipid peroxidation by thiobarbituric acid assay,Confirmatory,20071056.0,
1104,477295,3,3,,104234176,36462,Unspecified,,,,,"Octanol-water partition coefficient, log P of the compound",Other,20106561.0,
1105,479035,3,4,,104234176,36462,Inactive,,,,,Cytotoxicity in human Jurkat cells overexpressing Bcl2 assessed as cell death at 40 uM after 72 hrs by propidium iodide-staining based flow cytometry,Other,20346684.0,
1106,479389,5,2,,104234176,36462,Active,,,16.0,IC50,Cytotoxicity against human A549 cells after 48 hrs by resazurin reduction assay,Confirmatory,20413315.0,
1107,479390,5,2,,104234176,36462,Active,,,10.0,IC50,Cytotoxicity against human DLD1 cells after 48 hrs by resazurin reduction assay,Confirmatory,20413315.0,
1108,479391,5,3,,104234176,36462,Active,,,4.3,IC50,Cytotoxicity against human WS1 cells after 48 hrs by resazurin reduction assay,Confirmatory,20413315.0,
1109,479392,5,2,,104234176,36462,Active,,,0.042,IC50,Cytotoxicity against human HL60 cells after 72 hrs by MTT assay,Confirmatory,20415462.0,
1110,479393,5,2,,104234176,36462,Active,,,0.63,IC50,Cytotoxicity against human A549 cells after 72 hrs by SRB assay,Confirmatory,20415462.0,
1111,479787,5,2,,104234176,36462,Active,,,8.93,IC50,Cytotoxicity against human HeLa cells by MTT assay,Confirmatory,20356735.0,
1112,479788,5,2,,104234176,36462,Active,,,1.81,IC50,Cytotoxicity against human HL60 cells by MTT assay,Confirmatory,20356735.0,
1113,480103,3,9,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of human recombinant TOP2A-mediated relaxation of supercoiled Escherichia coli pBR322 DNA at 100 uM after 30 mins by transillumination,Other,20392646.0,
1114,480104,4,8,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of human recombinant TOP2A-mediated relaxation of supercoiled Escherichia coli pBR322 DNA at 20 uM after 30 mins by transillumination,Other,20392646.0,
1115,480107,5,2,,104234176,36462,Active,,,0.7,IC50,Cytotoxicity against human MDA-MB-231 cells after 2 days by automatic ELISA reader system,Confirmatory,20392646.0,
1116,480108,5,2,,104234176,36462,Active,,,1.4,IC50,Cytotoxicity against human HeLa cells after 2 days by automatic ELISA reader system,Confirmatory,20392646.0,
1117,480109,5,2,,104234176,36462,Active,,,0.5,IC50,Cytotoxicity against human DU145 cells after 2 days by automatic ELISA reader system,Confirmatory,20392646.0,
1118,480110,5,2,,104234176,36462,Active,,,1.1,IC50,Cytotoxicity against human HCT15 cells after 2 days by automatic ELISA reader system,Confirmatory,20392646.0,
1119,480111,5,2,,104234176,36462,Active,,,1.0,IC50,Cytotoxicity against human HL60 cells after 2 days by automatic ELISA reader system,Confirmatory,20392646.0,
1120,481439,3,4,,104234176,36462,Unspecified,,,,,Absolute bioavailability in human,Other,20373811.0,
1121,481442,3,6,,104234176,36462,Unspecified,,,,,Transcellular permeability at pH 6.5 calculated from in vitro P app values in Caco-2 and/or MDCK cells,Other,20373811.0,
1122,481850,5,2,,104234176,36462,Active,,,30.38,IC50,Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay,Confirmatory,20405844.0,
1123,481851,5,2,,104234176,36462,Active,,,23.22,IC50,Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay,Confirmatory,20405844.0,
1124,481852,5,2,,104234176,36462,Unspecified,,,69.54,IC50,Cytotoxicity against human PC3 cells after 48 hrs by MTT assay,Confirmatory,20405844.0,
1125,481863,5,3,,104234176,36462,Unspecified,,,62.97,IC50,Cytotoxicity against mouse 3T3 cells after 48 hrs by MTT assay,Confirmatory,20405844.0,
1126,481929,3,4,,104234176,36462,Active,,,,,Induction of apoptosis in human HepG2 cells expressing wild type p53 gene assessed as caspase 3 activation,Other,20455578.0,
1127,481931,3,3,,104234176,36462,Inactive,,,,,Induction of apoptosis in human Hep3B cells deficient in p53 gene assessed as caspase 3 activation,Other,20455578.0,
1128,485270,1,1,,49681767,36462,Inactive,222080095.0,3061.0,,,FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
1129,485272,1,1,,49681767,36462,Inactive,216548487.0,23569.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4) (1536 HTS),Screening,,
1130,485273,2,1,,49681767,36462,Inactive,4507793.0,7334.0,,,uHTS identification of UBC13 Polyubiquitin Inhibitors via a TR-FRET Assay,Screening,,
1131,485275,1,3,,49681767,36462,Inactive,,,,,Phenotypic HTS multiplex for antifungal efflux pump inhibitors,Screening,,
1132,485317,1,2,,49681767,36462,Inactive,54112432.0,2671.0,,,HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS,Screening,,
1133,485346,1,1,,49681767,36462,Active,88702791.0,4194.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
1134,485346,1,1,,49681767,36462,Active,89993689.0,4193.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
1135,487391,5,2,,104234176,36462,Active,,,0.39,IC50,Cytotoxicity against human HL60 cells after 72 hrs by MTT assay,Confirmatory,20524638.0,
1136,488839,1,1,,56463308,36462,Inactive,20072248.0,8851.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1137,488839,1,1,,56463308,36462,Inactive,48146199.0,1020.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1138,488847,1,3,,49681767,36462,Inactive,148539876.0,156.0,,,RNA aptamer-based HTS for inhibitors of GRK2,Screening,,
1139,488862,1,1,,56463308,36462,Inactive,,,,,Inhibitors of Prion Protein 5' UTR mRNA Measured in Cell-Based System Using Plate Reader - 2078-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1140,488890,1,2,,49681767,36462,Inactive,,,,IC50,"Elucidation of physiology of non-replicating, drug-tolerant Mycobacterium tuberculosis",Confirmatory,,
1141,488895,1,2,,56463308,36462,Inactive,90111653.0,948321.0,,,High Throughput Screen for Tat Transport Inhibitors Measured in Microorganism System Using Plate Reader - 2093-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1142,488896,1,1,,56463308,36462,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1143,488899,1,1,,56463308,36462,Inactive,40807040.0,4286.0,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1144,488922,1,2,,49681767,36462,Inactive,7706135.0,,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9,Screening,,
1145,488965,1,2,,56463308,36462,Inactive,218891639.0,,,,Fluorescent Biochemical Primary HTS to Identify Inhibitors of P. aeruginosa PvdQ acylase Measured in Biochemical System Using Plate Reader and Imaging Combination - 2091-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1146,488966,1,1,,56463308,36462,Inactive,,,,IC50,Primary and Confirmatory Screening for Inhibitors of Bacterial Capsule Biogenesis,Confirmatory,,
1147,488975,1,2,,49681767,36462,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT),Screening,,
1148,488977,1,2,,49681767,36462,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that allosterically activate the Choline Transporter (CHT),Screening,,
1149,489028,1,2,,49681767,36462,Active,88702791.0,4194.0,,,Single concentration confirmation of uHTS for Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
1150,489028,1,2,,49681767,36462,Active,89993689.0,4193.0,,,Single concentration confirmation of uHTS for Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
1151,489030,2,1,,49681767,36462,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of inhibitors of Apaf-1,Screening,,
1152,489031,2,1,,49681767,36462,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of activators of Apaf-1,Screening,,
1153,490078,5,2,,104234176,36462,Active,,,1.3,IC50,Cytotoxicity against human topoisomerase 2-sensitive HL60 cells after 72 hrs by MTT assay,Confirmatory,20570510.0,
1154,490079,5,3,,104234176,36462,Active,,,11.9,IC50,Cytotoxicity against human HL60/MX2 cells after 72 hrs by MTT assay,Confirmatory,20570510.0,
1155,490082,3,5,,104234176,36462,Unspecified,,,,,Binding affinity to calf thymus DNA assessed as change in melting temperature at 10 uM,Other,20570510.0,
1156,490083,3,5,,104234176,36462,Unspecified,,,,,Binding affinity to calf thymus DNA assessed as change in melting temperature at 20 uM,Other,20570510.0,
1157,490084,3,5,,104234176,36462,Unspecified,,,,,Binding affinity to [poly(dAdT)]2 DNA assessed as change in melting temperature at 10 uM,Other,20570510.0,
1158,490085,3,5,,104234176,36462,Unspecified,,,,,Binding affinity to [poly(dAdT)]2 DNA assessed as change in melting temperature at 20 uM,Other,20570510.0,
1159,490286,5,3,,104234176,36462,Active,,,0.5,IC50,Antiproliferative activity against mouse SFME cells after 24 hrs by MTT assay,Confirmatory,20398972.0,
1160,490287,5,3,,104234176,36462,Active,,,9.0,IC50,Antiproliferative activity against mouse r/m HM-SFME-1 cells after 24 hrs by MTT assay,Confirmatory,20398972.0,
1161,490305,5,1,,104234176,36462,Unspecified,,,,,Toxicity against Artemia salina nauplii larvae,Other,20399542.0,
1162,492484,9,1,,104234176,36462,Active,,,,IC50,Cytotoxicity against human KB cells after 72 hrs by MTT assay,Confirmatory,20187635.0,
1163,492485,5,3,,104234176,36462,Active,,,34.8,IC50,Cytotoxicity against human KB1 cells after 72 hrs by MTT assay,Confirmatory,20187635.0,
1164,492486,9,1,,104234176,36462,Unspecified,,,77.5,IC50,Cytotoxicity against human KB-7d cells after 72 hrs by MTT assay,Confirmatory,20187635.0,
1165,492487,5,2,,104234176,36462,Active,,,28.7,IC50,Cytotoxicity against human vincristine-resistant KB cells after 72 hrs by MTT assay,Confirmatory,20187635.0,
1166,492953,1,1,,56463308,36462,Inactive,296080766.0,5049.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1b, catalytic subunit 2 (PAFAH1B2)",Screening,,
1167,492956,1,1,,56463308,36462,Inactive,4758878.0,5051.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet activating factor acetylhydrolase 2 (PAFAH2),Screening,,
1168,492972,1,1,,56463308,36462,Inactive,225543099.0,5050.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1B, catalytic subunit 3 (PAFAH1B3)",Screening,,
1169,493005,1,1,,56463308,36462,Inactive,5454140.0,7251.0,,Potency,qHTS Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
1170,493008,1,1,,56463308,36462,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1171,493008,1,1,,56463308,36462,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1172,493008,1,1,,56463308,36462,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1173,493008,1,1,,56463308,36462,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1174,493011,1,1,,49681767,36462,Inactive,21955158.0,200315.0,,,uHTS identification of APOBEC3A DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
1175,493012,1,1,,49681767,36462,Inactive,13399304.0,60489.0,,,uHTS identification of APOBEC3G DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
1176,493036,1,2,,49681767,36462,Inactive,110611243.0,4923.0,,,Image-Based HTS for Selective Agonists for NTR1,Screening,,
1177,493087,1,1,,56463308,36462,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify activators of insulin-degrading enzyme (IDE),Screening,,
1178,493091,1,1,,56463308,36462,Inactive,10864009.0,58190.0,,,uHTS Colorimetric assay for identification of inhibitors of Scp-1,Screening,,
1179,493098,1,1,,56463308,36462,Inactive,37187860.0,1235.0,,,uHTS identification of small molecule antagonists of the CCR6 receptor via a luminescent beta-arrestin assay,Screening,,
1180,493131,1,1,,56463308,36462,Inactive,6679827.0,14282.0,,,Activator for delta FosB/delta FosB homodimer Measured in Biochemical System Using Plate Reader - 2072-01_Activator_SinglePoint_HTS_Activity,Screening,,
1181,493160,1,1,,56463308,36462,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of inhibitors of hexokinase domain containing  I (HKDC1),Screening,,
1182,493187,1,2,,56463308,36462,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of activators of hexokinase domain containing  I (HKDC1),Screening,,
1183,493244,1,1,,56463308,36462,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1184,493244,1,1,,56463308,36462,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1185,493244,1,1,,56463308,36462,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1186,493244,1,1,,56463308,36462,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1187,494581,4,2,,104234176,36462,Active,,,19.0,IC50,Cytotoxicity activity against human A375 cells after 24 hrs by NRU assay,Confirmatory,20570625.0,
1188,494582,2,4,,104234176,36462,Unspecified,,,,,Cytotoxicity activity against human A375 cells at 50 uM after 24 hrs by NRU assay,Other,20570625.0,
1189,494583,4,2,,104234176,36462,Active,,,12.0,IC50,Cytotoxicity activity against human A375 cells after 48 hrs by NRU assay,Confirmatory,20570625.0,
1190,494584,2,4,,104234176,36462,Unspecified,,,,,Cytotoxicity activity against human A375 cells at 50 uM after 48 hrs by NRU assay,Other,20570625.0,
1191,494585,4,2,,104234176,36462,Active,,,9.0,IC50,Cytotoxicity activity against mouse B16 cells after 24 hrs by NRU assay,Confirmatory,20570625.0,
1192,494586,2,4,,104234176,36462,Unspecified,,,,,Cytotoxicity activity against mouse B16 cells at 50 uM after 24 hrs by NRU assay,Other,20570625.0,
1193,494587,4,2,,104234176,36462,Active,,,0.13,IC50,Cytotoxicity activity against mouse B16 cells after 48 hrs by NRU assay,Confirmatory,20570625.0,
1194,494588,2,4,,104234176,36462,Unspecified,,,,,Cytotoxicity activity against mouse B16 cells at 50 uM after 48 hrs by NRU assay,Other,20570625.0,
1195,496817,4,2,,104234176,36462,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma cruzi,Confirmatory,20185316.0,
1196,496818,4,2,,104234176,36462,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma brucei brucei,Confirmatory,20185316.0,
1197,496819,4,2,,104234176,36462,Inconclusive,,,,IC50,Antimicrobial activity against Plasmodium falciparum,Confirmatory,20185316.0,
1198,496820,4,2,,104234176,36462,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma brucei,Confirmatory,20185316.0,
1199,496821,4,2,,104234176,36462,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania,Confirmatory,20185316.0,
1200,496823,4,2,,104234176,36462,Inconclusive,,,,IC50,Antimicrobial activity against Trichomonas vaginalis,Confirmatory,20185316.0,
1201,496824,4,2,,104234176,36462,Inconclusive,,,,IC50,Antimicrobial activity against Toxoplasma gondii,Confirmatory,20185316.0,
1202,496825,4,2,,104234176,36462,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania mexicana,Confirmatory,20185316.0,
1203,496826,4,2,,104234176,36462,Inconclusive,,,,IC50,Antimicrobial activity against Entamoeba histolytica,Confirmatory,20185316.0,
1204,496827,4,2,,104234176,36462,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania amazonensis,Confirmatory,20185316.0,
1205,496828,4,2,,104234176,36462,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania donovani,Confirmatory,20185316.0,
1206,496829,4,2,,104234176,36462,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania infantum,Confirmatory,20185316.0,
1207,496830,4,2,,104234176,36462,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania major,Confirmatory,20185316.0,
1208,496831,4,2,,104234176,36462,Inconclusive,,,,IC50,Antimicrobial activity against Cryptosporidium parvum,Confirmatory,20185316.0,
1209,496832,4,2,,104234176,36462,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma brucei rhodesiense,Confirmatory,20185316.0,
1210,497005,4,2,,104234176,36462,Inconclusive,,,,IC50,Antimicrobial activity against Pneumocystis carinii,Confirmatory,20185316.0,
1211,503706,2,4,,104234176,36462,Active,,,,,Induction of apoptosis in human HL60 cells assessed as mitochondrial membrane depolarization at 10 uM after 12 hrs by fluorescence assay,Other,16936720.0,
1212,503707,2,4,,104234176,36462,Active,,,,,Induction of apoptosis in human HL60 cells assessed as increase in caspase-3 activity at 10 uM after 12 hrs,Other,16936720.0,
1213,503710,2,4,,104234176,36462,Active,,,,,Induction of apoptosis in human HL60 cells assessed as increase in PARP1 cleavage at 10 uM after 12 hrs by fluorescence assay,Other,16936720.0,
1214,503711,2,4,,104234176,36462,Active,,,,,Induction of apoptosis in human HL60 cells assessed as increase in PARP1 cleavage at 100 uM after 12 hrs by fluorescence assay,Other,16936720.0,
1215,503714,4,7,,104234176,36462,Unspecified,77416852.0,836.0,50.0,IC50,Activation of procaspase-3-mediated human UACC62 cell death after 72 hrs by MTS/PMS assay,Confirmatory,16936720.0,
1216,503715,4,7,,104234176,36462,Unspecified,77416852.0,836.0,50.0,IC50,Activation of procaspase-3-mediated human CRL1782 cell death after 72 hrs by MTS/PMS assay,Confirmatory,16936720.0,
1217,503716,4,7,,104234176,36462,Unspecified,77416852.0,836.0,50.0,IC50,Activation of procaspase-3-mediated human B16-F10 cell death after 72 hrs by MTS/PMS assay,Confirmatory,16936720.0,
1218,503717,4,7,,104234176,36462,Unspecified,77416852.0,836.0,50.0,IC50,Activation of procaspase-3-mediated human Hs 578T cell death after 72 hrs by MTS/PMS assay,Confirmatory,16936720.0,
1219,503718,4,7,,104234176,36462,Unspecified,77416852.0,836.0,50.0,IC50,Activation of procaspase-3-mediated human NCI-H226 cell death after 72 hrs by MTS/PMS assay,Confirmatory,16936720.0,
1220,503719,7,5,,104234176,36462,Active,77416852.0,836.0,1.0,IC50,Activation of procaspase-3-mediated human HL60 cell death after 72 hrs by MTS/PMS assay,Confirmatory,16936720.0,
1221,503720,4,7,,104234176,36462,Active,77416852.0,836.0,1.0,IC50,Activation of procaspase-3-mediated human U937 cell death after 72 hrs by MTS/PMS assay,Confirmatory,16936720.0,
1222,503721,4,7,,104234176,36462,Active,77416852.0,836.0,1.0,IC50,Activation of procaspase-3-mediated human SK-N-SH cell death after 72 hrs by MTS/PMS assay,Confirmatory,16936720.0,
1223,503722,4,7,,104234176,36462,Active,77416852.0,836.0,1.0,IC50,Activation of procaspase-3-mediated human PC12 cell death after 72 hrs by MTS/PMS assay,Confirmatory,16936720.0,
1224,504326,1,2,,56463308,36462,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
1225,504326,1,2,,56463308,36462,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
1226,504329,1,1,,56463308,36462,Inactive,227977143.0,23308111.0,,IC50,Discovery of Small Molecule Probes for H1N1 Influenza NS1A,Confirmatory,,
1227,504339,1,1,,56463308,36462,Inactive,162330054.0,,,Potency,qHTS Assay for Inhibitors of JMJD2A-Tudor Domain,Confirmatory,,
1228,504357,1,1,,56463308,36462,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
1229,504357,1,1,,56463308,36462,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
1230,504406,1,1,,49681767,36462,Inactive,15610945.0,886142.0,,,Inhibitors of Mycobacterium tuberculosis UDP-galactopyranose mutase (UGM) enzyme - High throughput screening using Fluorescent polarization assay Measured in Biochemical System Using Plate Reader - 2105-01_Inhibitor_SinglePoint_HTS_Activity_Set6,Screening,,
1231,504408,2,1,,49681767,36462,Inactive,,,,,Heat Shock Factor-1 (HSF-1) Measured in Cell-Based System Using Plate Reader - 2038-01_Activator_SinglePoint_HTS_Activity,Screening,,
1232,504411,1,1,,56463308,36462,Inactive,218931251.0,221955.0,,,"Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of human diacylglycerol lipase, beta (DAGLB)",Screening,,
1233,504414,1,1,,56463308,36462,Inactive,9966877.0,57120.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1234,504414,1,1,,56463308,36462,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1235,504423,1,1,,56463308,36462,Inactive,312275222.0,,,,C-LANA FP assay Measured in Biochemical System Using Plate Reader - 2117-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1236,504441,1,1,,56463308,36462,Inactive,6978787.0,25255.0,,,Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1237,504444,1,1,,56463308,36462,Inconclusive,224028257.0,4780.0,0.6513,Potency,Nrf2 qHTS screen for inhibitors,Confirmatory,,
1238,504454,1,3,,56463308,36462,Inactive,4501969.0,154.0,,,HTS for Beta-2AR agonists via FAP method,Screening,,
1239,504462,1,1,,56463308,36462,Inactive,47132611.0,23192.0,,,uHTS fluorescent assay for identification of inhibitors of ATG4B,Screening,,
1240,504490,1,2,,56463308,36462,Inactive,13177715.0,408.0,,,Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction That Mediate GPCR Degradation and Recycling,Screening,,
1241,504523,1,1,,56463308,36462,Inactive,45269145.0,9817.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1242,504523,1,1,,56463308,36462,Inactive,224028257.0,4780.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1243,504558,1,1,,56463308,36462,Active,23893668.0,3783750.0,,,Inhibitors of Epstein-Barr LMP1 inducible NF-kappaB luciferase reporter Measured in Cell-Based System Using Plate Reader - 2122-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1244,504577,2,2,,56463308,36462,Inactive,6325022.0,855842.0,,,HTS of Small Molecules that Regulate V-ATPase Proton Transport in Yeast using pHLuorin,Screening,,
1245,504582,2,1,,56463308,36462,Inactive,124809271.0,811941.0,,,In vivo-based yeast HTS to detect compounds rescuing yeast growth/survival of Plasmodium Falciparum HSP40-mediated toxicity Measured in Whole Organism System Using Plate Reader - 2120-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1246,504607,1,1,,49681767,36462,Inactive,,,,,Single concentration confirmation of inhibitors of Mdm2/MdmX interaction using a Full-Length Luciferase Counterscreen assay,Screening,,
1247,504621,1,1,,56463308,36462,Inactive,124809506.0,811999.0,,,Anti-Malarial Hsp90 Inhibitors Measured in Microorganism System Using Plate Reader - 2121-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1248,504634,1,1,,56463308,36462,Inactive,13236497.0,3361.0,,,Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
1249,504648,1,1,,56463308,36462,Inactive,,,,Potency,Nrf2 qHTS screen for inhibitors: counterscreen for cytotoxicity,Confirmatory,,
1250,504668,1,1,,49681767,36462,Active,728984.0,672.0,,,Single concentration confirmation of inhibitors of Mdm2/MdmX interaction using a Brca1/Bard1 BiLC Counterscreen assay.,Screening,,
1251,504668,1,1,,49681767,36462,Active,116241265.0,580.0,,,Single concentration confirmation of inhibitors of Mdm2/MdmX interaction using a Brca1/Bard1 BiLC Counterscreen assay.,Screening,,
1252,504690,1,3,,56463308,36462,Inactive,12381848.0,,,,uHTS identification of small molecule inhibitors of Plasmodium falciparum Glucose-6-phosphate dehydrogenase via a fluorescence intensity assay,Screening,,
1253,504692,2,2,,56463308,36462,Inactive,13236497.0,3361.0,,,Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
1254,504700,1,1,,56463308,36462,Inactive,46909587.0,5567.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
1255,504700,1,1,,56463308,36462,Inactive,47132585.0,5577.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
1256,504707,1,1,,56463308,36462,Inactive,6755076.0,18749.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
1257,504707,1,1,,56463308,36462,Inactive,115496662.0,615074.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
1258,504720,1,1,,56463308,36462,Inactive,16130689.0,947252.0,,,uHTS identification of MazEF TA System activators  via a fluorescence-based single-stranded RNase assay,Screening,,
1259,504734,1,1,,56463308,36462,Inactive,194068499.0,54106.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.,Screening,,
1260,504766,2,1,,56463308,36462,Inactive,5016090.0,190.0,,,"Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)",Screening,,
1261,504775,1,1,,56463308,36462,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity,Screening,,
1262,504803,1,1,,56463308,36462,Inactive,121945198.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1),Screening,,
1263,504845,1,1,,56463308,36462,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
1264,504847,1,1,,56463308,36462,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
1265,504861,1,1,,56463308,36462,Active,23893668.0,3783750.0,26.497,AC50_uM,Viability counterscreen of potential LMP-1 inhibitors in HEK293 cell background Measured in Cell-Based System Using Plate Reader - 2122-02_Inhibitor_Dose_CherryPick_Activity,Confirmatory,,
1266,504882,1,1,,56463308,36462,Active,23893668.0,3783750.0,0.531,AC50_uM,Lymphoblastoid Cells (LCL) Cytotoxicity Secondary Assay Measured in Cell-Based System Using Plate Reader - 2122-03_Inhibitor_Dose_CherryPick_Activity_Set2,Confirmatory,,
1267,504884,1,2,,56463308,36462,Inactive,115347926.0,1175052.0,,,Inhibitors of Y. pestis Topo-I using cleavage product accumulation Measured in Biochemical System Using Plate Reader - 2123-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1268,504891,1,1,,56463308,36462,Inactive,5453898.0,5300.0,,Potency,qHTS Assay to Find Inhibitors of Pin1,Confirmatory,,
1269,504894,1,1,,56463308,36462,Inactive,553160.0,,,Potency,Activators of T cell receptors: qHTS campaign,Confirmatory,,
1270,504937,1,2,,56463308,36462,Inactive,179095.0,6609.0,,Potency,Inhibitors of Secretory Acid Sphingomyelinase (S-ASM): qHTS,Confirmatory,,
1271,510624,4,2,,104234176,36462,Active,,,16.3,IC50,Cytotoxicity against human MDA-MB-231 cells after 4 days by MTT assay,Confirmatory,20619511.0,
1272,510625,4,2,,104234176,36462,Active,,,17.5,IC50,Cytotoxicity against human MCF7 cells after 4 days by MTT assay,Confirmatory,20619511.0,
1273,510626,4,2,,104234176,36462,Active,,,11.9,IC50,Cytotoxicity against human HCT116 cells after 4 days by MTT assay,Confirmatory,20619511.0,
1274,510627,4,2,,104234176,36462,Active,,,13.8,IC50,Cytotoxicity against human DU145 cells after 4 days by MTT assay,Confirmatory,20619511.0,
1275,510628,4,2,,104234176,36462,Active,,,18.2,IC50,Cytotoxicity against human HeLa cells after 4 days by MTT assay,Confirmatory,20619511.0,
1276,510633,2,9,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of human topoisomerase 2alpha-mediated relaxation of supercoiled pBR322 DNA at 20 uM after 30 mins by agarose gel electrophoresis,Other,20619511.0,
1277,510634,2,9,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of human topoisomerase 2alpha-mediated relaxation of supercoiled pBR322 DNA at 100 uM after 30 mins by agarose gel electrophoresis,Other,20619511.0,
1278,521208,4,2,,104234176,36462,Active,,,0.34,EC50,Antiproliferative activity against mouse neural precursor cells by MTT assay,Confirmatory,17417631.0,
1279,521209,4,3,,104234176,36462,Active,,,0.433,EC50,Antiproliferative activity against mouse astrocyte cells by MTT assay,Confirmatory,17417631.0,
1280,521210,4,1,,104234176,36462,Unspecified,,,,,Ratio of EC50 for mouse astrocytes to EC50 for mouse neural precursor cells by MTT assay,Other,17417631.0,
1281,521214,4,2,,104234176,36462,Active,,,0.20800000000000002,EC50,Antiproliferative activity against mouse medulloblastoma cells harboring heterozygous ptch1 gene by MTT assay,Confirmatory,17417631.0,
1282,521215,4,2,,104234176,36462,Inconclusive,,,,EC50,Antiproliferative activity against mouse neural precursor cells by colony formation assay,Confirmatory,17417631.0,
1283,521220,3,3,,104234176,36462,Inactive,,,,,Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay,Other,17417631.0,
1284,524790,7,2,,104234176,36462,Active,,,3.16228,IC50,Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
1285,524791,7,2,,104234176,36462,Active,,,3.98107,IC50,Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
1286,524792,7,2,,104234176,36462,Active,,,5.01187,IC50,Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
1287,524793,7,2,,104234176,36462,Active,,,6.30957,IC50,Antiplasmodial activity against Plasmodium falciparum Dd2 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
1288,524794,7,1,,104234176,36462,Active,,,5.01187,IC50,Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
1289,524795,7,2,,104234176,36462,Active,,,5.01187,IC50,Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
1290,524796,7,1,,104234176,36462,Active,,,3.98107,IC50,Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
1291,536032,1,4,,104234176,36462,Unspecified,,,,,Binding affinity to calf thymus DNA assessed as change in melting temperature at drug/DNA ratio 0.25,Other,20961767.0,
1292,536033,1,3,,104234176,36462,Unspecified,,,,,Displacement of DNA-bound ethidium bromide from calf thymus DNA at 10 uM by fluorescence assay,Other,20961767.0,
1293,536039,4,2,,104234176,36462,Active,,,0.486,IC50,Cytotoxicity against human HL60 cells after 72 hrs,Confirmatory,20961767.0,
1294,536040,4,3,,104234176,36462,Active,,,48.5,IC50,Cytotoxicity against human HL60/MX2 cells after 72 hrs,Confirmatory,20961767.0,
1295,536041,2,3,,104234176,36462,Unspecified,,,,,"Resistance index, ratio of IC50 for human HL60/MX2 cells to IC50 for human HL60 cells",Other,20961767.0,
1296,536656,4,2,,104234176,36462,Active,,,3.9,IC50,Cytotoxicity against human MRC5 cells after 72 hrs by MTT assay,Confirmatory,20828890.0,
1297,536657,4,2,,104234176,36462,Active,,,0.36,IC50,Cytotoxicity against human AGS cells after 72 hrs by MTT assay,Confirmatory,20828890.0,
1298,536658,4,3,,104234176,36462,Active,,,2.5,IC50,Cytotoxicity against human SKMES1 cells after 72 hrs by MTT assay,Confirmatory,20828890.0,
1299,536659,4,2,,104234176,36462,Active,,,2.8,IC50,Cytotoxicity against human J82 cells after 72 hrs by MTT assay,Confirmatory,20828890.0,
1300,536660,4,4,,104234176,36462,Active,,,0.8,IC50,Cytotoxicity against human HL-60(TB) cells after 72 hrs by MTT assay,Confirmatory,20828890.0,
1301,537733,2,3,,104234176,36462,Active,,,,,Binding affinity to Candida albicans CaCdr1p expressed in yeast AD1-8u,Other,20739103.0,
1302,537734,5,2,,104234176,36462,Unspecified,,,,,Antifungal activity against yeast AD1-8u expressing Candida albicans CaMdr1p by agar disk diffusion assay,Other,20739103.0,
1303,537735,2,3,,104234176,36462,Active,,,,,Binding affinity to Candida albicans CaMdr1p expressed in yeast AD1-8u,Other,20739103.0,
1304,537736,5,2,,104234176,36462,Unspecified,,,,,Antifungal activity against yeast AD1-8u expressing Candida albicans CaCdr1p by agar disk diffusion assay,Other,20739103.0,
1305,538064,3,4,,104234176,36462,Active,,,,,Inhibition of DNA topoisomerase 2 assessed as inhibition of relaxation of supercoiled pBR322 plasmid DNA at 10 uM by gel electrophoresis,Other,21074444.0,
1306,538065,4,3,,104234176,36462,Active,,,0.1,IC50,Anticancer activity against human 502713 cells assessed as cell viability after 48 hrs by SRB assay,Confirmatory,21074444.0,
1307,538066,4,2,,104234176,36462,Active,,,0.9,IC50,Anticancer activity against human HCT15 cells assessed as cell viability after 48 hrs by SRB assay,Confirmatory,21074444.0,
1308,538067,4,3,,104234176,36462,Active,,,0.9,IC50,Anticancer activity against human Hep2 cells assessed as cell viability after 48 hrs by SRB assay,Confirmatory,21074444.0,
1309,538068,4,3,,104234176,36462,Active,,,6.3,IC50,Anticancer activity against human IMR32 cells assessed as cell viability after 48 hrs by SRB assay,Confirmatory,21074444.0,
1310,538069,4,2,,104234176,36462,Active,,,3.08,IC50,Anticancer activity against human A549 cells assessed as cell viability after 48 hrs by SRB assay,Confirmatory,21074444.0,
1311,538070,4,2,,104234176,36462,Active,,,3.7,IC50,Anticancer activity against human DU145 cells assessed as cell viability after 48 hrs by SRB assay,Confirmatory,21074444.0,
1312,538071,4,2,,104234176,36462,Active,,,2.6,IC50,Anticancer activity against human PC3 cells assessed as cell viability after 48 hrs by SRB assay,Confirmatory,21074444.0,
1313,538320,3,8,,104234176,36462,Active,13959709.0,7153.0,,,Inhibition of human topoisomerase 2-mediated relaxation of supercoiled PUC19 DNA at 20 to 50 uM uM after 20 mins using ethidium bromide staining by agarose gel electrophoresis,Other,20863598.0,
1314,538322,2,4,,104234176,36462,Active,,,0.49,IC50,Cytotoxicity against human HL60 cells,Confirmatory,20863598.0,
1315,539593,4,2,,104234176,36462,Active,,,38.9045,GI50,Growth inhibition of human NCI60 cells by SBR assay,Confirmatory,21035334.0,
1316,539594,4,3,,104234176,36462,Unspecified,,,100.0,LC50,Cytotoxicity against human NCI60 cells by SBR assay,Confirmatory,21035334.0,
1317,540209,4,3,,104234176,36462,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,18426954.0,
1318,540210,4,3,,104234176,36462,Unspecified,,,,,Clearance in human after iv administration,Other,18426954.0,
1319,540211,2,5,,104234176,36462,Unspecified,,,,,Fraction unbound in human after iv administration,Other,18426954.0,
1320,540212,4,3,,104234176,36462,Unspecified,,,,,Mean residence time in human after iv administration,Other,18426954.0,
1321,540213,4,3,,104234176,36462,Unspecified,,,,,Half life in human after iv administration,Other,18426954.0,
1322,540235,1,3,,104234176,36462,Inactive,,,,,Phospholipidosis-negative literature compound,Other,17428028.0,
1323,540253,1,1,,56463308,36462,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
1324,540253,1,1,,56463308,36462,Inactive,5453555.0,5901.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
1325,540253,1,1,,56463308,36462,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
1326,540263,1,1,,56463308,36462,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
1327,540263,1,1,,56463308,36462,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
1328,540267,1,1,,56463308,36462,Inactive,,,,,Small Molecules that selectively kill Giardia lamblia: qHTS,Screening,,
1329,540295,1,1,,56463308,36462,Inactive,119508433.0,4160.0,,,TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R,Screening,,
1330,540303,1,1,,56463308,36462,Inconclusive,6679377.0,18792.0,0.3981,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
1331,540303,1,1,,56463308,36462,Inconclusive,7242179.0,18793.0,0.3981,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
1332,540303,1,1,,56463308,36462,Inconclusive,257471003.0,18815.0,0.3981,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
1333,540308,1,1,,56463308,36462,Inactive,119508433.0,4160.0,,,Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R,Screening,,
1334,540317,1,1,,56463308,36462,Inactive,187960037.0,10951.0,79.4328,Potency,HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
1335,540336,1,1,,56463308,36462,Inactive,68474550.0,3639678.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1336,540336,1,1,,56463308,36462,Inactive,68488893.0,3646682.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1337,540364,1,2,,56463308,36462,Inactive,,2395.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the GAA850 frataxin (FXN) promoter,Screening,,
1338,548077,2,10,,104234176,36462,Active,363548478.0,21973.0,,,Inhibition of mouse DNA topoisomerase 2-mediated supercoiled pBR322 DNA relaxation at 25 uM after 1 hr by agarose gel electrophoresis,Other,20884089.0,
1339,548078,4,2,,104234176,36462,Active,,,1.3,GI50,Growth inhibition of human gastric cancer cells after 72 hrs by sulforhodamine B assay,Confirmatory,20884089.0,
1340,548079,4,2,,104234176,36462,Active,,,1.3,GI50,Growth inhibition of human lung cancer cells after 72 hrs by sulforhodamine B assay,Confirmatory,20884089.0,
1341,548080,4,2,,104234176,36462,Active,,,1.3,GI50,Growth inhibition of human colon cancer cells after 72 hrs by sulforhodamine B assay,Confirmatory,20884089.0,
1342,549975,4,3,,104234176,36462,Unspecified,,,10.0,IC50,Antiproliferative activity against human HCT15/CL02 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20939516.0,
1343,549976,4,2,,104234176,36462,Active,,,1.6,IC50,Antiproliferative activity against human HCT15 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20939516.0,
1344,549977,4,3,,104234176,36462,Active,,,0.3,IC50,Antiproliferative activity against human MESSA cells after 48 hrs by sulforhodamine B assay,Confirmatory,20939516.0,
1345,549978,4,3,,104234176,36462,Unspecified,,,10.0,IC50,Antiproliferative activity against human MESSA/DX5 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20939516.0,
1346,550013,4,3,,104234176,36462,Active,,,4.5,EC50,Cytotoxicity against human KB cells after 3 days by sulforhodamine B assay,Confirmatory,21028898.0,
1347,550014,4,4,,104234176,36462,Unspecified,,,36.0,EC50,Cytotoxicity against human KBVIN cells after 3 days by sulforhodamine B assay,Confirmatory,21028898.0,
1348,552710,4,2,,104234176,36462,Active,,,1.98,IC50,Cytotoxicity against human MCF7 cells by MTT assay,Confirmatory,21115246.0,
1349,552711,4,2,,104234176,36462,Active,,,1.21,IC50,Cytotoxicity against human K562 cells by MTT assay,Confirmatory,21115246.0,
1350,552712,4,2,,104234176,36462,Active,,,1.44,IC50,Cytotoxicity against human DU145 cells by MTT assay,Confirmatory,21115246.0,
1351,552713,4,2,,104234176,36462,Active,,,2.03,IC50,Cytotoxicity against human HCT15 cells by MTT assay,Confirmatory,21115246.0,
1352,552715,2,10,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of human topoisomerase 2-mediated relaxation of supercoiled pBR322 at 100 uM by agarose gel electrophoresis,Other,21115246.0,
1353,552716,2,10,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of human topoisomerase 2-mediated relaxation of supercoiled pBR322 at 20 uM by agarose gel electrophoresis,Other,21115246.0,
1354,565903,2,4,,104234176,36462,Active,,,0.00461,IC50,Cytotoxicity against human KB cells after 72 hrs by MTT assay,Confirmatory,21145139.0,
1355,565904,2,5,,104234176,36462,Active,,,0.0834,IC50,Cytotoxicity against human KB/VCR cells after 72 hrs by MTT assay,Confirmatory,21145139.0,
1356,565905,2,4,,104234176,36462,Active,,,0.00256,IC50,Cytotoxicity against human A549 cells after 72 hrs by MTT assay,Confirmatory,21145139.0,
1357,565906,2,5,,104234176,36462,Active,,,0.0202,IC50,Cytotoxicity against human 95-D cells after 72 hrs by MTT assay,Confirmatory,21145139.0,
1358,565907,2,4,,104234176,36462,Unspecified,,,,,"Resistance factor, ratio of IC50 for human KB/VCR cells to IC50 for human KB cells",Other,21145139.0,
1359,567387,7,1,,104234176,36462,Unspecified,,,,GI50,Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay,Confirmatory,21115210.0,
1360,567388,7,1,,104234176,36462,Unspecified,,,,GI50,Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay,Confirmatory,21115210.0,
1361,567389,4,2,,104234176,36462,Active,,,12.59,GI50,Cytotoxicity against human K562 cells after 72 hrs by MTT assay,Confirmatory,21115210.0,
1362,567390,4,2,,104234176,36462,Inconclusive,,,,GI50,Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay,Confirmatory,21115210.0,
1363,567391,4,2,,104234176,36462,Active,,,0.63,GI50,Cytotoxicity against human PC3 cells after 72 hrs by MTT assay,Confirmatory,21115210.0,
1364,567392,4,3,,104234176,36462,Inconclusive,,,,GI50,Cytotoxicity against human MCF10A cells after 72 hrs by MTT assay,Confirmatory,21115210.0,
1365,568562,4,3,,104234176,36462,Inconclusive,,,,IC50,Cytotoxicity against human HuCCA1 cells by MTT assay,Confirmatory,21174408.0,
1366,568563,4,2,,104234176,36462,Active,,,15.8,IC50,Cytotoxicity against human HepG2 cells by MTT assay,Confirmatory,21174408.0,
1367,568564,4,2,,104234176,36462,Inconclusive,,,,IC50,Cytotoxicity against human A549 cells by MTT assay,Confirmatory,21174408.0,
1368,568565,4,3,,104234176,36462,Active,,,0.03,IC50,Cytotoxicity against human MOLT3 cells by XTT assay,Confirmatory,21174408.0,
1369,568678,4,2,,104234176,36462,Unspecified,,,,,Cytotoxicity against human KB cells after 3 days by MTT assay,Other,21216051.0,
1370,568679,5,3,,104234176,36462,Unspecified,,,,,Cytotoxicity against human HuCCa1 cells after 3 days by MTT assay,Other,21216051.0,
1371,568680,4,2,,104234176,36462,Unspecified,,,,,Cytotoxicity against human MDA-MB-231 cells after 3 days by MTT assay,Other,21216051.0,
1372,568681,4,2,,104234176,36462,Unspecified,,,,,Cytotoxicity against human T47D cells after 3 days by MTT assay,Other,21216051.0,
1373,568682,4,2,,104234176,36462,Unspecified,,,,,Cytotoxicity against human A549 cells after 3 days by MTT assay,Other,21216051.0,
1374,568684,5,3,,104234176,36462,Unspecified,,,,,Cytotoxicity against human H69AR cells after 3 days by MTT assay,Other,21216051.0,
1375,568685,4,2,,104234176,36462,Unspecified,,,,,Cytotoxicity against human HeLa cells after 3 days by MTT assay,Other,21216051.0,
1376,568686,4,2,,104234176,36462,Unspecified,,,,,Cytotoxicity against human HepG2 cells after 3 days by MTT assay,Other,21216051.0,
1377,568687,5,3,,104234176,36462,Unspecified,,,,,Cytotoxicity against human HCC-S102 cells after 3 days by MTT assay,Other,21216051.0,
1378,568688,4,2,,104234176,36462,Unspecified,,,,,Cytotoxicity against human HL60 cells after 3 days by MTT assay,Other,21216051.0,
1379,568689,4,2,,104234176,36462,Unspecified,,,,,Cytotoxicity against mouse P388 cells after 3 days by MTT assay,Other,21216051.0,
1380,568742,4,2,,104234176,36462,Active,,,1.85,IC50,Cytotoxicity against human A549 cells by SRB assay,Confirmatory,21182258.0,
1381,568743,4,2,,104234176,36462,Active,,,1.81,IC50,Cytotoxicity against human SKOV3 cells by SRB assay,Confirmatory,21182258.0,
1382,568744,4,2,,104234176,36462,Active,,,1.17,IC50,Cytotoxicity against human SK-MEL-2 cells by SRB assay,Confirmatory,21182258.0,
1383,568745,4,2,,104234176,36462,Active,,,1.72,IC50,Cytotoxicity against human XF498 cells by SRB assay,Confirmatory,21182258.0,
1384,587355,4,2,,104234176,36462,Active,,,13.5,IC50,Cytotoxicity against human HCT116 cells assessed as cell growth inhibition after 3 days by MTT assay,Confirmatory,21277655.0,
1385,587356,4,2,,104234176,36462,Active,,,4.9,IC50,Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 3 days by MTT assay,Confirmatory,21277655.0,
1386,587357,4,2,,104234176,36462,Active,,,21.4,IC50,Cytotoxicity against human A549 cells assessed as cell growth inhibition after 3 days by MTT assay,Confirmatory,21277655.0,
1387,588208,2,3,,104234176,36462,Unspecified,,,,,Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset,Other,20799726.0,
1388,588209,2,3,,104234176,36462,Unspecified,,,,,Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset,Other,20553011.0,
1389,588210,2,4,,104234176,36462,Unspecified,,,,,Human drug-induced liver injury (DILI) modelling dataset from Ekins et al,Other,20843939.0,
1390,588211,2,3,,104234176,36462,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans",Other,20014752.0,
1391,588212,2,3,,104234176,36462,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents",Other,20014752.0,
1392,588213,2,3,,104234176,36462,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents",Other,20014752.0,
1393,588214,2,3,,104234176,36462,Unspecified,,,,,"FDA HLAED, liver enzyme composite activity",Other,16472241.0,
1394,588215,2,3,,104234176,36462,Unspecified,,,,,"FDA HLAED, alkaline phosphatase increase",Other,16472241.0,
1395,588216,2,3,,104234176,36462,Unspecified,,,,,"FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase",Other,16472241.0,
1396,588217,2,3,,104234176,36462,Unspecified,,,,,"FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase",Other,16472241.0,
1397,588218,2,3,,104234176,36462,Unspecified,,,,,"FDA HLAED, lactate dehydrogenase (LDH) increase",Other,16472241.0,
1398,588219,2,3,,104234176,36462,Unspecified,,,,,"FDA HLAED, gamma-glutamyl transferase (GGT) increase",Other,16472241.0,
1399,588220,2,3,,104234176,36462,Unspecified,,,,,Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset,Other,20020916.0,
1400,588334,1,1,,56463308,36462,Inactive,,,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Activator_SinglePoint_HTS_Activity,Screening,,
1401,588335,1,1,,56463308,36462,Inactive,,,,,Counterscreen for inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis: Absorbance-based biochemical high throughput Glycerophosphate Dehydrogenase-Triosephosphate Isomerase (GDH-TPI) full deck assay to identify assay artifacts,Screening,,
1402,588343,1,1,,56463308,36462,Active,,,0.784,AC50_uM,Inhibitors of Epstein-Barr LMP1 inducible NF-kappaB luciferase reporter Measured in Cell-Based System Using Plate Reader - 2122-01_Inhibitor_Dose_CherryPick_Activity,Confirmatory,,
1403,588352,1,2,,56463308,36462,Active,32307126.0,8202.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 3 (SRC3; NCOA3),Screening,,
1404,588354,1,1,,56463308,36462,Active,22538455.0,8648.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1),Screening,,
1405,588358,1,2,,56463308,36462,Inactive,,,,,HTS to Find Inhibitors of Pathogenic Pemphigus Antibodies,Screening,,
1406,588391,1,1,,56463308,36462,Inactive,14790033.0,5034.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of Protein Disulfide Isomerase Measured in Biochemical System Using Plate Reader - 2137-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1407,588398,1,1,,56463308,36462,Active,23893668.0,3783750.0,0.4,AC50_uM,TES1 - eGFP vs TES2 -dsRED Pathway Differentiation Measured in Cell-Based System Using Imaging - 2122-04_Inhibitor_Dose_CherryPick_Activity,Confirmatory,,
1408,588405,1,1,,56463308,36462,Inactive,78486550.0,171071.0,,,HTS Assay for Peg3 Promoter Inhibitors,Screening,,
1409,588413,1,2,,56463308,36462,Active,6009644.0,14632.0,,,uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay,Screening,,
1410,588436,1,1,,56463308,36462,Inactive,,,,,"Cholera Quorum: HTS for inducers of light production in the absence ofautoinducers using BH1578 (luxS deficient, cqsA deficient) Measured in Microorganism System Using Plate Reader - 2132-01_Agonist_SinglePoint_HTS_Activity",Screening,,
1411,588453,1,1,,56463308,36462,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
1412,588456,1,1,,56463308,36462,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
1413,588458,1,1,,56463308,36462,Inactive,4503351.0,1786.0,,,uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay,Screening,,
1414,588473,1,1,,56463308,36462,Inactive,30219.0,1393.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
1415,588473,1,1,,56463308,36462,Inactive,38349113.0,1395.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
1416,588475,1,2,,56463308,36462,Inactive,30219.0,1393.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
1417,588475,1,2,,56463308,36462,Inactive,38349113.0,1395.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
1418,588478,1,2,,124800231,36462,Inactive,4877999.0,51377.0,,,"A screen for small molecule inhibitors of the human deubiquitinating enzyme, UCH37",Other,,
1419,588489,1,1,,56463308,36462,Inactive,46367787.0,26986.0,,,uHTS identification of microRNA-mediated mRNA deadenylation inhibitors by fluoresence polarization assay,Screening,,
1420,588492,1,1,,56463308,36462,Inactive,,,,,uHTS identification of small molecule modulators of myocardial damage,Screening,,
1421,588493,1,2,,56463308,36462,Inactive,16306916.0,10213.0,,,uHTS identification of inhibitors of Rpn11 in a Fluorescent Polarization assay,Screening,,
1422,588497,1,2,,56463308,36462,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,16604538.0,
1423,588497,1,2,,56463308,36462,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20035615.0,
1424,588497,1,2,,56463308,36462,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20938917.0,
1425,588499,1,3,,56463308,36462,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,16604538.0,
1426,588499,1,3,,56463308,36462,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20035615.0,
1427,588499,1,3,,56463308,36462,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20938917.0,
1428,588501,1,2,,56463308,36462,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,16604538.0,
1429,588501,1,2,,56463308,36462,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20035615.0,
1430,588501,1,2,,56463308,36462,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20938917.0,
1431,588511,1,2,,49681767,36462,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A),Screening,,
1432,588549,1,1,,56463308,36462,Inactive,1781172.0,,,,Fluorescence polarization to screen for inhibitor that competite the binding of FadD28 to bisubstrate Measured in Biochemical System Using Plate Reader - 2147-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1433,588579,1,1,,56463308,36462,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
1434,588590,1,1,,56463308,36462,Inactive,154350220.0,11201.0,100.0,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
1435,588591,1,1,,56463308,36462,Inactive,5729982.0,5429.0,,Potency,qHTS for Inhibitors of Polymerase Eta,Confirmatory,,
1436,588621,1,1,,56463308,36462,Inactive,90652859.0,84867.0,,,uHTS identification of small molecule inhibitors of Striatal-Enriched Phosphatase via a fluorescence intensity assay,Screening,,
1437,588627,1,1,,49681767,36462,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that activate MrgX1 receptor signaling,Screening,,
1438,588664,1,2,,56463308,36462,Inactive,62362414.0,25.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
1439,588664,1,2,,56463308,36462,Inactive,68989256.0,9610.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
1440,588674,1,2,,56463308,36462,Inactive,,,,,Schnurri-3 Inhibitors: specific inducers of adult bone formation Measured in Cell-Based System Using Plate Reader - 2134-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1441,588675,1,1,,49681767,36462,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that allosterically activate MrgX1 receptor signaling,Screening,,
1442,588676,1,1,,49681767,36462,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that antagonize MrgX1 receptor signaling,Screening,,
1443,588689,1,1,,56463308,36462,Inactive,219689243.0,,,IC50,Primary and Confirmatory Screening for Flavivirus Genomic Capping Enzyme Inhibition,Confirmatory,,
1444,588692,2,1,,56463308,36462,Inactive,,,,,Luciferase Reporter Cell Based HTS to identify inhibitors of N-linked Glycosylation Measured in Cell-Based System Using Plate Reader - 2146-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1445,588726,1,2,,56463308,36462,Inactive,15607504.0,886474.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis,Screening,,
1446,588727,1,1,,56463308,36462,Inactive,,,,IC50,"A Cell-Based Confirmatory Screen for Compounds that Inhibit VEEV, TC-83",Confirmatory,,
1447,588792,1,1,,56463308,36462,Active,32307126.0,8202.0,,,Luminescence-based cell-based high throughput confirmation assay for inhibitors of the Steroid Receptor Coactivator 3 (SRC3; NCOA3),Screening,,
1448,588794,1,1,,56463308,36462,Inactive,9629429.0,,,,Counterscreen for inhibitors of the Steroid Receptor Coactivator 3 (SRC3; NCOA3): Luminescence-based cell-based high throughput assay to identify inhibitors of the Herpes Virus Virion Protein 16 (VP16),Screening,,
1449,588795,1,1,,56463308,36462,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
1450,588814,1,3,,56463308,36462,Inactive,37622910.0,1128.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)",Screening,,
1451,588819,1,4,,56463308,36462,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).,Screening,,
1452,588820,1,1,,56463308,36462,Active,22538455.0,8648.0,,,Luminescence-based cell-based high throughput confirmation assay for inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1).,Screening,,
1453,588824,1,1,,56463308,36462,Inactive,9629429.0,,,,Counterscreen for inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1): Luminescence-based cell-based high throughput assay to identify inhibitors of the Herpes Virus Virion Protein 16 (VP16).,Screening,,
1454,588850,1,1,,56463308,36462,Inactive,90421313.0,1080.0,,,uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay,Screening,,
1455,588852,1,3,,56463308,36462,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1),Screening,,
1456,588855,1,1,,56463308,36462,Inactive,18418623.0,4088.0,,Potency,qHTS for Inhibitors of TGF-b,Confirmatory,,
1457,588856,1,1,,56463308,36462,Inactive,,,0.1259,Potency,qHTS for Inhibitors of TGF-b: Cytotox Counterscreen,Confirmatory,,
1458,588977,1,10,,104234176,36462,Unspecified,308153583.0,1244.0,,,"Substrates of transporters of clinical importance in the absorption and disposition of drugs, MRP2",Other,20190787.0,
1459,589056,1,10,,104234176,36462,Unspecified,116241312.0,1576.0,,,"Clinically relevant inducers of human liver microsomal P450 enzymes, isoform CYP3A4",Other,,
1460,590360,5,1,,104234176,36462,Active,,,0.75,IC50,Antiproliferative activity against human HT1080 cells after 96 hrs by MTT assay,Confirmatory,21296467.0,
1461,591075,3,2,,104234176,36462,Active,,,1.4,IC50,Cytotoxicity against human HL60 cells,Confirmatory,21439821.0,
1462,591076,3,3,,104234176,36462,Active,,,15.75,IC50,Cytotoxicity against human HL60/MX2 cells,Confirmatory,21439821.0,
1463,591077,1,3,,104234176,36462,Unspecified,,,,,"Resistance index, ratio IC50 for human HL60/MX2 cells to IC50 for human HL60 cells",Other,21439821.0,
1464,591081,2,3,,104234176,36462,Active,,,,,Inhibition of DNA topoisomerase 2 assessed as pUC19 DNA relaxation by agarose gel electrophoresis,Other,21439821.0,
1465,591307,3,2,,104234176,36462,Active,,,1.81,IC50,Anticancer activity against human SKOV3 cells by SRB assay,Confirmatory,21420296.0,
1466,591308,3,2,,104234176,36462,Active,,,1.85,IC50,Anticancer activity against human A549 cells by SRB assay,Confirmatory,21420296.0,
1467,591309,3,2,,104234176,36462,Active,,,1.17,IC50,Anticancer activity against human SK-MEL-2 cells by SRB assay,Confirmatory,21420296.0,
1468,591310,3,2,,104234176,36462,Active,,,1.72,IC50,Anticancer activity against human XF498 cells by SRB assay,Confirmatory,21420296.0,
1469,592682,1,4,,104234176,36462,Unspecified,,,,,Apparent permeability from apical to basolateral side of human Caco2 cells after 2 hrs by LC/MS/MS analysis,Other,21458999.0,
1470,592683,1,4,,104234176,36462,Unspecified,,,,,Apparent permeability from basolateral side to apical side of human Caco2 cells by LC/MS/MS analysis,Other,21458999.0,
1471,592695,3,2,,104234176,36462,Active,,,2.1,GI50,Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B based ELISA,Confirmatory,21402478.0,
1472,592696,3,2,,104234176,36462,Active,,,0.3,GI50,Cytotoxicity against human KB cells after 48 hrs by sulforhodamine B based ELISA,Confirmatory,21402478.0,
1473,592697,3,2,,104234176,36462,Active,,,0.13,GI50,Cytotoxicity against human COLO205 cells after 48 hrs by sulforhodamine B based ELISA,Confirmatory,21402478.0,
1474,592698,3,2,,104234176,36462,Active,,,3.08,GI50,Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B based ELISA,Confirmatory,21402478.0,
1475,592699,3,2,,104234176,36462,Active,,,1.3,GI50,Cytotoxicity against human A2780 cells after 48 hrs by sulforhodamine B based ELISA,Confirmatory,21402478.0,
1476,594863,1,4,,104234176,36462,Unspecified,,,,,Cytotoxicity against human A549 cells assessed as cell death at 1 ug after 48 hrs by MTT assay,Other,21397370.0,
1477,594864,1,4,,104234176,36462,Unspecified,,,,,Cytotoxicity against human A549 cells assessed as cell death at 2 ug after 48 hrs by MTT assay,Other,21397370.0,
1478,594918,1,4,,104234176,36462,Unspecified,,,,,Cytotoxicity against human A549 cells assessed as cell death at 5 ug after 48 hrs by MTT assay,Other,21397370.0,
1479,594919,1,4,,104234176,36462,Unspecified,,,,,Cytotoxicity against human A549 cells assessed as cell death at 10 ug after 48 hrs by MTT assay,Other,21397370.0,
1480,594920,1,4,,104234176,36462,Unspecified,,,,,Cytotoxicity against human A549 cells assessed as cell death at 25 ug after 48 hrs by MTT assay,Other,21397370.0,
1481,594921,3,2,,104234176,36462,Active,,,11.0,IC50,Cytotoxicity against human A549 cells after 48 hrs by MTT assay,Confirmatory,21397370.0,
1482,595816,3,2,,104234176,36462,Active,,,0.2,GI50,Growth inhibition of human ZR-75-1 cells after 48 hrs by sulforhodamine B assay,Confirmatory,21489802.0,
1483,595817,3,2,,104234176,36462,Active,,,2.1,GI50,Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay,Confirmatory,21489802.0,
1484,595818,3,2,,104234176,36462,Active,,,0.3,GI50,Growth inhibition of human KB cells after 48 hrs by sulforhodamine B assay,Confirmatory,21489802.0,
1485,595819,3,2,,104234176,36462,Active,,,0.5,GI50,Growth inhibition of human Gurav cells after 48 hrs by sulforhodamine B assay,Confirmatory,21489802.0,
1486,595820,3,2,,104234176,36462,Active,,,0.6,GI50,Growth inhibition of human DWD cells after 48 hrs by sulforhodamine B assay,Confirmatory,21489802.0,
1487,595821,3,2,,104234176,36462,Active,,,0.13,GI50,Growth inhibition of human COLO205 cells after 48 hrs by sulforhodamine B assay,Confirmatory,21489802.0,
1488,595822,3,2,,104234176,36462,Active,,,3.08,GI50,Growth inhibition of human A549 cells after 48 hrs by sulforhodamine B assay,Confirmatory,21489802.0,
1489,595823,3,2,,104234176,36462,Active,,,0.8,GI50,Growth inhibition of human HOP62 cells after 48 hrs by sulforhodamine B assay,Confirmatory,21489802.0,
1490,595824,3,2,,104234176,36462,Active,,,2.6,GI50,Growth inhibition of human PC3 cells after 48 hrs by sulforhodamine B assay,Confirmatory,21489802.0,
1491,595825,3,2,,104234176,36462,Active,,,3.1,GI50,Growth inhibition of human SiHa cells after 48 hrs by sulforhodamine B assay,Confirmatory,21489802.0,
1492,595826,3,2,,104234176,36462,Active,,,1.3,GI50,Growth inhibition of human A2780 cells after 48 hrs by sulforhodamine B assay,Confirmatory,21489802.0,
1493,598807,3,2,,104234176,36462,Active,,,4.0,IC50,Cytotoxicity against human HeLa cells after 72 hrs by MTT assay,Confirmatory,21570846.0,
1494,598808,3,2,,104234176,36462,Active,,,10.0,IC50,Cytotoxicity against human KB cells after 72 hrs by MTT assay,Confirmatory,21570846.0,
1495,599169,1,10,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of human topoisomerase 2alpha-mediated relaxation of supercoiled pBR322 DNA at 10 uM after 30 mins using ethidium bromide staining by transillumination analysis,Other,21419530.0,
1496,599170,1,10,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of human topoisomerase 2alpha-mediated relaxation of supercoiled pBR322 DNA at 20 uM after 30 mins using ethidium bromide staining by transillumination analysis,Other,21419530.0,
1497,599171,1,10,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of human topoisomerase 2alpha-mediated relaxation of supercoiled pBR322 DNA at 100 uM after 30 mins using ethidium bromide staining by transillumination analysis,Other,21419530.0,
1498,599172,3,2,,104234176,36462,Active,,,2.36,IC50,Cytotoxicity against human HeLa cells after 2 days,Confirmatory,21419530.0,
1499,599173,3,2,,104234176,36462,Active,,,9.5,IC50,Cytotoxicity against human HCT116 cells after 2 days,Confirmatory,21419530.0,
1500,599174,3,2,,104234176,36462,Active,,,2.19,IC50,Cytotoxicity against human DU145 cells after 2 days,Confirmatory,21419530.0,
1501,599175,3,2,,104234176,36462,Active,,,1.23,IC50,Cytotoxicity against human MDA-MB-231 cells after 2 days,Confirmatory,21419530.0,
1502,599176,3,2,,104234176,36462,Active,,,1.28,IC50,Cytotoxicity against human HL60 cells after 2 days,Confirmatory,21419530.0,
1503,600213,2,8,,104234176,36462,Active,13959709.0,7153.0,,,Inhibition of human topoisomerase 2 assessed as formation of nicked form of supercoiled pUC19 DNA at 50 uM after 45 mins using ethidium bromide staining by SDS-PAGE analysis,Other,21435753.0,
1504,600215,2,8,,104234176,36462,Active,13959709.0,7153.0,,,Inhibition of human topoisomerase 2 assessed as formation of linear form of supercoiled pUC19 DNA at 50 uM after 45 mins using ethidium bromide staining by SDS-PAGE analysis,Other,21435753.0,
1505,601510,3,2,,104234176,36462,Active,,,19.0,IC50,Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay,Confirmatory,21477899.0,
1506,601511,3,2,,104234176,36462,Active,,,7.15,IC50,Cytotoxicity against human HCT15 cells after 48 hrs by sulforhodamine B assay,Confirmatory,21477899.0,
1507,601512,3,3,,104234176,36462,Active,,,2.15,IC50,Cytotoxicity against human Hep2 cells after 48 hrs by sulforhodamine B assay,Confirmatory,21477899.0,
1508,601583,3,2,,104234176,36462,Active,,,17.5,IC50,Cytotoxicity against human PC3 cells after 48 hrs by sulforhodamine B assay,Confirmatory,21477899.0,
1509,601584,3,2,,104234176,36462,Active,,,13.5,IC50,Cytotoxicity against human SF295 cells after 48 hrs by sulforhodamine B assay,Confirmatory,21477899.0,
1510,601585,3,2,,104234176,36462,Active,,,5.62,IC50,Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay,Confirmatory,21477899.0,
1511,602123,1,1,,56463308,36462,Inactive,16128424.0,945085.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Escherichia coli DNA-binding ATP-dependent protease La (eLon),Screening,,
1512,602141,1,1,,56463308,36462,Inactive,,,,,uHTS determination of small molecule cytotoxicity in a fluorescence assay to identify cystic fibrosis induced NFkb Inhibitors,Screening,,
1513,602162,1,1,,56463308,36462,Inactive,9955963.0,10058.0,,,Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set,Screening,,
1514,602163,1,1,,56463308,36462,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify activators of Methionine sulfoxide reductase A (MsrA),Screening,,
1515,602166,1,1,,56463308,36462,Active,32307126.0,8202.0,2.4819999999999998,IC50,Luminescence-based cell-based high throughput dose response assay for inhibitors of the Steroid Receptor Coactivator 3 (SRC3; NCOA3),Confirmatory,,
1516,602167,1,1,,56463308,36462,Inactive,9629429.0,,35.872,IC50,Counterscreen for inhibitors of the Steroid Receptor Coactivator 3 (SRC3; NCOA3): Luminescence-based cell-based high throughput dose response assay to identify inhibitors of the Herpes Virus Virion Protein 16 (VP16),Confirmatory,,
1517,602168,1,1,,56463308,36462,Inactive,22538455.0,8648.0,11.957,IC50,Counterscreen for inhibitors of the Steroid Receptor Coactivator 3 (SRC3; NCOA3): Luminescence-based cell-based high throughput dose response assay to identify inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1),Confirmatory,,
1518,602179,1,2,,56463308,36462,Inactive,89573979.0,3417.0,,Potency,qHTS for Inhibitors of mutant isocitrate dehydrogenase 1 (IDH1): qHTS,Confirmatory,,
1519,602229,1,1,,56463308,36462,Inactive,216409728.0,10002.0,,,"Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)",Screening,,
1520,602233,1,1,,56463308,36462,Inactive,115503961.0,4357161.0,,Potency,qHTS Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
1521,602234,1,1,,56463308,36462,Active,32307126.0,8202.0,0.37472,IC50,Counterscreen for inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1): Luminescence-based cell-based high throughput dose response assay to identify inhibitors of the Steroid Receptor Coactivator 3 (SRC3; NCOA3),Confirmatory,,
1522,602235,1,1,,56463308,36462,Active,22538455.0,8648.0,1.153,IC50,Luminescence-based cell-based high throughput dose response assay for inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1),Confirmatory,,
1523,602236,1,1,,56463308,36462,Inactive,9629429.0,,35.872,IC50,Counterscreen for inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1): Luminescence-based cell-based high throughput dose response assay to identify inhibitors of the Herpes Virus Virion Protein 16 (VP16),Confirmatory,,
1524,602244,1,2,,56463308,36462,Inactive,5730106.0,10663.0,,,uHTS identification of CXCR6 Inhibitors in a B-arrestin luminescence assay,Screening,,
1525,602247,1,2,,56463308,36462,Inactive,,,,,Full deck counterscreen for positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
1526,602248,1,2,,56463308,36462,Inactive,,,,,Full deck counterscreen for agonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
1527,602250,1,2,,56463308,36462,Inactive,,,,,Full deck counterscreen for antagonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective inhibitors and assay artifacts using the parental CHOK1 cell line,Screening,,
1528,602252,1,1,,56463308,36462,Inactive,62868213.0,57120.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1529,602252,1,1,,56463308,36462,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1530,602261,1,1,,56463308,36462,Inactive,41872631.0,2194.0,,,uHTS identification of small molecule inhibitors of  the thioesterase domain of fatty acid synthase via a fluorescence intensity assay,Screening,,
1531,602274,1,2,,56463308,36462,Inactive,,,,,uHTS luminescent assay for identification of compounds that enhance the survival of human induced pluripotent stem cells when cultured as single cells,Screening,,
1532,602281,1,1,,56463308,36462,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
1533,602281,1,1,,56463308,36462,Inactive,116292172.0,440503.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
1534,602310,1,2,,56463308,36462,Inactive,13399304.0,60489.0,,Potency,qHTS for Inhibitors of Vif-A3G Interactions: qHTS,Confirmatory,,
1535,602313,1,1,,56463308,36462,Inactive,22907044.0,200316.0,,Potency,qHTS for Inhibitors of Vif-A3F Interactions: qHTS,Confirmatory,,
1536,602329,1,1,,56463308,36462,Inactive,216548193.0,8438.0,,,Identification of inhibitors of RAD54 Measured in Biochemical System Using Plate Reader - 2159-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1537,602332,1,1,,56463308,36462,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
1538,602340,1,2,,56463308,36462,Inactive,,,,,HTS for suppressors of simvastatin-induced mytoxicity in differentiated C2C12 cells Measured in Cell-Based System Using Plate Reader - 2112-01_Suppressor_SinglePoint_HTS_Activity,Screening,,
1539,602342,2,1,,56463308,36462,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1540,602346,1,1,,56463308,36462,Inconclusive,9629361.0,155459.0,,,Identification of VIF Inhibitors Measured in Cell-Based System Using Imaging - 2108-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1541,602363,1,1,,56463308,36462,Inactive,,,,,Whole cell Yeast HTS to identify compounds modulating the fidelity of the start codon recognition in eukaryotes. Measured in Whole Organism System Using Plate Reader - 2155-01_Other_SinglePoint_HTS_Activity,Screening,,
1542,602393,1,1,,56463308,36462,Inactive,291463269.0,20586.0,,,Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1543,602396,1,2,,56463308,36462,Inactive,4504343.0,2494.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2),Screening,,
1544,602399,1,2,,56463308,36462,Inactive,15927174.0,,,,uHTS identification of inhibitors of NadD in a Colorimetric assay,Screening,,
1545,602405,1,1,,56463308,36462,Inactive,75495260.0,,,,PgID: DNTB colorimetric HTS to detect inhibitor of PgID Measured in Biochemical System Using Plate Reader - 2164-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1546,602410,1,1,,56463308,36462,Inactive,11093520.0,3777.0,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3,Screening,,
1547,602429,1,1,,56463308,36462,Inactive,1762973.0,7341.0,,,uHTS identification of SUMO1-mediated protein-protein interactions,Screening,,
1548,602438,1,1,,56463308,36462,Inactive,160877737.0,,,,uHTS identification of modulators of interaction between CendR and NRP-1 using Fluorescence Polarization assay,Screening,,
1549,602440,1,1,,56463308,36462,Inactive,262118306.0,123228.0,,,uHTS Fluorescent Assay Using Nedd8 Protein Substrate for Identification of Inhibitors of Sentrin-Specific Protease 8 (SENP8),Screening,,
1550,602449,1,2,,56463308,36462,Inactive,,,,,uHTS identification of small molecule inhibitors of the mitochondrial permeability transition pore via an absorbance assay,Screening,,
1551,602481,1,1,,56463308,36462,Inactive,378544807.0,,,,Mycobacterium tuberculosis BioA enzyme inhibitor Measured in Biochemical System Using Plate Reader - 2163-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1552,608847,3,2,,104234176,36462,Active,,,1.0,IC50,Cytotoxicity against human HL60 cells after 2 days,Confirmatory,21601964.0,
1553,608848,3,2,,104234176,36462,Active,,,1.1,IC50,Cytotoxicity against human HCT15 cells after 2 days,Confirmatory,21601964.0,
1554,608849,3,2,,104234176,36462,Active,,,0.5,IC50,Cytotoxicity against human DU145 cells after 2 days,Confirmatory,21601964.0,
1555,608850,3,2,,104234176,36462,Active,,,1.4,IC50,Cytotoxicity against human HeLa cells after 2 days,Confirmatory,21601964.0,
1556,608851,1,8,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of human DNA topoisomerase 2 alpha assessed as inhibition of supercoiled pBR322 DNA relaxation at 20 uM after 30 mins by gel electrophoresis,Other,21601964.0,
1557,608852,1,4,,104234176,36462,Active,,,,,Cytotoxicity against human MDA-MB-231 cells after 2 days,Other,21601964.0,
1558,608853,1,8,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of human DNA topoisomerase 2 alpha assessed as inhibition of supercoiled pBR322 DNA relaxation at 100 uM after 30 mins by gel electrophoresis,Other,21601964.0,
1559,609231,3,2,,104234176,36462,Unspecified,,,,,Cytotoxicity against human U937 cells after 24 hrs by MTT assay,Other,21632155.0,
1560,609232,3,2,,104234176,36462,Unspecified,,,,,Cytotoxicity against human THP1 cells after 24 hrs by MTT assay,Other,21632155.0,
1561,609233,3,2,,104234176,36462,Unspecified,,,,,Cytotoxicity against human COLO205 cells after 24 hrs by MTT assay,Other,21632155.0,
1562,609549,3,2,,104234176,36462,Active,,,25.5,IC50,Cytotoxicity against human HCT116 cells after 72 hrs by MTS assay,Confirmatory,21724394.0,
1563,609550,3,2,,104234176,36462,Active,,,18.6,IC50,Cytotoxicity against human Caco2 cells after 72 hrs by MTS assay,Confirmatory,21724394.0,
1564,609551,3,3,,104234176,36462,Active,,,44.4,IC50,Cytotoxicity against human CCD-18Co cells after 72 hrs by MTS assay,Confirmatory,21724394.0,
1565,610074,1,9,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of human topoisomerase 2alpha-mediated relaxation of supercoiled pBR322 at 100 uM after 30 mins by electrophoresis analysis,Other,21741833.0,
1566,611125,6,5,,104234176,36462,Unspecified,13959709.0,7153.0,60.3,IC50,Inhibition of human topoisomerase 2 alpha-mediated relaxation of supercoiled pBR322 DNA after 30 mins by agarose gel electrophoresis,Confirmatory,21600681.0,
1567,611176,3,2,,104234176,36462,Active,,,0.2,GI50,Cytotoxicity against human ZR-75-1 cells after 48 hrs by sulforhodamine B assay,Confirmatory,21737288.0,
1568,611177,3,2,,104234176,36462,Active,,,2.1,GI50,Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay,Confirmatory,21737288.0,
1569,611178,3,3,,104234176,36462,Active,,,0.5,GI50,Cytotoxicity against human Gurav cells after 48 hrs by sulforhodamine B assay,Confirmatory,21737288.0,
1570,611179,3,3,,104234176,36462,Active,,,0.6,GI50,Cytotoxicity against human DWD cells after 48 hrs by sulforhodamine B assay,Confirmatory,21737288.0,
1571,611180,3,2,,104234176,36462,Active,,,0.13,GI50,Cytotoxicity against human COLO205 cells after 48 hrs by sulforhodamine B assay,Confirmatory,21737288.0,
1572,611181,3,2,,104234176,36462,Active,,,3.08,GI50,Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay,Confirmatory,21737288.0,
1573,611182,3,2,,104234176,36462,Active,,,0.8,GI50,Cytotoxicity against human HOP62 cells after 48 hrs by sulforhodamine B assay,Confirmatory,21737288.0,
1574,611183,3,2,,104234176,36462,Active,,,1.3,GI50,Cytotoxicity against human A2780 cells after 48 hrs by sulforhodamine B assay,Confirmatory,21737288.0,
1575,611184,1,4,,104234176,36462,Active,,,,,Cytotoxicity against human MCF7 cells at 2 to 4 uM after 24 hrs by MTT assay,Other,21737288.0,
1576,611185,1,4,,104234176,36462,Unspecified,,,,,Cell cycle arrest in human MCF7 cells assessed as accumulation at GO phase at 2 uM after 24 hrs by propidium iodide staining based flow cytometry (Rvb = 6.09%),Other,21737288.0,
1577,611186,1,4,,104234176,36462,Unspecified,,,,,Cell cycle arrest in human MCF7 cells assessed as accumulation at G1 phase at 2 uM after 24 hrs by propidium iodide staining based flow cytometry (Rvb = 60.5%),Other,21737288.0,
1578,611187,1,4,,104234176,36462,Unspecified,,,,,Cell cycle arrest in human MCF7 cells assessed as accumulation at S phase at 2 uM after 24 hrs by propidium iodide staining based flow cytometry (Rvb = 6.99%),Other,21737288.0,
1579,611188,1,4,,104234176,36462,Unspecified,,,,,Cell cycle arrest in human MCF7 cells assessed as accumulation at G2/M phase at 2 uM after 24 hrs by propidium iodide staining based flow cytometry (Rvb = 26.42%),Other,21737288.0,
1580,611189,1,4,,104234176,36462,Unspecified,,,,,Induction of apoptosis in human MCF7 cells assessed as single-strand DNA break at 2 uM after 24 hrs by comet assay relative to control,Other,21737288.0,
1581,611190,1,4,,104234176,36462,Unspecified,,,,,Induction of apoptosis in human MCF7 cells assessed as double-strand DNA breaks at 2 uM after 24 hrs measured as phosphorylation at ser-139 on H2AX protein by immunostaining relative to control,Other,21737288.0,
1582,611797,3,2,,104234176,36462,Active,,,0.36,IC50,Anticancer activity against human AGS cells after 3 days by MTT assay,Confirmatory,21621882.0,
1583,611798,3,2,,104234176,36462,Active,,,3.9,IC50,Anticancer activity against human MRC5 cells after 3 days by MTT assay,Confirmatory,21621882.0,
1584,611799,3,3,,104234176,36462,Active,,,2.8,IC50,Anticancer activity against human SKMES1 cells after 3 days by MTT assay,Confirmatory,21621882.0,
1585,611868,3,2,,104234176,36462,Active,,,0.8,IC50,Anticancer activity against human J82 cells after 3 days by MTT assay,Confirmatory,21621882.0,
1586,615936,3,2,,104234176,36462,Active,,,14.8,IC50,Cytotoxicity against human A549 cells after 48 hrs by MTT assay,Confirmatory,21733601.0,
1587,615937,3,2,,104234176,36462,Unspecified,,,50.6,IC50,Cytotoxicity against human HeLa cells after 48 hrs by MTT assay,Confirmatory,21733601.0,
1588,616014,3,2,,104234176,36462,Active,,,30.7,IC50,Cytotoxicity against human SiHa cells after 48 hrs by MTT assay,Confirmatory,21733601.0,
1589,616015,1,4,,104234176,36462,Unspecified,,,,,Induction of cell cycle arrest in human A549 cells assessed as accumulation at sub-G1 phase at 0.1 uM after 48 hrs using propidium iodide staining by FACS analysis (Rvb = 21.7 %),Other,21733601.0,
1590,616016,1,4,,104234176,36462,Unspecified,,,,,Induction of cell cycle arrest in human A549 cells assessed as accumulation at G1 phase at 0.1 uM after 48 hrs using propidium iodide staining by FACS analysis (Rvb = 59.9 %),Other,21733601.0,
1591,616017,1,4,,104234176,36462,Unspecified,,,,,Induction of cell cycle arrest in human A549 cells assessed as accumulation at S phase at 0.1 uM after 48 hrs using propidium iodide staining by FACS analysis (Rvb = 36.7 %),Other,21733601.0,
1592,616018,1,4,,104234176,36462,Unspecified,,,,,Induction of cell cycle arrest in human A549 cells assessed as accumulation at G2/M phase at 0.1 uM after 48 hrs using propidium iodide staining by FACS analysis (Rvb = 3.2 %),Other,21733601.0,
1593,618753,3,2,,104234176,36462,Unspecified,,,,,Anticancer activity against human MCF7 cells after 48 hrs by sulforhodamine B assay,Other,21816519.0,
1594,618754,3,2,,104234176,36462,Unspecified,,,,,Anticancer activity against human TK10 cells after 48 hrs by sulforhodamine B assay,Other,21816519.0,
1595,618755,3,2,,104234176,36462,Unspecified,,,,,Anticancer activity against human UACC62 cells after 48 hrs by sulforhodamine B assay,Other,21816519.0,
1596,618756,3,2,,104234176,36462,Unspecified,,,,,Anticancer activity against human HL60 cells after 48 hrs by MTT assay,Other,21816519.0,
1597,618757,3,2,,104234176,36462,Unspecified,,,,,Anticancer activity against human Jurkat cells after 48 hrs by MTT assay,Other,21816519.0,
1598,618833,3,2,,104234176,36462,Active,,,6.27,IC50,Cytotoxicity against human HeLa cells after 2 days by MTT assay,Confirmatory,21821321.0,
1599,618834,3,2,,104234176,36462,Active,,,2.11,IC50,Cytotoxicity against human K562 cells after 2 days by MTT assay,Confirmatory,21821321.0,
1600,618835,3,3,,104234176,36462,Unspecified,,,151.69,IC50,Cytotoxicity against human K562/A02 cells after 2 days by MTT assay,Confirmatory,21821321.0,
1601,620831,3,2,,104234176,36462,Active,,,0.09,CC50,Cytotoxicity against human MT4 cells infected with HTLV-1 after 96 hrs by MTT assay,Confirmatory,21741130.0,
1602,620832,3,2,,104234176,36462,Active,,,0.09,CC50,Antiproliferative activity against human CCRF-CEM cells after 96 hrs by MTT assay,Confirmatory,21741130.0,
1603,620833,3,2,,104234176,36462,Active,,,0.2,CC50,Antiproliferative activity against human WIL2-NS cells after 96 hrs by MTT assay,Confirmatory,21741130.0,
1604,620834,3,2,,104234176,36462,Active,,,0.1,CC50,Antiproliferative activity against human CCRF-SB cells after 96 hrs by MTT assay,Confirmatory,21741130.0,
1605,620840,3,2,,104234176,36462,Active,,,0.4,CC50,Antiproliferative activity against human DU145 cells after 96 hrs by MTT assay,Confirmatory,21741130.0,
1606,620841,3,2,,104234176,36462,Active,,,0.7,CC50,Antiproliferative activity against human HepG2 cells after 96 hrs by MTT assay,Confirmatory,21741130.0,
1607,620842,3,2,,104234176,36462,Active,,,1.0,CC50,Antiproliferative activity against human MCF7 cells after 96 hrs by MTT assay,Confirmatory,21741130.0,
1608,620843,3,3,,104234176,36462,Active,,,0.3,CC50,Antiproliferative activity against human SKMES1 cells after 96 hrs by MTT assay,Confirmatory,21741130.0,
1609,620844,3,2,,104234176,36462,Active,,,1.2,CC50,Antiproliferative activity against human SK-MEL-28 cells after 96 hrs by MTT assay,Confirmatory,21741130.0,
1610,623870,1,1,,56463308,36462,Inactive,2702319.0,405.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1611,623870,1,1,,56463308,36462,Inactive,5454102.0,10460.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1612,623877,1,1,,56463308,36462,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A),Screening,,
1613,623901,1,1,,56463308,36462,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Activator_SinglePoint_HTS_Activity,Screening,,
1614,624037,1,3,,56463308,36462,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
1615,624038,1,3,,56463308,36462,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
1616,624040,1,3,,56463308,36462,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
1617,624101,1,2,,85788790,36462,Inactive,62203298.0,3417.0,,,Development of  IDH1/2 inhibitors (CTD2project) Measured in Biochemical System Using Plate Reader - 2107-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1618,624125,1,4,,56463308,36462,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
1619,624126,1,3,,56463308,36462,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
1620,624127,1,2,,56463308,36462,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
1621,624137,1,1,,85788790,36462,Inactive,881546.0,3400.0,,,SMM ID4 Measured in Biochemical System Using Small Molecule MicroArray - 2128-01_Other_SinglePoint_HTS_Activity,Screening,,
1622,624151,1,1,,85788790,36462,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Re-Activators of the P53 Mutant Pathway Measured in Cell-Based System Using Plate Reader - 2071-01_Activator_SinglePoint_HTS_Activity,Screening,,
1623,624156,1,1,,85788790,36462,Inactive,,,,,Fluorescence Cell-Based Primary  HTS to Identify Reactive Oxygen Species Inducers in Cancer Cells Measured in Cell-Based System Using Plate Reader and Imaging Combination - 2044-01_Activator_SinglePoint_HTS_Activity,Screening,,
1624,624168,1,1,,56463308,36462,Inactive,47678551.0,9215.0,,,uHTS identification of small molecule activators of alpha dystroglycan glycosylation,Screening,,
1625,624169,1,1,,56463308,36462,Inactive,27753985.0,15558.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A),Screening,,
1626,624170,1,1,,56463308,36462,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
1627,624171,1,1,,56463308,36462,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators,Confirmatory,,
1628,624172,1,1,,56463308,36462,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
1629,624173,1,3,,56463308,36462,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
1630,624178,1,1,,56463308,36462,Unspecified,179095.0,6609.0,,Potency,qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native Substrate,Confirmatory,,
1631,624202,1,1,,56463308,36462,Inactive,1698399.0,672.0,,Potency,qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression,Confirmatory,,
1632,624204,1,2,,56463308,36462,Inactive,7657550.0,,,,"uHTS identification of small molecule inhibitors of the catalytic domain of the SUMO protease, SENP1 in a FRET assay",Screening,,
1633,624246,1,1,,56463308,36462,Inactive,343478176.0,2078.0,,Potency,qHTS for Small Molecule Inhibitors of the ERG Ets/DNA interaction,Confirmatory,,
1634,624256,1,2,,56463308,36462,Inconclusive,,3205.0,,,HTS to identify compounds that promote myeloid differentiation with MLPCN compound set,Screening,,
1635,624260,1,1,,85788790,36462,Inactive,109633019.0,7468.0,,,NSD2 Inhibitors Measured in Biochemical System Using Plate Reader - 2115-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1636,624263,1,1,,56463308,36462,Inactive,3063388.0,5071.0,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
1637,624263,1,1,,56463308,36462,Inactive,37183032.0,,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
1638,624267,1,2,,56463308,36462,Inactive,4506537.0,8767.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
1639,624267,1,2,,56463308,36462,Inactive,119603173.0,64127.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
1640,624268,1,3,,56463308,36462,Inactive,71746704.0,3662741.0,,,Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of Trypanosoma brucei methionyl tRNA synthetase (MetRS),Screening,,
1641,624288,1,1,,56463308,36462,Inactive,52000961.0,2778.0,,Potency,"qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS",Confirmatory,,
1642,624296,1,1,,56463308,36462,Inconclusive,7705682.0,51053.0,0.13,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
1643,624297,1,1,,56463308,36462,Active,7705682.0,51053.0,2.3109,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
1644,624304,1,2,,56463308,36462,Inactive,25148072.0,177343.0,,,uHTS identification of SKN-1 Inhibitors in a fluoresence assay,Screening,,
1645,624330,1,2,,56463308,36462,Inactive,21361397.0,29127.0,,IC50,Discovery of small molecule inhibitors of the oncogenic and cytokinetic protein MgcRacGAP -  Primary and Confirmatory Screens,Confirmatory,,
1646,624349,1,2,,92308660,36462,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
1647,624349,1,2,,92308790,36462,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
1648,624349,1,2,,121363248,36462,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
1649,624352,1,1,,56463308,36462,Inactive,40254439.0,2034.0,,,uHTS identification of HIF-2a Inhibitors in a luminesence assay,Screening,,
1650,624354,1,1,,56463308,36462,Inactive,224494019.0,8795.0,,,uHTS identification of Caspase-8 TRAIL sensitizers in a luminesence assay,Screening,,
1651,624377,1,1,,56463308,36462,Inactive,351542238.0,50807.0,,,"Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 (ASAP1)",Screening,,
1652,624414,1,1,,56463308,36462,Inactive,10092597.0,57192.0,,,qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
1653,624415,1,2,,56463308,36462,Inactive,10092597.0,57192.0,,,qHTS for Inhibitors of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
1654,624416,1,1,,56463308,36462,Inactive,9629363.0,155971.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify small molecules that bind to the HIV-1-gp120 binding antibody, PG9",Screening,,
1655,624417,1,1,,56463308,36462,Active,1724069.0,2740.0,2.8184,Potency,qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode),Confirmatory,,
1656,624418,1,1,,56463308,36462,Inconclusive,,,7.9433,Potency,qHTS of GLP-1 Receptor Inverse Agonists: Cytotox Screen,Confirmatory,,
1657,624463,1,1,,56463308,36462,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists,Other,,
1658,624464,1,1,,56463308,36462,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators,Other,,
1659,624465,1,1,,56463308,36462,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists,Other,,
1660,624466,1,3,,56463308,36462,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
1661,624467,1,1,,56463308,36462,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
1662,624483,1,1,,56463308,36462,Inactive,,,,,Counterscreen of compound fluorescence effects on High-throughput multiplex microsphere screening for inhibitors of toxin protease,Screening,,
1663,624622,3,1,,104234176,36462,Unspecified,238054374.0,5243.0,,,Apparent permeability (Papp) from apical to basolateral side determined in MDR1-MDCKII cells,Other,11602674.0,
1664,624623,3,1,,104234176,36462,Unspecified,238054374.0,5243.0,,,Apparent permeability (Papp) from basolateral to apical side determined in MDR1-MDCKII cells,Other,11602674.0,
1665,624626,1,9,,104234176,36462,Unspecified,238054374.0,5243.0,,,Ratio of apparent permeability from basolateral to apical side over apical to basolateral side determined in MDR1-MDCKII cells,Other,11602674.0,
1666,624628,1,9,,104234176,36462,Unspecified,238054374.0,5243.0,,,Drug-stimulated Pgp ATPase activity ratio determined in MDR1-Sf9 cell membranes with test compound at a concentration of 20uM,Other,11602674.0,
1667,624629,1,9,,104234176,36462,Unspecified,238054374.0,5243.0,,,Inhibition of Pgp expressed in MDR1-MDCKII cells measured by calcein-AM assay,Other,11602674.0,
1668,624630,3,7,,104234176,36462,Unspecified,136729.0,54658.0,503.0,Km,Drug glucuronidation reaction catalyzed by human recombinant UGT1A1,Confirmatory,15781124.0,
1669,625144,5,5,,104234176,36462,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
1670,625145,4,7,,104234176,36462,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
1671,625146,5,5,,104234176,36462,Active,126397.0,100009114.0,3.187,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
1672,625147,4,7,,104234176,36462,Unspecified,395398606.0,4159.0,,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
1673,625148,4,7,,104234176,36462,Unspecified,60392672.0,4160.0,,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
1674,625149,4,7,,104234176,36462,Unspecified,729996.0,4161.0,,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
1675,625150,5,5,,104234176,36462,Unspecified,113978.0,4128.0,,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
1676,625151,4,7,,104234176,36462,Unspecified,113118.0,1128.0,,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1677,625152,4,7,,104234176,36462,Unspecified,113122.0,1129.0,,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1678,625153,4,7,,104234176,36462,Unspecified,113125.0,1131.0,,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1679,625154,4,7,,104234176,36462,Unspecified,23503039.0,1132.0,,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1680,625155,4,7,,104234176,36462,Unspecified,543761.0,1133.0,,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1681,625156,1,9,,104234176,36462,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
1682,625157,6,2,,104234176,36462,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
1683,625158,3,4,,104234176,36462,Unspecified,,,,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
1684,625159,5,5,,104234176,36462,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
1685,625160,1,9,,104234176,36462,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
1686,625161,4,7,,104234176,36462,Unspecified,311033488.0,4985.0,,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
1687,625162,4,7,,104234176,36462,Unspecified,116242691.0,4986.0,,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
1688,625163,4,7,,104234176,36462,Unspecified,2851402.0,4988.0,,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
1689,625164,1,6,,104234176,36462,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
1690,625165,3,4,,104234176,36462,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
1691,625166,3,4,,104234176,36462,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
1692,625167,5,5,,104234176,36462,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
1693,625168,4,7,,104234176,36462,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
1694,625169,1,6,,104234176,36462,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
1695,625170,3,4,,104234176,36462,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
1696,625171,4,7,,104234176,36462,Unspecified,7531135.0,3757.0,,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
1697,625172,4,7,,104234176,36462,Unspecified,75071465.0,,,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
1698,625173,5,5,,104234176,36462,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
1699,625174,5,5,,104234176,36462,Unspecified,266321.0,834.0,,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
1700,625175,5,5,,104234176,36462,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
1701,625176,1,9,,104234176,36462,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
1702,625177,5,5,,104234176,36462,Unspecified,116852.0,4312.0,,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
1703,625178,5,5,,104234176,36462,Unspecified,269849668.0,4318.0,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
1704,625179,1,9,,104234176,36462,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
1705,625180,5,5,,104234176,36462,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
1706,625181,5,5,,104234176,36462,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
1707,625182,5,5,,104234176,36462,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
1708,625183,5,5,,104234176,36462,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
1709,625184,5,5,,104234176,36462,Unspecified,2811086.0,1956.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1710,625185,5,5,,104234176,36462,Unspecified,125370.0,2534.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1711,625186,5,5,,104234176,36462,Unspecified,119533.0,2064.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1712,625187,5,5,,104234176,36462,Unspecified,125474.0,3932.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1713,625188,1,9,,104234176,36462,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
1714,625189,1,7,,104234176,36462,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
1715,625190,4,5,,104234176,36462,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
1716,625191,4,7,,104234176,36462,Unspecified,112815.0,25075.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
1717,625192,4,7,,104234176,36462,Unspecified,543727.0,3356.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
1718,625193,5,5,,104234176,36462,Unspecified,113037.0,43.0,,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
1719,625194,4,7,,104234176,36462,Unspecified,231473.0,134.0,,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
1720,625195,4,7,,104234176,36462,Unspecified,543740.0,135.0,,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
1721,625196,5,6,,104234176,36462,Unspecified,803374855.0,140.0,,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
1722,625197,3,4,,104234176,36462,Unspecified,,,,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
1723,625198,4,7,,104234176,36462,Unspecified,1168247.0,29412.0,,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
1724,625199,4,7,,104234176,36462,Unspecified,543734.0,24173.0,,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
1725,625200,4,7,,104234176,36462,Unspecified,1168243.0,146.0,,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
1726,625201,4,7,,104234176,36462,Unspecified,1351829.0,150.0,,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
1727,625202,4,7,,104234176,36462,Unspecified,613504690.0,151.0,,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
1728,625203,4,7,,104234176,36462,Unspecified,20141211.0,152.0,,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
1729,625204,4,7,,104234176,36462,Unspecified,48429211.0,153.0,,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
1730,625205,4,7,,104234176,36462,Unspecified,296439450.0,154.0,,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
1731,625206,4,7,,104234176,36462,Unspecified,461604.0,155.0,,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
1732,625207,4,7,,104234176,36462,Unspecified,128616.0,6530.0,,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
1733,625208,5,5,,104234176,36462,Unspecified,1168407.0,24192.0,,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
1734,625209,4,7,,104234176,36462,Unspecified,1703214.0,186.0,,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
1735,625210,3,4,,104234176,36462,Unspecified,,,,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
1736,625211,1,6,,104234176,36462,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
1737,625212,3,4,,104234176,36462,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
1738,625213,4,7,,104234176,36462,Unspecified,2506481.0,624.0,,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
1739,625214,1,9,,104234176,36462,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
1740,625215,3,4,,104234176,36462,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
1741,625216,3,4,,104234176,36462,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
1742,625217,4,7,,104234176,36462,Unspecified,1168220.0,3357.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
1743,625218,4,7,,104234176,36462,Unspecified,112816.0,3358.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
1744,625219,3,4,,104234176,36462,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
1745,625220,4,7,,104234176,36462,Unspecified,6224984.0,100135548.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
1746,625221,4,7,,104234176,36462,Unspecified,1703010.0,3362.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
1747,625222,4,7,,104234176,36462,Unspecified,400630.0,6532.0,,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
1748,625223,4,7,,104234176,36462,Unspecified,74752153.0,10280.0,,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
1749,625224,3,4,,104234176,36462,Unspecified,,,,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
1750,625225,3,4,,104234176,36462,Unspecified,,,,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
1751,625226,4,7,,104234176,36462,Unspecified,128359.0,6869.0,,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
1752,625227,4,7,,104234176,36462,Unspecified,229462950.0,6865.0,,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
1753,625228,4,7,,104234176,36462,Unspecified,113832.0,24208.0,,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
1754,625229,5,5,,104234176,36462,Unspecified,254763392.0,6916.0,,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
1755,625230,1,6,,104234176,36462,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
1756,625231,4,7,,104234176,36462,Unspecified,143811474.0,2321.0,,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
1757,625232,1,9,,104234176,36462,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
1758,625233,4,7,,104234176,36462,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
1759,625234,3,4,,104234176,36462,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
1760,625235,4,7,,104234176,36462,Unspecified,115562.0,1268.0,,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
1761,625236,5,5,,104234176,36462,Unspecified,115456.0,760.0,,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
1762,625237,4,7,,104234176,36462,Unspecified,1168965.0,729230.0,,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
1763,625238,4,7,,104234176,36462,Unspecified,1705894.0,1233.0,,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
1764,625239,4,7,,104234176,36462,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
1765,625240,1,9,,104234176,36462,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
1766,625241,4,7,,104234176,36462,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
1767,625242,4,7,,104234176,36462,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
1768,625243,5,5,,104234176,36462,Unspecified,317373262.0,5742.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
1769,625244,5,5,,104234176,36462,Unspecified,3915797.0,5743.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
1770,625245,5,5,,104234176,36462,Unspecified,117144.0,1544.0,,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1771,625246,1,9,,104234176,36462,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
1772,625247,5,5,,104234176,36462,Unspecified,60416369.0,1557.0,,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1773,625248,5,5,,104234176,36462,Unspecified,6686268.0,1559.0,,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1774,625249,5,5,,104234176,36462,Unspecified,84028191.0,1565.0,,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1775,625250,5,5,,104234176,36462,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1776,625251,5,5,,104234176,36462,Unspecified,116241312.0,1576.0,,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
1777,625252,4,7,,104234176,36462,Unspecified,118228.0,1812.0,,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
1778,625253,4,7,,104234176,36462,Unspecified,118206.0,1813.0,,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
1779,625254,4,7,,104234176,36462,Unspecified,1169206.0,1814.0,,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
1780,625255,4,7,,104234176,36462,Unspecified,1345939.0,1815.0,,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
1781,625256,4,7,,104234176,36462,Unspecified,266667.0,6531.0,,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
1782,625257,4,7,,104234176,36462,Unspecified,119606.0,1909.0,,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
1783,625258,4,7,,104234176,36462,Unspecified,544257.0,2099.0,,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
1784,625259,4,7,,104234176,36462,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
1785,625260,3,4,,104234176,36462,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
1786,625261,3,4,,104234176,36462,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
1787,625262,3,4,,104234176,36462,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
1788,625263,4,7,,104234176,36462,Unspecified,121069.0,2908.0,,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
1789,625264,3,4,,104234176,36462,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
1790,625265,1,6,,104234176,36462,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
1791,625266,3,4,,104234176,36462,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
1792,625267,3,4,,104234176,36462,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
1793,625268,4,2,,104234176,36462,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1794,625268,4,2,,104234176,36462,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1795,625268,4,2,,104234176,36462,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1796,625268,4,2,,104234176,36462,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1797,625269,4,7,,104234176,36462,Unspecified,547645.0,3269.0,,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
1798,625270,4,7,,104234176,36462,Unspecified,123120.0,3274.0,,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
1799,625271,5,5,,104234176,36462,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
1800,625272,3,4,,104234176,36462,Unspecified,,,,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
1801,625273,4,6,,104234176,36462,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
1802,625274,1,6,,104234176,36462,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
1803,625275,3,4,,104234176,36462,Unspecified,,,,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
1804,625279,1,3,,104234176,36462,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia,Other,22194678.0,
1805,625280,1,3,,104234176,36462,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis,Other,22194678.0,
1806,625281,1,3,,104234176,36462,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis,Other,22194678.0,
1807,625282,1,3,,104234176,36462,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis,Other,22194678.0,
1808,625283,1,3,,104234176,36462,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests,Other,22194678.0,
1809,625284,1,3,,104234176,36462,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure,Other,22194678.0,
1810,625285,1,3,,104234176,36462,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis,Other,22194678.0,
1811,625286,1,3,,104234176,36462,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis,Other,22194678.0,
1812,625287,1,3,,104234176,36462,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly,Other,22194678.0,
1813,625288,1,3,,104234176,36462,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice,Other,22194678.0,
1814,625289,1,3,,104234176,36462,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease,Other,22194678.0,
1815,625290,1,3,,104234176,36462,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty,Other,22194678.0,
1816,625291,1,3,,104234176,36462,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal,Other,22194678.0,
1817,625292,1,3,,104234176,36462,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score,Other,22194678.0,
1818,626065,3,2,,104234176,36462,Active,,,23.33,IC50,Cytotoxicity against human HeLa cells assessed as inhibition of cell viability after 24 hrs by MTT assay,Confirmatory,21983445.0,
1819,626301,5,1,,104234176,36462,Inconclusive,,,,GI50,Growth inhibition of human A2780 cells,Confirmatory,21986585.0,
1820,626302,5,2,,104234176,36462,Active,,,2.3,GI50,Growth inhibition of human HBL100 cells,Confirmatory,21986585.0,
1821,626303,5,1,,104234176,36462,Active,,,3.0,GI50,Growth inhibition of human HeLa cells,Confirmatory,21986585.0,
1822,626304,3,2,,104234176,36462,Active,,,11.0,GI50,Growth inhibition of human Ishikawa cells,Confirmatory,21986585.0,
1823,626305,5,1,,104234176,36462,Active,,,15.0,GI50,Growth inhibition of human SW1573 cells,Confirmatory,21986585.0,
1824,626306,5,1,,104234176,36462,Active,,,22.0,GI50,Growth inhibition of human T47D cells,Confirmatory,21986585.0,
1825,626307,5,1,,104234176,36462,Active,,,23.0,GI50,Growth inhibition of human WiDr cells,Confirmatory,21986585.0,
1826,627505,1,9,,104234176,36462,Inactive,13959709.0,7153.0,,,Inhibition of etoposide poisoning activity against human recombinant DNA topoisomerase 2alpha assessed as enhancement of in relaxation of supercoiled plasmid pBR322 DNA at 200 uM after 30 mins by agarose gel electrophoresis,Other,21644529.0,
1827,627506,1,9,,104234176,36462,Active,13959709.0,7153.0,,,Inhibition of etoposide poisoning activity against human recombinant DNA topoisomerase 2alpha assessed as enhancement of in relaxation of supercoiled plasmid pBR322 DNA at 100 uM after 30 mins by agarose gel electrophoresis,Other,21644529.0,
1828,628068,1,3,,104234176,36462,Active,,,,,Antimitotic activity against Paracentrotus lividus embryo assessed as cleavage alteration treated 10 to 25 mins post fertilization followed by 45 to 60 mins before the first mitotic cycle completion by sea urchin embryo assay,Other,21916509.0,
1829,628069,1,3,,104234176,36462,Unspecified,,,,,Antimitotic activity against Paracentrotus lividus embryo assessed as cleavage arrest treated 10 to 25 mins post fertilization followed by 45 to 60 mins before the first mitotic cycle completion by sea urchin embryo assay,Other,21916509.0,
1830,628070,1,3,,104234176,36462,Unspecified,,,,,Antimitotic activity against Paracentrotus lividus embryo assessed as embryo spinning treated 10 to 25 mins post fertilization followed by 45 to 60 mins before the first mitotic cycle completion by sea urchin embryo assay,Other,21916509.0,
1831,628075,1,3,,104234176,36462,Active,,,,,Antimitotic activity against Paracentrotus lividus embryo assessed as larval malformation at 4 to 5 uM post hatching by microscopic analysis,Other,21916509.0,
1832,628076,1,3,,104234176,36462,Active,,,,,Antimitotic activity against Paracentrotus lividus embryo assessed as abnormal gastrula formation at 10 to 20 uM by microscopic analysis,Other,21916509.0,
1833,628077,1,3,,104234176,36462,Active,,,,,Induction of apoptosis in Paracentrotus lividus embryo assessed as developmental abnormalities at 40 to 68 uM after 2.5 hrs,Other,21916509.0,
1834,628162,1,4,,104234176,36462,Inconclusive,,,,,Inhibition of microtubule polymerization in human A549 cells assessed as total disruption of interphase microtubule network at 0.1 uM after 8 hrs by immunofluorescence microscopy,Other,21916509.0,
1835,628163,1,4,,104234176,36462,Inconclusive,,,,,Inhibition of microtubule polymerization in human A549 cells assessed as total disruption of interphase microtubule network at 0.5 uM after 8 hrs by immunofluorescence microscopy,Other,21916509.0,
1836,628164,1,4,,104234176,36462,Inconclusive,,,,,Inhibition of microtubule polymerization in human A549 cells assessed as total disruption of interphase microtubule network at 1 uM after 8 hrs by immunofluorescence microscopy,Other,21916509.0,
1837,628165,1,4,,104234176,36462,Inconclusive,,,,,Inhibition of microtubule polymerization in human A549 cells assessed as total disruption of interphase microtubule network at 5 uM after 8 hrs by immunofluorescence microscopy,Other,21916509.0,
1838,628168,1,4,,104234176,36462,Active,,,,,Cell cycle arrest in human Jurkat cells assessed as accumulation of cells in G0/G1 phase at 2 uM after 24 hrs by propidium iodide staining-based flow cytometry,Other,21916509.0,
1839,628180,1,4,,104234176,36462,Active,,,,,Induction of apoptosis in human Jurkat cells assessed as reduction in procaspase-8 levels at 2 uM after 24 hrs by Western blotting,Other,21916509.0,
1840,628259,1,3,,104234176,36462,Unspecified,,,,,Toxicity against Paracentrotus lividus embryo at 40 to 68 uM after 2.5 hrs,Other,21916509.0,
1841,628882,3,2,,104234176,36462,Unspecified,,,90.0,LC50,Cytotoxicity against human HEK293 cells assessed as cell survival after 48 hrs by MTT assay,Confirmatory,21644529.0,
1842,628887,1,9,,104234176,36462,Inactive,13959709.0,7153.0,,,Inhibition of topoisomerase 2 alpha-mediated DNA relaxation activity in human HEK293 cells assessed as increase in supercoiled DNA at 100 uM after 3 to 4 hrs by agarose gel electrophoresis in presence of 20 to 250 mM ATP,Other,21644529.0,
1843,628889,1,9,,104234176,36462,Active,13959709.0,7153.0,,,Inhibition of topoisomerase 2 alpha-mediated DNA relaxation activity in human HEK293 cells assessed as increase in supercoiled DNA at 100 uM after 3 to 4 hrs by agarose gel electrophoresis,Other,21644529.0,
1844,628893,1,9,,104234176,36462,Inactive,13959709.0,7153.0,,,Inhibition of human topoisomerase 2 alpha-mediated unwinding of supercoiled DNA assessed as DNA intercalation at 100 uM by agarose gel electrophoresis,Other,21644529.0,
1845,632951,3,2,,104234176,36462,Unspecified,,,,,Cytotoxicity against human HCT116 cells after 72 hrs by MTS assay,Other,22032697.0,
1846,632952,3,2,,104234176,36462,Unspecified,,,,,Cytotoxicity against human Caco2 cells after 72 hrs by MTS assay,Other,22032697.0,
1847,632953,3,3,,104234176,36462,Unspecified,,,,,Cytotoxicity against human CCD-18Co cells after 72 hrs by MTS assay,Other,22032697.0,
1848,633358,3,2,,104234176,36462,Active,,,24.9,IC50,Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay,Confirmatory,22041063.0,
1849,633359,3,2,,104234176,36462,Active,,,40.4,IC50,Cytotoxicity against human SiHa cells assessed as growth inhibition after 48 hrs by MTT assay,Confirmatory,22041063.0,
1850,633360,3,2,,104234176,36462,Active,,,2.76,IC50,Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by CCK-8 assay,Confirmatory,22041063.0,
1851,633361,3,2,,104234176,36462,Active,,,2.85,IC50,Cytotoxicity against human HL60 cells assessed as growth inhibition after 48 hrs by CCK-8 assay,Confirmatory,22041063.0,
1852,633362,1,4,,104234176,36462,Unspecified,,,,,"Octanol-water partition coefficient, log P of the compound",Other,22041063.0,
1853,634094,3,2,,104234176,36462,Active,,,2.34,IC50,Anticancer activity against human A549 cells after 48 hrs by MTT assay,Confirmatory,22136907.0,
1854,634095,3,2,,104234176,36462,Active,,,1.39,IC50,Anticancer activity against human A375 cells after 48 hrs by MTT assay,Confirmatory,22136907.0,
1855,634096,3,2,,104234176,36462,Active,,,0.68,IC50,Anticancer activity against human MCF7 cells after 48 hrs by MTT assay,Confirmatory,22136907.0,
1856,634097,3,2,,104234176,36462,Active,,,1.81,IC50,Anticancer activity against human HT-29 cells after 48 hrs by MTT assay,Confirmatory,22136907.0,
1857,634098,3,2,,104234176,36462,Active,,,7.61,IC50,Anticancer activity against human ACHN cells after 48 hrs by MTT assay,Confirmatory,22136907.0,
1858,634099,1,4,,104234176,36462,Active,,,,,Induction of apoptosis in human A549 cells assessed as cytoplasmic condensation at 2 uM after 24 hrs by Hoechst staining-based fluorescent microscopic analysis,Other,22136907.0,
1859,634100,1,4,,104234176,36462,Active,,,,,Induction of apoptosis in human A549 cells assessed as cytoplasmic condensation at 5 uM after 24 hrs by Hoechst staining-based fluorescent microscopic analysis,Other,22136907.0,
1860,634101,1,4,,104234176,36462,Active,,,,,Induction of apoptosis in human A549 cells assessed as presence of apoptotic bodies at 2 uM after 24 hrs by Hoechst staining-based fluorescent microscopic analysis,Other,22136907.0,
1861,634102,1,4,,104234176,36462,Active,,,,,Induction of apoptosis in human A549 cells assessed as presence of apoptotic bodies at 5 uM after 24 hrs by Hoechst staining-based fluorescent microscopic analysis,Other,22136907.0,
1862,634103,1,4,,104234176,36462,Active,,,,,Induction of apoptosis in human A549 cells assessed as nuclear fragmentation at 2 uM after 24 hrs by Hoechst staining-based fluorescent microscopic analysis,Other,22136907.0,
1863,634104,1,4,,104234176,36462,Active,,,,,Induction of apoptosis in human A549 cells assessed as nuclear fragmentation at 5 uM after 24 hrs by Hoechst staining-based fluorescent microscopic analysis,Other,22136907.0,
1864,634105,1,4,,104234176,36462,Active,,,,,Induction of apoptosis in human A549 cells assessed as induction of DNA fragmentation at 5 uM after 48 hrs by agarose gel electrophoresis,Other,22136907.0,
1865,634106,1,4,,104234176,36462,Unspecified,,,,,Cell cycle arrest in human A549 cells assessed as accumulation at subG1 phase at 1 uM after by propidium iodide staining-based fluorescence analysis (Rvb = 2.74%),Other,22136907.0,
1866,634108,1,4,,104234176,36462,Unspecified,,,,,Cell cycle arrest in human A549 cells assessed as accumulation at G0/G1 phase at 1 uM after by propidium iodide staining-based fluorescence analysis (Rvb = 83.43%),Other,22136907.0,
1867,634110,1,4,,104234176,36462,Unspecified,,,,,Cell cycle arrest in human A549 cells assessed as accumulation at S phase at 1 uM after by propidium iodide staining-based fluorescence analysis (Rvb = 2.74%),Other,22136907.0,
1868,634112,1,4,,104234176,36462,Unspecified,,,,,Cell cycle arrest in human A549 cells assessed as accumulation at G2/M phase at 1 uM after by propidium iodide staining-based fluorescence analysis (Rvb = 9.27%),Other,22136907.0,
1869,634114,1,4,,104234176,36462,Unspecified,,,,,Induction of apoptosis in human A549 cells assessed as caspase 3 activation using Ac-DEVD as substrate at 2 uM after 48 hrs by fluorometric analysis relative to control,Other,22136907.0,
1870,634366,3,2,,104234176,36462,Active,,,12.59,GI50,Cytotoxicity against human CCRF-CEM cells after 72 hrs by MTT assay,Confirmatory,22104973.0,
1871,634367,3,2,,104234176,36462,Active,,,31.62,GI50,Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay,Confirmatory,22104973.0,
1872,634368,3,3,,104234176,36462,Inconclusive,,,,GI50,Cytotoxicity against human HTB-54 cells after 72 hrs by MTT assay,Confirmatory,22104973.0,
1873,634369,3,2,,104234176,36462,Active,,,19.95,GI50,Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay,Confirmatory,22104973.0,
1874,634370,3,3,,104234176,36462,Inconclusive,,,,GI50,Cytotoxicity against human 184B5 cells after 72 hrs by MTT assay,Confirmatory,22104973.0,
1875,634371,3,3,,104234176,36462,Inconclusive,,,,GI50,Cytotoxicity against human BEAS2B cells after 72 hrs by MTT assay,Confirmatory,22104973.0,
1876,634819,3,2,,104234176,36462,Active,,,0.91,IC50,Cytotoxicity against human HCT116 cells after 72 hrs by sulforhodamine B and MTT assay,Confirmatory,22119124.0,
1877,634820,3,2,,104234176,36462,Active,,,1.09,IC50,Cytotoxicity against human MCF7 cells after 72 hrs by sulforhodamine B and MTT assay,Confirmatory,22119124.0,
1878,634821,3,2,,104234176,36462,Active,,,0.85,IC50,Cytotoxicity against human KB cells after 72 hrs by sulforhodamine B and MTT assay,Confirmatory,22119124.0,
1879,634822,3,2,,104234176,36462,Unspecified,,,153.26,IC50,Cytotoxicity against vincristine-selected multi drug-resistant human KB cells after 72 hrs by sulforhodamine B and MTT assay,Confirmatory,22119124.0,
1880,634823,3,2,,104234176,36462,Active,,,5.16,IC50,Cytotoxicity against human K562 cells after 72 hrs by sulforhodamine B and MTT assay,Confirmatory,22119124.0,
1881,634824,3,2,,104234176,36462,Unspecified,,,242.8,IC50,Cytotoxicity against adriamycin-selected multi drug-resistant human K562 cells after 72 hrs by sulforhodamine B and MTT assay,Confirmatory,22119124.0,
1882,634825,1,4,,104234176,36462,Unspecified,,,,,"Resistance index, ratio of IC50 for vincristine-selected multi drug-resistant human KB cells to IC50 for human KB cells",Other,22119124.0,
1883,634826,1,4,,104234176,36462,Unspecified,,,,,"Resistance index, ratio of IC50 for adriamycin-selected multi drug-resistant human K562 cells to IC50 for human K562 cells",Other,22119124.0,
1884,634827,1,9,,104234176,36462,Inactive,13959709.0,7153.0,,,Inhibition of human topoisomerase 2-mediated decatenation of kinetoplast DNA at 100 uM after 15 mins by agarose gel electrophoresis,Other,22119124.0,
1885,635428,3,2,,104234176,36462,Active,,,11.0,Kd,Binding affinity to calf thymus DNA after 48 hrs by equilibrium dialysis,Confirmatory,22041173.0,
1886,636724,3,2,,104234176,36462,Active,,,0.44,IC50,Cytotoxicity against human A549 cells by sulforhodamine B assay,Confirmatory,21936523.0,
1887,636725,3,2,,104234176,36462,Active,,,1.31,IC50,Cytotoxicity against human SKOV3 cells by sulforhodamine B assay,Confirmatory,21936523.0,
1888,636726,3,2,,104234176,36462,Active,,,0.41,IC50,Cytotoxicity against human SK-MEL-2 cells by sulforhodamine B assay,Confirmatory,21936523.0,
1889,636727,3,2,,104234176,36462,Active,,,1.86,IC50,Cytotoxicity against HUVEC by sulforhodamine B assay,Confirmatory,21936523.0,
1890,636892,1,4,,104234176,36462,Unspecified,,,,,Growth inhibition of human MCF7 cells at 100 uM after 48 hrs by XTT assay,Other,22014228.0,
1891,636893,1,4,,104234176,36462,Unspecified,,,,,Growth inhibition of human HeLa cells at 100 uM after 48 hrs by XTT assay,Other,22014228.0,
1892,636894,1,4,,104234176,36462,Unspecified,,,,,Growth inhibition of human HepG2 cells at 100 uM after 48 hrs by XTT assay,Other,22014228.0,
1893,638642,3,2,,104234176,36462,Active,,,17.94,IC50,Cytotoxicity against human U937 cells after 48 hrs by MTT assay,Confirmatory,22115593.0,
1894,638643,3,2,,104234176,36462,Active,,,2.16,IC50,Cytotoxicity against human THP1 cells after 48 hrs by MTT assay,Confirmatory,22115593.0,
1895,638644,3,3,,104234176,36462,Active,,,18.69,IC50,Cytotoxicity against mouse B16F10 cells after 48 hrs by MTT assay,Confirmatory,22115593.0,
1896,638645,1,3,,104234176,36462,Unspecified,,,,,Ratio of IC50 for human U937 cells to IC50 for human THP1 cells after 48 hrs by MTT assay,Other,22115593.0,
1897,638646,1,3,,104234176,36462,Unspecified,,,,,Ratio of IC50 for mouse B16F10 cells to IC50 for human THP1 cells after 48 hrs by MTT assay,Other,22115593.0,
1898,642528,5,1,,104234176,36462,Active,,,1.1,IC50,Growth inhibition of human KB cells after 72 hrs by methylene blue assay,Confirmatory,22060033.0,
1899,642531,5,1,,104234176,36462,Active,,,23.0,IC50,Growth inhibition of human KB-VIN10 cells after 72 hrs by methylene blue assay,Confirmatory,22060033.0,
1900,642532,5,1,,104234176,36462,Unspecified,,,54.0,IC50,Growth inhibition of human KB-7d cells after 72 hrs by methylene blue assay,Confirmatory,22060033.0,
1901,642533,5,1,,104234176,36462,Active,,,3.5,IC50,Growth inhibition of human KB-S15 cells after 72 hrs by methylene blue assay,Confirmatory,22060033.0,
1902,644045,3,2,,104234176,36462,Active,,,2.85,IC50,Cytotoxicity against human HL60 cells after 48 hrs by CCK-8 assay,Confirmatory,22244588.0,
1903,644046,3,2,,104234176,36462,Active,,,24.9,IC50,Cytotoxicity against human A549 cells after 48 hrs by MTT assay,Confirmatory,22244588.0,
1904,644047,3,2,,104234176,36462,Active,,,40.4,IC50,Cytotoxicity against human HeLa cells after 48 hrs by CCK-8 assay,Confirmatory,22244588.0,
1905,644048,3,2,,104234176,36462,Active,,,2.76,IC50,Cytotoxicity against human SiHa cells after 48 hrs by MTT assay,Confirmatory,22244588.0,
1906,644778,1,8,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of recombinant human DNA topoisomerase 2alpha using supercoiled pBR322 DNA as substrate at 100 uM after 30 mins by agarose gel electrophoresis,Other,22318164.0,
1907,644779,1,8,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of recombinant human DNA topoisomerase 2alpha using supercoiled pBR322 DNA as substrate at 20 uM after 30 mins by agarose gel electrophoresis,Other,22318164.0,
1908,644780,3,2,,104234176,36462,Active,,,1.33,IC50,Cytotoxicity against human HCT15 cells after 2 days,Confirmatory,22318164.0,
1909,644781,3,2,,104234176,36462,Active,,,2.09,IC50,Cytotoxicity against human K562 cells after 2 days,Confirmatory,22318164.0,
1910,644782,3,2,,104234176,36462,Active,,,2.94,IC50,Cytotoxicity against human DU145 cells after 2 days,Confirmatory,22318164.0,
1911,644783,3,2,,104234176,36462,Active,,,3.25,IC50,Cytotoxicity against human MCF7 cells after 2 days,Confirmatory,22318164.0,
1912,644784,3,2,,104234176,36462,Active,,,3.2,IC50,Cytotoxicity against human HeLa cells after 2 days,Confirmatory,22318164.0,
1913,647592,3,2,,104234176,36462,Active,,,9.51,IC50,Cytotoxicity against human A549 cells after 2 days by MTT assay,Confirmatory,22325897.0,
1914,647593,3,2,,104234176,36462,Active,,,2.16,IC50,Cytotoxicity against human THP1 cells after 2 days by MTT assay,Confirmatory,22325897.0,
1915,647594,3,2,,104234176,36462,Active,,,1.83,IC50,Cytotoxicity against human HL60 cells after 2 days by MTT assay,Confirmatory,22325897.0,
1916,647595,3,2,,104234176,36462,Active,,,5.35,IC50,Cytotoxicity against human Jurkat cells after 2 days by MTT assay,Confirmatory,22325897.0,
1917,647596,3,2,,104234176,36462,Active,,,17.94,IC50,Cytotoxicity against human U937 cells after 2 days by MTT assay,Confirmatory,22325897.0,
1918,647781,3,2,,104234176,36462,Unspecified,,,,,Cytotoxicity against human MCF7 cells by MTT assay,Other,22341788.0,
1919,647782,3,2,,104234176,36462,Unspecified,,,,,Cytotoxicity against human SK-N-MC cells by MTT assay,Other,22341788.0,
1920,647783,3,2,,104234176,36462,Unspecified,,,,,Cytotoxicity against human MDA-MB-231 cells by MTT assay,Other,22341788.0,
1921,647800,3,2,,104234176,36462,Active,,,23.8,IC50,Cytotoxicity against human A549 cells after 72 hrs by MTT assay,Confirmatory,22342101.0,
1922,647801,3,3,,104234176,36462,Active,,,12.4,IC50,Cytotoxicity against human U87 cells after 72 hrs by MTT assay,Confirmatory,22342101.0,
1923,647802,3,3,,104234176,36462,Active,,,6.7,IC50,Cytotoxicity against human Hep3B cells after 72 hrs by MTT assay,Confirmatory,22342101.0,
1924,649520,3,2,,104234176,36462,Active,,,0.2,GI50,Growth inhibition of human ZR-75-1 cells after 48 hrs by sulforhodamine B assay,Confirmatory,22364746.0,
1925,649521,3,2,,104234176,36462,Active,,,2.11,GI50,Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay,Confirmatory,22364746.0,
1926,649522,3,2,,104234176,36462,Active,,,0.31,GI50,Growth inhibition of human KB cells after 48 hrs by sulforhodamine B assay,Confirmatory,22364746.0,
1927,649523,3,2,,104234176,36462,Active,,,0.62,GI50,Growth inhibition of human DWD cells after 48 hrs by sulforhodamine B assay,Confirmatory,22364746.0,
1928,649524,3,2,,104234176,36462,Active,,,0.13,GI50,Growth inhibition of human COLO205 cells after 48 hrs by sulforhodamine B assay,Confirmatory,22364746.0,
1929,649525,3,2,,104234176,36462,Active,,,3.08,GI50,Growth inhibition of human A549 cells after 48 hrs by sulforhodamine B assay,Confirmatory,22364746.0,
1930,649526,3,2,,104234176,36462,Active,,,0.8,GI50,Growth inhibition of human HOP62 cells after 48 hrs by sulforhodamine B assay,Confirmatory,22364746.0,
1931,649527,3,2,,104234176,36462,Active,,,1.31,GI50,Growth inhibition of human A2780 cells after 48 hrs by sulforhodamine B assay,Confirmatory,22364746.0,
1932,649528,1,4,,104234176,36462,Active,,,,,Cytotoxicity against human COLO205 cells at 2 uM after 24 hrs by MTT assay,Other,22364746.0,
1933,649529,1,4,,104234176,36462,Active,,,,,Cytotoxicity against human COLO205 cells at 4 uM after 24 hrs by MTT assay,Other,22364746.0,
1934,649530,1,4,,104234176,36462,Active,,,,,Cytotoxicity against human COLO205 cells at 8 uM after 24 hrs by MTT assay,Other,22364746.0,
1935,649531,1,4,,104234176,36462,Unspecified,,,,,Cell cycle arrest in human COLO205 cells assessed as accumulation at G0 phase at 4 uM after 24 hrs by FACS analysis (Rvb = 4.29%),Other,22364746.0,
1936,649532,1,4,,104234176,36462,Unspecified,,,,,Cell cycle arrest in human COLO205 cells assessed as accumulation at G1 phase at 4 uM after 24 hrs by FACS analysis (Rvb = 60.89%),Other,22364746.0,
1937,649673,1,4,,104234176,36462,Unspecified,,,,,Cell cycle arrest in human COLO205 cells assessed as accumulation at S phase at 4 uM after 24 hrs by FACS analysis (Rvb = 8.91%),Other,22364746.0,
1938,649674,1,4,,104234176,36462,Unspecified,,,,,Cell cycle arrest in human COLO205 cells assessed as accumulation at G2/M phase at 4 uM after 24 hrs by FACS analysis (Rvb = 25.92%),Other,22364746.0,
1939,649675,1,4,,104234176,36462,Unspecified,,,,,"Cell cycle arrest in human COLO205 cells assessed as accumulation at G0 phase at 4 uM after 24 hrs by FACS analysis in presence of HDAC inhibitor, trichostatin A (Rvb = 4.06%)",Other,22364746.0,
1940,649676,1,4,,104234176,36462,Unspecified,,,,,"Cell cycle arrest in human COLO205 cells assessed as accumulation at G1 phase at 4 uM after 24 hrs by FACS analysis in presence of HDAC inhibitor, trichostatin A (Rvb = 70.57%)",Other,22364746.0,
1941,649677,1,4,,104234176,36462,Unspecified,,,,,"Cell cycle arrest in human COLO205 cells assessed as accumulation at S phase at 4 uM after 24 hrs by FACS analysis in presence of HDAC inhibitor, trichostatin A (Rvb = 7.89%)",Other,22364746.0,
1942,649678,1,4,,104234176,36462,Unspecified,,,,,"Cell cycle arrest in human COLO205 cells assessed as accumulation at G2/M phase at 4 uM after 24 hrs by FACS analysis in presence of HDAC inhibitor, trichostatin A (Rvb = 17.41%)",Other,22364746.0,
1943,649679,1,9,,104234176,36462,Active,13959709.0,7153.0,,,Inhibition of topoisomerase 2alpha in human in COLO205 cells assessed as induction of single-strand DNA breaks at 4 uM after 24 hrs by comet assay,Other,22364746.0,
1944,649680,1,9,,104234176,36462,Active,20141946.0,7155.0,,,Inhibition of topoisomerase 2beta in human in COLO205 cells assessed as induction of double-strand DNA breaks at 4 uM after 24 hrs by gamma-H2AX staining-based Western blotting analysis,Other,22364746.0,
1945,649682,1,4,,104234176,36462,Active,,,,,Down regulation of topoisomerase 2beta in human COLO205 cells at 4 uM after 24 hrs by Western blotting analysis,Other,22364746.0,
1946,649683,1,4,,104234176,36462,Active,,,,,"Up-regulation of topoisomerase 2alpha in human COLO205 cells at 4 uM after 24 hrs by Western blotting analysis in presence of HDAC inhibitor, trichostatin A",Other,22364746.0,
1947,649684,1,6,,104234176,36462,Active,,,,,Inhibition of topoisomerase 2alpha using pBR322 DNA as substrate at 50 uM after 30 mins by gel electrophoresis,Other,22364746.0,
1948,649685,1,9,,104234176,36462,Active,575773389.0,472.0,,,Induction of ATM activation in human COLO205 cells at 4 uM after 24 hrs by ATM S1981 staining,Other,22364746.0,
1949,649686,1,9,,104234176,36462,Active,317373343.0,1111.0,,,Increase in Chk1 phosphorylation at Ser345 in human COLO205 cells after 24 hrs,Other,22364746.0,
1950,649687,1,4,,104234176,36462,Active,,,,,Induction of apoptosis in human COLO205 cells assessed as increase in caspase 3 activation at 4 uM after 24 hrs by ELISA,Other,22364746.0,
1951,649688,1,4,,104234176,36462,Active,,,,,Induction of apoptosis in human COLO205 cells assessed as increase in caspase 3 activation at 4 uM after 24 hrs by Western blotting analysis,Other,22364746.0,
1952,649689,1,4,,104234176,36462,Active,,,,,Induction of apoptosis in human COLO205 cells assessed as down regulation of Bcl-2 at 4 uM after 24 hrs by ELISA,Other,22364746.0,
1953,649690,1,4,,104234176,36462,Active,,,,,Induction of apoptosis in human COLO205 cells assessed as up-regulation of p21 at 4 uM after 24 hrs by Western blotting analysis,Other,22364746.0,
1954,649691,1,4,,104234176,36462,Active,,,,,Induction of apoptosis in human COLO205 cells assessed as up-regulation of p16 at 4 uM after 24 hrs by Western blotting analysis,Other,22364746.0,
1955,649692,1,4,,104234176,36462,Active,,,,,Induction of apoptosis in human COLO205 cells assessed as up-regulation of NF-kappaB at 4 uM after 24 hrs by Western blotting analysis,Other,22364746.0,
1956,649693,1,9,,104234176,36462,Unspecified,76363529.0,21974.0,,,Inhibition of topoisomerase 2beta in mouse embryonic fibroblasts after 1.5 hrs by comet assay,Other,22364746.0,
1957,651548,1,1,,85788790,36462,Inactive,21361095.0,2146.0,,,EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1958,651550,1,1,,56463308,36462,Inactive,60391226.0,207.0,,,HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen,Screening,,
1959,651560,1,1,,56463308,36462,Inactive,1709543.0,52.0,,,"uHTS identification of small molecule inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase, LMPTP, via a fluorescence intensity assay",Screening,,
1960,651572,1,2,,56463308,36462,Inactive,21489979.0,246310.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ADP-ribosylation factor GTPase activating protein 1 (ARFGAP1),Screening,,
1961,651582,1,1,,56463308,36462,Inactive,,,,,uHTS identification of small molecule Triacylglycerol inhbitors in a fluoresence assay,Screening,,
1962,651602,1,1,,56463308,36462,Inactive,16130723.0,947287.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
1963,651602,1,1,,56463308,36462,Inactive,16130724.0,947286.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
1964,651602,1,1,,56463308,36462,Inactive,16130726.0,947294.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
1965,651610,2,1,,56463308,36462,Inactive,,,,,HIV entry: Env-mediated Cell Fusion Measured in Cell-Based System Using Plate Reader - 7013-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1966,651611,1,1,,56463308,36462,Active,,,,,Counterscreen for inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2): Luminescence-based cell-based high throughput assay to identify nonselective inhibitors of the Steroidogenic acute regulatory protein (StAR) promoter or luminescence assay artifacts,Screening,,
1967,651613,1,1,,56463308,36462,Active,4504343.0,2494.0,,,Luminescence-based cell-based high throughput confirmation assay for inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2),Screening,,
1968,651614,1,1,,56463308,36462,Active,20070193.0,2516.0,,,Counterscreen for inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2): Luminescence-based cell-based high throughput assay to identify inverse agonists of the Steroidogenic Factor 1 Nuclear Receptor (SF1; NR5A1),Screening,,
1969,651615,1,1,,56463308,36462,Inactive,9629429.0,,,,Counterscreen for inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2): Luminescence-based cell-based high throughput assay to identify inhibitors of the Herpes Virus Virion Protein 16 (VP16),Screening,,
1970,651635,1,3,,56463308,36462,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
1971,651636,1,1,,56463308,36462,Inactive,4826706.0,1880.0,,,uHTS identification of small molecule antagonists of the EBI2 receptor via a luminescent beta-arrestin assay,Screening,,
1972,651640,1,1,,56463308,36462,Inactive,,,,,DENV2 CPE-Based HTS Measured in Cell-Based and Microorganism Combination System Using Plate Reader - 2149-01_Other_SinglePoint_HTS_Activity,Screening,,
1973,651644,1,1,,56463308,36462,Inactive,28872817.0,155807.0,,Potency,qHTS Assay for Inhibitors of the HIV-1 protein Vpr,Confirmatory,,
1974,651647,1,1,,56463308,36462,Inactive,4826834.0,4323.0,,,uHTS identification of inhibitors of MT1-MMP activation in a fluoresence assay,Screening,,
1975,651654,1,1,,56463308,36462,Inactive,,,,,HTS for the detection of C. neoformans cell lysis via adenylate kinase (AK) release Measured in Microorganism System Using Plate Reader - 2162-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1976,651658,1,1,,56463308,36462,Inactive,10190672.0,27006.0,,,Small Molecule Inhibitors of FGF22-Mediated Excitatory Synaptogenesis & Epilepsy Measured in Biochemical System Using RT-PCR - 7012-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1977,651661,2,1,,56463308,36462,Active,,,,,Luminescence Cell-Based Primary HTS to identify inhibitors of the oncoprotein EWS/Fli transcriptional activity Measured in Cell-Based System Using Plate Reader - 7014-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1978,651687,1,1,,56463308,36462,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1979,651699,1,1,,56463308,36462,Inactive,4502169.0,8883.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
1980,651699,1,1,,56463308,36462,Inactive,4507791.0,9040.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
1981,651702,1,2,,56463308,36462,Inactive,,,,,Flow Cytometric HTS Screening for Inhibitors of Lytic Granule Exocytosis with MLPCN Compound Library,Screening,,
1982,651704,2,1,,56463308,36462,Inactive,156104889.0,4300.0,,,Inhibition of the MLL-AF4-AF9 Interaction in Pediatric Leukemia Measured in Biochemical System Using Plate Reader - 2160-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1983,651710,1,1,,56463308,36462,Inactive,109637798.0,5893.0,,,FRET-based HTS for detection of RAD52 Inhibitors Measured in Biochemical System Using Plate Reader - 7018-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1984,651711,2,1,,56463308,36462,Inactive,2501205.0,10130.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of ERp5 Measured in Biochemical System Using Plate Reader - 7002-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1985,651718,1,2,,56463308,36462,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of Methionine sulfoxide reductase A (MsrA),Screening,,
1986,651719,1,2,,56463308,36462,Inactive,4503907.0,8484.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the Galanin Receptor 3 (GalR3),Screening,,
1987,651723,1,1,,56463308,36462,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Activator_SinglePoint_HTS_Activity,Screening,,
1988,651724,1,1,,56463308,36462,Inactive,1730321.0,5932.0,,,qHTS Assay for Inhibitors of the CtBP/E1A Interaction,Screening,,
1989,651725,1,1,,56463308,36462,Inactive,1246761.0,6495.0,,,qHTS Assay for Inhibitors of the Six1/Eya2 Interaction,Screening,,
1990,651768,1,2,,56463308,36462,Inactive,3719421.0,7486.0,,Potency,qHTS for Inhibitors of WRN Helicase,Confirmatory,,
1991,651800,1,1,,56463308,36462,Inactive,2358024.0,6955.0,,,Fluorescence-based biochemical primary high throughput assay to identify inhibitors of T-cell receptor (TCR)-CD3 interaction using a TAMRA-labeled TCR probe,Screening,,
1992,651819,1,1,,56463308,36462,Inactive,83758679.0,153562.0,,,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity,Screening,,
1993,651820,1,1,,56463308,36462,Inconclusive,,,5.6234,Potency,qHTS Assay for Inhibitors of Hepatitis C Virus (HCV),Confirmatory,,
1994,651821,2,4,,56463308,36462,Inactive,,,,,Fluorescence-based biochemical primary high throughput screening assay to identify molecules that bind r(CAG) RNA repeats,Screening,,
1995,651828,1,2,,92308660,36462,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
1996,651828,1,2,,92308790,36462,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
1997,651957,1,1,,56463308,36462,Inactive,5729858.0,10499.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 2 (SRC2; NCOA2),Screening,,
1998,651958,1,1,,56463308,36462,Inactive,76364066.0,2943075.0,,,Fluorescence-based biochemical high throughput screening primary assay to identify inhibitors of Crimean-Congo Hemorrhagic Fever (CCHF) viral ovarian tumor domain protease (vOTU): Pep-AMC substrate,Screening,,
1999,651965,1,1,,56463308,36462,Inactive,2668494.0,,,Potency,qHTS Assay for Activators of ClpP,Confirmatory,,
2000,651999,1,1,,56463308,36462,Inactive,38027923.0,10987.0,,,"uHTS identification of small molecule inhibitors of Csn-mediated Deneddylation of Cullin-Ring Ligases, vis a fluorescence polarization assay",Screening,,
2001,652010,1,1,,56463308,36462,Inactive,5016090.0,190.0,,,"Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1",Screening,,
2002,652017,1,1,,56463308,36462,Inactive,119579215.0,6595.0,,,"Luminescence-based cell-based primary high throughput screening assay to identify activators of the function of SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2, BRM)",Screening,,
2003,652025,1,1,,56463308,36462,Inactive,7110653.0,16183.0,,Potency,qHTS of IL-2 Activators,Confirmatory,,
2004,652039,1,1,,56463308,36462,Inactive,21327705.0,5650.0,,,Fluorescence Intensity-based biochemical primary high throughput screening assay to identify activators of kallikrein-7 (K7) zymogen,Screening,,
2005,652048,1,2,,56463308,36462,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
2006,652051,1,1,,56463308,36462,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
2007,652054,1,1,,56463308,36462,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Antagonist: qHTS,Screening,,
2008,652067,1,4,,56463308,36462,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite H. contortus (hcDAF-12),Screening,,
2009,652104,1,1,,56463308,36462,Inactive,20140568.0,23435.0,,Potency,qHTS of TDP-43 Inhibitors,Confirmatory,,
2010,652105,1,1,,56463308,36462,Inactive,18266879.0,5305.0,,Potency,qHTS for Inhibitors of phosphatidylinositol 5-phosphate 4-kinase (PI5P4K),Confirmatory,,
2011,652106,1,1,,56463308,36462,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
2012,652115,1,1,,56463308,36462,Inactive,38258652.0,23408.0,,,MLPCN SirT-5 Measured in Biochemical System Using Imaging - 7044-01_Inhibitor_SinglePoint_HTS_Activity_Set5,Screening,,
2013,652126,1,3,,56463308,36462,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite S. stercoralis (ssDAF-12),Screening,,
2014,652154,1,1,,56463308,36462,Inactive,998701.0,7849.0,,,HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2015,652162,2,1,,56463308,36462,Inactive,126698238.0,4914074.0,,,C. difficile toxins: HTS for inhibitors of TcdB glycohydrolase activity Measured in Biochemical System Using Plate Reader - 7074-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2016,652163,1,1,,56463308,36462,Inactive,47496637.0,6275.0,,,S100A4: HTS Measured in Biochemical System Using Plate Reader - 7045-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2017,652197,1,1,,56463308,36462,Inactive,21315078.0,51752.0,,,MLPCN ERAP1 Measured in Biochemical System Using Plate Reader - 7016-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2018,652257,1,1,,56463308,36462,Inactive,32425330.0,3276.0,,,Primary biochemical fluorescence polarization-based high throughput screening assay to identify inhibitors of protein arginine methyltransferase 1 (PRMT1),Screening,,
2019,652627,2,2,,104234176,36462,Active,,,18.0,LC50,Cytotoxicity against african green monkey Vero cells after 48 hrs by MTT assay,Confirmatory,22381050.0,
2020,652628,2,2,,104234176,36462,Active,,,28.0,LC50,Cytotoxicity against human HEK293 cells after 48 hrs by MTT assay,Confirmatory,22381050.0,
2021,654542,2,2,,104234176,36462,Active,,,0.09,IC50,Cytotoxicity against human MT4 cells after 96 hrs,Confirmatory,22276775.0,
2022,654543,2,2,,104234176,36462,Active,,,4.0,IC50,Cytotoxicity against human HepG2 cells after 96 hrs,Confirmatory,22276775.0,
2023,654544,2,2,,104234176,36462,Active,,,3.0,IC50,Cytotoxicity against human DU145 cells after 96 hrs,Confirmatory,22276775.0,
2024,657319,4,2,,104234176,36462,Active,,,21.8,IC50,Inhibition of topoisomerase 2,Confirmatory,22483608.0,
2025,662399,2,2,,104234176,36462,Active,,,17.96,IC50,Antiproliferative activity against human U937 cells after 48 hrs by MTT assay,Confirmatory,22578452.0,
2026,662400,2,2,,104234176,36462,Active,,,2.16,IC50,Antiproliferative activity against human THP1 cells after 48 hrs by MTT assay,Confirmatory,22578452.0,
2027,662401,2,2,,104234176,36462,Active,,,0.43,IC50,Antiproliferative activity against human COLO205 cells after 48 hrs by MTT assay,Confirmatory,22578452.0,
2028,662402,2,2,,104234176,36462,Active,,,4.76,IC50,Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay,Confirmatory,22578452.0,
2029,662403,2,3,,104234176,36462,Active,,,18.71,IC50,Antiproliferative activity against mouse B16F10 cells after 48 hrs by MTT assay,Confirmatory,22578452.0,
2030,665211,4,1,,104234176,36462,Active,,,0.48,IC50,Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay,Confirmatory,22564383.0,
2031,665212,4,1,,104234176,36462,Active,,,0.62,IC50,Cytotoxicity against human U87 cells expressing wild-type p53 after 48 hrs by MTT assay,Confirmatory,22564383.0,
2032,665213,4,1,,104234176,36462,Active,,,0.46,IC50,Cytotoxicity against human T98G cells expressing mutant p53 after 48 hrs by MTT assay,Confirmatory,22564383.0,
2033,670433,2,2,,104234176,36462,Active,,,7.19,GI50,Antiproliferative activity against human TK10 cells after 48 hrs by SRB assay,Confirmatory,22682920.0,
2034,670434,2,2,,104234176,36462,Active,,,0.89,GI50,Antiproliferative activity against human UACC62 cells after 48 hrs by SRB assay,Confirmatory,22682920.0,
2035,670435,2,2,,104234176,36462,Active,,,0.56,GI50,Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay,Confirmatory,22682920.0,
2036,670436,2,2,,104234176,36462,Active,,,3.56,GI50,Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay,Confirmatory,22682920.0,
2037,670481,2,2,,104234176,36462,Unspecified,,,64.26,IC50,Cytotoxicity against human DU145 cells after 72 hrs by MTT assay,Confirmatory,22687745.0,
2038,670482,2,3,,104234176,36462,Active,,,12.09,IC50,Cytotoxicity against human SGC7901 cells after 72 hrs by MTT assay,Confirmatory,22687745.0,
2039,670483,2,2,,104234176,36462,Active,,,10.12,IC50,Cytotoxicity against human A549 cells after 72 hrs by MTT assay,Confirmatory,22687745.0,
2040,670484,2,4,,104234176,36462,Active,,,5.37,IC50,Cytotoxicity against human SH-SY5Y cells after 72 hrs by MTT assay,Confirmatory,22687745.0,
2041,670485,2,2,,104234176,36462,Active,,,5.48,IC50,Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay,Confirmatory,22687745.0,
2042,670486,2,2,,104234176,36462,Unspecified,,,96.26,IC50,Cytotoxicity against human HeLa cells after 72 hrs by MTT assay,Confirmatory,22687745.0,
2043,670487,2,2,,104234176,36462,Active,,,1.0,IC50,Cytotoxicity against mouse L929 cells after 72 hrs by MTT assay,Confirmatory,22687745.0,
2044,670488,2,2,,104234176,36462,Active,,,31.14,IC50,Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay,Confirmatory,22687745.0,
2045,670573,2,2,,104234176,36462,Unspecified,,,,,Cytotoxicity against human HL60 cells assessed as decrease in cell number after 24 hrs by MTT assay,Other,22704923.0,
2046,670574,2,2,,104234176,36462,Unspecified,,,,,Cytotoxicity against human U937 cells assessed as decrease in cell number after 24 hrs by MTT assay,Other,22704923.0,
2047,674863,1,7,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of human DNA topoisomerase 2alpha-mediated relaxation of supercoiled pBR322 DNA at 100 uM after 30 mins by agarose gel electrophoretic analysis,Other,22819942.0,
2048,674864,1,7,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of human DNA topoisomerase 2alpha-mediated relaxation of supercoiled pBR322 DNA at 20 uM after 30 mins by agarose gel electrophoretic analysis,Other,22819942.0,
2049,674865,2,2,,104234176,36462,Active,,,1.21,IC50,Cytotoxicity against human T47D cells after 72 hrs by MTT assay,Confirmatory,22819942.0,
2050,674866,2,2,,104234176,36462,Active,,,0.28,IC50,Cytotoxicity against human HCT15 cells after 72 hrs by MTT assay,Confirmatory,22819942.0,
2051,674867,2,2,,104234176,36462,Active,,,1.42,IC50,Cytotoxicity against human DU145 cells after 72 hrs by MTT assay,Confirmatory,22819942.0,
2052,674868,2,2,,104234176,36462,Active,,,0.41,IC50,Cytotoxicity against human HEK293 cells after 72 hrs by MTT assay,Confirmatory,22819942.0,
2053,675408,2,2,,104234176,36462,Active,,,5.89,GI50,Cytotoxicity against human TK10 cells after 48 hrs by sulforhodamine B assay,Confirmatory,22889556.0,
2054,675409,2,2,,104234176,36462,Active,,,3.41,GI50,Cytotoxicity against human UACC62 cells after 48 hrs by sulforhodamine B assay,Confirmatory,22889556.0,
2055,675410,2,2,,104234176,36462,Active,,,0.83,GI50,Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay,Confirmatory,22889556.0,
2056,677831,1,7,,104234176,36462,Active,13959709.0,7153.0,,,Inhibition of human topoisomerase 2-mediated DNA cleavage at 50 uM incubated for 45 mins followed by enzyme addition measured after 30 mins by agarose gel electrophoresis,Other,22620261.0,
2057,678712,1,8,,104234176,36462,Active,117144.0,1544.0,,,Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins,Other,22931300.0,
2058,678713,1,8,,104234176,36462,Active,6686268.0,1559.0,,,Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins,Other,22931300.0,
2059,678714,1,8,,104234176,36462,Active,60416369.0,1557.0,,,Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins,Other,22931300.0,
2060,678715,1,8,,104234176,36462,Active,84028191.0,1565.0,,,Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins,Other,22931300.0,
2061,678716,1,8,,104234176,36462,Active,116241312.0,1576.0,,,Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins,Other,22931300.0,
2062,678717,1,8,,104234176,36462,Active,116241312.0,1576.0,,,Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins,Other,22931300.0,
2063,678718,1,5,,104234176,36462,Unspecified,,,,,Metabolic stability in human liver microsomes assessed as high signal/noise ratio (S/N of >100) by measuring GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis,Other,22931300.0,
2064,678722,1,5,,104234176,36462,Inconclusive,,,,,Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH,Other,22931300.0,
2065,678783,1,8,,104234176,36462,Unspecified,269849624.0,368.0,,,TP_TRANSPORTER: drug resistance in MRP6-expressing CHO cells,Other,12414644.0,
2066,678916,1,8,,104234176,36462,Unspecified,239938877.0,18671.0,,,TP_TRANSPORTER: decrease in permeability in ileum in mdr1a(-/-) mouse,Other,11959808.0,
2067,679090,1,8,,104234176,36462,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: transepithelial transport of Etoposide (VP-16) at a concentration of 25 uM in MDR1-expressing MDCK cells,Other,12948019.0,
2068,679091,1,8,,104234176,36462,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: transepithelial transport of Etoposide (VP-16) at a concentration of 25 uM in Caco-2 cells,Other,12948019.0,
2069,679223,1,8,,104234176,36462,Unspecified,74756298.0,89845.0,,,"TP_TRANSPORTER: inhibition of E217betaG uptake (E217betaG: 1 uM, VP-16: 30 uM) in membrane vesicles from MRP7-expressing HEK293 cells",Other,12527806.0,
2070,679232,2,7,,104234176,36462,Unspecified,238054374.0,5243.0,254.96,Km,TP_TRANSPORTER: transepithelial transport (basal to apical) in MDR1-expressing MDCKII cells,Confirmatory,11901101.0,
2071,679495,1,8,,104234176,36462,Unspecified,52783101.0,17250.0,,,TP_TRANSPORTER: efflux in Mrp1-expressing HEK293 cells,Other,9281595.0,
2072,680301,1,8,,104234176,36462,Unspecified,238054374.0,5243.0,,,"TP_TRANSPORTER: increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.5 uM, Etoposide: 200 uM) in MDR1-expressing NIH-3T3 cells",Other,14985103.0,
2073,680419,1,7,,104234176,36462,Unspecified,74761045.0,,,,"TP_TRANSPORTER: inhibition of MTX uptake (MTX: 1 uM, VP-16: 300 uM) in membrane vesicles from MRP3-expressing HEK293 cells",Other,11585759.0,
2074,680601,1,7,,104234176,36462,Unspecified,74761045.0,,,,TP_TRANSPORTER: efflux in MRP3-expressing fibroblast from kidney of mdr1a/1b and mrp1 (-/-) mouse,Other,11581266.0,
2075,680785,2,7,,104234176,36462,Unspecified,308153583.0,1244.0,616.54,Km,TP_TRANSPORTER: transepithelial transport (basal to apical) in MRP2-expressing MDCKII cells,Confirmatory,11901101.0,
2076,681088,1,8,,104234176,36462,Unspecified,296439301.0,4363.0,,,TP_TRANSPORTER: transepithelial transport (basal to apical) in MRP1-expressing MDCKII cells,Other,11901101.0,
2077,681119,3,6,,104234176,36462,Unspecified,239938877.0,18671.0,50.0,IC50,TP_TRANSPORTER: inhibition of Calcein-AM efflux in Mdr1a-expressing LLC-PK1 cells,Confirmatory,12699389.0,
2078,681120,1,8,,104234176,36462,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: inhibition of Rhodamine 123 efflux in Caco-2 cells,Other,12699389.0,
2079,681121,1,8,,104234176,36462,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: inhibition of Calcein-AM efflux in MDR1-expressing MDCKII cells,Other,11602674.0,
2080,681122,3,6,,104234176,36462,Unspecified,238054374.0,5243.0,50.0,IC50,TP_TRANSPORTER: inhibition of Calcein-AM efflux in MDR1-expressing LLC-PK1 cells,Confirmatory,12699389.0,
2081,681128,3,6,,104234176,36462,Unspecified,126927.0,18669.0,50.0,IC50,TP_TRANSPORTER: inhibition of Calcein-AM efflux in Mdr1b-expressing LLC-PK1 cells,Confirmatory,12699389.0,
2082,681132,1,8,,104234176,36462,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: ATP hydrolysis in MDR1-expressing Sf9 cells,Other,11602674.0,
2083,681170,1,8,,104234176,36462,Unspecified,52783101.0,17250.0,,,TP_TRANSPORTER: drug resistance in MRP1-expressing HEK293 cells,Other,12867490.0,
2084,681274,1,8,,104234176,36462,Unspecified,68052328.0,26357.0,,,TP_TRANSPORTER: transepithelial transport (basal to apical) in BCRP-expressing MDCKII cells,Other,12649196.0,
2085,681281,1,8,,104234176,36462,Unspecified,296439301.0,4363.0,,,"TP_TRANSPORTER: inhibition of DNP-SG uptake (DNP-SG: 0.01 uM, VP-16: 10 uM) in membrane vesicles from GLC4/ADR cells",Other,9188796.0,
2086,681356,3,6,,104234176,36462,Unspecified,238054374.0,5243.0,768.0,Ki,TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical) in MDR1-expressing MDCK cells,Confirmatory,12134945.0,
2087,681383,3,6,,104234176,36462,Unspecified,238054374.0,5243.0,276.0,Ki,TP_TRANSPORTER: inhibition of Taxol transepithelial transport (basal to apical) in Caco-2 cells,Confirmatory,11405287.0,
2088,681507,1,8,,104234176,36462,Unspecified,296439301.0,4363.0,,,TP_TRANSPORTER: efflux in MRP1-expressing HEK293 cells,Other,9281595.0,
2089,681563,1,8,,104234176,36462,Unspecified,67462103.0,9429.0,,,TP_TRANSPORTER: Cytotoxicity in MT-4 and MT-4/DOX500 cells,Other,12488537.0,
2090,681572,1,8,,104234176,36462,Unspecified,68052328.0,26357.0,,,TP_TRANSPORTER: drug resistance in BCRP-expressing MEF3.8 cells,Other,12649196.0,
2091,681596,3,6,,104234176,36462,Unspecified,308153583.0,1244.0,756.0,Ki,TP_TRANSPORTER: inhibition of Vinblastine transepithelial transport (basal to apical) in MRP2-expressing MDCK cells,Confirmatory,12134946.0,
2092,681609,1,8,,104234176,36462,Unspecified,296439301.0,4363.0,,,TP_TRANSPORTER: drug resistance in MRP1-expressing PEAKSTABEL cells,Other,12657726.0,
2093,682246,1,8,,104234176,36462,Unspecified,7387886.0,81642.0,,,"TP_TRANSPORTER: inhibition of photolabeling by IAARh123 (IAARh123: 1 uM, VP-16: 1000 uM) in membranes from Mrp6-expressing P. pastoris",Other,12069597.0,
2094,686940,1,1,,56463308,36462,Inactive,14149746.0,7026.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2),Screening,,
2095,686964,1,1,,56463308,36462,Inactive,21595776.0,8932.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of 5-meCpG-binding domain protein 2 (MBD2)-DBD binding to methylated oligonucleotide,Screening,,
2096,686970,1,2,,56463308,36462,Inactive,49168486.0,3417.0,,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line,Confirmatory,,
2097,686971,1,2,,56463308,36462,Inconclusive,,,4.6109,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-IDH1KD cell line,Confirmatory,,
2098,686977,2,1,,49699016,36462,Inactive,9657203.0,2615631.0,,IC50,Vibrio cholerae assay for pro-quorum sensing small molecules,Confirmatory,,
2099,686978,1,1,,56463308,36462,Active,79154014.0,55775.0,0.1636,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
2100,686979,1,1,,56463308,36462,Active,79154014.0,55775.0,0.1636,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
2101,686992,2,1,,56463308,36462,Inactive,187960042.0,6401.0,,,Identification of agents that induce E-selectin on human endothelial cells Measured in Cell-Based System Using Imaging - 2152-01_Activator_SinglePoint_HTS_Activity,Screening,,
2102,687014,1,1,,56463308,36462,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the DAF-12 from the parasite H. glycines (hgDAF-12).,Screening,,
2103,687016,1,1,,56463308,36462,Inactive,115430235.0,29128.0,,,Counterscreen for inhibitors of 5-meCpG-binding domain protein 2 (MBD2): TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of binding of ubiquitin-like with PHD and ring finger domains 1 (UHRF1) to methylated oligonucleotide,Screening,,
2104,687157,2,2,,104234176,36462,Active,,,0.11,IC50,Cytotoxicity against human HL60 cells assessed as cell viability after 48 hrs by celltiter-blue assay,Confirmatory,22582991.0,
2105,687158,4,1,,104234176,36462,Active,,,2.3,IC50,Cytotoxicity against human K562 cells assessed as cell viability after 48 hrs by celltiter-blue assay,Confirmatory,22582991.0,
2106,687159,4,1,,104234176,36462,Active,,,0.24,IC50,Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 48 hrs by celltiter-blue assay,Confirmatory,22582991.0,
2107,687160,1,2,,104234176,36462,Unspecified,,,,,Ratio of IC50 for human HL60/MX2 cells to IC50 for human HL60 cells,Other,22582991.0,
2108,687161,1,2,,104234176,36462,Unspecified,,,,,Ratio of IC50 for human HL60/ADR cells to IC50 for human HL60 cells,Other,22582991.0,
2109,687162,1,2,,104234176,36462,Unspecified,,,,,Ratio of IC50 for daunorubicin-resistant human HL60 cells to IC50 for human HL60 cells,Other,22582991.0,
2110,687163,1,2,,104234176,36462,Unspecified,,,,,Ratio of IC50 for doxorubicin-resistant human HL60 cells to IC50 for human HL60 cells,Other,22582991.0,
2111,687164,1,2,,104234176,36462,Unspecified,,,,,Ratio of IC50 for doxorubicin-resistant human K562 cells to IC50 for human K562 cells,Other,22582991.0,
2112,687165,1,2,,104234176,36462,Unspecified,,,,,Ratio of IC50 for human K562/HHT300 cells to IC50 for human K562 cells,Other,22582991.0,
2113,687166,1,2,,104234176,36462,Unspecified,,,,,Ratio of IC50 for human CCRF-CEM/C2 cells IC50 for human CCRF-CEM cells,Other,22582991.0,
2114,687167,1,2,,104234176,36462,Unspecified,,,,,Ratio of IC50 for human CCRF-CEM/VM-1-5 cells IC50 for human CCRF-CEM cells,Other,22582991.0,
2115,687168,1,2,,104234176,36462,Unspecified,,,,,Ratio of IC50 for human CCRF-CEM/VLB100 cells IC50 for human CCRF-CEM cells,Other,22582991.0,
2116,693555,2,2,,104234176,36462,Active,,,7.2,GI50,Growth inhibition of human MDA-MB-231 cells after 72 hrs by SRB assay,Confirmatory,23153810.0,
2117,693556,2,2,,104234176,36462,Active,,,9.4,GI50,Growth inhibition of human HT-29 cells after 72 hrs by SRB assay,Confirmatory,23153810.0,
2118,693557,2,2,,104234176,36462,Active,,,2.2,GI50,Growth inhibition of human A549 cells after 72 hrs by SRB assay,Confirmatory,23153810.0,
2119,696321,1,2,,104234176,36462,Active,,,0.475,IC50,Antiproliferative activity against human KB cells after 72 hrs by ethylene blue dye assay,Confirmatory,22698783.0,
2120,696322,1,2,,104234176,36462,Active,,,0.336,IC50,Antiproliferative activity against human camptothecin-resistant KBCPT100 cells after 72 hrs by ethylene blue dye assay,Confirmatory,22698783.0,
2121,696323,1,2,,104234176,36462,Active,,,0.374,IC50,Antiproliferative activity against human partially revertant camptothecin-resistant KBCPT100 cells after 72 hrs by ethylene blue dye assay,Confirmatory,22698783.0,
2122,696324,1,2,,104234176,36462,Unspecified,,,55.0,IC50,Antiproliferative activity against human VP16-resistant KB-7d cells overexpressing MRP after 72 hrs by ethylene blue dye assay,Confirmatory,22698783.0,
2123,696910,4,1,,104234176,36462,Unspecified,,,5.0,GI50,Growth inhibition of human MCF7 cells after 72 hrs by celltiter-blue viability assay,Confirmatory,21348461.0,
2124,696915,4,2,,104234176,36462,Unspecified,,,5.0,GI50,Growth inhibition of human MCF10A cells after 72 hrs by celltiter-blue viability assay,Confirmatory,21348461.0,
2125,697006,1,3,,104234176,36462,Unspecified,,,,,Growth inhibition of human MCF10A cells after 72 hrs by celltiter-blue viability assay relative to control,Other,21348461.0,
2126,697852,1,7,,104234176,36462,Unspecified,14916521.0,,,,Inhibition of electric eel AChE at 2 mg/ml by Ellman's method,Other,23062825.0,
2127,697853,1,7,,104234176,36462,Unspecified,21362409.0,100033901.0,,,Inhibition of horse BChE at 2 mg/ml by Ellman's method,Other,23062825.0,
2128,699146,1,7,,104234176,36462,Active,13959709.0,7153.0,,,Stimulation of human topoisomerase 2-mediated DNA cleavage at 7.5 uM after 10 mins by agarose gel electrophoresis,Other,22867097.0,
2129,699539,1,7,,104234176,36462,Unspecified,12643959.0,10599.0,,,Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting,Other,22541068.0,
2130,699540,1,7,,104234176,36462,Unspecified,27734563.0,28234.0,,,Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
2131,699541,1,7,,104234176,36462,Unspecified,313104012.0,11309.0,,,Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
2132,700314,2,3,,104234176,36462,Active,,,0.28,IC50,Cytotoxicity against human etoposide-resistant DOGUM cells after 72 hrs by MTT assay,Confirmatory,23031590.0,
2133,700315,1,2,,104234176,36462,Unspecified,,,,,Resistance ratio of IC50 for human etoposide-resistant DOGUM cells to IC50 for human DOGUM cells,Other,23031590.0,
2134,700316,1,2,,104234176,36462,Unspecified,,,,,Resistance ratio of IC50 for human etoposide-resistant GUMBUS cells to IC50 for human GUMBUS cells,Other,23031590.0,
2135,700318,2,3,,104234176,36462,Active,,,0.57,IC50,Cytotoxicity against human etoposide-resistant GUMBUS cells after 72 hrs by MTT assay,Confirmatory,23031590.0,
2136,700319,2,3,,104234176,36462,Active,,,0.075,IC50,Cytotoxicity against human DOGUM cells after 72 hrs by MTT assay,Confirmatory,23031590.0,
2137,700323,2,3,,104234176,36462,Active,,,0.042,IC50,Cytotoxicity against human GUMBUS cells after 72 hrs by MTT assay,Confirmatory,23031590.0,
2138,702852,1,7,,104234176,36462,Active,13959709.0,7153.0,,,Inhibition of human Top2alpha assessed as stabilization of Top2-pBr322 DNA cleavage complex measuring linear DNA formation at 100 uM incubated for 20 mins by electrophoresis method,Other,22867019.0,
2139,702855,1,7,,104234176,36462,Active,13959709.0,7153.0,,,Inhibition of human Top2alpha assessed as suppression of supercoiled pBR322 DNA relaxation at 50 uM incubated for 30 mins by electrophoresis method,Other,22867019.0,
2140,704293,2,2,,104234176,36462,Active,,,2.39,IC50,Cytotoxicity against human T47D cells after 2 days by cell counting kit-8 analysis,Confirmatory,22503656.0,
2141,704294,2,2,,104234176,36462,Active,,,1.17,IC50,Cytotoxicity against human HCT15 cells after 2 days by cell counting kit-8 analysis,Confirmatory,22503656.0,
2142,704295,2,2,,104234176,36462,Active,,,1.21,IC50,Cytotoxicity against human DU145 cells after 2 days by cell counting kit-8 analysis,Confirmatory,22503656.0,
2143,704296,2,2,,104234176,36462,Active,,,1.21,IC50,Cytotoxicity against human HEK293 cells after 2 days by cell counting kit-8 analysis,Confirmatory,22503656.0,
2144,704297,1,7,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of human DNA topoisomerase-2alpha-mediated relaxation of supercoiled pBR322 at 20 uM after 30 mins using ethidium bromide staining by agarose gel electrophoresis,Other,22503656.0,
2145,704298,1,7,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of human DNA topoisomerase-2alpha-mediated relaxation of supercoiled pBR322 at 100 uM after 30 mins using ethidium bromide staining by agarose gel electrophoresis,Other,22503656.0,
2146,711437,2,3,,104234176,36462,Active,,,0.08,IC50,Cytotoxicity against human SGC7901 cells,Confirmatory,23092389.0,
2147,711438,2,2,,104234176,36462,Active,,,0.08,IC50,Cytotoxicity against mouse P388 cells,Confirmatory,23092389.0,
2148,711439,2,3,,104234176,36462,Active,,,0.08,IC50,Cytotoxicity against human Bel7402 cells,Confirmatory,23092389.0,
2149,711441,2,2,,104234176,36462,Active,,,0.08,IC50,Cytotoxicity against human HeLa cells,Confirmatory,23092389.0,
2150,716220,2,2,,104234176,36462,Active,,,0.8,IC50,Antiproliferative activity at human A549 cells after 72 hrs by MTT assay,Confirmatory,22861499.0,
2151,716221,2,3,,104234176,36462,Active,,,1.5,IC50,Antiproliferative activity at human DMS53 cells after 72 hrs by MTT assay,Confirmatory,22861499.0,
2152,720504,1,1,,56463308,36462,Inactive,21359873.0,5347.0,,Potency,qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen,Confirmatory,,
2153,720508,1,1,,56463308,36462,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
2154,720509,1,1,,56463308,36462,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
2155,720511,1,1,,56463308,36462,Inactive,89348172.0,1080.0,,,Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity,Screening,,
2156,720542,1,2,,56463308,36462,Inactive,23496270.0,810891.0,,Potency,qHTS for Inhibitors of AMA1-RON; Towards Development of Antimalarial Drug Lead: Primary Screen,Confirmatory,,
2157,720543,1,1,,56463308,36462,Inactive,326937491.0,105501.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of alpha/beta hydrolase domain containing 4 (ABHD4).,Screening,,
2158,720551,1,2,,56463308,36462,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS,Confirmatory,,
2159,720553,1,2,,56463308,36462,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS,Confirmatory,,
2160,720554,1,3,,92308660,36462,Inactive,52423132.0,3087402.0,,,Inhibition of the Burkholderia mallei acyl-homoserine lactone synthase BmaI1,Other,,
2161,720579,2,1,,56463308,36462,Inconclusive,222762.0,3707576.0,7.9433,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
2162,720580,1,1,,56463308,36462,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
2163,720582,1,1,,56463308,36462,Inactive,2393947.0,102.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM10.,Screening,,
2164,720596,1,1,,56463308,36462,Inactive,4506113.0,5621.0,,,TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC),Screening,,
2165,720641,1,2,,92308660,36462,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
2166,720641,1,2,,92308790,36462,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
2167,720647,1,2,,56463308,36462,Inactive,,,,,Bursicon-induced LGR2 mediated cAMP production in LGR-2/CRE6x-Luciferase co-transfected HEK293 cells Inhibition,Screening,,
2168,720648,1,1,,56463308,36462,Inactive,73747889.0,6868.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17.,Screening,,
2169,720700,1,4,,56463308,36462,Inactive,223459640.0,5335.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).,Screening,,
2170,720702,1,1,,56463308,36462,Inactive,23510348.0,51567.0,,,Epi Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of human tyrosyl-DNA phosphodiesterase 2 (TDP2),Screening,,
2171,720704,1,4,,56463308,36462,Inactive,148745659.0,5331.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-beta3).,Screening,,
2172,720707,1,2,,56463308,36462,Inactive,317373593.0,10411.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
2173,720708,1,2,,56463308,36462,Inactive,32171491.0,11069.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 2 (EPAC2): primary screen,Confirmatory,,
2174,720709,1,2,,56463308,36462,Inactive,317373593.0,10411.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
2175,720711,1,2,,56463308,36462,Inactive,32171491.0,11069.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 4 (EPAC2): primary screen,Confirmatory,,
2176,720717,1,3,,92308660,36462,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
2177,720717,1,3,,92308790,36462,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
2178,721440,1,2,,104234176,36462,Unspecified,,,59.75,IC50,Antitumor activity against human MCF7 cells assessed as growth inhibition measured after 48 hrs by MTT assay,Confirmatory,23313635.0,
2179,721441,1,2,,104234176,36462,Active,,,9.14,IC50,Antitumor activity against human HepG2 cells assessed as growth inhibition measured after 48 hrs by MTT assay,Confirmatory,23313635.0,
2180,721442,1,2,,104234176,36462,Active,,,8.32,IC50,Antitumor activity against human HeLa cells assessed as growth inhibition measured after 48 hrs by MTT assay,Confirmatory,23313635.0,
2181,723327,1,2,,104234176,36462,Unspecified,,,,,Induction of apoptosis in human A549 cells assessed as increase in caspase3 activity at 3 uM after 48 hrs relative to control,Other,23182091.0,
2182,723330,1,2,,104234176,36462,Active,,,,,Induction of apoptosis in human A549 cells assessed as increase in fluorescence at 3 uM after 24 hrs by Hoechst staining method relative to control,Other,23182091.0,
2183,723331,1,2,,104234176,36462,Active,,,,,Induction of apoptosis in human A549 cells assessed as nuclear fragmentation at 3 uM after 24 hrs by Hoechst staining method,Other,23182091.0,
2184,723333,1,2,,104234176,36462,Active,,,,,Induction of apoptosis in human A549 cells assessed as apoptotic bodies at 3 uM after 24 hrs by Hoechst staining method,Other,23182091.0,
2185,723335,1,2,,104234176,36462,Active,,,,,Induction of apoptosis in human A549 cells assessed as cytoplasmic condensation at 3 uM after 24 hrs by Hoechst staining method,Other,23182091.0,
2186,723337,1,2,,104234176,36462,Active,,,,,Induction of apoptosis in human A549 cells assessed as DNA fragmentation at 3 uM after 48 hrs by agarose gel electrophoretic analysis,Other,23182091.0,
2187,723338,1,2,,104234176,36462,Unspecified,,,,,Induction of cell cycle arrest in human A549 cells assessed as G2/M phase cells at 3 uM by FACS analysis (Rvb = 9.89%),Other,23182091.0,
2188,723339,1,2,,104234176,36462,Unspecified,,,,,Induction of cell cycle arrest in human A549 cells assessed as G2/M phase cells at 1 uM by FACS analysis (Rvb = 9.89%),Other,23182091.0,
2189,723340,1,2,,104234176,36462,Unspecified,,,,,Induction of cell cycle arrest in human A549 cells assessed as S phase cells at 3 uM by FACS analysis (Rvb = 3.69%),Other,23182091.0,
2190,723341,1,2,,104234176,36462,Unspecified,,,,,Induction of cell cycle arrest in human A549 cells assessed as S phase cells at 1 uM by FACS analysis (Rvb = 3.69%),Other,23182091.0,
2191,723342,1,2,,104234176,36462,Unspecified,,,,,Induction of cell cycle arrest in human A549 cells assessed as G1 phase cells at 3 uM by FACS analysis (Rvb = 85.33%),Other,23182091.0,
2192,723343,1,2,,104234176,36462,Unspecified,,,,,Induction of cell cycle arrest in human A549 cells assessed as G1 phase cells at 1 uM by FACS analysis (Rvb = 85.33%),Other,23182091.0,
2193,723344,1,2,,104234176,36462,Unspecified,,,,,Induction of cell cycle arrest in human A549 cells assessed as sub G1 phase cells at 3 uM by FACS analysis (Rvb = 1.08%),Other,23182091.0,
2194,723345,1,2,,104234176,36462,Unspecified,,,,,Induction of cell cycle arrest in human A549 cells assessed as sub G1 phase cells at 1 uM by FACS analysis (Rvb = 1.08%),Other,23182091.0,
2195,723346,1,2,,104234176,36462,Active,,,1.52,IC50,Cytotoxicity against human HeLa cells after 72 hrs by MTT assay,Confirmatory,23182091.0,
2196,723347,1,2,,104234176,36462,Active,,,7.61,IC50,Cytotoxicity against human ACHN cells after 72 hrs by MTT assay,Confirmatory,23182091.0,
2197,723348,1,2,,104234176,36462,Active,,,1.39,IC50,Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay,Confirmatory,23182091.0,
2198,723349,1,2,,104234176,36462,Active,,,1.81,IC50,Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay,Confirmatory,23182091.0,
2199,723350,1,2,,104234176,36462,Active,,,2.8,IC50,Cytotoxicity against human A549 cells after 72 hrs by MTT assay,Confirmatory,23182091.0,
2200,725286,1,2,,104234176,36462,Unspecified,,,,,Cytotoxicity against human colon cancer line A549 assessed as cell death measured at 10 ug/mL after 24 hrs by MTT assay,Other,23305918.0,
2201,725287,1,2,,104234176,36462,Unspecified,,,,,Cytotoxicity against human colon cancer line A549 assessed as cell death measured at 7 ug/mL after 24 hrs by MTT assay,Other,23305918.0,
2202,725288,1,2,,104234176,36462,Unspecified,,,,,Cytotoxicity against human colon cancer line A549 assessed as cell death measured at 5 ug/mL after 24 hrs by MTT assay,Other,23305918.0,
2203,725289,1,2,,104234176,36462,Unspecified,,,,,Cytotoxicity against human colon cancer line A549 assessed as cell death measured at 2 ug/mL after 24 hrs by MTT assay,Other,23305918.0,
2204,725290,1,2,,104234176,36462,Unspecified,,,,,Cytotoxicity against human colon cancer line A549 assessed as cell death measured at 1 ug/mL after 24 hrs by MTT assay,Other,23305918.0,
2205,725291,1,2,,104234176,36462,Unspecified,,,,,Cytotoxicity against human colon cancer line MCF7 assessed as cell death measured at 10 ug/mL after 24 hrs by MTT assay,Other,23305918.0,
2206,725292,1,2,,104234176,36462,Unspecified,,,,,Cytotoxicity against human colon cancer line MCF7 assessed as cell death measured at 7 ug/mL after 24 hrs by MTT assay,Other,23305918.0,
2207,725293,1,2,,104234176,36462,Unspecified,,,,,Cytotoxicity against human colon cancer line MCF7 assessed as cell death measured at 5 ug/mL after 24 hrs by MTT assay,Other,23305918.0,
2208,725294,1,2,,104234176,36462,Unspecified,,,,,Cytotoxicity against human colon cancer line MCF7 assessed as cell death measured at 2 ug/mL after 24 hrs by MTT assay,Other,23305918.0,
2209,725295,1,2,,104234176,36462,Unspecified,,,,,Cytotoxicity against human colon cancer line MCF7 assessed as cell death measured at 1 ug/mL after 24 hrs by MTT assay,Other,23305918.0,
2210,725296,1,4,,104234176,36462,Unspecified,,,,,Cytotoxicity against human colon cancer line COLO205 assessed as cell death measured at 10 ug/mL after 24 hrs by MTT assay,Other,23305918.0,
2211,725297,1,4,,104234176,36462,Unspecified,,,,,Cytotoxicity against human colon cancer line COLO205 assessed as cell death measured at 7 ug/mL after 24 hrs by MTT assay,Other,23305918.0,
2212,725298,1,4,,104234176,36462,Unspecified,,,,,Cytotoxicity against human colon cancer line COLO205 assessed as cell death measured at 5 ug/mL after 24 hrs by MTT assay,Other,23305918.0,
2213,725299,1,4,,104234176,36462,Unspecified,,,,,Cytotoxicity against human colon cancer line COLO205 assessed as cell death measured at 2 ug/mL after 24 hrs by MTT assay,Other,23305918.0,
2214,725300,1,4,,104234176,36462,Unspecified,,,,,Cytotoxicity against human colon cancer line COLO205 assessed as cell death measured at 1 ug/mL after 24 hrs by MTT assay,Other,23305918.0,
2215,725303,1,2,,104234176,36462,Active,,,2.1,IC50,Cytotoxicity against human lung adenocarcinoma cell line A549 assessed as inhibition of cell viability measured after 24 hrs by MTT assay,Confirmatory,23305918.0,
2216,725305,1,2,,104234176,36462,Active,,,16.3,IC50,Cytotoxicity against human breast cancer cell line MCF7 assessed as inhibition of cell viability measured after 24 hrs by MTT assay,Confirmatory,23305918.0,
2217,725306,1,4,,104234176,36462,Active,,,5.3,IC50,Cytotoxicity against human colon cancer line COLO205 assessed as inhibition of cell viability measured after 24 hrs by MTT assay,Confirmatory,23305918.0,
2218,727501,1,2,,104234176,36462,Active,,,17.68,IC50,Cytotoxicity against human HeLa cells after 24 hrs by MTT assay,Confirmatory,23369687.0,
2219,727502,1,3,,104234176,36462,Active,,,26.85,IC50,Cytotoxicity against human BGC832 cells after 24 hrs by MTT assay,Confirmatory,23369687.0,
2220,727503,1,2,,104234176,36462,Active,,,2.85,IC50,Cytotoxicity against human K562 cells after 24 hrs by MTT assay,Confirmatory,23369687.0,
2221,727504,1,2,,104234176,36462,Unspecified,,,103.81,IC50,Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay,Confirmatory,23369687.0,
2222,729587,1,3,,104234176,36462,Unspecified,,,,,Cytotoxicity against human KBVIN cells,Other,23043462.0,
2223,729588,1,2,,104234176,36462,Unspecified,,,,,Cytotoxicity against human A549 cells,Other,23043462.0,
2224,729589,1,4,,104234176,36462,Unspecified,,,,,Cytotoxicity against human KB cells,Other,23043462.0,
2225,729590,1,2,,104234176,36462,Unspecified,,,,,Cytotoxicity against human MCF7 cells,Other,23043462.0,
2226,729745,1,6,,104234176,36462,Active,13959709.0,7153.0,,,Inhibition of DNA topoisomerase 2 (unknown origin)-mediated relaxation of supercoiled pHOT DNA at 50 to 200 uM after 30 to 45 mins by agarose gel electrophoresis,Other,23360284.0,
2227,729912,1,2,,104234176,36462,Unspecified,,,,,Selectivity ratio of IC50 for human MRC5 cells to IC50 for human HL60 cells,Other,23454511.0,
2228,729913,1,2,,104234176,36462,Unspecified,,,,,Selectivity ratio of IC50 for human MRC5 cells to IC50 for human J82 cells,Other,23454511.0,
2229,729914,1,2,,104234176,36462,Unspecified,,,,,Selectivity ratio of IC50 for human MRC5 cells to IC50 for human SKMES1 cells,Other,23454511.0,
2230,729915,1,3,,104234176,36462,Active,,,1.8,IC50,Cytotoxicity against human HL60 cells assessed as cell viability after 72 hrs by MTT assay,Confirmatory,23454511.0,
2231,729916,1,2,,104234176,36462,Unspecified,,,,,Selectivity ratio of IC50 for human MRC5 cells to IC50 for human AGS cells,Other,23454511.0,
2232,729917,1,2,,104234176,36462,Active,,,2.8,IC50,Cytotoxicity against human J82 cells assessed as cell viability after 72 hrs by MTT assay,Confirmatory,23454511.0,
2233,729918,1,3,,104234176,36462,Active,,,2.5,IC50,Cytotoxicity against human SKMES1 cells assessed as cell viability after 72 hrs by MTT assay,Confirmatory,23454511.0,
2234,729919,1,2,,104234176,36462,Active,,,0.36,IC50,Cytotoxicity against human AGS cells assessed as cell viability after 72 hrs by MTT assay,Confirmatory,23454511.0,
2235,729920,1,2,,104234176,36462,Active,,,3.9,IC50,Cytotoxicity against human MRC5 cells assessed as cell viability after 72 hrs by MTT assay,Confirmatory,23454511.0,
2236,735334,1,6,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of human DNA topoisomerase 2 alpha-mediated supercoiled pBR322 DNA relaxation at 20 uM after 1 hr by agarose gel electrophoresis,Other,23550966.0,
2237,735559,1,2,,104234176,36462,Active,,,,,Inhibition of calf thymus topoisomerase 1-mediated pBR322 relaxation at 100 uM after 30 mins by agarose gel electrophoresis,Other,23353750.0,
2238,735560,1,6,,104234176,36462,Active,13959709.0,7153.0,,,Inhibition of human topoisomerase 2a-mediated kinetoplast decatenation at 100 uM after 30 mins by agarose gel electrophoresis,Other,23353750.0,
2239,736815,1,2,,104234176,36462,Active,,,17.0,LC50,Cytotoxicity against HEK293 cells after 48 hrs by MTT assay,Confirmatory,23321564.0,
2240,736816,1,3,,104234176,36462,Inactive,,,,,Induction of DNA intercalation in negatively Escherichia coli super coiled small circular plasmid DNA assessed as retradation of DNA migration at 100 uM incubated for 20 mins at 37 degC by agarose-gel electrophoresis,Other,23321564.0,
2241,736817,1,2,,104234176,36462,Active,,,29.0,LC50,Cytotoxicity against african green monkey Vero cells after 48 hrs by MTT assay,Confirmatory,23321564.0,
2242,739935,1,3,,104234176,36462,Unspecified,,,20.0,IC50,Cytotoxicity against human KBVIN cells after 72 hrs by SRB assay,Confirmatory,23490151.0,
2243,739936,1,4,,104234176,36462,Active,,,3.88,IC50,Cytotoxicity against human KB cells after 72 hrs by SRB assay,Confirmatory,23490151.0,
2244,739937,1,2,,104234176,36462,Active,,,2.58,IC50,Cytotoxicity against human A549 cells after 72 hrs by SRB assay,Confirmatory,23490151.0,
2245,739938,1,3,,104234176,36462,Active,,,2.03,IC50,Cytotoxicity against human DU145 cells after 72 hrs by SRB assay,Confirmatory,23490151.0,
2246,741697,1,3,,104234176,36462,Active,,,7.068289999999999,IC50,SANGER: Inhibition of human NCI-H1563 cell growth in a cell viability assay.,Confirmatory,,
2247,741699,1,3,,104234176,36462,Active,,,37.647,IC50,SANGER: Inhibition of human NCI-H1581 cell growth in a cell viability assay.,Confirmatory,,
2248,741700,1,3,,104234176,36462,Active,,,40.1041,IC50,SANGER: Inhibition of human NCI-H1618 cell growth in a cell viability assay.,Confirmatory,,
2249,741701,1,3,,104234176,36462,Active,,,13.9776,IC50,SANGER: Inhibition of human NCI-H1623 cell growth in a cell viability assay.,Confirmatory,,
2250,741702,1,3,,104234176,36462,Active,,,26.3623,IC50,SANGER: Inhibition of human NCI-H1648 cell growth in a cell viability assay.,Confirmatory,,
2251,741703,1,3,,104234176,36462,Active,,,1.73565,IC50,SANGER: Inhibition of human NCI-H1650 cell growth in a cell viability assay.,Confirmatory,,
2252,741704,1,3,,104234176,36462,Active,,,32.7543,IC50,SANGER: Inhibition of human NCI-H1651 cell growth in a cell viability assay.,Confirmatory,,
2253,741706,1,3,,104234176,36462,Unspecified,,,101.67299999999999,IC50,SANGER: Inhibition of human NCI-H1693 cell growth in a cell viability assay.,Confirmatory,,
2254,741707,1,3,,104234176,36462,Active,,,1.3718299999999999,IC50,SANGER: Inhibition of human NCI-H1694 cell growth in a cell viability assay.,Confirmatory,,
2255,741708,1,3,,104234176,36462,Active,,,1.29939,IC50,SANGER: Inhibition of human NCI-H1703 cell growth in a cell viability assay.,Confirmatory,,
2256,741709,1,3,,104234176,36462,Active,,,1.5050299999999999,IC50,SANGER: Inhibition of human NCI-H1734 cell growth in a cell viability assay.,Confirmatory,,
2257,741710,1,3,,104234176,36462,Active,,,49.3468,IC50,SANGER: Inhibition of human NCI-H1755 cell growth in a cell viability assay.,Confirmatory,,
2258,741711,1,3,,104234176,36462,Active,,,3.86539,IC50,SANGER: Inhibition of human NCI-H1770 cell growth in a cell viability assay.,Confirmatory,,
2259,741712,1,3,,104234176,36462,Active,,,42.6858,IC50,SANGER: Inhibition of human NCI-H1792 cell growth in a cell viability assay.,Confirmatory,,
2260,741713,1,3,,104234176,36462,Active,,,5.30922,IC50,SANGER: Inhibition of human NCI-H1793 cell growth in a cell viability assay.,Confirmatory,,
2261,741714,1,3,,104234176,36462,Unspecified,,,2465.38,IC50,SANGER: Inhibition of human NCI-H1838 cell growth in a cell viability assay.,Confirmatory,,
2262,741715,1,3,,104234176,36462,Active,,,0.67362,IC50,SANGER: Inhibition of human NCI-H187 cell growth in a cell viability assay.,Confirmatory,,
2263,741716,1,3,,104234176,36462,Active,,,2.67868,IC50,SANGER: Inhibition of human NCI-H1882 cell growth in a cell viability assay.,Confirmatory,,
2264,741717,1,3,,104234176,36462,Active,,,12.0942,IC50,SANGER: Inhibition of human NCI-H1963 cell growth in a cell viability assay.,Confirmatory,,
2265,741719,1,3,,104234176,36462,Unspecified,,,549.591,IC50,SANGER: Inhibition of human NCI-H1993 cell growth in a cell viability assay.,Confirmatory,,
2266,741720,1,3,,104234176,36462,Active,,,0.69655,IC50,SANGER: Inhibition of human NCI-H2009 cell growth in a cell viability assay.,Confirmatory,,
2267,741722,1,3,,104234176,36462,Active,,,0.22991999999999999,IC50,SANGER: Inhibition of human NCI-H2030 cell growth in a cell viability assay.,Confirmatory,,
2268,741723,1,3,,104234176,36462,Active,,,11.4502,IC50,SANGER: Inhibition of human NCI-H2052 cell growth in a cell viability assay.,Confirmatory,,
2269,741724,1,3,,104234176,36462,Active,,,4.91765,IC50,SANGER: Inhibition of human NCI-H2081 cell growth in a cell viability assay.,Confirmatory,,
2270,741725,1,3,,104234176,36462,Active,,,0.7630600000000001,IC50,SANGER: Inhibition of human NCI-H2087 cell growth in a cell viability assay.,Confirmatory,,
2271,741726,1,3,,104234176,36462,Active,,,1.20699,IC50,SANGER: Inhibition of human NCI-H209 cell growth in a cell viability assay.,Confirmatory,,
2272,741728,1,3,,104234176,36462,Active,,,5.39424,IC50,SANGER: Inhibition of human NCI-H2122 cell growth in a cell viability assay.,Confirmatory,,
2273,741729,1,3,,104234176,36462,Active,,,10.3993,IC50,SANGER: Inhibition of human NCI-H2126 cell growth in a cell viability assay.,Confirmatory,,
2274,741730,1,3,,104234176,36462,Active,,,8.522269999999999,IC50,SANGER: Inhibition of human NCI-H2141 cell growth in a cell viability assay.,Confirmatory,,
2275,741731,1,3,,104234176,36462,Active,,,1.85285,IC50,SANGER: Inhibition of human NCI-H2170 cell growth in a cell viability assay.,Confirmatory,,
2276,741732,1,3,,104234176,36462,Unspecified,,,101.273,IC50,SANGER: Inhibition of human NCI-H2171 cell growth in a cell viability assay.,Confirmatory,,
2277,741733,1,3,,104234176,36462,Active,,,7.494860000000001,IC50,SANGER: Inhibition of human NCI-H2196 cell growth in a cell viability assay.,Confirmatory,,
2278,741734,1,3,,104234176,36462,Unspecified,,,241.31799999999998,IC50,SANGER: Inhibition of human NCI-H2227 cell growth in a cell viability assay.,Confirmatory,,
2279,741735,1,3,,104234176,36462,Active,,,2.65509,IC50,SANGER: Inhibition of human NCI-H2228 cell growth in a cell viability assay.,Confirmatory,,
2280,741736,1,3,,104234176,36462,Active,,,11.1518,IC50,SANGER: Inhibition of human NCI-H226 cell growth in a cell viability assay.,Confirmatory,,
2281,741738,1,3,,104234176,36462,Active,,,13.1861,IC50,SANGER: Inhibition of human NCI-H23 cell growth in a cell viability assay.,Confirmatory,,
2282,741739,1,3,,104234176,36462,Active,,,0.55508,IC50,SANGER: Inhibition of human NCI-H2342 cell growth in a cell viability assay.,Confirmatory,,
2283,741740,1,3,,104234176,36462,Active,,,9.663910000000001,IC50,SANGER: Inhibition of human NCI-H2347 cell growth in a cell viability assay.,Confirmatory,,
2284,741741,1,3,,104234176,36462,Active,,,2.4356400000000002,IC50,SANGER: Inhibition of human NCI-H2405 cell growth in a cell viability assay.,Confirmatory,,
2285,741742,1,3,,104234176,36462,Unspecified,,,902.051,IC50,SANGER: Inhibition of human NCI-H2452 cell growth in a cell viability assay.,Confirmatory,,
2286,741744,1,3,,104234176,36462,Active,,,39.4002,IC50,SANGER: Inhibition of human NCI-H28 cell growth in a cell viability assay.,Confirmatory,,
2287,741745,1,3,,104234176,36462,Active,,,4.7095,IC50,SANGER: Inhibition of human NCI-H292 cell growth in a cell viability assay.,Confirmatory,,
2288,741746,1,3,,104234176,36462,Unspecified,,,2863.18,IC50,SANGER: Inhibition of human NCI-H322M cell growth in a cell viability assay.,Confirmatory,,
2289,741747,1,3,,104234176,36462,Unspecified,,,420.79900000000004,IC50,SANGER: Inhibition of human NCI-H345 cell growth in a cell viability assay.,Confirmatory,,
2290,741748,1,3,,104234176,36462,Active,,,3.1515400000000002,IC50,SANGER: Inhibition of human NCI-H358 cell growth in a cell viability assay.,Confirmatory,,
2291,741750,1,3,,104234176,36462,Active,,,11.165999999999999,IC50,SANGER: Inhibition of human NCI-H441 cell growth in a cell viability assay.,Confirmatory,,
2292,741751,1,3,,104234176,36462,Unspecified,,,376.29900000000004,IC50,SANGER: Inhibition of human NCI-H446 cell growth in a cell viability assay.,Confirmatory,,
2293,741752,1,3,,104234176,36462,Active,,,0.23571,IC50,SANGER: Inhibition of human NCI-H460 cell growth in a cell viability assay.,Confirmatory,,
2294,741753,1,3,,104234176,36462,Active,,,8.65064,IC50,SANGER: Inhibition of human NCI-H510A cell growth in a cell viability assay.,Confirmatory,,
2295,741754,1,3,,104234176,36462,Active,,,8.039069999999999,IC50,SANGER: Inhibition of human NCI-H520 cell growth in a cell viability assay.,Confirmatory,,
2296,741755,1,3,,104234176,36462,Active,,,3.3576599999999996,IC50,SANGER: Inhibition of human NCI-H522 cell growth in a cell viability assay.,Confirmatory,,
2297,741756,1,3,,104234176,36462,Unspecified,,,128.805,IC50,SANGER: Inhibition of human NCI-H524 cell growth in a cell viability assay.,Confirmatory,,
2298,741757,1,3,,104234176,36462,Active,,,0.45611999999999997,IC50,SANGER: Inhibition of human NCI-H526 cell growth in a cell viability assay.,Confirmatory,,
2299,741758,1,3,,104234176,36462,Active,,,18.2999,IC50,SANGER: Inhibition of human NCI-H596 cell growth in a cell viability assay.,Confirmatory,,
2300,741759,1,3,,104234176,36462,Active,,,9.12079,IC50,SANGER: Inhibition of human NCI-H630 cell growth in a cell viability assay.,Confirmatory,,
2301,741760,1,3,,104234176,36462,Active,,,3.99787,IC50,SANGER: Inhibition of human NCI-H64 cell growth in a cell viability assay.,Confirmatory,,
2302,741761,1,3,,104234176,36462,Active,,,1.7097099999999998,IC50,SANGER: Inhibition of human NCI-H650 cell growth in a cell viability assay.,Confirmatory,,
2303,741762,1,3,,104234176,36462,Active,,,4.3417900000000005,IC50,SANGER: Inhibition of human NCI-H661 cell growth in a cell viability assay.,Confirmatory,,
2304,741763,1,3,,104234176,36462,Active,,,8.18234,IC50,SANGER: Inhibition of human NCI-H69 cell growth in a cell viability assay.,Confirmatory,,
2305,741764,1,3,,104234176,36462,Unspecified,,,521.22,IC50,SANGER: Inhibition of human NCI-H716 cell growth in a cell viability assay.,Confirmatory,,
2306,741765,1,3,,104234176,36462,Unspecified,,,1193.77,IC50,SANGER: Inhibition of human NCI-H719 cell growth in a cell viability assay.,Confirmatory,,
2307,741766,1,3,,104234176,36462,Unspecified,,,1356.35,IC50,SANGER: Inhibition of human NCI-H720 cell growth in a cell viability assay.,Confirmatory,,
2308,741767,1,3,,104234176,36462,Unspecified,,,1179.63,IC50,SANGER: Inhibition of human NCI-H727 cell growth in a cell viability assay.,Confirmatory,,
2309,741768,1,3,,104234176,36462,Active,,,27.2478,IC50,SANGER: Inhibition of human NCI-H747 cell growth in a cell viability assay.,Confirmatory,,
2310,741769,1,3,,104234176,36462,Active,,,0.87069,IC50,SANGER: Inhibition of human NCI-H748 cell growth in a cell viability assay.,Confirmatory,,
2311,741770,1,3,,104234176,36462,Active,,,1.58283,IC50,SANGER: Inhibition of human NCI-H810 cell growth in a cell viability assay.,Confirmatory,,
2312,741771,1,3,,104234176,36462,Unspecified,,,66.7345,IC50,SANGER: Inhibition of human NCI-H82 cell growth in a cell viability assay.,Confirmatory,,
2313,741772,1,3,,104234176,36462,Active,,,17.9844,IC50,SANGER: Inhibition of human NCI-H838 cell growth in a cell viability assay.,Confirmatory,,
2314,741773,1,3,,104234176,36462,Unspecified,,,1068.13,IC50,SANGER: Inhibition of human NCI-H889 cell growth in a cell viability assay.,Confirmatory,,
2315,741774,1,3,,104234176,36462,Active,,,15.8106,IC50,SANGER: Inhibition of human NCI-N87 cell growth in a cell viability assay.,Confirmatory,,
2316,741775,1,3,,104234176,36462,Active,,,1.75327,IC50,SANGER: Inhibition of human NCI-SNU-1 cell growth in a cell viability assay.,Confirmatory,,
2317,741776,1,3,,104234176,36462,Unspecified,,,5353.77,IC50,SANGER: Inhibition of human NCI-SNU-16 cell growth in a cell viability assay.,Confirmatory,,
2318,741777,1,3,,104234176,36462,Active,,,7.91903,IC50,SANGER: Inhibition of human NCI-SNU-5 cell growth in a cell viability assay.,Confirmatory,,
2319,741778,1,3,,104234176,36462,Active,,,0.53895,IC50,SANGER: Inhibition of human NEC8 cell growth in a cell viability assay.,Confirmatory,,
2320,741779,1,3,,104234176,36462,Active,,,0.67198,IC50,SANGER: Inhibition of human NH-12 cell growth in a cell viability assay.,Confirmatory,,
2321,741780,1,3,,104234176,36462,Active,,,0.42516000000000004,IC50,SANGER: Inhibition of human NKM-1 cell growth in a cell viability assay.,Confirmatory,,
2322,741781,1,3,,104234176,36462,Active,,,3.3243199999999997,IC50,SANGER: Inhibition of human NMC-G1 cell growth in a cell viability assay.,Confirmatory,,
2323,741782,1,3,,104234176,36462,Active,,,2.18798,IC50,SANGER: Inhibition of human NOMO-1 cell growth in a cell viability assay.,Confirmatory,,
2324,741783,1,3,,104234176,36462,Active,,,3.58057,IC50,SANGER: Inhibition of human NOS-1 cell growth in a cell viability assay.,Confirmatory,,
2325,741784,1,4,,104234176,36462,Active,,,0.02502,IC50,SANGER: Inhibition of human NTERA-S-cl-D1 cell growth in a cell viability assay.,Confirmatory,,
2326,741785,1,3,,104234176,36462,Active,,,0.9808100000000001,IC50,SANGER: Inhibition of human NUGC-3 cell growth in a cell viability assay.,Confirmatory,,
2327,741786,1,3,,104234176,36462,Active,,,4.48988,IC50,SANGER: Inhibition of human NY cell growth in a cell viability assay.,Confirmatory,,
2328,741787,1,3,,104234176,36462,Active,,,2.15234,IC50,SANGER: Inhibition of human OAW-28 cell growth in a cell viability assay.,Confirmatory,,
2329,741788,1,3,,104234176,36462,Active,,,6.05896,IC50,SANGER: Inhibition of human OAW-42 cell growth in a cell viability assay.,Confirmatory,,
2330,741790,1,3,,104234176,36462,Active,,,0.55935,IC50,SANGER: Inhibition of human OCI-AML2 cell growth in a cell viability assay.,Confirmatory,,
2331,741791,1,3,,104234176,36462,Active,,,0.04455,IC50,SANGER: Inhibition of human OCUB-M cell growth in a cell viability assay.,Confirmatory,,
2332,741792,1,3,,104234176,36462,Active,,,36.9759,IC50,SANGER: Inhibition of human OE19 cell growth in a cell viability assay.,Confirmatory,,
2333,741793,1,3,,104234176,36462,Active,,,5.12216,IC50,SANGER: Inhibition of human OE33 cell growth in a cell viability assay.,Confirmatory,,
2334,741794,1,3,,104234176,36462,Active,,,36.8562,IC50,SANGER: Inhibition of human OMC-1 cell growth in a cell viability assay.,Confirmatory,,
2335,741795,1,3,,104234176,36462,Active,,,0.75429,IC50,SANGER: Inhibition of human ONS-76 cell growth in a cell viability assay.,Confirmatory,,
2336,741796,1,3,,104234176,36462,Active,,,24.6118,IC50,SANGER: Inhibition of human OPM-2 cell growth in a cell viability assay.,Confirmatory,,
2337,741797,1,3,,104234176,36462,Active,,,11.2175,IC50,SANGER: Inhibition of human OS-RC-2 cell growth in a cell viability assay.,Confirmatory,,
2338,741798,1,3,,104234176,36462,Active,,,22.2139,IC50,SANGER: Inhibition of human OVCAR-3 cell growth in a cell viability assay.,Confirmatory,,
2339,741799,1,3,,104234176,36462,Active,,,17.3428,IC50,SANGER: Inhibition of human OVCAR-4 cell growth in a cell viability assay.,Confirmatory,,
2340,741800,1,3,,104234176,36462,Active,,,1.53748,IC50,SANGER: Inhibition of human OVCAR-5 cell growth in a cell viability assay.,Confirmatory,,
2341,741801,1,3,,104234176,36462,Active,,,1.09145,IC50,SANGER: Inhibition of human OVCAR-8 cell growth in a cell viability assay.,Confirmatory,,
2342,741802,1,3,,104234176,36462,Active,,,0.31679,IC50,SANGER: Inhibition of human P12-ICHIKAWA cell growth in a cell viability assay.,Confirmatory,,
2343,741803,1,3,,104234176,36462,Active,,,1.2112399999999999,IC50,SANGER: Inhibition of human P30-OHK cell growth in a cell viability assay.,Confirmatory,,
2344,741804,1,3,,104234176,36462,Unspecified,,,2399.07,IC50,SANGER: Inhibition of human P31-FUJ cell growth in a cell viability assay.,Confirmatory,,
2345,741805,1,3,,104234176,36462,Active,,,0.13219,IC50,SANGER: Inhibition of human PA-1 cell growth in a cell viability assay.,Confirmatory,,
2346,741806,1,3,,104234176,36462,Active,,,1.6369,IC50,SANGER: Inhibition of human PANC-03-27 cell growth in a cell viability assay.,Confirmatory,,
2347,741807,1,3,,104234176,36462,Unspecified,,,153.42600000000002,IC50,SANGER: Inhibition of human PANC-08-13 cell growth in a cell viability assay.,Confirmatory,,
2348,741808,1,3,,104234176,36462,Active,,,2.8877900000000003,IC50,SANGER: Inhibition of human PANC-10-05 cell growth in a cell viability assay.,Confirmatory,,
2349,741809,1,3,,104234176,36462,Active,,,9.722339999999999,IC50,SANGER: Inhibition of human PC-14 cell growth in a cell viability assay.,Confirmatory,,
2350,741810,1,3,,104234176,36462,Unspecified,,,61.2744,IC50,SANGER: Inhibition of human PC-3 cell growth in a cell viability assay.,Confirmatory,,
2351,741811,1,3,,104234176,36462,Active,,,0.72388,IC50,SANGER: Inhibition of human PF-382 cell growth in a cell viability assay.,Confirmatory,,
2352,741812,1,3,,104234176,36462,Unspecified,,,94.6893,IC50,SANGER: Inhibition of human PFSK-1 cell growth in a cell viability assay.,Confirmatory,,
2353,741813,1,3,,104234176,36462,Active,,,25.4198,IC50,SANGER: Inhibition of human PLC-PRF-5 cell growth in a cell viability assay.,Confirmatory,,
2354,741814,1,3,,104234176,36462,Unspecified,,,137.116,IC50,SANGER: Inhibition of human PSN1 cell growth in a cell viability assay.,Confirmatory,,
2355,741815,1,3,,104234176,36462,Active,,,0.15458,IC50,SANGER: Inhibition of human QIMR-WIL cell growth in a cell viability assay.,Confirmatory,,
2356,741816,1,3,,104234176,36462,Unspecified,,,98.09200000000001,IC50,SANGER: Inhibition of human RCC10RGB cell growth in a cell viability assay.,Confirmatory,,
2357,741817,1,3,,104234176,36462,Active,,,20.9952,IC50,SANGER: Inhibition of human RCM-1 cell growth in a cell viability assay.,Confirmatory,,
2358,741818,1,3,,104234176,36462,Active,,,4.80409,IC50,SANGER: Inhibition of human RD cell growth in a cell viability assay.,Confirmatory,,
2359,741819,1,3,,104234176,36462,Active,,,0.22424000000000002,IC50,SANGER: Inhibition of human REH cell growth in a cell viability assay.,Confirmatory,,
2360,741820,1,3,,104234176,36462,Active,,,2.4941299999999997,IC50,SANGER: Inhibition of human RERF-LC-MS cell growth in a cell viability assay.,Confirmatory,,
2361,741821,1,3,,104234176,36462,Active,,,0.01778,IC50,SANGER: Inhibition of human RH-1 cell growth in a cell viability assay.,Confirmatory,,
2362,741823,1,3,,104234176,36462,Active,,,0.47075,IC50,SANGER: Inhibition of human RKO cell growth in a cell viability assay.,Confirmatory,,
2363,741824,1,3,,104234176,36462,Unspecified,,,1229.9,IC50,SANGER: Inhibition of human RL cell growth in a cell viability assay.,Confirmatory,,
2364,741825,1,3,,104234176,36462,Active,,,1.1103399999999999,IC50,SANGER: Inhibition of human RL95-2 cell growth in a cell viability assay.,Confirmatory,,
2365,741826,1,3,,104234176,36462,Unspecified,,,70.5002,IC50,SANGER: Inhibition of human RMG-I cell growth in a cell viability assay.,Confirmatory,,
2366,741827,1,3,,104234176,36462,Unspecified,,,105.23700000000001,IC50,SANGER: Inhibition of human RO82-W-1 cell growth in a cell viability assay.,Confirmatory,,
2367,741828,1,3,,104234176,36462,Active,,,0.57196,IC50,SANGER: Inhibition of human RPMI-2650 cell growth in a cell viability assay.,Confirmatory,,
2368,741829,1,3,,104234176,36462,Active,,,1.03221,IC50,SANGER: Inhibition of human RPMI-6666 cell growth in a cell viability assay.,Confirmatory,,
2369,741830,1,3,,104234176,36462,Active,,,2.2858400000000003,IC50,SANGER: Inhibition of human RPMI-7951 cell growth in a cell viability assay.,Confirmatory,,
2370,741831,1,3,,104234176,36462,Active,,,14.3243,IC50,SANGER: Inhibition of human RPMI-8226 cell growth in a cell viability assay.,Confirmatory,,
2371,741832,1,3,,104234176,36462,Active,,,0.27109,IC50,SANGER: Inhibition of human RPMI-8402 cell growth in a cell viability assay.,Confirmatory,,
2372,741833,1,3,,104234176,36462,Active,,,4.64882,IC50,SANGER: Inhibition of human RPMI-8866 cell growth in a cell viability assay.,Confirmatory,,
2373,741834,1,3,,104234176,36462,Active,,,0.19612000000000002,IC50,SANGER: Inhibition of human RS4-11 cell growth in a cell viability assay.,Confirmatory,,
2374,741835,1,3,,104234176,36462,Active,,,0.62053,IC50,SANGER: Inhibition of human RT-112 cell growth in a cell viability assay.,Confirmatory,,
2375,741836,1,3,,104234176,36462,Unspecified,,,155.756,IC50,SANGER: Inhibition of human RT4 cell growth in a cell viability assay.,Confirmatory,,
2376,741837,1,3,,104234176,36462,Unspecified,,,106.12799999999999,IC50,SANGER: Inhibition of human RVH-421 cell growth in a cell viability assay.,Confirmatory,,
2377,741838,1,3,,104234176,36462,Active,,,33.7866,IC50,SANGER: Inhibition of human RXF393 cell growth in a cell viability assay.,Confirmatory,,
2378,741839,1,3,,104234176,36462,Active,,,8.319410000000001,IC50,SANGER: Inhibition of human Raji cell growth in a cell viability assay.,Confirmatory,,
2379,741840,1,3,,104234176,36462,Active,,,9.938080000000001,IC50,SANGER: Inhibition of human Ramos-2G6-4C10 cell growth in a cell viability assay.,Confirmatory,,
2380,741841,1,3,,104234176,36462,Unspecified,,,1270.23,IC50,SANGER: Inhibition of human S-117 cell growth in a cell viability assay.,Confirmatory,,
2381,741842,1,3,,104234176,36462,Active,,,1.2672,IC50,SANGER: Inhibition of human SAS cell growth in a cell viability assay.,Confirmatory,,
2382,741843,1,3,,104234176,36462,Active,,,39.1276,IC50,SANGER: Inhibition of human SBC-1 cell growth in a cell viability assay.,Confirmatory,,
2383,741844,1,3,,104234176,36462,Active,,,0.30262,IC50,SANGER: Inhibition of human SBC-5 cell growth in a cell viability assay.,Confirmatory,,
2384,741845,1,3,,104234176,36462,Active,,,13.1497,IC50,SANGER: Inhibition of human SCC-15 cell growth in a cell viability assay.,Confirmatory,,
2385,741846,1,3,,104234176,36462,Active,,,6.634060000000001,IC50,SANGER: Inhibition of human SCC-25 cell growth in a cell viability assay.,Confirmatory,,
2386,741847,1,3,,104234176,36462,Active,,,1.21017,IC50,SANGER: Inhibition of human SCC-3 cell growth in a cell viability assay.,Confirmatory,,
2387,741848,1,3,,104234176,36462,Active,,,7.2023399999999995,IC50,SANGER: Inhibition of human SCC-4 cell growth in a cell viability assay.,Confirmatory,,
2388,741849,1,3,,104234176,36462,Active,,,0.84957,IC50,SANGER: Inhibition of human SCC-9 cell growth in a cell viability assay.,Confirmatory,,
2389,741850,1,3,,104234176,36462,Unspecified,,,2787.84,IC50,SANGER: Inhibition of human SCH cell growth in a cell viability assay.,Confirmatory,,
2390,741851,1,3,,104234176,36462,Unspecified,,,1838.32,IC50,SANGER: Inhibition of human SCLC-21H cell growth in a cell viability assay.,Confirmatory,,
2391,741852,1,3,,104234176,36462,Active,,,1.44086,IC50,SANGER: Inhibition of human SF126 cell growth in a cell viability assay.,Confirmatory,,
2392,741853,1,3,,104234176,36462,Active,,,2.54745,IC50,SANGER: Inhibition of human SF268 cell growth in a cell viability assay.,Confirmatory,,
2393,741854,1,3,,104234176,36462,Active,,,1.6560599999999999,IC50,SANGER: Inhibition of human SF295 cell growth in a cell viability assay.,Confirmatory,,
2394,741855,1,3,,104234176,36462,Active,,,1.60689,IC50,SANGER: Inhibition of human SF539 cell growth in a cell viability assay.,Confirmatory,,
2395,741856,1,3,,104234176,36462,Active,,,3.1346,IC50,SANGER: Inhibition of human SH-4 cell growth in a cell viability assay.,Confirmatory,,
2396,741857,1,3,,104234176,36462,Unspecified,,,400.601,IC50,SANGER: Inhibition of human SHP-77 cell growth in a cell viability assay.,Confirmatory,,
2397,741858,1,3,,104234176,36462,Active,,,0.13082,IC50,SANGER: Inhibition of human SIG-M5 cell growth in a cell viability assay.,Confirmatory,,
2398,741859,1,3,,104234176,36462,Active,,,8.852310000000001,IC50,SANGER: Inhibition of human SIMA cell growth in a cell viability assay.,Confirmatory,,
2399,741860,1,3,,104234176,36462,Active,,,4.72366,IC50,SANGER: Inhibition of human SJRH30 cell growth in a cell viability assay.,Confirmatory,,
2400,741861,1,3,,104234176,36462,Active,,,2.9841599999999997,IC50,SANGER: Inhibition of human SJSA-1 cell growth in a cell viability assay.,Confirmatory,,
2401,741862,1,3,,104234176,36462,Active,,,1.62804,IC50,SANGER: Inhibition of human SK-CO-1 cell growth in a cell viability assay.,Confirmatory,,
2402,741863,1,3,,104234176,36462,Active,,,0.26711999999999997,IC50,SANGER: Inhibition of human SK-HEP-1 cell growth in a cell viability assay.,Confirmatory,,
2403,741864,1,3,,104234176,36462,Active,,,0.5528,IC50,SANGER: Inhibition of human SK-LMS-1 cell growth in a cell viability assay.,Confirmatory,,
2404,741865,1,3,,104234176,36462,Active,,,1.28962,IC50,SANGER: Inhibition of human SK-LU-1 cell growth in a cell viability assay.,Confirmatory,,
2405,741866,1,3,,104234176,36462,Unspecified,,,1031.6,IC50,SANGER: Inhibition of human SK-MEL-1 cell growth in a cell viability assay.,Confirmatory,,
2406,741867,1,3,,104234176,36462,Active,,,21.2698,IC50,SANGER: Inhibition of human SK-MEL-2 cell growth in a cell viability assay.,Confirmatory,,
2407,741868,1,3,,104234176,36462,Unspecified,,,100.182,IC50,SANGER: Inhibition of human SK-MEL-24 cell growth in a cell viability assay.,Confirmatory,,
2408,741869,1,3,,104234176,36462,Unspecified,,,179.22799999999998,IC50,SANGER: Inhibition of human SK-MEL-28 cell growth in a cell viability assay.,Confirmatory,,
2409,741870,1,3,,104234176,36462,Active,,,10.1322,IC50,SANGER: Inhibition of human SK-MEL-3 cell growth in a cell viability assay.,Confirmatory,,
2410,741871,1,3,,104234176,36462,Active,,,8.24405,IC50,SANGER: Inhibition of human SK-MEL-30 cell growth in a cell viability assay.,Confirmatory,,
2411,741873,1,3,,104234176,36462,Active,,,0.80842,IC50,SANGER: Inhibition of human SK-MES-1 cell growth in a cell viability assay.,Confirmatory,,
2412,741875,1,3,,104234176,36462,Active,,,9.68223,IC50,SANGER: Inhibition of human SK-MM-2 cell growth in a cell viability assay.,Confirmatory,,
2413,741876,1,3,,104234176,36462,Unspecified,,,187.485,IC50,SANGER: Inhibition of human SK-N-AS cell growth in a cell viability assay.,Confirmatory,,
2414,741877,1,3,,104234176,36462,Active,,,31.4228,IC50,SANGER: Inhibition of human SK-N-DZ cell growth in a cell viability assay.,Confirmatory,,
2415,741878,1,3,,104234176,36462,Unspecified,,,404.05699999999996,IC50,SANGER: Inhibition of human SK-N-FI cell growth in a cell viability assay.,Confirmatory,,
2416,741879,1,3,,104234176,36462,Active,,,1.9014799999999998,IC50,SANGER: Inhibition of human SK-NEP-1 cell growth in a cell viability assay.,Confirmatory,,
2417,741880,1,3,,104234176,36462,Active,,,10.8274,IC50,SANGER: Inhibition of human SK-OV-3 cell growth in a cell viability assay.,Confirmatory,,
2418,741881,1,3,,104234176,36462,Active,,,0.34228000000000003,IC50,SANGER: Inhibition of human SK-PN-DW cell growth in a cell viability assay.,Confirmatory,,
2419,741882,1,3,,104234176,36462,Active,,,0.04237,IC50,SANGER: Inhibition of human SK-UT-1 cell growth in a cell viability assay.,Confirmatory,,
2420,741883,1,3,,104234176,36462,Active,,,38.976,IC50,SANGER: Inhibition of human SKG-IIIa cell growth in a cell viability assay.,Confirmatory,,
2421,741885,1,3,,104234176,36462,Active,,,1.88379,IC50,SANGER: Inhibition of human SN12C cell growth in a cell viability assay.,Confirmatory,,
2422,741886,1,3,,104234176,36462,Active,,,10.9411,IC50,SANGER: Inhibition of human SNB75 cell growth in a cell viability assay.,Confirmatory,,
2423,741887,1,3,,104234176,36462,Active,,,1.1636799999999998,IC50,SANGER: Inhibition of human SNG-M cell growth in a cell viability assay.,Confirmatory,,
2424,741888,1,3,,104234176,36462,Active,,,43.2181,IC50,SANGER: Inhibition of human SNU-387 cell growth in a cell viability assay.,Confirmatory,,
2425,741889,1,3,,104234176,36462,Active,,,1.75342,IC50,SANGER: Inhibition of human SNU-423 cell growth in a cell viability assay.,Confirmatory,,
2426,741890,1,3,,104234176,36462,Active,,,16.6657,IC50,SANGER: Inhibition of human SNU-449 cell growth in a cell viability assay.,Confirmatory,,
2427,741891,1,3,,104234176,36462,Unspecified,,,66.7492,IC50,SANGER: Inhibition of human SNU-475 cell growth in a cell viability assay.,Confirmatory,,
2428,741892,1,3,,104234176,36462,Unspecified,,,261.955,IC50,SANGER: Inhibition of human SNU-C1 cell growth in a cell viability assay.,Confirmatory,,
2429,741893,1,3,,104234176,36462,Active,,,30.4898,IC50,SANGER: Inhibition of human SNU-C2B cell growth in a cell viability assay.,Confirmatory,,
2430,741894,1,3,,104234176,36462,Active,,,0.44265,IC50,SANGER: Inhibition of human SR cell growth in a cell viability assay.,Confirmatory,,
2431,741895,1,3,,104234176,36462,Active,,,2.24988,IC50,SANGER: Inhibition of human ST486 cell growth in a cell viability assay.,Confirmatory,,
2432,741896,1,3,,104234176,36462,Active,,,0.95915,IC50,SANGER: Inhibition of human SU-DHL-1 cell growth in a cell viability assay.,Confirmatory,,
2433,741897,1,3,,104234176,36462,Active,,,0.70586,IC50,SANGER: Inhibition of human SUP-T1 cell growth in a cell viability assay.,Confirmatory,,
2434,741898,1,3,,104234176,36462,Unspecified,,,856.528,IC50,SANGER: Inhibition of human SW1088 cell growth in a cell viability assay.,Confirmatory,,
2435,741900,1,3,,104234176,36462,Active,,,1.80203,IC50,SANGER: Inhibition of human SW13 cell growth in a cell viability assay.,Confirmatory,,
2436,741901,1,3,,104234176,36462,Unspecified,,,1254.98,IC50,SANGER: Inhibition of human SW1417 cell growth in a cell viability assay.,Confirmatory,,
2437,741902,1,3,,104234176,36462,Unspecified,,,133.509,IC50,SANGER: Inhibition of human SW1463 cell growth in a cell viability assay.,Confirmatory,,
2438,741903,1,3,,104234176,36462,Active,,,2.25339,IC50,SANGER: Inhibition of human SW1573 cell growth in a cell viability assay.,Confirmatory,,
2439,741904,1,3,,104234176,36462,Active,,,0.5183800000000001,IC50,SANGER: Inhibition of human SW1710 cell growth in a cell viability assay.,Confirmatory,,
2440,741905,1,3,,104234176,36462,Active,,,3.05871,IC50,SANGER: Inhibition of human SW1783 cell growth in a cell viability assay.,Confirmatory,,
2441,741906,1,3,,104234176,36462,Active,,,5.638999999999999,IC50,SANGER: Inhibition of human SW1990 cell growth in a cell viability assay.,Confirmatory,,
2442,741907,1,3,,104234176,36462,Active,,,0.86895,IC50,SANGER: Inhibition of human SW48 cell growth in a cell viability assay.,Confirmatory,,
2443,741908,1,3,,104234176,36462,Active,,,0.38448000000000004,IC50,SANGER: Inhibition of human SW620 cell growth in a cell viability assay.,Confirmatory,,
2444,741909,1,3,,104234176,36462,Active,,,8.90372,IC50,SANGER: Inhibition of human SW626 cell growth in a cell viability assay.,Confirmatory,,
2445,741910,1,3,,104234176,36462,Unspecified,,,57.3048,IC50,SANGER: Inhibition of human SW684 cell growth in a cell viability assay.,Confirmatory,,
2446,741911,1,3,,104234176,36462,Active,,,2.98046,IC50,SANGER: Inhibition of human SW756 cell growth in a cell viability assay.,Confirmatory,,
2447,741912,1,3,,104234176,36462,Active,,,21.109,IC50,SANGER: Inhibition of human SW780 cell growth in a cell viability assay.,Confirmatory,,
2448,741913,1,3,,104234176,36462,Unspecified,,,76.2617,IC50,SANGER: Inhibition of human SW837 cell growth in a cell viability assay.,Confirmatory,,
2449,741914,1,3,,104234176,36462,Active,,,0.6404,IC50,SANGER: Inhibition of human SW872 cell growth in a cell viability assay.,Confirmatory,,
2450,741916,1,3,,104234176,36462,Unspecified,,,308.431,IC50,SANGER: Inhibition of human SW948 cell growth in a cell viability assay.,Confirmatory,,
2451,741917,1,3,,104234176,36462,Active,,,1.96311,IC50,SANGER: Inhibition of human SW954 cell growth in a cell viability assay.,Confirmatory,,
2452,741918,1,3,,104234176,36462,Active,,,16.9729,IC50,SANGER: Inhibition of human SW962 cell growth in a cell viability assay.,Confirmatory,,
2453,741919,1,3,,104234176,36462,Active,,,0.13069,IC50,SANGER: Inhibition of human SW982 cell growth in a cell viability assay.,Confirmatory,,
2454,741920,1,3,,104234176,36462,Active,,,26.0963,IC50,SANGER: Inhibition of human Saos-2 cell growth in a cell viability assay.,Confirmatory,,
2455,741921,1,3,,104234176,36462,Unspecified,,,519.307,IC50,SANGER: Inhibition of human SiHa cell growth in a cell viability assay.,Confirmatory,,
2456,741922,1,3,,104234176,36462,Active,,,18.0868,IC50,SANGER: Inhibition of human T-24 cell growth in a cell viability assay.,Confirmatory,,
2457,741923,1,3,,104234176,36462,Active,,,11.6637,IC50,SANGER: Inhibition of human T47D cell growth in a cell viability assay.,Confirmatory,,
2458,741924,1,3,,104234176,36462,Unspecified,,,796.447,IC50,SANGER: Inhibition of human T84 cell growth in a cell viability assay.,Confirmatory,,
2459,741925,1,3,,104234176,36462,Active,,,8.81581,IC50,SANGER: Inhibition of human T98G cell growth in a cell viability assay.,Confirmatory,,
2460,741926,1,3,,104234176,36462,Unspecified,,,1368.03,IC50,SANGER: Inhibition of human TALL-1 cell growth in a cell viability assay.,Confirmatory,,
2461,741928,1,3,,104234176,36462,Active,,,11.6187,IC50,SANGER: Inhibition of human TCCSUP cell growth in a cell viability assay.,Confirmatory,,
2462,741929,1,3,,104234176,36462,Active,,,21.4838,IC50,SANGER: Inhibition of human TE-1 cell growth in a cell viability assay.,Confirmatory,,
2463,741930,1,3,,104234176,36462,Active,,,1.53054,IC50,SANGER: Inhibition of human 22RV1 cell growth in a cell viability assay.,Confirmatory,,
2464,741931,1,3,,104234176,36462,Active,,,0.50139,IC50,SANGER: Inhibition of human 23132-87 cell growth in a cell viability assay.,Confirmatory,,
2465,741932,1,3,,104234176,36462,Active,,,0.86693,IC50,SANGER: Inhibition of human 5637 cell growth in a cell viability assay.,Confirmatory,,
2466,741933,1,3,,104234176,36462,Active,,,1.00797,IC50,SANGER: Inhibition of human 639-V cell growth in a cell viability assay.,Confirmatory,,
2467,741934,1,3,,104234176,36462,Active,,,0.48733999999999994,IC50,SANGER: Inhibition of human 647-V cell growth in a cell viability assay.,Confirmatory,,
2468,741935,1,3,,104234176,36462,Active,,,0.2432,IC50,SANGER: Inhibition of human 697 cell growth in a cell viability assay.,Confirmatory,,
2469,741936,1,3,,104234176,36462,Active,,,2.25653,IC50,SANGER: Inhibition of human 769-P cell growth in a cell viability assay.,Confirmatory,,
2470,741937,1,3,,104234176,36462,Active,,,0.4922,IC50,SANGER: Inhibition of human 786-0 cell growth in a cell viability assay.,Confirmatory,,
2471,741938,1,3,,104234176,36462,Active,,,0.04687,IC50,SANGER: Inhibition of human 8-MG-BA cell growth in a cell viability assay.,Confirmatory,,
2472,741939,1,3,,104234176,36462,Active,,,2.3206700000000002,IC50,SANGER: Inhibition of human 8305C cell growth in a cell viability assay.,Confirmatory,,
2473,741940,1,3,,104234176,36462,Active,,,0.69275,IC50,SANGER: Inhibition of human 8505C cell growth in a cell viability assay.,Confirmatory,,
2474,741941,1,3,,104234176,36462,Active,,,1.19812,IC50,SANGER: Inhibition of human A101D cell growth in a cell viability assay.,Confirmatory,,
2475,741942,1,3,,104234176,36462,Active,,,8.64964,IC50,SANGER: Inhibition of human A172 cell growth in a cell viability assay.,Confirmatory,,
2476,741943,1,3,,104234176,36462,Active,,,0.23248000000000002,IC50,SANGER: Inhibition of human A204 cell growth in a cell viability assay.,Confirmatory,,
2477,741944,1,3,,104234176,36462,Active,,,0.42536999999999997,IC50,SANGER: Inhibition of human A2058 cell growth in a cell viability assay.,Confirmatory,,
2478,741945,1,3,,104234176,36462,Active,,,0.018430000000000002,IC50,SANGER: Inhibition of human A253 cell growth in a cell viability assay.,Confirmatory,,
2479,741946,1,3,,104234176,36462,Active,,,1.10527,IC50,SANGER: Inhibition of human A2780 cell growth in a cell viability assay.,Confirmatory,,
2480,741947,1,3,,104234176,36462,Active,,,0.35825999999999997,IC50,SANGER: Inhibition of human A3-KAW cell growth in a cell viability assay.,Confirmatory,,
2481,741948,1,3,,104234176,36462,Active,,,0.63084,IC50,SANGER: Inhibition of human A375 cell growth in a cell viability assay.,Confirmatory,,
2482,741949,1,3,,104234176,36462,Active,,,3.32957,IC50,SANGER: Inhibition of human A388 cell growth in a cell viability assay.,Confirmatory,,
2483,741950,1,3,,104234176,36462,Active,,,0.8410299999999999,IC50,SANGER: Inhibition of human A4-Fuk cell growth in a cell viability assay.,Confirmatory,,
2484,741951,1,3,,104234176,36462,Active,,,0.10338,IC50,SANGER: Inhibition of human A427 cell growth in a cell viability assay.,Confirmatory,,
2485,741952,1,3,,104234176,36462,Active,,,0.7975399999999999,IC50,SANGER: Inhibition of human A431 cell growth in a cell viability assay.,Confirmatory,,
2486,741953,1,3,,104234176,36462,Active,,,37.4282,IC50,SANGER: Inhibition of human A498 cell growth in a cell viability assay.,Confirmatory,,
2487,741955,1,3,,104234176,36462,Active,,,2.16359,IC50,SANGER: Inhibition of human A673 cell growth in a cell viability assay.,Confirmatory,,
2488,741956,1,3,,104234176,36462,Unspecified,,,890.732,IC50,SANGER: Inhibition of human A704 cell growth in a cell viability assay.,Confirmatory,,
2489,741957,1,3,,104234176,36462,Active,,,0.40453,IC50,SANGER: Inhibition of human ABC-1 cell growth in a cell viability assay.,Confirmatory,,
2490,741958,1,3,,104234176,36462,Active,,,0.8387399999999999,IC50,SANGER: Inhibition of human ACHN cell growth in a cell viability assay.,Confirmatory,,
2491,741959,1,3,,104234176,36462,Active,,,0.07896,IC50,SANGER: Inhibition of human ACN cell growth in a cell viability assay.,Confirmatory,,
2492,741960,1,3,,104234176,36462,Active,,,0.31823,IC50,SANGER: Inhibition of human AGS cell growth in a cell viability assay.,Confirmatory,,
2493,741961,1,3,,104234176,36462,Active,,,0.68979,IC50,SANGER: Inhibition of human ALL-PO cell growth in a cell viability assay.,Confirmatory,,
2494,741962,1,3,,104234176,36462,Active,,,3.6670599999999998,IC50,SANGER: Inhibition of human AM-38 cell growth in a cell viability assay.,Confirmatory,,
2495,741963,1,3,,104234176,36462,Active,,,2.20226,IC50,SANGER: Inhibition of human AN3-CA cell growth in a cell viability assay.,Confirmatory,,
2496,741964,1,3,,104234176,36462,Active,,,2.18911,IC50,SANGER: Inhibition of human ARH-77 cell growth in a cell viability assay.,Confirmatory,,
2497,741965,1,3,,104234176,36462,Active,,,0.20385999999999999,IC50,SANGER: Inhibition of human ATN-1 cell growth in a cell viability assay.,Confirmatory,,
2498,741966,1,3,,104234176,36462,Active,,,2.6112599999999997,IC50,SANGER: Inhibition of human AU565 cell growth in a cell viability assay.,Confirmatory,,
2499,741967,1,3,,104234176,36462,Unspecified,,,302.62,IC50,SANGER: Inhibition of human AsPC-1 cell growth in a cell viability assay.,Confirmatory,,
2500,741969,1,3,,104234176,36462,Active,,,0.06418,IC50,SANGER: Inhibition of human BB30-HNC cell growth in a cell viability assay.,Confirmatory,,
2501,741970,1,3,,104234176,36462,Active,,,37.3849,IC50,SANGER: Inhibition of human BB49-HNC cell growth in a cell viability assay.,Confirmatory,,
2502,741971,1,3,,104234176,36462,Active,,,0.97887,IC50,SANGER: Inhibition of human BB65-RCC cell growth in a cell viability assay.,Confirmatory,,
2503,741972,1,3,,104234176,36462,Active,,,0.54533,IC50,SANGER: Inhibition of human BC-1 cell growth in a cell viability assay.,Confirmatory,,
2504,741973,1,3,,104234176,36462,Active,,,2.47545,IC50,SANGER: Inhibition of human BC-3 cell growth in a cell viability assay.,Confirmatory,,
2505,741974,1,3,,104234176,36462,Active,,,0.73695,IC50,SANGER: Inhibition of human BCPAP cell growth in a cell viability assay.,Confirmatory,,
2506,741975,1,3,,104234176,36462,Active,,,0.50368,IC50,SANGER: Inhibition of human BE-13 cell growth in a cell viability assay.,Confirmatory,,
2507,741976,1,3,,104234176,36462,Unspecified,,,83.0148,IC50,SANGER: Inhibition of human BEN cell growth in a cell viability assay.,Confirmatory,,
2508,741977,1,3,,104234176,36462,Active,,,0.42621000000000003,IC50,SANGER: Inhibition of human BFTC-905 cell growth in a cell viability assay.,Confirmatory,,
2509,741978,1,3,,104234176,36462,Active,,,1.1614799999999998,IC50,SANGER: Inhibition of human BFTC-909 cell growth in a cell viability assay.,Confirmatory,,
2510,741979,1,3,,104234176,36462,Active,,,3.10736,IC50,SANGER: Inhibition of human BHT-101 cell growth in a cell viability assay.,Confirmatory,,
2511,741980,1,3,,104234176,36462,Active,,,1.53169,IC50,SANGER: Inhibition of human BHY cell growth in a cell viability assay.,Confirmatory,,
2512,741981,1,3,,104234176,36462,Active,,,2.08098,IC50,SANGER: Inhibition of human BL-41 cell growth in a cell viability assay.,Confirmatory,,
2513,741982,1,3,,104234176,36462,Active,,,7.07066,IC50,SANGER: Inhibition of human BL-70 cell growth in a cell viability assay.,Confirmatory,,
2514,741983,1,3,,104234176,36462,Active,,,1.63222,IC50,SANGER: Inhibition of human BOKU cell growth in a cell viability assay.,Confirmatory,,
2515,741984,1,3,,104234176,36462,Active,,,0.9428200000000001,IC50,SANGER: Inhibition of human BPH-1 cell growth in a cell viability assay.,Confirmatory,,
2516,741985,1,3,,104234176,36462,Active,,,4.5794,IC50,SANGER: Inhibition of human BT-20 cell growth in a cell viability assay.,Confirmatory,,
2517,741986,1,3,,104234176,36462,Unspecified,,,105.95200000000001,IC50,SANGER: Inhibition of human BT-474 cell growth in a cell viability assay.,Confirmatory,,
2518,741988,1,3,,104234176,36462,Active,,,5.0532900000000005,IC50,SANGER: Inhibition of human BV-173 cell growth in a cell viability assay.,Confirmatory,,
2519,741989,1,3,,104234176,36462,Active,,,11.8156,IC50,SANGER: Inhibition of human Becker cell growth in a cell viability assay.,Confirmatory,,
2520,741990,1,3,,104234176,36462,Active,,,16.8611,IC50,SANGER: Inhibition of human BxPC-3 cell growth in a cell viability assay.,Confirmatory,,
2521,741991,1,3,,104234176,36462,Active,,,0.86169,IC50,SANGER: Inhibition of human C-33-A cell growth in a cell viability assay.,Confirmatory,,
2522,741992,1,3,,104234176,36462,Active,,,1.7135599999999998,IC50,SANGER: Inhibition of human C-4-II cell growth in a cell viability assay.,Confirmatory,,
2523,741993,1,3,,104234176,36462,Unspecified,,,70.8382,IC50,SANGER: Inhibition of human C2BBe1 cell growth in a cell viability assay.,Confirmatory,,
2524,741994,1,3,,104234176,36462,Unspecified,,,1236.58,IC50,SANGER: Inhibition of human C32 cell growth in a cell viability assay.,Confirmatory,,
2525,741995,1,3,,104234176,36462,Active,,,7.930510000000001,IC50,SANGER: Inhibition of human C3A cell growth in a cell viability assay.,Confirmatory,,
2526,741996,1,3,,104234176,36462,Active,,,1.6773,IC50,SANGER: Inhibition of human C8166 cell growth in a cell viability assay.,Confirmatory,,
2527,741997,1,3,,104234176,36462,Unspecified,,,65.0373,IC50,SANGER: Inhibition of human CA46 cell growth in a cell viability assay.,Confirmatory,,
2528,741998,1,3,,104234176,36462,Active,,,6.65287,IC50,SANGER: Inhibition of human CAKI-1 cell growth in a cell viability assay.,Confirmatory,,
2529,741999,1,3,,104234176,36462,Active,,,15.6326,IC50,SANGER: Inhibition of human CAL-120 cell growth in a cell viability assay.,Confirmatory,,
2530,742000,1,3,,104234176,36462,Active,,,11.136,IC50,SANGER: Inhibition of human CAL-12T cell growth in a cell viability assay.,Confirmatory,,
2531,742001,1,3,,104234176,36462,Active,,,0.62544,IC50,SANGER: Inhibition of human CAL-148 cell growth in a cell viability assay.,Confirmatory,,
2532,742002,1,3,,104234176,36462,Active,,,10.4443,IC50,SANGER: Inhibition of human CAL-27 cell growth in a cell viability assay.,Confirmatory,,
2533,742003,1,3,,104234176,36462,Active,,,0.6858,IC50,SANGER: Inhibition of human CAL-33 cell growth in a cell viability assay.,Confirmatory,,
2534,742004,1,3,,104234176,36462,Active,,,4.63617,IC50,SANGER: Inhibition of human CAL-39 cell growth in a cell viability assay.,Confirmatory,,
2535,742005,1,3,,104234176,36462,Active,,,1.08397,IC50,SANGER: Inhibition of human CAL-51 cell growth in a cell viability assay.,Confirmatory,,
2536,742006,1,3,,104234176,36462,Active,,,8.92125,IC50,SANGER: Inhibition of human CAL-54 cell growth in a cell viability assay.,Confirmatory,,
2537,742007,1,3,,104234176,36462,Active,,,0.8511700000000001,IC50,SANGER: Inhibition of human CAL-62 cell growth in a cell viability assay.,Confirmatory,,
2538,742008,1,3,,104234176,36462,Unspecified,,,54.5044,IC50,SANGER: Inhibition of human CAL-72 cell growth in a cell viability assay.,Confirmatory,,
2539,742009,1,3,,104234176,36462,Active,,,2.15944,IC50,SANGER: Inhibition of human CAL-85-1 cell growth in a cell viability assay.,Confirmatory,,
2540,742010,1,3,,104234176,36462,Active,,,2.38102,IC50,SANGER: Inhibition of human TE-10 cell growth in a cell viability assay.,Confirmatory,,
2541,742011,1,3,,104234176,36462,Active,,,7.455030000000001,IC50,SANGER: Inhibition of human TE-11 cell growth in a cell viability assay.,Confirmatory,,
2542,742012,1,3,,104234176,36462,Unspecified,,,78.9774,IC50,SANGER: Inhibition of human TE-12 cell growth in a cell viability assay.,Confirmatory,,
2543,742013,1,3,,104234176,36462,Active,,,0.9596399999999999,IC50,SANGER: Inhibition of human TE-15 cell growth in a cell viability assay.,Confirmatory,,
2544,742014,1,3,,104234176,36462,Active,,,39.1447,IC50,SANGER: Inhibition of human TE-441-T cell growth in a cell viability assay.,Confirmatory,,
2545,742015,1,3,,104234176,36462,Active,,,1.18327,IC50,SANGER: Inhibition of human TE-5 cell growth in a cell viability assay.,Confirmatory,,
2546,742016,1,3,,104234176,36462,Active,,,29.723000000000003,IC50,SANGER: Inhibition of human TE-6 cell growth in a cell viability assay.,Confirmatory,,
2547,742017,1,3,,104234176,36462,Active,,,8.75118,IC50,SANGER: Inhibition of human TE-8 cell growth in a cell viability assay.,Confirmatory,,
2548,742018,1,3,,104234176,36462,Active,,,0.055929999999999994,IC50,SANGER: Inhibition of human TE-9 cell growth in a cell viability assay.,Confirmatory,,
2549,742020,1,3,,104234176,36462,Unspecified,,,126.031,IC50,SANGER: Inhibition of human TGBC1TKB cell growth in a cell viability assay.,Confirmatory,,
2550,742021,1,3,,104234176,36462,Unspecified,,,211.667,IC50,SANGER: Inhibition of human TGBC24TKB cell growth in a cell viability assay.,Confirmatory,,
2551,742022,1,3,,104234176,36462,Active,,,46.3289,IC50,SANGER: Inhibition of human TGW cell growth in a cell viability assay.,Confirmatory,,
2552,742023,1,3,,104234176,36462,Unspecified,,,311.493,IC50,SANGER: Inhibition of human THP-1 cell growth in a cell viability assay.,Confirmatory,,
2553,742025,1,3,,104234176,36462,Active,,,7.49225,IC50,SANGER: Inhibition of human TK10 cell growth in a cell viability assay.,Confirmatory,,
2554,742026,1,3,,104234176,36462,Unspecified,,,513.452,IC50,SANGER: Inhibition of human TT cell growth in a cell viability assay.,Confirmatory,,
2555,742027,1,3,,104234176,36462,Active,,,0.72224,IC50,SANGER: Inhibition of human TUR cell growth in a cell viability assay.,Confirmatory,,
2556,742028,1,3,,104234176,36462,Active,,,2.41237,IC50,SANGER: Inhibition of human TYK-nu cell growth in a cell viability assay.,Confirmatory,,
2557,742029,1,3,,104234176,36462,Unspecified,,,430.671,IC50,SANGER: Inhibition of human U-118-MG cell growth in a cell viability assay.,Confirmatory,,
2558,742030,1,3,,104234176,36462,Unspecified,,,810.574,IC50,SANGER: Inhibition of human U-2-OS cell growth in a cell viability assay.,Confirmatory,,
2559,742031,1,3,,104234176,36462,Active,,,19.9794,IC50,SANGER: Inhibition of human U-266 cell growth in a cell viability assay.,Confirmatory,,
2560,742032,1,3,,104234176,36462,Active,,,12.4627,IC50,SANGER: Inhibition of human U-698-M cell growth in a cell viability assay.,Confirmatory,,
2561,742033,1,3,,104234176,36462,Active,,,27.5565,IC50,SANGER: Inhibition of human U-87-MG cell growth in a cell viability assay.,Confirmatory,,
2562,742034,1,4,,104234176,36462,Active,,,11.2885,IC50,SANGER: Inhibition of human U031 cell growth in a cell viability assay.,Confirmatory,,
2563,742035,1,3,,104234176,36462,Active,,,0.50083,IC50,SANGER: Inhibition of human U251 cell growth in a cell viability assay.,Confirmatory,,
2564,742036,1,3,,104234176,36462,Unspecified,,,56.376999999999995,IC50,SANGER: Inhibition of human UACC-257 cell growth in a cell viability assay.,Confirmatory,,
2565,742037,1,3,,104234176,36462,Active,,,2.91997,IC50,SANGER: Inhibition of human UACC-62 cell growth in a cell viability assay.,Confirmatory,,
2566,742038,1,3,,104234176,36462,Active,,,16.4249,IC50,SANGER: Inhibition of human UACC-812 cell growth in a cell viability assay.,Confirmatory,,
2567,742039,1,3,,104234176,36462,Unspecified,,,460.337,IC50,SANGER: Inhibition of human UACC-893 cell growth in a cell viability assay.,Confirmatory,,
2568,742040,1,3,,104234176,36462,Active,,,1.14554,IC50,SANGER: Inhibition of human UM-UC-3 cell growth in a cell viability assay.,Confirmatory,,
2569,742041,1,3,,104234176,36462,Active,,,24.3195,IC50,SANGER: Inhibition of human UMC-11 cell growth in a cell viability assay.,Confirmatory,,
2570,742042,1,3,,104234176,36462,Active,,,0.41481,IC50,SANGER: Inhibition of human VA-ES-BJ cell growth in a cell viability assay.,Confirmatory,,
2571,742043,1,3,,104234176,36462,Active,,,2.57875,IC50,SANGER: Inhibition of human VM-CUB-1 cell growth in a cell viability assay.,Confirmatory,,
2572,742044,1,3,,104234176,36462,Active,,,1.96786,IC50,SANGER: Inhibition of human VMRC-RCZ cell growth in a cell viability assay.,Confirmatory,,
2573,742045,1,3,,104234176,36462,Unspecified,,,702.185,IC50,SANGER: Inhibition of human WM-115 cell growth in a cell viability assay.,Confirmatory,,
2574,742046,1,3,,104234176,36462,Active,,,4.3604400000000005,IC50,SANGER: Inhibition of human WSU-NHL cell growth in a cell viability assay.,Confirmatory,,
2575,742047,1,3,,104234176,36462,Active,,,30.5644,IC50,SANGER: Inhibition of human YAPC cell growth in a cell viability assay.,Confirmatory,,
2576,742049,1,3,,104234176,36462,Active,,,1.2275399999999999,IC50,SANGER: Inhibition of human YKG-1 cell growth in a cell viability assay.,Confirmatory,,
2577,742050,1,3,,104234176,36462,Active,,,18.2712,IC50,SANGER: Inhibition of human YT cell growth in a cell viability assay.,Confirmatory,,
2578,742052,1,3,,104234176,36462,Active,,,3.4887300000000003,IC50,SANGER: Inhibition of human no-10 cell growth in a cell viability assay.,Confirmatory,,
2579,742053,1,3,,104234176,36462,Active,,,7.557939999999999,IC50,SANGER: Inhibition of human no-11 cell growth in a cell viability assay.,Confirmatory,,
2580,742054,1,3,,104234176,36462,Active,,,13.0046,IC50,SANGER: Inhibition of human CAMA-1 cell growth in a cell viability assay.,Confirmatory,,
2581,742055,1,3,,104234176,36462,Active,,,1.24645,IC50,SANGER: Inhibition of human CAPAN-1 cell growth in a cell viability assay.,Confirmatory,,
2582,742056,1,3,,104234176,36462,Active,,,17.5833,IC50,SANGER: Inhibition of human CAS-1 cell growth in a cell viability assay.,Confirmatory,,
2583,742057,1,3,,104234176,36462,Active,,,6.91149,IC50,SANGER: Inhibition of human CCF-STTG1 cell growth in a cell viability assay.,Confirmatory,,
2584,742058,1,3,,104234176,36462,Active,,,0.17043,IC50,SANGER: Inhibition of human CCRF-CEM cell growth in a cell viability assay.,Confirmatory,,
2585,742059,1,3,,104234176,36462,Active,,,0.38386,IC50,SANGER: Inhibition of human CESS cell growth in a cell viability assay.,Confirmatory,,
2586,742061,1,3,,104234176,36462,Active,,,0.05741,IC50,SANGER: Inhibition of human CGTH-W-1 cell growth in a cell viability assay.,Confirmatory,,
2587,742062,1,3,,104234176,36462,Active,,,0.8829,IC50,SANGER: Inhibition of human CHL-1 cell growth in a cell viability assay.,Confirmatory,,
2588,742063,1,3,,104234176,36462,Active,,,6.273969999999999,IC50,SANGER: Inhibition of human CHP-126 cell growth in a cell viability assay.,Confirmatory,,
2589,742065,1,3,,104234176,36462,Active,,,1.41096,IC50,SANGER: Inhibition of human CHP-212 cell growth in a cell viability assay.,Confirmatory,,
2590,742066,1,3,,104234176,36462,Active,,,2.68446,IC50,SANGER: Inhibition of human CMK cell growth in a cell viability assay.,Confirmatory,,
2591,742067,1,3,,104234176,36462,Active,,,0.26497,IC50,SANGER: Inhibition of human COLO-205 cell growth in a cell viability assay.,Confirmatory,,
2592,742068,1,3,,104234176,36462,Active,,,9.73489,IC50,SANGER: Inhibition of human COLO-320-HSR cell growth in a cell viability assay.,Confirmatory,,
2593,742069,1,3,,104234176,36462,Active,,,1.66431,IC50,SANGER: Inhibition of human COLO-668 cell growth in a cell viability assay.,Confirmatory,,
2594,742070,1,3,,104234176,36462,Unspecified,,,501.902,IC50,SANGER: Inhibition of human COLO-678 cell growth in a cell viability assay.,Confirmatory,,
2595,742071,1,3,,104234176,36462,Active,,,0.16303,IC50,SANGER: Inhibition of human COLO-679 cell growth in a cell viability assay.,Confirmatory,,
2596,742072,1,3,,104234176,36462,Active,,,8.256210000000001,IC50,SANGER: Inhibition of human COLO-680N cell growth in a cell viability assay.,Confirmatory,,
2597,742073,1,3,,104234176,36462,Active,,,16.7953,IC50,SANGER: Inhibition of human COLO-684 cell growth in a cell viability assay.,Confirmatory,,
2598,742074,1,3,,104234176,36462,Active,,,48.8966,IC50,SANGER: Inhibition of human COLO-741 cell growth in a cell viability assay.,Confirmatory,,
2599,742075,1,3,,104234176,36462,Unspecified,,,226.611,IC50,SANGER: Inhibition of human COLO-792 cell growth in a cell viability assay.,Confirmatory,,
2600,742076,1,3,,104234176,36462,Active,,,2.09855,IC50,SANGER: Inhibition of human COLO-800 cell growth in a cell viability assay.,Confirmatory,,
2601,742077,1,3,,104234176,36462,Unspecified,,,131.409,IC50,SANGER: Inhibition of human COLO-824 cell growth in a cell viability assay.,Confirmatory,,
2602,742078,1,3,,104234176,36462,Active,,,1.76857,IC50,SANGER: Inhibition of human COLO-829 cell growth in a cell viability assay.,Confirmatory,,
2603,742079,1,3,,104234176,36462,Active,,,9.56953,IC50,SANGER: Inhibition of human COR-L105 cell growth in a cell viability assay.,Confirmatory,,
2604,742080,1,3,,104234176,36462,Active,,,6.18279,IC50,SANGER: Inhibition of human COR-L23 cell growth in a cell viability assay.,Confirmatory,,
2605,742081,1,3,,104234176,36462,Active,,,1.26744,IC50,SANGER: Inhibition of human COR-L279 cell growth in a cell viability assay.,Confirmatory,,
2606,742082,1,3,,104234176,36462,Active,,,48.735,IC50,SANGER: Inhibition of human COR-L88 cell growth in a cell viability assay.,Confirmatory,,
2607,742083,1,3,,104234176,36462,Unspecified,,,804.816,IC50,SANGER: Inhibition of human CP50-MEL-B cell growth in a cell viability assay.,Confirmatory,,
2608,742084,1,3,,104234176,36462,Active,,,6.25378,IC50,SANGER: Inhibition of human CP66-MEL cell growth in a cell viability assay.,Confirmatory,,
2609,742086,1,3,,104234176,36462,Active,,,18.426,IC50,SANGER: Inhibition of human CPC-N cell growth in a cell viability assay.,Confirmatory,,
2610,742088,1,3,,104234176,36462,Active,,,1.68766,IC50,SANGER: Inhibition of human CTB-1 cell growth in a cell viability assay.,Confirmatory,,
2611,742089,1,3,,104234176,36462,Active,,,0.40968999999999994,IC50,SANGER: Inhibition of human CTV-1 cell growth in a cell viability assay.,Confirmatory,,
2612,742090,1,3,,104234176,36462,Unspecified,,,535.496,IC50,SANGER: Inhibition of human CW-2 cell growth in a cell viability assay.,Confirmatory,,
2613,742091,1,3,,104234176,36462,Active,,,2.32829,IC50,SANGER: Inhibition of human Ca-Ski cell growth in a cell viability assay.,Confirmatory,,
2614,742092,1,3,,104234176,36462,Active,,,2.18807,IC50,SANGER: Inhibition of human Ca9-22 cell growth in a cell viability assay.,Confirmatory,,
2615,742093,1,3,,104234176,36462,Active,,,8.60091,IC50,SANGER: Inhibition of human CaR-1 cell growth in a cell viability assay.,Confirmatory,,
2616,742094,1,3,,104234176,36462,Active,,,7.890219999999999,IC50,SANGER: Inhibition of human Calu-1 cell growth in a cell viability assay.,Confirmatory,,
2617,742095,1,3,,104234176,36462,Active,,,0.49556000000000006,IC50,SANGER: Inhibition of human Calu-3 cell growth in a cell viability assay.,Confirmatory,,
2618,742096,1,3,,104234176,36462,Active,,,4.05854,IC50,SANGER: Inhibition of human Calu-6 cell growth in a cell viability assay.,Confirmatory,,
2619,742097,1,3,,104234176,36462,Active,,,29.2229,IC50,SANGER: Inhibition of human Caov-3 cell growth in a cell viability assay.,Confirmatory,,
2620,742098,1,3,,104234176,36462,Unspecified,,,158.388,IC50,SANGER: Inhibition of human Caov-4 cell growth in a cell viability assay.,Confirmatory,,
2621,742099,1,3,,104234176,36462,Unspecified,,,84.7051,IC50,SANGER: Inhibition of human Capan-2 cell growth in a cell viability assay.,Confirmatory,,
2622,742100,1,3,,104234176,36462,Active,,,3.79409,IC50,SANGER: Inhibition of human ChaGo-K-1 cell growth in a cell viability assay.,Confirmatory,,
2623,742101,1,3,,104234176,36462,Active,,,18.052,IC50,SANGER: Inhibition of human D-247MG cell growth in a cell viability assay.,Confirmatory,,
2624,742102,1,3,,104234176,36462,Unspecified,,,1467.5,IC50,SANGER: Inhibition of human D-263MG cell growth in a cell viability assay.,Confirmatory,,
2625,742103,1,4,,104234176,36462,Active,,,2.19537,IC50,SANGER: Inhibition of human D-283MED cell growth in a cell viability assay.,Confirmatory,,
2626,742104,1,3,,104234176,36462,Unspecified,,,58.4095,IC50,SANGER: Inhibition of human D-336MG cell growth in a cell viability assay.,Confirmatory,,
2627,742105,1,3,,104234176,36462,Unspecified,,,81.0459,IC50,SANGER: Inhibition of human D-392MG cell growth in a cell viability assay.,Confirmatory,,
2628,742107,1,3,,104234176,36462,Unspecified,,,1421.77,IC50,SANGER: Inhibition of human D-502MG cell growth in a cell viability assay.,Confirmatory,,
2629,742108,1,3,,104234176,36462,Unspecified,,,239.27,IC50,SANGER: Inhibition of human D-542MG cell growth in a cell viability assay.,Confirmatory,,
2630,742110,1,3,,104234176,36462,Active,,,6.5298,IC50,SANGER: Inhibition of human DB cell growth in a cell viability assay.,Confirmatory,,
2631,742111,1,3,,104234176,36462,Active,,,2.62832,IC50,SANGER: Inhibition of human DBTRG-05MG cell growth in a cell viability assay.,Confirmatory,,
2632,742112,1,3,,104234176,36462,Active,,,0.31149,IC50,SANGER: Inhibition of human DEL cell growth in a cell viability assay.,Confirmatory,,
2633,742113,1,3,,104234176,36462,Unspecified,,,825.419,IC50,SANGER: Inhibition of human DG-75 cell growth in a cell viability assay.,Confirmatory,,
2634,742114,1,3,,104234176,36462,Active,,,0.20294,IC50,SANGER: Inhibition of human DJM-1 cell growth in a cell viability assay.,Confirmatory,,
2635,742115,1,3,,104234176,36462,Unspecified,,,458.702,IC50,SANGER: Inhibition of human DK-MG cell growth in a cell viability assay.,Confirmatory,,
2636,742116,1,3,,104234176,36462,Unspecified,,,2665.11,IC50,SANGER: Inhibition of human DMS-114 cell growth in a cell viability assay.,Confirmatory,,
2637,742117,1,3,,104234176,36462,Active,,,16.9247,IC50,SANGER: Inhibition of human DMS-153 cell growth in a cell viability assay.,Confirmatory,,
2638,742118,1,3,,104234176,36462,Active,,,0.57348,IC50,SANGER: Inhibition of human DMS-273 cell growth in a cell viability assay.,Confirmatory,,
2639,742119,1,3,,104234176,36462,Unspecified,,,165.708,IC50,SANGER: Inhibition of human DMS-53 cell growth in a cell viability assay.,Confirmatory,,
2640,742120,1,3,,104234176,36462,Unspecified,,,110.53,IC50,SANGER: Inhibition of human DMS-79 cell growth in a cell viability assay.,Confirmatory,,
2641,742121,1,3,,104234176,36462,Active,,,0.34733,IC50,SANGER: Inhibition of human DOHH-2 cell growth in a cell viability assay.,Confirmatory,,
2642,742122,1,3,,104234176,36462,Unspecified,,,93.8293,IC50,SANGER: Inhibition of human DOK cell growth in a cell viability assay.,Confirmatory,,
2643,742123,1,3,,104234176,36462,Active,,,2.36138,IC50,SANGER: Inhibition of human DSH1 cell growth in a cell viability assay.,Confirmatory,,
2644,742124,1,3,,104234176,36462,Active,,,0.59125,IC50,SANGER: Inhibition of human DU-145 cell growth in a cell viability assay.,Confirmatory,,
2645,742125,1,3,,104234176,36462,Active,,,0.09615,IC50,SANGER: Inhibition of human DU-4475 cell growth in a cell viability assay.,Confirmatory,,
2646,742126,1,3,,104234176,36462,Active,,,41.9741,IC50,SANGER: Inhibition of human DV-90 cell growth in a cell viability assay.,Confirmatory,,
2647,742127,1,3,,104234176,36462,Active,,,0.36773,IC50,SANGER: Inhibition of human Daoy cell growth in a cell viability assay.,Confirmatory,,
2648,742128,1,3,,104234176,36462,Active,,,5.36115,IC50,SANGER: Inhibition of human Daudi cell growth in a cell viability assay.,Confirmatory,,
2649,742129,1,3,,104234176,36462,Active,,,11.0756,IC50,SANGER: Inhibition of human Detroit562 cell growth in a cell viability assay.,Confirmatory,,
2650,742130,1,3,,104234176,36462,Active,,,1.04831,IC50,SANGER: Inhibition of human DoTc2-4510 cell growth in a cell viability assay.,Confirmatory,,
2651,742131,1,3,,104234176,36462,Active,,,40.6243,IC50,SANGER: Inhibition of human EB-3 cell growth in a cell viability assay.,Confirmatory,,
2652,742132,1,3,,104234176,36462,Active,,,0.39146,IC50,SANGER: Inhibition of human EB2 cell growth in a cell viability assay.,Confirmatory,,
2653,742133,1,3,,104234176,36462,Unspecified,,,277.205,IC50,SANGER: Inhibition of human EC-GI-10 cell growth in a cell viability assay.,Confirmatory,,
2654,742135,1,3,,104234176,36462,Active,,,0.9543799999999999,IC50,SANGER: Inhibition of human ECC12 cell growth in a cell viability assay.,Confirmatory,,
2655,742136,1,3,,104234176,36462,Active,,,48.0182,IC50,SANGER: Inhibition of human ECC4 cell growth in a cell viability assay.,Confirmatory,,
2656,742137,1,3,,104234176,36462,Unspecified,,,328.72900000000004,IC50,SANGER: Inhibition of human EFE-184 cell growth in a cell viability assay.,Confirmatory,,
2657,742138,1,3,,104234176,36462,Active,,,0.8675200000000001,IC50,SANGER: Inhibition of human EFM-19 cell growth in a cell viability assay.,Confirmatory,,
2658,742139,1,3,,104234176,36462,Active,,,11.8503,IC50,SANGER: Inhibition of human EFO-21 cell growth in a cell viability assay.,Confirmatory,,
2659,742140,1,3,,104234176,36462,Active,,,3.35777,IC50,SANGER: Inhibition of human EFO-27 cell growth in a cell viability assay.,Confirmatory,,
2660,742141,1,3,,104234176,36462,Active,,,3.27013,IC50,SANGER: Inhibition of human EGI-1 cell growth in a cell viability assay.,Confirmatory,,
2661,742142,1,3,,104234176,36462,Active,,,30.3605,IC50,SANGER: Inhibition of human EHEB cell growth in a cell viability assay.,Confirmatory,,
2662,742143,1,3,,104234176,36462,Unspecified,,,448.458,IC50,SANGER: Inhibition of human EKVX cell growth in a cell viability assay.,Confirmatory,,
2663,742144,1,3,,104234176,36462,Active,,,1.57782,IC50,SANGER: Inhibition of human EM-2 cell growth in a cell viability assay.,Confirmatory,,
2664,742146,1,3,,104234176,36462,Active,,,0.25434,IC50,SANGER: Inhibition of human ES1 cell growth in a cell viability assay.,Confirmatory,,
2665,742147,1,3,,104234176,36462,Active,,,0.62849,IC50,SANGER: Inhibition of human ES3 cell growth in a cell viability assay.,Confirmatory,,
2666,742148,1,3,,104234176,36462,Active,,,0.52145,IC50,SANGER: Inhibition of human ES4 cell growth in a cell viability assay.,Confirmatory,,
2667,742149,1,3,,104234176,36462,Unspecified,,,1506.26,IC50,SANGER: Inhibition of human ES5 cell growth in a cell viability assay.,Confirmatory,,
2668,742150,1,3,,104234176,36462,Active,,,19.6334,IC50,SANGER: Inhibition of human ES6 cell growth in a cell viability assay.,Confirmatory,,
2669,742151,1,3,,104234176,36462,Active,,,0.76713,IC50,SANGER: Inhibition of human ES7 cell growth in a cell viability assay.,Confirmatory,,
2670,742152,1,3,,104234176,36462,Active,,,0.14221,IC50,SANGER: Inhibition of human ES8 cell growth in a cell viability assay.,Confirmatory,,
2671,742153,1,3,,104234176,36462,Active,,,0.53078,IC50,SANGER: Inhibition of human ESS-1 cell growth in a cell viability assay.,Confirmatory,,
2672,742154,1,3,,104234176,36462,Active,,,2.7452799999999997,IC50,SANGER: Inhibition of human ETK-1 cell growth in a cell viability assay.,Confirmatory,,
2673,742155,1,3,,104234176,36462,Unspecified,,,277.01,IC50,SANGER: Inhibition of human EVSA-T cell growth in a cell viability assay.,Confirmatory,,
2674,742156,1,3,,104234176,36462,Active,,,1.4584700000000002,IC50,SANGER: Inhibition of human EW-1 cell growth in a cell viability assay.,Confirmatory,,
2675,742157,1,3,,104234176,36462,Active,,,4.76565,IC50,SANGER: Inhibition of human EW-11 cell growth in a cell viability assay.,Confirmatory,,
2676,742159,1,3,,104234176,36462,Active,,,0.08885,IC50,SANGER: Inhibition of human EW-13 cell growth in a cell viability assay.,Confirmatory,,
2677,742160,1,3,,104234176,36462,Active,,,0.021480000000000003,IC50,SANGER: Inhibition of human EW-16 cell growth in a cell viability assay.,Confirmatory,,
2678,742161,1,3,,104234176,36462,Active,,,32.7339,IC50,SANGER: Inhibition of human EW-18 cell growth in a cell viability assay.,Confirmatory,,
2679,742163,1,3,,104234176,36462,Unspecified,,,207.362,IC50,SANGER: Inhibition of human EW-24 cell growth in a cell viability assay.,Confirmatory,,
2680,742164,1,3,,104234176,36462,Active,,,14.3337,IC50,SANGER: Inhibition of human EW-3 cell growth in a cell viability assay.,Confirmatory,,
2681,742165,1,3,,104234176,36462,Active,,,0.12506,IC50,SANGER: Inhibition of human EW-7 cell growth in a cell viability assay.,Confirmatory,,
2682,742166,1,3,,104234176,36462,Active,,,0.30172,IC50,SANGER: Inhibition of human EoL-1-cell cell growth in a cell viability assay.,Confirmatory,,
2683,742167,1,3,,104234176,36462,Active,,,1.28154,IC50,SANGER: Inhibition of human FADU cell growth in a cell viability assay.,Confirmatory,,
2684,742168,1,3,,104234176,36462,Active,,,3.5890800000000005,IC50,SANGER: Inhibition of human FTC-133 cell growth in a cell viability assay.,Confirmatory,,
2685,742169,1,3,,104234176,36462,Active,,,0.8338700000000001,IC50,SANGER: Inhibition of human G-361 cell growth in a cell viability assay.,Confirmatory,,
2686,742170,1,3,,104234176,36462,Active,,,1.4369299999999998,IC50,SANGER: Inhibition of human G-401 cell growth in a cell viability assay.,Confirmatory,,
2687,742171,1,3,,104234176,36462,Active,,,0.8981899999999999,IC50,SANGER: Inhibition of human G-402 cell growth in a cell viability assay.,Confirmatory,,
2688,742172,1,3,,104234176,36462,Active,,,25.1015,IC50,SANGER: Inhibition of human GAK cell growth in a cell viability assay.,Confirmatory,,
2689,742173,1,3,,104234176,36462,Active,,,2.61355,IC50,SANGER: Inhibition of human GAMG cell growth in a cell viability assay.,Confirmatory,,
2690,742174,1,3,,104234176,36462,Active,,,1.6093600000000001,IC50,SANGER: Inhibition of human GB-1 cell growth in a cell viability assay.,Confirmatory,,
2691,742175,1,3,,104234176,36462,Active,,,0.9254899999999999,IC50,SANGER: Inhibition of human GCIY cell growth in a cell viability assay.,Confirmatory,,
2692,742176,1,3,,104234176,36462,Active,,,3.2657599999999998,IC50,SANGER: Inhibition of human GCT cell growth in a cell viability assay.,Confirmatory,,
2693,742177,1,3,,104234176,36462,Active,,,3.4020599999999996,IC50,SANGER: Inhibition of human GDM-1 cell growth in a cell viability assay.,Confirmatory,,
2694,742178,1,3,,104234176,36462,Active,,,0.71317,IC50,SANGER: Inhibition of human GI-1 cell growth in a cell viability assay.,Confirmatory,,
2695,742179,1,3,,104234176,36462,Active,,,9.82616,IC50,SANGER: Inhibition of human GI-ME-N cell growth in a cell viability assay.,Confirmatory,,
2696,742180,1,3,,104234176,36462,Unspecified,,,59.9621,IC50,SANGER: Inhibition of human GMS-10 cell growth in a cell viability assay.,Confirmatory,,
2697,742181,1,3,,104234176,36462,Active,,,6.37509,IC50,SANGER: Inhibition of human GOTO cell growth in a cell viability assay.,Confirmatory,,
2698,742182,1,3,,104234176,36462,Active,,,5.8311,IC50,SANGER: Inhibition of human GP5d cell growth in a cell viability assay.,Confirmatory,,
2699,742183,1,3,,104234176,36462,Active,,,6.68733,IC50,SANGER: Inhibition of human GR-ST cell growth in a cell viability assay.,Confirmatory,,
2700,742184,1,3,,104234176,36462,Active,,,0.40644,IC50,SANGER: Inhibition of human GT3TKB cell growth in a cell viability assay.,Confirmatory,,
2701,742186,1,3,,104234176,36462,Active,,,0.29654,IC50,SANGER: Inhibition of human H4 cell growth in a cell viability assay.,Confirmatory,,
2702,742188,1,3,,104234176,36462,Active,,,3.8044300000000004,IC50,SANGER: Inhibition of human HAL-01 cell growth in a cell viability assay.,Confirmatory,,
2703,742189,1,3,,104234176,36462,Active,,,0.54032,IC50,SANGER: Inhibition of human HC-1 cell growth in a cell viability assay.,Confirmatory,,
2704,742190,1,3,,104234176,36462,Unspecified,,,216.875,IC50,SANGER: Inhibition of human HCC1143 cell growth in a cell viability assay.,Confirmatory,,
2705,742191,1,3,,104234176,36462,Unspecified,,,73.4668,IC50,SANGER: Inhibition of human HCC1187 cell growth in a cell viability assay.,Confirmatory,,
2706,742192,1,3,,104234176,36462,Active,,,44.7952,IC50,SANGER: Inhibition of human HCC1395 cell growth in a cell viability assay.,Confirmatory,,
2707,742193,1,3,,104234176,36462,Unspecified,,,1180.08,IC50,SANGER: Inhibition of human HCC1419 cell growth in a cell viability assay.,Confirmatory,,
2708,742194,1,3,,104234176,36462,Active,,,3.5837199999999996,IC50,SANGER: Inhibition of human HCC1569 cell growth in a cell viability assay.,Confirmatory,,
2709,742195,1,3,,104234176,36462,Active,,,0.61627,IC50,SANGER: Inhibition of human HCC1599 cell growth in a cell viability assay.,Confirmatory,,
2710,742196,1,3,,104234176,36462,Active,,,4.7310099999999995,IC50,SANGER: Inhibition of human HCC1806 cell growth in a cell viability assay.,Confirmatory,,
2711,742197,1,3,,104234176,36462,Active,,,15.7725,IC50,SANGER: Inhibition of human HCC1937 cell growth in a cell viability assay.,Confirmatory,,
2712,742198,1,3,,104234176,36462,Active,,,10.0429,IC50,SANGER: Inhibition of human HCC1954 cell growth in a cell viability assay.,Confirmatory,,
2713,742199,1,3,,104234176,36462,Active,,,20.3328,IC50,SANGER: Inhibition of human HCC2157 cell growth in a cell viability assay.,Confirmatory,,
2714,742200,1,3,,104234176,36462,Unspecified,,,667.34,IC50,SANGER: Inhibition of human HCC2218 cell growth in a cell viability assay.,Confirmatory,,
2715,742201,1,3,,104234176,36462,Active,,,1.25705,IC50,SANGER: Inhibition of human HCC2998 cell growth in a cell viability assay.,Confirmatory,,
2716,742202,1,3,,104234176,36462,Active,,,2.27106,IC50,SANGER: Inhibition of human HCC38 cell growth in a cell viability assay.,Confirmatory,,
2717,742203,1,3,,104234176,36462,Unspecified,,,221.862,IC50,SANGER: Inhibition of human HCC70 cell growth in a cell viability assay.,Confirmatory,,
2718,742204,1,3,,104234176,36462,Active,,,0.80135,IC50,SANGER: Inhibition of human HCE-4 cell growth in a cell viability assay.,Confirmatory,,
2719,742205,1,3,,104234176,36462,Active,,,49.301,IC50,SANGER: Inhibition of human HCE-T cell growth in a cell viability assay.,Confirmatory,,
2720,742206,1,3,,104234176,36462,Active,,,1.00749,IC50,SANGER: Inhibition of human HCT-116 cell growth in a cell viability assay.,Confirmatory,,
2721,742207,1,3,,104234176,36462,Active,,,7.870589999999999,IC50,SANGER: Inhibition of human HCT-15 cell growth in a cell viability assay.,Confirmatory,,
2722,742208,1,3,,104234176,36462,Active,,,8.53777,IC50,SANGER: Inhibition of human HD-MY-Z cell growth in a cell viability assay.,Confirmatory,,
2723,742209,1,3,,104234176,36462,Active,,,13.7938,IC50,SANGER: Inhibition of human HDLM-2 cell growth in a cell viability assay.,Confirmatory,,
2724,742210,1,3,,104234176,36462,Active,,,2.3745,IC50,SANGER: Inhibition of human HEC-1 cell growth in a cell viability assay.,Confirmatory,,
2725,742211,1,3,,104234176,36462,Active,,,3.89764,IC50,SANGER: Inhibition of human HEL cell growth in a cell viability assay.,Confirmatory,,
2726,742212,1,3,,104234176,36462,Active,,,0.10212,IC50,SANGER: Inhibition of human HGC-27 cell growth in a cell viability assay.,Confirmatory,,
2727,742213,1,3,,104234176,36462,Active,,,4.44423,IC50,SANGER: Inhibition of human HH cell growth in a cell viability assay.,Confirmatory,,
2728,742214,1,3,,104234176,36462,Active,,,2.29181,IC50,SANGER: Inhibition of human HL-60 cell growth in a cell viability assay.,Confirmatory,,
2729,742215,1,3,,104234176,36462,Active,,,0.53357,IC50,SANGER: Inhibition of human HLE cell growth in a cell viability assay.,Confirmatory,,
2730,742216,1,3,,104234176,36462,Active,,,0.56879,IC50,SANGER: Inhibition of human HMV-II cell growth in a cell viability assay.,Confirmatory,,
2731,742217,1,3,,104234176,36462,Active,,,18.5533,IC50,SANGER: Inhibition of human HN cell growth in a cell viability assay.,Confirmatory,,
2732,742218,1,3,,104234176,36462,Active,,,2.37868,IC50,SANGER: Inhibition of human HO-1-N-1 cell growth in a cell viability assay.,Confirmatory,,
2733,742219,1,3,,104234176,36462,Active,,,0.52437,IC50,SANGER: Inhibition of human HOP-62 cell growth in a cell viability assay.,Confirmatory,,
2734,742220,1,3,,104234176,36462,Active,,,5.0227699999999995,IC50,SANGER: Inhibition of human HOP-92 cell growth in a cell viability assay.,Confirmatory,,
2735,742221,1,3,,104234176,36462,Active,,,0.47376,IC50,SANGER: Inhibition of human HOS cell growth in a cell viability assay.,Confirmatory,,
2736,742222,1,3,,104234176,36462,Active,,,17.6768,IC50,SANGER: Inhibition of human HPAF-II cell growth in a cell viability assay.,Confirmatory,,
2737,742223,1,3,,104234176,36462,Active,,,0.70578,IC50,SANGER: Inhibition of human HSC-2 cell growth in a cell viability assay.,Confirmatory,,
2738,742224,1,3,,104234176,36462,Active,,,1.4358899999999999,IC50,SANGER: Inhibition of human HSC-3 cell growth in a cell viability assay.,Confirmatory,,
2739,742225,1,3,,104234176,36462,Active,,,1.26252,IC50,SANGER: Inhibition of human HSC-4 cell growth in a cell viability assay.,Confirmatory,,
2740,742226,1,3,,104234176,36462,Active,,,15.2889,IC50,SANGER: Inhibition of human HT cell growth in a cell viability assay.,Confirmatory,,
2741,742227,1,3,,104234176,36462,Active,,,0.10853,IC50,SANGER: Inhibition of human HT-1080 cell growth in a cell viability assay.,Confirmatory,,
2742,742228,1,3,,104234176,36462,Active,,,25.8682,IC50,SANGER: Inhibition of human HT-1197 cell growth in a cell viability assay.,Confirmatory,,
2743,742229,1,3,,104234176,36462,Active,,,5.81886,IC50,SANGER: Inhibition of human HT-1376 cell growth in a cell viability assay.,Confirmatory,,
2744,742230,1,3,,104234176,36462,Active,,,0.02009,IC50,SANGER: Inhibition of human HT-144 cell growth in a cell viability assay.,Confirmatory,,
2745,742231,1,3,,104234176,36462,Active,,,1.97537,IC50,SANGER: Inhibition of human HT-29 cell growth in a cell viability assay.,Confirmatory,,
2746,742232,1,3,,104234176,36462,Active,,,1.12847,IC50,SANGER: Inhibition of human HT-3 cell growth in a cell viability assay.,Confirmatory,,
2747,742233,1,3,,104234176,36462,Active,,,25.82,IC50,SANGER: Inhibition of human HT55 cell growth in a cell viability assay.,Confirmatory,,
2748,742234,1,3,,104234176,36462,Active,,,30.8174,IC50,SANGER: Inhibition of human HTC-C3 cell growth in a cell viability assay.,Confirmatory,,
2749,742235,1,3,,104234176,36462,Active,,,0.21675999999999998,IC50,SANGER: Inhibition of human HUTU-80 cell growth in a cell viability assay.,Confirmatory,,
2750,742236,1,3,,104234176,36462,Unspecified,,,1660.34,IC50,SANGER: Inhibition of human Hs-578-T cell growth in a cell viability assay.,Confirmatory,,
2751,742237,1,3,,104234176,36462,Active,,,1.9106400000000001,IC50,SANGER: Inhibition of human HuCCT1 cell growth in a cell viability assay.,Confirmatory,,
2752,742238,1,3,,104234176,36462,Active,,,2.56377,IC50,SANGER: Inhibition of human HuH-7 cell growth in a cell viability assay.,Confirmatory,,
2753,742239,1,3,,104234176,36462,Active,,,7.71346,IC50,SANGER: Inhibition of human HuO-3N1 cell growth in a cell viability assay.,Confirmatory,,
2754,742240,1,3,,104234176,36462,Active,,,0.9257799999999999,IC50,SANGER: Inhibition of human HuO9 cell growth in a cell viability assay.,Confirmatory,,
2755,742241,1,3,,104234176,36462,Active,,,30.9157,IC50,SANGER: Inhibition of human HuP-T3 cell growth in a cell viability assay.,Confirmatory,,
2756,742242,1,3,,104234176,36462,Active,,,1.45259,IC50,SANGER: Inhibition of human HuP-T4 cell growth in a cell viability assay.,Confirmatory,,
2757,742243,1,3,,104234176,36462,Active,,,3.43569,IC50,SANGER: Inhibition of human IA-LM cell growth in a cell viability assay.,Confirmatory,,
2758,742244,1,3,,104234176,36462,Active,,,1.59112,IC50,SANGER: Inhibition of human IGR-1 cell growth in a cell viability assay.,Confirmatory,,
2759,742245,1,3,,104234176,36462,Active,,,0.17072,IC50,SANGER: Inhibition of human IGROV-1 cell growth in a cell viability assay.,Confirmatory,,
2760,742246,1,3,,104234176,36462,Active,,,41.6341,IC50,SANGER: Inhibition of human IM-9 cell growth in a cell viability assay.,Confirmatory,,
2761,742247,1,3,,104234176,36462,Active,,,0.46935,IC50,SANGER: Inhibition of human IMR-5 cell growth in a cell viability assay.,Confirmatory,,
2762,742248,1,3,,104234176,36462,Active,,,4.33485,IC50,SANGER: Inhibition of human IPC-298 cell growth in a cell viability assay.,Confirmatory,,
2763,742249,1,3,,104234176,36462,Active,,,2.99943,IC50,SANGER: Inhibition of human IST-MEL1 cell growth in a cell viability assay.,Confirmatory,,
2764,742250,1,3,,104234176,36462,Unspecified,,,145.014,IC50,SANGER: Inhibition of human IST-MES1 cell growth in a cell viability assay.,Confirmatory,,
2765,742251,1,3,,104234176,36462,Active,,,19.8912,IC50,SANGER: Inhibition of human IST-SL1 cell growth in a cell viability assay.,Confirmatory,,
2766,742252,1,3,,104234176,36462,Active,,,0.85003,IC50,SANGER: Inhibition of human IST-SL2 cell growth in a cell viability assay.,Confirmatory,,
2767,742253,1,3,,104234176,36462,Active,,,1.59438,IC50,SANGER: Inhibition of human J-RT3-T3-5 cell growth in a cell viability assay.,Confirmatory,,
2768,742254,1,3,,104234176,36462,Active,,,3.33987,IC50,SANGER: Inhibition of human J82 cell growth in a cell viability assay.,Confirmatory,,
2769,742255,1,3,,104234176,36462,Unspecified,,,72.4391,IC50,SANGER: Inhibition of human JAR cell growth in a cell viability assay.,Confirmatory,,
2770,742256,1,3,,104234176,36462,Active,,,3.04067,IC50,SANGER: Inhibition of human JEG-3 cell growth in a cell viability assay.,Confirmatory,,
2771,742257,1,3,,104234176,36462,Unspecified,,,803.1619999999999,IC50,SANGER: Inhibition of human JVM-2 cell growth in a cell viability assay.,Confirmatory,,
2772,742258,1,3,,104234176,36462,Unspecified,,,1609.63,IC50,SANGER: Inhibition of human JVM-3 cell growth in a cell viability assay.,Confirmatory,,
2773,742259,1,4,,104234176,36462,Active,,,2.5428,IC50,SANGER: Inhibition of human JiyoyeP-2003 cell growth in a cell viability assay.,Confirmatory,,
2774,742260,1,3,,104234176,36462,Unspecified,,,1231.49,IC50,SANGER: Inhibition of human K-562 cell growth in a cell viability assay.,Confirmatory,,
2775,742261,1,3,,104234176,36462,Unspecified,,,62.8193,IC50,SANGER: Inhibition of human K052 cell growth in a cell viability assay.,Confirmatory,,
2776,742262,1,3,,104234176,36462,Active,,,25.5193,IC50,SANGER: Inhibition of human K5 cell growth in a cell viability assay.,Confirmatory,,
2777,742263,1,3,,104234176,36462,Active,,,10.3029,IC50,SANGER: Inhibition of human KALS-1 cell growth in a cell viability assay.,Confirmatory,,
2778,742264,1,3,,104234176,36462,Active,,,19.2708,IC50,SANGER: Inhibition of human KARPAS-299 cell growth in a cell viability assay.,Confirmatory,,
2779,742265,1,3,,104234176,36462,Active,,,4.3292,IC50,SANGER: Inhibition of human KARPAS-422 cell growth in a cell viability assay.,Confirmatory,,
2780,742266,1,3,,104234176,36462,Active,,,48.2359,IC50,SANGER: Inhibition of human KARPAS-45 cell growth in a cell viability assay.,Confirmatory,,
2781,742267,1,4,,104234176,36462,Active,,,1.32239,IC50,SANGER: Inhibition of human KASUMI-1 cell growth in a cell viability assay.,Confirmatory,,
2782,742268,1,3,,104234176,36462,Active,,,0.04072,IC50,SANGER: Inhibition of human KE-37 cell growth in a cell viability assay.,Confirmatory,,
2783,742269,1,3,,104234176,36462,Active,,,9.72465,IC50,SANGER: Inhibition of human KG-1 cell growth in a cell viability assay.,Confirmatory,,
2784,742270,1,3,,104234176,36462,Active,,,0.35189000000000004,IC50,SANGER: Inhibition of human KGN cell growth in a cell viability assay.,Confirmatory,,
2785,742271,1,3,,104234176,36462,Active,,,39.2733,IC50,SANGER: Inhibition of human KINGS-1 cell growth in a cell viability assay.,Confirmatory,,
2786,742272,1,3,,104234176,36462,Active,,,10.2925,IC50,SANGER: Inhibition of human KLE cell growth in a cell viability assay.,Confirmatory,,
2787,742273,1,3,,104234176,36462,Active,,,1.6694200000000001,IC50,SANGER: Inhibition of human KM-H2 cell growth in a cell viability assay.,Confirmatory,,
2788,742274,1,3,,104234176,36462,Active,,,1.8793799999999998,IC50,SANGER: Inhibition of human KM12 cell growth in a cell viability assay.,Confirmatory,,
2789,742275,1,3,,104234176,36462,Active,,,8.03697,IC50,SANGER: Inhibition of human KMOE-2 cell growth in a cell viability assay.,Confirmatory,,
2790,742276,1,3,,104234176,36462,Active,,,9.91106,IC50,SANGER: Inhibition of human KMS-12-PE cell growth in a cell viability assay.,Confirmatory,,
2791,742277,1,3,,104234176,36462,Active,,,13.6511,IC50,SANGER: Inhibition of human KNS-42 cell growth in a cell viability assay.,Confirmatory,,
2792,742279,1,3,,104234176,36462,Unspecified,,,176.396,IC50,SANGER: Inhibition of human KNS-81-FD cell growth in a cell viability assay.,Confirmatory,,
2793,742280,1,3,,104234176,36462,Unspecified,,,86.0156,IC50,SANGER: Inhibition of human KOSC-2 cell growth in a cell viability assay.,Confirmatory,,
2794,742281,1,3,,104234176,36462,Active,,,0.41615,IC50,SANGER: Inhibition of human KP-4 cell growth in a cell viability assay.,Confirmatory,,
2795,742284,1,3,,104234176,36462,Active,,,4.2358199999999995,IC50,SANGER: Inhibition of human KP-N-YS cell growth in a cell viability assay.,Confirmatory,,
2796,742285,1,3,,104234176,36462,Active,,,0.33444,IC50,SANGER: Inhibition of human KS-1 cell growth in a cell viability assay.,Confirmatory,,
2797,742286,1,3,,104234176,36462,Unspecified,,,136.791,IC50,SANGER: Inhibition of human KU-19-19 cell growth in a cell viability assay.,Confirmatory,,
2798,742287,1,3,,104234176,36462,Active,,,2.0319700000000003,IC50,SANGER: Inhibition of human KU812 cell growth in a cell viability assay.,Confirmatory,,
2799,742288,1,3,,104234176,36462,Active,,,0.6986,IC50,SANGER: Inhibition of human KURAMOCHI cell growth in a cell viability assay.,Confirmatory,,
2800,742289,1,3,,104234176,36462,Active,,,47.0932,IC50,SANGER: Inhibition of human KY821 cell growth in a cell viability assay.,Confirmatory,,
2801,742290,1,3,,104234176,36462,Active,,,4.91746,IC50,SANGER: Inhibition of human KYSE-140 cell growth in a cell viability assay.,Confirmatory,,
2802,742291,1,3,,104234176,36462,Active,,,0.5303899999999999,IC50,SANGER: Inhibition of human KYSE-150 cell growth in a cell viability assay.,Confirmatory,,
2803,742292,1,3,,104234176,36462,Active,,,2.06953,IC50,SANGER: Inhibition of human KYSE-180 cell growth in a cell viability assay.,Confirmatory,,
2804,742293,1,3,,104234176,36462,Active,,,0.25188,IC50,SANGER: Inhibition of human KYSE-270 cell growth in a cell viability assay.,Confirmatory,,
2805,742294,1,3,,104234176,36462,Active,,,12.8456,IC50,SANGER: Inhibition of human KYSE-410 cell growth in a cell viability assay.,Confirmatory,,
2806,742295,1,3,,104234176,36462,Active,,,3.68871,IC50,SANGER: Inhibition of human KYSE-450 cell growth in a cell viability assay.,Confirmatory,,
2807,742296,1,3,,104234176,36462,Active,,,0.56639,IC50,SANGER: Inhibition of human KYSE-510 cell growth in a cell viability assay.,Confirmatory,,
2808,742297,1,3,,104234176,36462,Active,,,24.0956,IC50,SANGER: Inhibition of human KYSE-520 cell growth in a cell viability assay.,Confirmatory,,
2809,742298,1,3,,104234176,36462,Active,,,32.3637,IC50,SANGER: Inhibition of human KYSE-70 cell growth in a cell viability assay.,Confirmatory,,
2810,742299,1,3,,104234176,36462,Active,,,6.589980000000001,IC50,SANGER: Inhibition of human L-363 cell growth in a cell viability assay.,Confirmatory,,
2811,742300,1,3,,104234176,36462,Active,,,2.98894,IC50,SANGER: Inhibition of human L-428 cell growth in a cell viability assay.,Confirmatory,,
2812,742301,1,3,,104234176,36462,Active,,,1.0579100000000001,IC50,SANGER: Inhibition of human L-540 cell growth in a cell viability assay.,Confirmatory,,
2813,742302,1,3,,104234176,36462,Active,,,9.20893,IC50,SANGER: Inhibition of human LAMA-84 cell growth in a cell viability assay.,Confirmatory,,
2814,742303,1,3,,104234176,36462,Unspecified,,,983.4789999999999,IC50,SANGER: Inhibition of human LAN-6 cell growth in a cell viability assay.,Confirmatory,,
2815,742304,1,3,,104234176,36462,Active,,,2.13516,IC50,SANGER: Inhibition of human LB1047-RCC cell growth in a cell viability assay.,Confirmatory,,
2816,742305,1,3,,104234176,36462,Active,,,31.1031,IC50,SANGER: Inhibition of human LB2241-RCC cell growth in a cell viability assay.,Confirmatory,,
2817,742306,1,3,,104234176,36462,Active,,,48.5056,IC50,SANGER: Inhibition of human LB2518-MEL cell growth in a cell viability assay.,Confirmatory,,
2818,742307,1,3,,104234176,36462,Unspecified,,,176.21900000000002,IC50,SANGER: Inhibition of human LB373-MEL-D cell growth in a cell viability assay.,Confirmatory,,
2819,742308,1,3,,104234176,36462,Active,,,2.0011900000000002,IC50,SANGER: Inhibition of human LB647-SCLC cell growth in a cell viability assay.,Confirmatory,,
2820,742309,1,3,,104234176,36462,Unspecified,,,113.859,IC50,SANGER: Inhibition of human LB771-HNC cell growth in a cell viability assay.,Confirmatory,,
2821,742310,1,3,,104234176,36462,Active,,,6.150469999999999,IC50,SANGER: Inhibition of human LB831-BLC cell growth in a cell viability assay.,Confirmatory,,
2822,742311,1,3,,104234176,36462,Active,,,38.6567,IC50,SANGER: Inhibition of human LB996-RCC cell growth in a cell viability assay.,Confirmatory,,
2823,742312,1,3,,104234176,36462,Unspecified,,,373.277,IC50,SANGER: Inhibition of human LC-1F cell growth in a cell viability assay.,Confirmatory,,
2824,742313,1,3,,104234176,36462,Active,,,2.06407,IC50,SANGER: Inhibition of human LC-2-ad cell growth in a cell viability assay.,Confirmatory,,
2825,742314,1,3,,104234176,36462,Active,,,3.22759,IC50,SANGER: Inhibition of human LC4-1 cell growth in a cell viability assay.,Confirmatory,,
2826,742315,1,3,,104234176,36462,Active,,,0.6511,IC50,SANGER: Inhibition of human LCLC-103H cell growth in a cell viability assay.,Confirmatory,,
2827,742316,1,3,,104234176,36462,Active,,,0.7662399999999999,IC50,SANGER: Inhibition of human LCLC-97TM1 cell growth in a cell viability assay.,Confirmatory,,
2828,742317,1,3,,104234176,36462,Active,,,1.40757,IC50,SANGER: Inhibition of human LK-2 cell growth in a cell viability assay.,Confirmatory,,
2829,742318,1,3,,104234176,36462,Unspecified,,,57.7077,IC50,SANGER: Inhibition of human LN-405 cell growth in a cell viability assay.,Confirmatory,,
2830,742319,1,3,,104234176,36462,Active,,,23.5156,IC50,SANGER: Inhibition of human LNCaP-Clone-FGC cell growth in a cell viability assay.,Confirmatory,,
2831,742320,1,3,,104234176,36462,Active,,,0.1766,IC50,SANGER: Inhibition of human LOUCY cell growth in a cell viability assay.,Confirmatory,,
2832,742321,1,3,,104234176,36462,Active,,,19.9253,IC50,SANGER: Inhibition of human LOXIMVI cell growth in a cell viability assay.,Confirmatory,,
2833,742322,1,3,,104234176,36462,Unspecified,,,2430.08,IC50,SANGER: Inhibition of human LP-1 cell growth in a cell viability assay.,Confirmatory,,
2834,742323,1,3,,104234176,36462,Active,,,33.1173,IC50,SANGER: Inhibition of human LS-1034 cell growth in a cell viability assay.,Confirmatory,,
2835,742324,1,3,,104234176,36462,Active,,,4.02035,IC50,SANGER: Inhibition of human LS-123 cell growth in a cell viability assay.,Confirmatory,,
2836,742325,1,3,,104234176,36462,Active,,,0.92538,IC50,SANGER: Inhibition of human LS-411N cell growth in a cell viability assay.,Confirmatory,,
2837,742326,1,3,,104234176,36462,Unspecified,,,1376.84,IC50,SANGER: Inhibition of human LS-513 cell growth in a cell viability assay.,Confirmatory,,
2838,742327,1,3,,104234176,36462,Active,,,0.29919,IC50,SANGER: Inhibition of human LU-134-A cell growth in a cell viability assay.,Confirmatory,,
2839,742329,1,3,,104234176,36462,Active,,,4.0086699999999995,IC50,SANGER: Inhibition of human LU-139 cell growth in a cell viability assay.,Confirmatory,,
2840,742330,1,3,,104234176,36462,Active,,,28.8005,IC50,SANGER: Inhibition of human LU-165 cell growth in a cell viability assay.,Confirmatory,,
2841,742331,1,4,,104234176,36462,Active,,,30.8083,IC50,SANGER: Inhibition of human LU-65 cell growth in a cell viability assay.,Confirmatory,,
2842,742332,1,3,,104234176,36462,Active,,,2.42772,IC50,SANGER: Inhibition of human LU-99A cell growth in a cell viability assay.,Confirmatory,,
2843,742333,1,3,,104234176,36462,Active,,,2.0752200000000003,IC50,SANGER: Inhibition of human LXF-289 cell growth in a cell viability assay.,Confirmatory,,
2844,742334,1,3,,104234176,36462,Active,,,2.06081,IC50,SANGER: Inhibition of human LoVo cell growth in a cell viability assay.,Confirmatory,,
2845,742335,1,3,,104234176,36462,Active,,,0.36401,IC50,SANGER: Inhibition of human M059J cell growth in a cell viability assay.,Confirmatory,,
2846,742336,1,3,,104234176,36462,Active,,,7.94538,IC50,SANGER: Inhibition of human M14 cell growth in a cell viability assay.,Confirmatory,,
2847,742337,1,3,,104234176,36462,Active,,,0.57962,IC50,SANGER: Inhibition of human MC-CAR cell growth in a cell viability assay.,Confirmatory,,
2848,742338,1,3,,104234176,36462,Active,,,0.11512,IC50,SANGER: Inhibition of human MC-IXC cell growth in a cell viability assay.,Confirmatory,,
2849,742339,1,3,,104234176,36462,Unspecified,,,68.3737,IC50,SANGER: Inhibition of human MC116 cell growth in a cell viability assay.,Confirmatory,,
2850,742340,1,3,,104234176,36462,Active,,,0.8305,IC50,SANGER: Inhibition of human MCF7 cell growth in a cell viability assay.,Confirmatory,,
2851,742341,1,3,,104234176,36462,Unspecified,,,203.456,IC50,SANGER: Inhibition of human MDA-MB-134-VI cell growth in a cell viability assay.,Confirmatory,,
2852,742342,1,3,,104234176,36462,Active,,,12.6094,IC50,SANGER: Inhibition of human MDA-MB-157 cell growth in a cell viability assay.,Confirmatory,,
2853,742343,1,3,,104234176,36462,Unspecified,,,62.0005,IC50,SANGER: Inhibition of human MDA-MB-175-VII cell growth in a cell viability assay.,Confirmatory,,
2854,742344,1,3,,104234176,36462,Active,,,9.08645,IC50,SANGER: Inhibition of human MDA-MB-231 cell growth in a cell viability assay.,Confirmatory,,
2855,742345,1,3,,104234176,36462,Active,,,20.8051,IC50,SANGER: Inhibition of human MDA-MB-361 cell growth in a cell viability assay.,Confirmatory,,
2856,742346,1,3,,104234176,36462,Unspecified,,,185.313,IC50,SANGER: Inhibition of human MDA-MB-415 cell growth in a cell viability assay.,Confirmatory,,
2857,742347,1,3,,104234176,36462,Unspecified,,,613.553,IC50,SANGER: Inhibition of human MDA-MB-453 cell growth in a cell viability assay.,Confirmatory,,
2858,742348,1,3,,104234176,36462,Active,,,1.46554,IC50,SANGER: Inhibition of human MDA-MB-468 cell growth in a cell viability assay.,Confirmatory,,
2859,742349,1,3,,104234176,36462,Active,,,0.8238,IC50,SANGER: Inhibition of human ME-180 cell growth in a cell viability assay.,Confirmatory,,
2860,742350,1,3,,104234176,36462,Active,,,4.7491699999999994,IC50,SANGER: Inhibition of human MEG-01 cell growth in a cell viability assay.,Confirmatory,,
2861,742351,1,3,,104234176,36462,Active,,,0.7287399999999999,IC50,SANGER: Inhibition of human MEL-HO cell growth in a cell viability assay.,Confirmatory,,
2862,742352,1,3,,104234176,36462,Active,,,0.6571,IC50,SANGER: Inhibition of human MEL-JUSO cell growth in a cell viability assay.,Confirmatory,,
2863,742353,1,3,,104234176,36462,Active,,,0.45821000000000006,IC50,SANGER: Inhibition of human MES-SA cell growth in a cell viability assay.,Confirmatory,,
2864,742354,1,3,,104234176,36462,Active,,,40.5005,IC50,SANGER: Inhibition of human MFE-280 cell growth in a cell viability assay.,Confirmatory,,
2865,742355,1,3,,104234176,36462,Active,,,0.76297,IC50,SANGER: Inhibition of human MFE-296 cell growth in a cell viability assay.,Confirmatory,,
2866,742356,1,3,,104234176,36462,Active,,,0.7513,IC50,SANGER: Inhibition of human MFH-ino cell growth in a cell viability assay.,Confirmatory,,
2867,742357,1,3,,104234176,36462,Unspecified,,,1131.42,IC50,SANGER: Inhibition of human MFM-223 cell growth in a cell viability assay.,Confirmatory,,
2868,742358,1,3,,104234176,36462,Active,,,1.1799899999999999,IC50,SANGER: Inhibition of human MG-63 cell growth in a cell viability assay.,Confirmatory,,
2869,742359,1,3,,104234176,36462,Active,,,37.3808,IC50,SANGER: Inhibition of human MHH-CALL-2 cell growth in a cell viability assay.,Confirmatory,,
2870,742360,1,3,,104234176,36462,Active,,,0.46271,IC50,SANGER: Inhibition of human MHH-ES-1 cell growth in a cell viability assay.,Confirmatory,,
2871,742361,1,3,,104234176,36462,Active,,,0.5244300000000001,IC50,SANGER: Inhibition of human MHH-NB-11 cell growth in a cell viability assay.,Confirmatory,,
2872,742362,1,3,,104234176,36462,Active,,,16.4817,IC50,SANGER: Inhibition of human MHH-PREB-1 cell growth in a cell viability assay.,Confirmatory,,
2873,742363,1,3,,104234176,36462,Active,,,2.6613,IC50,SANGER: Inhibition of human MIA-PaCa-2 cell growth in a cell viability assay.,Confirmatory,,
2874,742364,1,3,,104234176,36462,Active,,,0.38169000000000003,IC50,SANGER: Inhibition of human MKN1 cell growth in a cell viability assay.,Confirmatory,,
2875,742365,1,3,,104234176,36462,Active,,,2.5466900000000003,IC50,SANGER: Inhibition of human MKN28 cell growth in a cell viability assay.,Confirmatory,,
2876,742366,1,3,,104234176,36462,Active,,,1.87359,IC50,SANGER: Inhibition of human MKN45 cell growth in a cell viability assay.,Confirmatory,,
2877,742367,1,3,,104234176,36462,Unspecified,,,261.52,IC50,SANGER: Inhibition of human MKN7 cell growth in a cell viability assay.,Confirmatory,,
2878,742368,1,3,,104234176,36462,Active,,,0.17847000000000002,IC50,SANGER: Inhibition of human ML-2 cell growth in a cell viability assay.,Confirmatory,,
2879,742369,1,3,,104234176,36462,Active,,,3.38191,IC50,SANGER: Inhibition of human MLMA cell growth in a cell viability assay.,Confirmatory,,
2880,742370,1,3,,104234176,36462,Active,,,6.87553,IC50,SANGER: Inhibition of human MMAC-SF cell growth in a cell viability assay.,Confirmatory,,
2881,742371,1,3,,104234176,36462,Active,,,29.5512,IC50,SANGER: Inhibition of human MN-60 cell growth in a cell viability assay.,Confirmatory,,
2882,742373,1,3,,104234176,36462,Active,,,12.462,IC50,SANGER: Inhibition of human MOLT-16 cell growth in a cell viability assay.,Confirmatory,,
2883,742374,1,3,,104234176,36462,Active,,,0.41753999999999997,IC50,SANGER: Inhibition of human MOLT-4 cell growth in a cell viability assay.,Confirmatory,,
2884,742375,1,4,,104234176,36462,Active,,,12.1309,IC50,SANGER: Inhibition of human MONO-MAC-6 cell growth in a cell viability assay.,Confirmatory,,
2885,742376,1,3,,104234176,36462,Active,,,20.7595,IC50,SANGER: Inhibition of human MPP-89 cell growth in a cell viability assay.,Confirmatory,,
2886,742377,1,3,,104234176,36462,Active,,,0.1162,IC50,SANGER: Inhibition of human MRK-nu-1 cell growth in a cell viability assay.,Confirmatory,,
2887,742378,1,3,,104234176,36462,Active,,,5.64297,IC50,SANGER: Inhibition of human MS-1 cell growth in a cell viability assay.,Confirmatory,,
2888,742379,1,3,,104234176,36462,Unspecified,,,2160.92,IC50,SANGER: Inhibition of human MSTO-211H cell growth in a cell viability assay.,Confirmatory,,
2889,742380,1,3,,104234176,36462,Active,,,0.15120999999999998,IC50,SANGER: Inhibition of human MV-4-11 cell growth in a cell viability assay.,Confirmatory,,
2890,742381,1,3,,104234176,36462,Active,,,0.8111,IC50,SANGER: Inhibition of human MZ1-PC cell growth in a cell viability assay.,Confirmatory,,
2891,742382,1,3,,104234176,36462,Active,,,2.17939,IC50,SANGER: Inhibition of human MZ2-MEL cell growth in a cell viability assay.,Confirmatory,,
2892,742383,1,3,,104234176,36462,Active,,,4.29859,IC50,SANGER: Inhibition of human MZ7-mel cell growth in a cell viability assay.,Confirmatory,,
2893,742384,1,3,,104234176,36462,Active,,,6.792260000000001,IC50,SANGER: Inhibition of human Mewo cell growth in a cell viability assay.,Confirmatory,,
2894,742385,1,4,,104234176,36462,Unspecified,,,165.28799999999998,IC50,SANGER: Inhibition of human Mo-T cell growth in a cell viability assay.,Confirmatory,,
2895,742386,1,3,,104234176,36462,Active,,,0.20584000000000002,IC50,SANGER: Inhibition of human NALM-6 cell growth in a cell viability assay.,Confirmatory,,
2896,742387,1,3,,104234176,36462,Active,,,10.2077,IC50,SANGER: Inhibition of human NB1 cell growth in a cell viability assay.,Confirmatory,,
2897,742388,1,3,,104234176,36462,Active,,,15.9987,IC50,SANGER: Inhibition of human NB10 cell growth in a cell viability assay.,Confirmatory,,
2898,742389,1,3,,104234176,36462,Active,,,1.0835700000000001,IC50,SANGER: Inhibition of human NB12 cell growth in a cell viability assay.,Confirmatory,,
2899,742390,1,3,,104234176,36462,Active,,,2.76358,IC50,SANGER: Inhibition of human NB13 cell growth in a cell viability assay.,Confirmatory,,
2900,742393,1,3,,104234176,36462,Active,,,21.8619,IC50,SANGER: Inhibition of human NB5 cell growth in a cell viability assay.,Confirmatory,,
2901,742394,1,3,,104234176,36462,Unspecified,,,136.281,IC50,SANGER: Inhibition of human NB6 cell growth in a cell viability assay.,Confirmatory,,
2902,742395,1,3,,104234176,36462,Active,,,1.0875,IC50,SANGER: Inhibition of human NB69 cell growth in a cell viability assay.,Confirmatory,,
2903,742398,1,3,,104234176,36462,Active,,,24.4841,IC50,SANGER: Inhibition of human NCCIT cell growth in a cell viability assay.,Confirmatory,,
2904,742400,1,3,,104234176,36462,Unspecified,,,395.915,IC50,SANGER: Inhibition of human NCI-H1092 cell growth in a cell viability assay.,Confirmatory,,
2905,742401,1,3,,104234176,36462,Active,,,11.02,IC50,SANGER: Inhibition of human NCI-H1155 cell growth in a cell viability assay.,Confirmatory,,
2906,742403,1,3,,104234176,36462,Active,,,2.0703,IC50,SANGER: Inhibition of human NCI-H1299 cell growth in a cell viability assay.,Confirmatory,,
2907,742404,1,3,,104234176,36462,Active,,,2.3040599999999998,IC50,SANGER: Inhibition of human NCI-H1304 cell growth in a cell viability assay.,Confirmatory,,
2908,742405,1,3,,104234176,36462,Active,,,0.38971999999999996,IC50,SANGER: Inhibition of human NCI-H1355 cell growth in a cell viability assay.,Confirmatory,,
2909,742406,1,3,,104234176,36462,Unspecified,,,2373.89,IC50,SANGER: Inhibition of human NCI-H1395 cell growth in a cell viability assay.,Confirmatory,,
2910,742407,1,3,,104234176,36462,Active,,,4.60594,IC50,SANGER: Inhibition of human NCI-H1417 cell growth in a cell viability assay.,Confirmatory,,
2911,742408,1,3,,104234176,36462,Unspecified,,,104.48299999999999,IC50,SANGER: Inhibition of human NCI-H1436 cell growth in a cell viability assay.,Confirmatory,,
2912,742409,1,3,,104234176,36462,Active,,,3.38115,IC50,SANGER: Inhibition of human NCI-H1437 cell growth in a cell viability assay.,Confirmatory,,
2913,742410,1,3,,104234176,36462,Unspecified,,,195.19,IC50,SANGER: Inhibition of human NCI-H1522 cell growth in a cell viability assay.,Confirmatory,,
2914,743126,1,1,,56463308,36462,Inactive,119580345.0,50487.0,,,QFRET-based biochemical high throughput primary assay to identify inhibitors of human group III secreted phospholipase A2 enzyme (HGIII-sPLA2),Screening,,
2915,743238,1,1,,56463308,36462,Inactive,,,,,High Content Cell-Based Imaging Primary HTS to Identify Small Molecules Involved in X-Chromosome Reactivation and Reprogramming Measured in Cell-Based System Using Imaging - 7015-01_Activator_SinglePoint_HTS_Activity_Set2,Screening,,
2916,743247,1,2,,56463308,36462,Inactive,,,,,Inhibition of Alexa 488-Fibronectin deposition #on AH1F cell monolayers Measured in Cell-Based System Using Plate Reader - 7059-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2917,743255,1,1,,56463308,36462,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Primary Screen,Confirmatory,,
2918,743266,1,2,,56463308,36462,Inactive,296080761.0,5745.0,,Potency,qHTS of PTHR Inhibitors: Primary Screen,Confirmatory,,
2919,743268,1,1,,172080538,36462,Inactive,,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors of the NIH Clinical Collection: biochemical high-throughput screening assay to identify compounds that enhance or quench fluorescence of a Cy5-labeled substrate oligonucliotide bound to E. coli SSB,Screening,,
2920,743269,1,1,,56463308,36462,Inactive,2853980.0,,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
2921,743269,1,1,,56463308,36462,Inactive,6708281.0,11168.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
2922,743270,1,1,,172080538,36462,Inactive,125541954.0,,,,Fluorescence polarization based primary biochemical high throughput screening  assay of the NIH Clinical Collections to identify inhibitors of hepatitis C non-structural protein 3 helicase,Screening,,
2923,743271,1,1,,172080538,36462,Inactive,,,,,Biochemical high throughput counterscreening assay of the NIH Clinical Collection for inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3): fluorescence polarization based assay to identify compounds that can displace E. coli single stranded binding protein,Screening,,
2924,743272,1,1,,172080538,36462,Inactive,,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors of the NIH Clinical Collection: a biochemical high-throughput screening assay to identify compounds that cause fluorescent interference,Screening,,
2925,743279,1,2,,56463308,36462,Inactive,10835145.0,3553.0,,,qHTS for Inhibitors of Inflammasome Signaling:  IL-1-beta AlphaLISA Primary Screen,Screening,,
2926,743281,1,1,,46386954,36462,Inactive,1778357.0,22341.0,,,Microplate-based screening for small molecule inhibitors of Neuropilin-2/VEGF-C interactions,Screening,,
2927,743281,1,1,,46386954,36462,Inactive,219520294.0,8828.0,,,Microplate-based screening for small molecule inhibitors of Neuropilin-2/VEGF-C interactions,Screening,,
2928,743397,1,1,,56463308,36462,Inactive,,,,,HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2929,743398,1,1,,56463308,36462,Inactive,,,,,Wnt/Beta-catenin HTS Measured in Cell-Based System Using Plate Reader - 2161-01_Activator_SinglePoint_HTS_Activity,Screening,,
2930,743470,1,1,,164339423,36462,Inactive,,,,AbsAC35_uM,HEK293 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader_7071-01_Inhibitor_Dose_DryPowder_Activity_Set15,Confirmatory,,
2931,743471,1,1,,164339423,36462,Inactive,,,,AbsAC35_uM,HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set12,Confirmatory,,
2932,743472,1,1,,164339423,36462,Inactive,,,,AbsAC35_uM,A549 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-06_Inhibitor_Dose_DryPowder_Activity_Set12,Confirmatory,,
2933,743477,1,1,,164339423,36462,Active,,,0.5770000000000001,AbsAC35_uM,Luminescence cell-based Retest at Dose assay to determine EWS/Fli1 dependent TC71 mammalian cell cytotoxity  Measured in Cell-Based System Using Plate Reader - 7014-04_Inhibitor_Dose_DryPowder_Activity,Confirmatory,,
2934,743478,1,1,,164339423,36462,Active,,,0.7509999999999999,AbsAC35_uM,Luminescence cell-based Retest at Dose assay to determine EWS/Fli1 dependent A673 mammalian cell cytotoxity  Measured in Cell-Based System Using Plate Reader - 7014-03_Inhibitor_Dose_DryPowder_Activity,Confirmatory,,
2935,743479,1,1,,164339423,36462,Active,,,3.01,AbsAC35_uM,Luminescence Cell-Based Primary HTS to identify inhibitors of the oncoprotein EWS/Fli transcriptional activity Measured in Cell-Based System Using Plate Reader - 7014-01_Inhibitor_Dose_DryPowder_Activity,Confirmatory,,
2936,746646,1,5,,104234176,36462,Active,13959709.0,7153.0,,,Inhibition of human topoisomerase 2-mediated relaxation of supercoiled plasmid DNA assessed as formation of linear DNA at 100 uM by agarose gel electrophoresis,Other,23566520.0,
2937,747455,1,1,,104234176,36462,Active,,,2.57,IC50,Cytotoxicity against human SNU638 cells by MTT assay,Confirmatory,23608763.0,
2938,747456,1,1,,104234176,36462,Active,,,4.98,IC50,Cytotoxicity against human T47D cells by MTT assay,Confirmatory,23608763.0,
2939,747459,1,5,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of human topoisomerase 2 at 20 uM relative to control,Other,23608763.0,
2940,747460,1,5,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of human topoisomerase 2 at 100 uM relative to control,Other,23608763.0,
2941,753831,1,1,,104234176,36462,Active,,,6.41,IC50,Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay,Confirmatory,23668986.0,
2942,754069,1,5,,104234176,36462,Active,13959709.0,7153.0,,,Inhibition of DNA topoisomerase-2 (unknown origin) assessed as inhibition of pBR322 DNA relaxation at 100 uM by agarose gel electrophoresis,Other,23711769.0,
2943,754083,1,1,,104234176,36462,Active,,,7.06,IC50,Cytotoxicity against human HCT8 cells assessed as growth inhibition after 48 hrs by MTT assay,Confirmatory,23711769.0,
2944,754084,1,1,,104234176,36462,Active,,,3.2,IC50,Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay,Confirmatory,23711769.0,
2945,754085,1,1,,104234176,36462,Active,,,1.15,IC50,Cytotoxicity against human HL60 cells assessed as growth inhibition after 48 hrs by CCK-8 assay,Confirmatory,23711769.0,
2946,754086,1,1,,104234176,36462,Active,,,2.91,IC50,Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay,Confirmatory,23711769.0,
2947,758259,1,1,,104234176,36462,Unspecified,,,,,Cytotoxicity in Artemia cysts assessed as mortality of nauplii after 24 hrs,Other,23747804.0,
2948,762391,3,1,,104234176,36462,Unspecified,,,,GI50,Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay,Confirmatory,23831811.0,
2949,762392,3,1,,104234176,36462,Unspecified,,,,GI50,Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay,Confirmatory,23831811.0,
2950,765432,1,2,,104234176,36462,Active,,,1.0,IC50,Cytotoxicity against human H460 cells after 48 hrs by MTT assay,Confirmatory,23867385.0,
2951,765436,1,1,,104234176,36462,Active,,,5.48,IC50,Cytotoxicity against human HL60 cells after 48 hrs by MTT assay,Confirmatory,23867385.0,
2952,767199,1,5,,104234176,36462,Active,13959709.0,7153.0,,,Inhibition of human topoisomerase-2alpha using pRYG as substrate assessed as inhibition of pRYG relaxation at 100 uM after 30 mins by agarose gel electrophoresis,Other,23920485.0,
2953,767201,1,5,,104234176,36462,Unspecified,13959709.0,7153.0,78.4,IC50,Inhibition of human topoisomerase-2alpha using kDNA as substrate assessed as inhibition of ATP-dependent kDNA decatenation after 30 mins by agarose gel electrophoresis,Confirmatory,23920485.0,
2954,767210,1,2,,104234176,36462,Unspecified,,,,,Cytotoxicity against human buccal cavity cells assessed as induction of apoptosis at 100 uM by MTT assay relative to control,Other,23920485.0,
2955,767211,1,1,,104234176,36462,Active,,,20.9,IC50,Cytotoxicity against human MCF7 cells assessed as growth inhibition by MTT assay,Confirmatory,23920485.0,
2956,767212,1,2,,104234176,36462,Active,,,30.0,IC50,Cytotoxicity against human H460 cells assessed as growth inhibition by MTT assay,Confirmatory,23920485.0,
2957,767213,1,1,,104234176,36462,Active,,,18.2,IC50,Cytotoxicity against human PC3 cells assessed as growth inhibition by MTT assay,Confirmatory,23920485.0,
2958,768620,1,3,,104234176,36462,Active,,,,,Induction of apoptosis in human COLO205 cells assessed as blebbing at 2 to 4 uM after 24 hrs by Hoechst staining-based confocal microscopic analysis,Other,23849207.0,
2959,768621,1,3,,104234176,36462,Active,,,,,Induction of apoptosis in human COLO205 cells assessed as DNA fragmentation at 2 to 4 uM after 24 hrs by Hoechst staining-based confocal microscopic analysis,Other,23849207.0,
2960,768622,1,3,,104234176,36462,Active,,,,,Induction of apoptosis in human COLO205 cells assessed as caspase-3 activation at 2 uM after 24 hrs by Western blotting analysis,Other,23849207.0,
2961,768624,1,3,,104234176,36462,Active,,,,,Induction of apoptosis in human COLO205 cells assessed as caspase-3 activation at 2 uM after 24 hrs by ELISA,Other,23849207.0,
2962,768626,1,3,,104234176,36462,Unspecified,,,,,Cell cycle arrest in human COLO205 cells assessed as accumulation at G2/M phase at 2 uM after 24 hrs by propidium iodide staining-based FACS flow cytometric analysis (Rvb = 29.52%),Other,23849207.0,
2963,768627,1,3,,104234176,36462,Unspecified,,,,,Cell cycle arrest in human COLO205 cells assessed as accumulation at S phase at 2 uM after 24 hrs by propidium iodide staining-based FACS flow cytometric analysis (Rvb = 4.21%),Other,23849207.0,
2964,768628,1,3,,104234176,36462,Unspecified,,,,,Cell cycle arrest in human COLO205 cells assessed as accumulation at G0/G1 phase at 2 uM after 24 hrs by propidium iodide staining-based FACS flow cytometric analysis (Rvb = 65.23%),Other,23849207.0,
2965,768629,1,3,,104234176,36462,Active,,,,,Cytotoxicity against human COLO205 cells assessed as reduction in cellular ATP level at 2 uM after 24 hrs by bioluminescence assay,Other,23849207.0,
2966,768630,1,3,,104234176,36462,Active,,,,,Cytotoxicity against human COLO205 cells assessed as viable cells at 2 uM after 24 hrs by trypan blue exclusion assay,Other,23849207.0,
2967,768631,1,1,,104234176,36462,Active,,,,,Cytotoxicity against human MDA-MB-231 cells assessed as cell viability at 2 to 4 uM after 24 hrs by MTT assay,Other,23849207.0,
2968,768632,1,3,,104234176,36462,Active,,,,,Cytotoxicity against human COLO205 cells assessed as cell viability at 2 to 4 uM after 24 hrs by MTT assay,Other,23849207.0,
2969,768633,1,1,,104234176,36462,Inactive,,,,,Cytotoxicity against human MDA-MB-231 cells assessed as cell viability at <0.5 to 1 uM after 24 hrs by MTT assay,Other,23849207.0,
2970,768634,1,3,,104234176,36462,Inactive,,,,,Cytotoxicity against human COLO205 cells assessed as cell viability at <0.5 to 1 uM after 24 hrs by MTT assay,Other,23849207.0,
2971,768635,1,1,,104234176,36462,Active,,,1.31,GI50,Growth inhibition of human A2780 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23849207.0,
2972,768636,1,1,,104234176,36462,Active,,,3.11,GI50,Growth inhibition of human SiHa cells after 48 hrs by sulforhodamine B assay,Confirmatory,23849207.0,
2973,768637,1,1,,104234176,36462,Active,,,3.08,GI50,Growth inhibition of human A549 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23849207.0,
2974,768638,1,1,,104234176,36462,Active,,,0.8,GI50,Growth inhibition of human HOP62 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23849207.0,
2975,768639,1,3,,104234176,36462,Active,,,0.13,GI50,Growth inhibition of human COLO205 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23849207.0,
2976,768640,1,1,,104234176,36462,Active,,,0.62,GI50,Growth inhibition of human DWD cells after 48 hrs by sulforhodamine B assay,Confirmatory,23849207.0,
2977,768641,1,1,,104234176,36462,Active,,,0.51,GI50,Growth inhibition of human Gurav cells after 48 hrs by sulforhodamine B assay,Confirmatory,23849207.0,
2978,768642,1,3,,104234176,36462,Active,,,0.31,GI50,Growth inhibition of human KB cells after 48 hrs by sulforhodamine B assay,Confirmatory,23849207.0,
2979,768643,1,1,,104234176,36462,Active,,,2.11,GI50,Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23849207.0,
2980,768644,1,1,,104234176,36462,Active,,,0.2,GI50,Growth inhibition of human ZR-75-1 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23849207.0,
2981,769611,1,2,,104234176,36462,Active,,,1.4,IC50,Cytotoxicity against human U937 cells after 72 hrs by MTT assay,Confirmatory,23865778.0,
2982,769612,1,2,,104234176,36462,Active,,,0.5,IC50,Cytotoxicity against human HL60 cells after 72 hrs by MTT assay,Confirmatory,23865778.0,
2983,770634,1,1,,104234176,36462,Unspecified,,,63.71,IC50,Cytotoxicity against human HeLa cells after 48 hrs by MTT assay,Confirmatory,23968711.0,
2984,770635,1,1,,104234176,36462,Active,,,0.33,IC50,Cytotoxicity against human HL60 cells after 48 hrs by MTT assay,Confirmatory,23968711.0,
2985,770636,1,1,,104234176,36462,Active,,,8.45,IC50,Cytotoxicity against human K562 cells after 48 hrs by MTT assay,Confirmatory,23968711.0,
2986,770637,1,5,,104234176,36462,Active,13959709.0,7153.0,,,Inhibition of human topoisomerase 2alpha assessed as formation of linear form of supercoiled pBR322 DNA at 100 uM after 30 mins by agarose gel electrophoresis,Other,23968711.0,
2987,770638,1,1,,104234176,36462,Active,,,32.05,IC50,Cytotoxicity against human A549 cells after 48 hrs by MTT assay,Confirmatory,23968711.0,
2988,771004,1,1,,104234176,36462,Active,,,,,Induction of DNA damage in human MDA-MB-435 cells assessed as phosphorylation of p53 at Ser15 at 10 uM after 12 hrs by Western blotting analysis,Other,23974019.0,
2989,771005,1,1,,104234176,36462,Active,,,,,Induction of DNA damage in human MDA-MB-435 cells assessed as phosphorylation of H2AX at Ser139 at 10 uM after 12 hrs by Western blotting analysis,Other,23974019.0,
2990,771006,1,1,,104234176,36462,Active,,,,,Induction of DNA damage in human MDA-MB-435 cells assessed as phosphorylation of ATM at Ser1981 at 10 uM after 12 hrs by Western blotting analysis,Other,23974019.0,
2991,771545,1,5,,104234176,36462,Active,13959709.0,7153.0,,,Inhibition of human DNA topoisomerase 2 assessed as decatenation of kinetoplast DNA at 100 ug/ml after 30 mins,Other,24012683.0,
2992,771883,3,1,,104234176,36462,Active,,,0.051,IC50,Cytotoxicity against human MOLT3 cells after 48 hrs by XTT assay,Confirmatory,,
2993,771884,3,1,,104234176,36462,Inconclusive,,,,IC50,Cytotoxicity against human A549 cells after 48 hrs by MTT assay,Confirmatory,,
2994,771885,3,1,,104234176,36462,Inconclusive,,,,IC50,Cytotoxicity against human HuCCa1 cells after 48 hrs by MTT assay,Confirmatory,,
2995,771886,3,1,,104234176,36462,Active,,,30.16,IC50,Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay,Confirmatory,,
2996,771975,1,3,,104234176,36462,Unspecified,,,,GI50,Cytotoxicity against human SF268 cells after 48 hrs by SRB assay,Confirmatory,,
2997,773019,1,1,,104234176,36462,Active,,,,,Induction of apoptosis in human MCF7 cells assessed as increase in caspase-9 activity at 2 uM after 1 hr by fluorescence assay,Other,23999041.0,
2998,773020,1,1,,104234176,36462,Active,,,,,Down regulation of VEGF protein expression in human MCF7 cells at 2 to 4 uM after 24 hrs by Western blotting analysis,Other,23999041.0,
2999,773021,1,1,,104234176,36462,Active,,,,,Down regulation of integrin alpha5beta3 protein expression in human MCF7 cells at 2 to 4 uM after 24 hrs by Western blotting analysis,Other,23999041.0,
3000,773022,1,5,,104234176,36462,Active,119554.0,5594.0,,,Inhibition of ERK1/2 phosphorylation in human MCF7 cells at 2 to 4 uM after 24 hrs by Western blotting analysis,Other,23999041.0,
3001,773022,1,5,,104234176,36462,Active,232066.0,5595.0,,,Inhibition of ERK1/2 phosphorylation in human MCF7 cells at 2 to 4 uM after 24 hrs by Western blotting analysis,Other,23999041.0,
3002,773023,1,1,,104234176,36462,Active,,,,,Down regulation of MEK1 protein expression in human MCF7 cells at 2 to 4 uM after 24 hrs by Western blotting analysis,Other,23999041.0,
3003,773024,1,1,,104234176,36462,Active,,,,,Down regulation of Ras protein expression in human MCF7 cells at 2 to 4 uM after 24 hrs by Western blotting analysis,Other,23999041.0,
3004,773025,1,1,,104234176,36462,Unspecified,,,,,Cell cycle arrest in human MCF7 cells assessed as accumulation at G2/M phase at 4 uM after 24 hrs by propidium iodide staining-based FACS analysis (Rvb = 26%),Other,23999041.0,
3005,773026,1,1,,104234176,36462,Unspecified,,,,,Cell cycle arrest in human MCF7 cells assessed as accumulation at G2/M phase at 2 uM after 24 hrs by propidium iodide staining-based FACS analysis (Rvb = 26%),Other,23999041.0,
3006,773027,1,1,,104234176,36462,Unspecified,,,,,Cell cycle arrest in human MCF7 cells assessed as accumulation at S phase at 4 uM after 24 hrs by propidium iodide staining-based FACS analysis (Rvb = 10%),Other,23999041.0,
3007,773028,1,1,,104234176,36462,Unspecified,,,,,Cell cycle arrest in human MCF7 cells assessed as accumulation at S phase at 2 uM after 24 hrs by propidium iodide staining-based FACS analysis (Rvb = 10%),Other,23999041.0,
3008,773029,1,1,,104234176,36462,Unspecified,,,,,Cell cycle arrest in human MCF7 cells assessed as accumulation at G0/G1 phase at 4 uM after 24 hrs by propidium iodide staining-based FACS analysis (Rvb = 58%),Other,23999041.0,
3009,773030,1,1,,104234176,36462,Unspecified,,,,,Cell cycle arrest in human MCF7 cells assessed as accumulation at G0/G1 phase at 2 uM after 24 hrs by propidium iodide staining-based FACS analysis (Rvb = 58%),Other,23999041.0,
3010,773031,1,1,,104234176,36462,Unspecified,,,,,Cell cycle arrest in human MCF7 cells assessed as accumulation at subG0 phase at 4 uM after 24 hrs by propidium iodide staining-based FACS analysis (Rvb = 5%),Other,23999041.0,
3011,773032,1,1,,104234176,36462,Unspecified,,,,,Cell cycle arrest in human MCF7 cells assessed as accumulation at subG0 phase at 2 uM after 24 hrs by propidium iodide staining-based FACS analysis (Rvb = 5%),Other,23999041.0,
3012,773034,1,1,,104234176,36462,Unspecified,,,,,"Selectivity index, ratio of IC50 for human MCF10A cells to IC50 for human MDA-MB-231 cells",Other,23999041.0,
3013,773035,1,1,,104234176,36462,Active,,,36.26,IC50,Cytotoxicity against human MCF10A cells after 72 hrs by MTT assay,Confirmatory,23999041.0,
3014,773036,1,1,,104234176,36462,Unspecified,,,,,"Selectivity index, ratio of IC50 for human MCF10A cells to IC50 for human MCF7 cells",Other,23999041.0,
3015,773037,1,1,,104234176,36462,Active,,,1.5,IC50,Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay,Confirmatory,23999041.0,
3016,773038,1,1,,104234176,36462,Active,,,1.2,IC50,Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay,Confirmatory,23999041.0,
3017,773039,1,1,,104234176,36462,Active,,,0.87,GI50,Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay,Confirmatory,23999041.0,
3018,773040,1,1,,104234176,36462,Active,,,1.67,GI50,Cytotoxicity against human MDA-MB-231 cells after 48 hrs by SRB assay,Confirmatory,23999041.0,
3019,774446,1,3,,104234176,36462,Active,,,1.84,IC50,Cytotoxicity against human HL60 cells after 24 hrs by MTT assay,Confirmatory,,
3020,774447,1,3,,104234176,36462,Active,,,29.49,IC50,Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay,Confirmatory,,
3021,774448,1,5,,104234176,36462,Active,,,12.3,IC50,Cytotoxicity against human COLO205 cells after 24 hrs by MTT assay,Confirmatory,,
3022,774449,1,3,,104234176,36462,Active,,,3.66,IC50,Cytotoxicity against human THP1 cells after 24 hrs by MTT assay,Confirmatory,,
3023,774450,1,3,,104234176,36462,Active,,,10.43,IC50,Cytotoxicity against human U937 cells after 24 hrs by MTT assay,Confirmatory,,
3024,774944,1,1,,104234176,36462,Active,,,,,Induction of DNA damage in human HCT15 cells at 10 uM after 24 hrs by comet assay,Other,24013413.0,
3025,774954,1,5,,104234176,36462,Unspecified,13959709.0,7153.0,,,Competitive inhibition of recombinant human DNA topoisomerase-2alpha assessed as relaxation of supercoiled pBR322 DNA at 100 uM after 30 mins by agarose gel electrophoresis in presence of 1.5 mM ATP relative to control,Other,24013413.0,
3026,774960,1,5,,104234176,36462,Unspecified,13959709.0,7153.0,,,Competitive inhibition of recombinant human DNA topoisomerase-2alpha assessed as relaxation of supercoiled pBR322 DNA at 100 uM after 30 mins by agarose gel electrophoresis in presence of 1 mM ATP relative to control,Other,24013413.0,
3027,774964,1,1,,104234176,36462,Active,,,0.72,IC50,Cytotoxicity against HEK293 cells after 2 days by CCK-8 assay,Confirmatory,24013413.0,
3028,774965,1,1,,104234176,36462,Active,,,9.29,IC50,Cytotoxicity against human DU145 cells after 2 days by CCK-8 assay,Confirmatory,24013413.0,
3029,774966,1,1,,104234176,36462,Active,,,5.12,IC50,Cytotoxicity against human HCT15 cells after 2 days by CCK-8 assay,Confirmatory,24013413.0,
3030,774967,1,1,,104234176,36462,Active,,,3.42,IC50,Cytotoxicity against human T47D cells after 2 days by CCK-8 assay,Confirmatory,24013413.0,
3031,774968,1,5,,104234176,36462,Active,13959709.0,7153.0,28.2,IC50,Inhibition of human DNA topoisomerase-2alpha assessed as relaxation of supercoiled pBR322 DNA after 30 mins by agarose gel electrophoresis,Confirmatory,24013413.0,
3032,774969,1,5,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of human DNA topoisomerase-2alpha assessed as relaxation of supercoiled pBR322 DNA at 100 uM after 30 mins by agarose gel electrophoresis relative to control,Other,24013413.0,
3033,774970,1,5,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of human DNA topoisomerase-2alpha assessed as relaxation of supercoiled pBR322 DNA at 20 uM after 30 mins by agarose gel electrophoresis relative to control,Other,24013413.0,
3034,774971,1,5,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of human DNA topoisomerase-2alpha assessed as relaxation of supercoiled pBR322 DNA at 10 uM after 30 mins by agarose gel electrophoresis relative to control,Other,24013413.0,
3035,776103,1,5,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of human topoisomerase 2alpha-mediated relaxation of supercoiled pBR322 DNA at 20 uM after 30 mins by agarose gel electrophoresis relative to control,Other,24090914.0,
3036,776104,1,5,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of human topoisomerase 2alpha-mediated relaxation of supercoiled pBR322 DNA at 100 uM after 30 mins by agarose gel electrophoresis relative to control,Other,24090914.0,
3037,779078,1,1,,104234176,36462,Unspecified,,,,,"Selectivity index, ratio of IC50 for HUVEC to IC50 for human A549 cells",Other,24012378.0,
3038,779079,1,1,,104234176,36462,Unspecified,,,,,"Selectivity index, ratio of IC50 for HUVEC to IC50 for human CCRF-CEM cells",Other,24012378.0,
3039,779080,1,1,,104234176,36462,Unspecified,,,,,"Selectivity index, ratio of IC50 for HUVEC to IC50 for human HeLa cells",Other,24012378.0,
3040,779081,1,1,,104234176,36462,Unspecified,,,,,"Selectivity index, ratio of IC50 for HUVEC to IC50 for human MDA-MB-231 cells",Other,24012378.0,
3041,779082,1,1,,104234176,36462,Unspecified,,,,,"Selectivity index, ratio of IC50 for HUVEC to IC50 for human MCF7 cells",Other,24012378.0,
3042,779084,1,1,,104234176,36462,Active,,,1.25,IC50,Cytotoxicity against HUVEC assessed as cell viability after 48 hrs by MTT assay,Confirmatory,24012378.0,
3043,779085,1,1,,104234176,36462,Active,,,14.3,IC50,Antiproliferative activity against human A549 cells assessed as cell viability after 72 hrs by MTT assay,Confirmatory,24012378.0,
3044,779086,1,1,,104234176,36462,Active,,,3.9,IC50,Antiproliferative activity against human HeLa cells assessed as cell viability after 72 hrs by MTT assay,Confirmatory,24012378.0,
3045,779087,1,1,,104234176,36462,Active,,,1.1,IC50,Antiproliferative activity against human CCRF-CEM cells assessed as cell viability after 72 hrs by MTT assay,Confirmatory,24012378.0,
3046,779088,1,1,,104234176,36462,Active,,,21.2,IC50,Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 72 hrs by MTT assay,Confirmatory,24012378.0,
3047,779089,1,1,,104234176,36462,Active,,,1.2,IC50,Antiproliferative activity against human Jurkat cells assessed as cell viability after 72 hrs by MTT assay,Confirmatory,24012378.0,
3048,779090,1,1,,104234176,36462,Active,,,10.9,IC50,Antiproliferative activity against human MCF7 cells assessed as cell viability after 72 hrs by MTT assay,Confirmatory,24012378.0,
3049,779091,1,1,,104234176,36462,Unspecified,,,,,"Selectivity index, ratio of IC50 for HUVEC to IC50 for human Jurkat cells",Other,24012378.0,
3050,779539,1,1,,104234176,36462,Active,,,,,Antiinvasive activity in human MCF7 cells assessed as downregulation of alphaVbeta3 integrin protein expression at 4 uM after 24 hrs by Western blot analysis,Other,24055291.0,
3051,779540,1,1,,104234176,36462,Active,,,,,Disruption of mitochondrial membrane potential in human MCF7 cells at 4 uM after 24 hrs by JC-1 dye-based fluorescence assay,Other,24055291.0,
3052,779541,1,1,,104234176,36462,Active,,,,,Induction of apoptosis in human MCF7 cells assessed as upregulation of cytochrome-c protein expression in cytosol at 4 uM after 24 hrs by Western blotting analysis,Other,24055291.0,
3053,779542,1,1,,104234176,36462,Active,,,,,Induction of apoptosis in human MCF7 cells assessed as upregulation of caspase-9 protein expression at 4 uM after 24 hrs by Western blotting analysis,Other,24055291.0,
3054,779553,1,1,,104234176,36462,Unspecified,,,,,Cytotoxicity against HUVEC assessed as cell viability at 1 uM after 6 hrs by MTT assay,Other,24055291.0,
3055,779555,1,1,,104234176,36462,Unspecified,,,,,Cell cycle arrest in human MCF7 cells assessed as accumulation at G2/M phase at 4 uM after 24 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 15%),Other,24055291.0,
3056,779556,1,1,,104234176,36462,Unspecified,,,,,Cell cycle arrest in human MCF7 cells assessed as accumulation at S phase at 4 uM after 24 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 5%),Other,24055291.0,
3057,779557,1,1,,104234176,36462,Unspecified,,,,,Cell cycle arrest in human MCF7 cells assessed as accumulation at G1 phase at 4 uM after 24 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 77%),Other,24055291.0,
3058,779558,1,1,,104234176,36462,Unspecified,,,,,Cell cycle arrest in human MCF7 cells assessed as accumulation at G0 phase at 4 uM after 24 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 3%),Other,24055291.0,
3059,780580,1,5,,104234176,36462,Active,13959709.0,7153.0,,,Inhibition of Topoisomerase 2 (unknown origin) assessed as impairment of pBR322 DNA decatenation at 100 uM after 30 mins by agarose gel electrophoresis,Other,24095018.0,
3060,780581,1,1,,104234176,36462,Active,,,1.71,IC50,Antiproliferative activity against human A549 cells assessed as cell viability after 72 hrs by MTT assay,Confirmatory,24095018.0,
3061,780585,1,1,,104234176,36462,Active,,,0.87,IC50,Antiproliferative activity against human HCT116 cells assessed as cell viability after 72 hrs by MTT assay,Confirmatory,24095018.0,
3062,780588,4,2,,104234176,36462,Unspecified,2498443.0,3065.0,,IC50,Inhibition of human recombinant HDAC1 expressed in baculovirus infected insect high5 cells using Ac-Lys-Tyr-Lys (epsilon-acetyl)-AMC as substrate after 3 to 24 hrs by fluorescence assay,Confirmatory,24095018.0,
3063,780612,1,1,,104234176,36462,Active,,,4.73,IC50,Cytotoxicity against human HeLa cells after 48 hrs by MTT assay,Confirmatory,24095019.0,
3064,780613,1,1,,104234176,36462,Active,,,6.54,IC50,Cytotoxicity against human HCT8 cells after 48 hrs by MTT assay,Confirmatory,24095019.0,
3065,780614,1,1,,104234176,36462,Active,,,14.9,IC50,Cytotoxicity against human A549 cells after 48 hrs by MTT assay,Confirmatory,24095019.0,
3066,780615,1,1,,104234176,36462,Active,,,11.52,IC50,Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay,Confirmatory,24095019.0,
3067,780975,3,1,,104234176,36462,Unspecified,,,54.0,IC50,Cytotoxicity against human KB-7d cells overexpressing MRP assessed as growth inhibition after 72 hrs by methylene blue staining-based assay,Confirmatory,24106982.0,
3068,780976,3,1,,104234176,36462,Active,,,3.5,IC50,Cytotoxicity against human KB-S15 cells overexpressing P-gp170/MDR assessed as growth inhibition after 72 hrs by methylene blue staining-based assay,Confirmatory,24106982.0,
3069,780977,3,1,,104234176,36462,Active,,,23.0,IC50,Cytotoxicity against human KB-VIN10 cells overexpressing P-gp170/MDR assessed as growth inhibition after 72 hrs by methylene blue staining-based assay,Confirmatory,24106982.0,
3070,780985,3,2,,104234176,36462,Active,,,1.1,IC50,Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by methylene blue staining-based assay,Confirmatory,24106982.0,
3071,883566,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 555/11,Other,,
3072,883567,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 555/11,Other,,
3073,883568,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 555/11,Other,,
3074,883569,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 555/11,Other,,
3075,883570,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 555/11,Other,,
3076,883571,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 555/11,Other,,
3077,884250,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 555/11,Other,,
3078,884251,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 555/11,Other,,
3079,884252,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 555/11,Other,,
3080,884253,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 555/11,Other,,
3081,884254,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 555/11,Other,,
3082,884255,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 555/11,Other,,
3083,884256,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 555/11,Other,,
3084,884257,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 555/11,Other,,
3085,884258,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 555/11,Other,,
3086,884259,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 555/11,Other,,
3087,884260,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 555/11,Other,,
3088,884261,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 555/11,Other,,
3089,884262,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 555/11,Other,,
3090,884263,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 555/11,Other,,
3091,884264,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 555/12,Other,,
3092,884265,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 555/12,Other,,
3093,884266,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 555/12,Other,,
3094,884267,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 555/12,Other,,
3095,884268,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 555/12,Other,,
3096,884269,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 555/12,Other,,
3097,884270,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 555/12,Other,,
3098,884271,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 555/12,Other,,
3099,884272,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 555/12,Other,,
3100,884273,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 555/12,Other,,
3101,884274,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 555/12,Other,,
3102,884275,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 555/12,Other,,
3103,884276,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 555/12,Other,,
3104,884277,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 555/12,Other,,
3105,884278,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 555/12,Other,,
3106,884279,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 555/12,Other,,
3107,884280,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 555/12,Other,,
3108,884281,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 555/12,Other,,
3109,884282,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 555/12,Other,,
3110,884283,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 555/12,Other,,
3111,884284,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 555/12,Other,,
3112,884285,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 555/13,Other,,
3113,884286,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 555/13,Other,,
3114,884287,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 555/13,Other,,
3115,884288,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 555/13,Other,,
3116,884289,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 555/13,Other,,
3117,884290,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 555/13,Other,,
3118,884357,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 554/5,Other,,
3119,884358,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 554/5,Other,,
3120,884359,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 554/5,Other,,
3121,884360,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 554/5,Other,,
3122,884361,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 554/5,Other,,
3123,884362,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 554/5,Other,,
3124,884363,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 554/5,Other,,
3125,884364,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 554/5,Other,,
3126,884365,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 554/5,Other,,
3127,884366,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 554/5,Other,,
3128,884367,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 554/5,Other,,
3129,884368,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 554/5,Other,,
3130,884369,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 554/5,Other,,
3131,884370,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 554/5,Other,,
3132,884371,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 554/5,Other,,
3133,884372,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 554/5,Other,,
3134,884373,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 554/5,Other,,
3135,884374,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 554/5,Other,,
3136,884375,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 554/5,Other,,
3137,884376,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 554/5,Other,,
3138,884377,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 554/5,Other,,
3139,884378,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 554/6,Other,,
3140,884379,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 554/6,Other,,
3141,884380,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 554/6,Other,,
3142,884381,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 554/6,Other,,
3143,884382,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 554/6,Other,,
3144,884383,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 554/6,Other,,
3145,884384,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 554/6,Other,,
3146,884385,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 554/6,Other,,
3147,885065,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 554/6,Other,,
3148,885066,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 554/6,Other,,
3149,885067,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 554/6,Other,,
3150,885068,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 554/6,Other,,
3151,885069,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 554/6,Other,,
3152,885070,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 554/6,Other,,
3153,885071,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 554/6,Other,,
3154,885072,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 554/6,Other,,
3155,885073,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 554/6,Other,,
3156,885074,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 554/6,Other,,
3157,885075,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 554/6,Other,,
3158,885076,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 554/6,Other,,
3159,885077,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 554/6,Other,,
3160,885078,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 554/7,Other,,
3161,885079,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 554/7,Other,,
3162,885080,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 554/7,Other,,
3163,887140,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 555/13,Other,,
3164,887141,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 555/13,Other,,
3165,887142,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 555/13,Other,,
3166,887143,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 555/13,Other,,
3167,887144,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 555/13,Other,,
3168,887145,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 555/13,Other,,
3169,887146,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 555/13,Other,,
3170,887147,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 555/13,Other,,
3171,887148,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 555/13,Other,,
3172,887149,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 555/13,Other,,
3173,887150,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 555/13,Other,,
3174,887151,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 555/13,Other,,
3175,887152,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 555/13,Other,,
3176,887153,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 555/13,Other,,
3177,887154,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 555/13,Other,,
3178,887155,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 555/14,Other,,
3179,887156,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 555/14,Other,,
3180,887157,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 555/14,Other,,
3181,887158,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 555/14,Other,,
3182,887159,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 555/14,Other,,
3183,887160,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 555/14,Other,,
3184,887161,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 555/14,Other,,
3185,887162,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 555/14,Other,,
3186,887163,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 555/14,Other,,
3187,887164,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 555/14,Other,,
3188,887165,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 555/14,Other,,
3189,887166,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 555/14,Other,,
3190,887167,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 555/14,Other,,
3191,887168,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 555/14,Other,,
3192,887169,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 555/14,Other,,
3193,887170,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 555/14,Other,,
3194,887171,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 555/14,Other,,
3195,887172,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 555/14,Other,,
3196,887173,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 555/14,Other,,
3197,887174,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 555/14,Other,,
3198,887175,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 555/14,Other,,
3199,887176,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 555/15,Other,,
3200,887177,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 555/15,Other,,
3201,887178,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 555/15,Other,,
3202,887179,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 555/15,Other,,
3203,887180,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 555/15,Other,,
3204,887181,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 555/15,Other,,
3205,887862,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 555/15,Other,,
3206,887863,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 555/15,Other,,
3207,887864,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 555/15,Other,,
3208,887865,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 555/15,Other,,
3209,887866,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 555/15,Other,,
3210,890035,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 555/15,Other,,
3211,890036,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 555/15,Other,,
3212,890037,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 555/15,Other,,
3213,890038,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 555/15,Other,,
3214,890039,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 555/15,Other,,
3215,890040,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 555/15,Other,,
3216,890041,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 555/15,Other,,
3217,890042,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 555/15,Other,,
3218,890043,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 555/15,Other,,
3219,890044,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 555/15,Other,,
3220,890045,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 555/16,Other,,
3221,890046,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 555/16,Other,,
3222,890047,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 555/16,Other,,
3223,890048,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 555/16,Other,,
3224,890049,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 555/16,Other,,
3225,890050,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 555/16,Other,,
3226,890051,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 555/16,Other,,
3227,890052,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 555/16,Other,,
3228,890053,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 555/16,Other,,
3229,890054,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 555/16,Other,,
3230,890055,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 555/16,Other,,
3231,890056,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 555/16,Other,,
3232,890057,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 555/16,Other,,
3233,890058,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 555/16,Other,,
3234,890059,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 555/16,Other,,
3235,890060,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 555/16,Other,,
3236,890061,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 555/16,Other,,
3237,890062,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 555/16,Other,,
3238,890063,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 555/16,Other,,
3239,890064,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 555/16,Other,,
3240,890065,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 555/16,Other,,
3241,916801,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 555/6,Other,,
3242,916802,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 555/6,Other,,
3243,916803,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 555/6,Other,,
3244,916804,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 555/6,Other,,
3245,916805,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 555/6,Other,,
3246,916806,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 555/6,Other,,
3247,916807,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 555/6,Other,,
3248,916808,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 555/6,Other,,
3249,916809,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 555/6,Other,,
3250,916810,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 555/7,Other,,
3251,916811,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 555/7,Other,,
3252,916812,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 555/7,Other,,
3253,916813,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 555/7,Other,,
3254,916814,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 555/7,Other,,
3255,916815,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 555/7,Other,,
3256,917224,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 554/14,Other,,
3257,917225,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 554/14,Other,,
3258,917226,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 554/14,Other,,
3259,917227,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 554/14,Other,,
3260,917228,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 554/14,Other,,
3261,917229,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 554/14,Other,,
3262,917230,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 554/14,Other,,
3263,917231,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 554/14,Other,,
3264,917232,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 554/14,Other,,
3265,917233,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 554/14,Other,,
3266,917234,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 554/14,Other,,
3267,917235,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 554/14,Other,,
3268,917236,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 554/14,Other,,
3269,917237,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 554/14,Other,,
3270,917238,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 554/14,Other,,
3271,917239,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 554/14,Other,,
3272,917240,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 554/14,Other,,
3273,917241,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 554/14,Other,,
3274,917242,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 554/14,Other,,
3275,917243,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 554/14,Other,,
3276,917244,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 554/14,Other,,
3277,917245,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 554/15,Other,,
3278,917246,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 554/15,Other,,
3279,917247,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 554/15,Other,,
3280,917248,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 554/15,Other,,
3281,917249,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 554/15,Other,,
3282,917250,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 554/15,Other,,
3283,917251,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 554/15,Other,,
3284,917252,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 554/15,Other,,
3285,917253,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 554/15,Other,,
3286,917254,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 554/15,Other,,
3287,917255,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 554/15,Other,,
3288,917256,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 554/15,Other,,
3289,917257,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 554/15,Other,,
3290,917258,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 554/15,Other,,
3291,917259,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 554/15,Other,,
3292,917260,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 554/15,Other,,
3293,917261,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 554/15,Other,,
3294,917262,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 554/15,Other,,
3295,917263,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 554/15,Other,,
3296,917264,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 554/15,Other,,
3297,917265,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 555/7,Other,,
3298,917266,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 555/7,Other,,
3299,917267,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 555/7,Other,,
3300,917268,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 555/7,Other,,
3301,917269,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 555/7,Other,,
3302,917270,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 555/7,Other,,
3303,917271,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 555/7,Other,,
3304,917272,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 555/7,Other,,
3305,917273,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 555/7,Other,,
3306,917274,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 555/7,Other,,
3307,917275,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 555/7,Other,,
3308,917276,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 555/7,Other,,
3309,917277,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 555/7,Other,,
3310,917278,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 555/7,Other,,
3311,917279,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 555/7,Other,,
3312,917280,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 555/8,Other,,
3313,917281,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 555/8,Other,,
3314,917282,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 555/8,Other,,
3315,917283,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 555/8,Other,,
3316,917284,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 555/8,Other,,
3317,917285,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 555/8,Other,,
3318,917286,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 555/8,Other,,
3319,917287,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 555/8,Other,,
3320,917288,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 555/8,Other,,
3321,917289,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 555/8,Other,,
3322,917290,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 555/8,Other,,
3323,917291,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 555/8,Other,,
3324,917292,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 555/8,Other,,
3325,917293,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 555/8,Other,,
3326,917294,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 555/8,Other,,
3327,917295,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 555/8,Other,,
3328,917296,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 555/8,Other,,
3329,917706,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 554/15,Other,,
3330,917707,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 554/16,Other,,
3331,917708,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 554/16,Other,,
3332,917709,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 554/16,Other,,
3333,917710,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 554/16,Other,,
3334,917711,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 554/16,Other,,
3335,917712,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 554/16,Other,,
3336,918614,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 554/7,Other,,
3337,918615,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 554/7,Other,,
3338,918616,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 554/7,Other,,
3339,918617,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 554/7,Other,,
3340,918618,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 554/7,Other,,
3341,918619,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 554/7,Other,,
3342,918620,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 554/7,Other,,
3343,918621,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 554/7,Other,,
3344,918622,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 554/7,Other,,
3345,918623,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 554/7,Other,,
3346,918624,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 554/7,Other,,
3347,918625,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 554/7,Other,,
3348,918626,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 554/7,Other,,
3349,918627,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 554/7,Other,,
3350,918628,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 554/7,Other,,
3351,918629,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 554/7,Other,,
3352,918630,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 554/7,Other,,
3353,918631,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 554/7,Other,,
3354,918632,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 554/8,Other,,
3355,918633,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 554/8,Other,,
3356,918634,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 554/8,Other,,
3357,918635,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 554/8,Other,,
3358,918636,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 554/8,Other,,
3359,918676,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 555/8,Other,,
3360,918677,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 555/8,Other,,
3361,918678,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 555/8,Other,,
3362,918679,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 555/8,Other,,
3363,918680,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 555/9,Other,,
3364,918681,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 555/9,Other,,
3365,919041,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 554/8,Other,,
3366,919042,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 554/8,Other,,
3367,919043,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 554/8,Other,,
3368,919044,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 554/8,Other,,
3369,919045,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 554/8,Other,,
3370,919046,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 554/8,Other,,
3371,919047,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 554/8,Other,,
3372,919048,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 554/8,Other,,
3373,919049,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 554/8,Other,,
3374,919050,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 554/8,Other,,
3375,919051,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 554/8,Other,,
3376,919052,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 554/8,Other,,
3377,919053,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 554/8,Other,,
3378,919054,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 554/8,Other,,
3379,919055,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 554/8,Other,,
3380,919056,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 554/9,Other,,
3381,919057,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 554/9,Other,,
3382,919058,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 554/9,Other,,
3383,919059,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 554/9,Other,,
3384,919060,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 554/9,Other,,
3385,919061,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 554/9,Other,,
3386,919062,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 554/9,Other,,
3387,919063,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 554/9,Other,,
3388,919064,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 554/9,Other,,
3389,919085,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 554/8,Other,,
3390,919086,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 555/9,Other,,
3391,919087,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 555/9,Other,,
3392,919088,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 555/9,Other,,
3393,919089,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 555/9,Other,,
3394,919090,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 555/9,Other,,
3395,919091,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 555/9,Other,,
3396,919092,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 555/9,Other,,
3397,919093,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 555/9,Other,,
3398,919094,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 555/9,Other,,
3399,919095,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 555/9,Other,,
3400,919096,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 555/9,Other,,
3401,919097,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 555/9,Other,,
3402,919098,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 555/9,Other,,
3403,919099,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 555/9,Other,,
3404,919100,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 555/9,Other,,
3405,919101,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 555/9,Other,,
3406,919102,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 555/9,Other,,
3407,919103,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 555/9,Other,,
3408,919104,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 555/9,Other,,
3409,919105,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 555/10,Other,,
3410,919106,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 555/10,Other,,
3411,919107,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 555/10,Other,,
3412,919108,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 555/10,Other,,
3413,919109,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 555/10,Other,,
3414,919110,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 555/10,Other,,
3415,919111,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 555/10,Other,,
3416,919112,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 555/10,Other,,
3417,919113,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 555/10,Other,,
3418,919114,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 555/10,Other,,
3419,919115,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 555/10,Other,,
3420,919116,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 555/10,Other,,
3421,919117,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 555/10,Other,,
3422,919118,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 555/10,Other,,
3423,919119,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 555/10,Other,,
3424,919120,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 555/10,Other,,
3425,919121,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 555/10,Other,,
3426,919122,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 555/10,Other,,
3427,919123,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 555/10,Other,,
3428,919124,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 555/10,Other,,
3429,919125,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 555/10,Other,,
3430,919126,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 555/11,Other,,
3431,920407,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 554/9,Other,,
3432,920408,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 554/9,Other,,
3433,920409,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 554/9,Other,,
3434,920410,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 554/9,Other,,
3435,920411,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 554/9,Other,,
3436,920412,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 554/9,Other,,
3437,920413,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 554/9,Other,,
3438,920414,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 554/9,Other,,
3439,920415,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 554/9,Other,,
3440,920416,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 554/9,Other,,
3441,920417,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 554/9,Other,,
3442,920418,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 554/9,Other,,
3443,920419,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 554/10,Other,,
3444,920420,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 554/10,Other,,
3445,920822,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 554/10,Other,,
3446,920823,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 554/10,Other,,
3447,920824,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 554/10,Other,,
3448,920825,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 554/10,Other,,
3449,920826,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 554/10,Other,,
3450,920827,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 554/10,Other,,
3451,920828,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 554/10,Other,,
3452,920829,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 554/10,Other,,
3453,920830,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 554/10,Other,,
3454,920831,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 554/10,Other,,
3455,920832,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 554/10,Other,,
3456,920833,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 554/10,Other,,
3457,920834,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 554/10,Other,,
3458,920835,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 554/10,Other,,
3459,920836,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 554/10,Other,,
3460,920837,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 554/10,Other,,
3461,920838,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 554/10,Other,,
3462,920839,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 554/10,Other,,
3463,920840,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 554/10,Other,,
3464,920841,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 554/11,Other,,
3465,920842,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 554/11,Other,,
3466,920843,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 554/11,Other,,
3467,920844,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 554/11,Other,,
3468,920845,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 554/11,Other,,
3469,920846,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 554/11,Other,,
3470,920847,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 554/11,Other,,
3471,920848,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 554/11,Other,,
3472,920849,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 554/11,Other,,
3473,920850,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 554/11,Other,,
3474,920851,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 554/11,Other,,
3475,920852,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 554/11,Other,,
3476,920853,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 554/11,Other,,
3477,920854,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 554/11,Other,,
3478,920855,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 554/11,Other,,
3479,942490,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S011009,Other,,
3480,942491,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S011009,Other,,
3481,942492,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S011009,Other,,
3482,942493,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S011009,Other,,
3483,942494,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S011009,Other,,
3484,943124,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S011009,Other,,
3485,943125,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S011009,Other,,
3486,943126,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S011009,Other,,
3487,943127,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S011009,Other,,
3488,943128,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S011009,Other,,
3489,943129,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S011009,Other,,
3490,943130,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S011009,Other,,
3491,943131,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S011009,Other,,
3492,943132,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S011009,Other,,
3493,943133,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S011009",Other,,
3494,943134,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S011009,Other,,
3495,943135,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S011009,Other,,
3496,943136,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S011009,Other,,
3497,943137,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S011009,Other,,
3498,943924,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S011204,Other,,
3499,943925,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S011204,Other,,
3500,943926,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S011204,Other,,
3501,943927,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S011204,Other,,
3502,943928,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S011204,Other,,
3503,943929,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S011204,Other,,
3504,943930,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S011204,Other,,
3505,943931,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S011204,Other,,
3506,943932,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S011204,Other,,
3507,943933,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S011204,Other,,
3508,943934,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S011204,Other,,
3509,943935,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S011204,Other,,
3510,943936,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S011204",Other,,
3511,943937,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S011204,Other,,
3512,943938,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S011204,Other,,
3513,943939,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S011204,Other,,
3514,943940,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S011204,Other,,
3515,943941,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S011204,Other,,
3516,943942,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S011204,Other,,
3517,945963,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S011009,Other,,
3518,945964,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S011009,Other,,
3519,945965,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S011009,Other,,
3520,945966,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S011009,Other,,
3521,945967,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S011009,Other,,
3522,945968,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S011009,Other,,
3523,945969,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S011009,Other,,
3524,945970,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S011009",Other,,
3525,945971,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S011009,Other,,
3526,945972,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S011009,Other,,
3527,945973,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S011009,Other,,
3528,945974,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S011009,Other,,
3529,945975,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S011009,Other,,
3530,945976,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S011009,Other,,
3531,945977,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S011009,Other,,
3532,945978,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S011009,Other,,
3533,946610,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S011009,Other,,
3534,946611,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S011009,Other,,
3535,946612,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S011009,Other,,
3536,948871,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S011204,Other,,
3537,948872,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S011204,Other,,
3538,948873,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S011204,Other,,
3539,948874,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S011204,Other,,
3540,948875,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S011204,Other,,
3541,948876,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S011204,Other,,
3542,948877,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S011204,Other,,
3543,948878,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S011204",Other,,
3544,948879,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S011204,Other,,
3545,948880,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S011204,Other,,
3546,948881,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S011204,Other,,
3547,948882,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S011204,Other,,
3548,948883,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S011204,Other,,
3549,948884,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S011204,Other,,
3550,948885,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S011204,Other,,
3551,948886,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S011204,Other,,
3552,948887,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S011204,Other,,
3553,948888,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S011204,Other,,
3554,948889,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S011204,Other,,
3555,954387,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S011204,Other,,
3556,954388,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S011204,Other,,
3557,954389,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S011204,Other,,
3558,954390,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S011204,Other,,
3559,954391,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S011204,Other,,
3560,954392,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S011204,Other,,
3561,954393,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S011204,Other,,
3562,954394,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S011204,Other,,
3563,954395,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S011204,Other,,
3564,954396,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S011204,Other,,
3565,954397,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S011204,Other,,
3566,954398,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S011204,Other,,
3567,954986,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S011204,Other,,
3568,954987,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S011204,Other,,
3569,954988,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S011204,Other,,
3570,954989,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S011204,Other,,
3571,954990,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S011204,Other,,
3572,954991,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S011204,Other,,
3573,954992,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S011204,Other,,
3574,954993,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S011009,Other,,
3575,954994,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S011009,Other,,
3576,954995,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S011009,Other,,
3577,954996,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S011009,Other,,
3578,954997,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S011009,Other,,
3579,954998,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S011009,Other,,
3580,954999,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S011009,Other,,
3581,955000,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S011009,Other,,
3582,955001,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S011009,Other,,
3583,955002,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S011009,Other,,
3584,955003,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S011009,Other,,
3585,955004,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S011009,Other,,
3586,955005,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S011009,Other,,
3587,955006,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S011009,Other,,
3588,955007,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S011009,Other,,
3589,955008,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S011009,Other,,
3590,955009,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S011009,Other,,
3591,955010,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S011009,Other,,
3592,956864,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S011009,Other,,
3593,963423,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S011204,Other,,
3594,963424,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S011204,Other,,
3595,963425,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S011204,Other,,
3596,963848,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S011204,Other,,
3597,963849,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S011204,Other,,
3598,963850,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S011204,Other,,
3599,963851,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S011204,Other,,
3600,963852,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S011204,Other,,
3601,963853,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S011204,Other,,
3602,963854,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S011204,Other,,
3603,963855,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S011204,Other,,
3604,963856,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S011204,Other,,
3605,963857,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S011204,Other,,
3606,963858,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S011204,Other,,
3607,963859,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S011204,Other,,
3608,963860,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S011204,Other,,
3609,963861,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S011204,Other,,
3610,963862,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S011204,Other,,
3611,963863,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S011204,Other,,
3612,969660,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S011009,Other,,
3613,969661,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S011009,Other,,
3614,969662,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S011009,Other,,
3615,969663,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S011009,Other,,
3616,969664,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S011009,Other,,
3617,969665,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S011009,Other,,
3618,969666,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S011009,Other,,
3619,969667,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S011009,Other,,
3620,969668,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S011009,Other,,
3621,969669,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S011009,Other,,
3622,969670,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S011009,Other,,
3623,971692,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S011009,Other,,
3624,971693,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S011009,Other,,
3625,971694,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S011009,Other,,
3626,971695,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S011009,Other,,
3627,971696,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S011009,Other,,
3628,971697,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S011009,Other,,
3629,971698,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S011009,Other,,
3630,971699,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S011009,Other,,
3631,977599,1,1,,104234176,36462,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
3632,977602,1,2,,104234176,36462,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
3633,987843,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S011009",Other,,
3634,987844,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S011009",Other,,
3635,987845,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S011009",Other,,
3636,987846,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S011009",Other,,
3637,987847,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S011009,Other,,
3638,987848,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S011009,Other,,
3639,987849,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S011009",Other,,
3640,987850,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011009",Other,,
3641,987851,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011009",Other,,
3642,987852,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S011009",Other,,
3643,987853,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S011009,Other,,
3644,987854,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011009",Other,,
3645,987855,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S011009",Other,,
3646,987856,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S011009",Other,,
3647,987857,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S011009",Other,,
3648,987858,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S011009,Other,,
3649,987859,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011009",Other,,
3650,987860,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S011009",Other,,
3651,987861,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S011009",Other,,
3652,987862,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S011009",Other,,
3653,987863,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S011009",Other,,
3654,987864,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S011009",Other,,
3655,987865,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S011009",Other,,
3656,987866,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S011009,Other,,
3657,987867,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S011009",Other,,
3658,987868,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S011009",Other,,
3659,987869,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S011009,Other,,
3660,987870,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S011009",Other,,
3661,987871,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S011009",Other,,
3662,987872,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S011009",Other,,
3663,987873,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S011009",Other,,
3664,987874,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S011009",Other,,
3665,987875,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S011009",Other,,
3666,989092,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011009",Other,,
3667,989093,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S011009",Other,,
3668,989094,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S011009",Other,,
3669,989095,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S011009",Other,,
3670,989096,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S011009",Other,,
3671,989097,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011009",Other,,
3672,989098,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S011009,Other,,
3673,989099,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S011009",Other,,
3674,989100,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S011009,Other,,
3675,989101,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S011009",Other,,
3676,989102,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S011009",Other,,
3677,989103,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S011009",Other,,
3678,989104,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S011009",Other,,
3679,989105,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S011009",Other,,
3680,989106,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S011009",Other,,
3681,989107,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S011009",Other,,
3682,989108,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S011009",Other,,
3683,989109,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S011009",Other,,
3684,989110,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011009",Other,,
3685,989111,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011009",Other,,
3686,989112,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S011009",Other,,
3687,989113,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S011009",Other,,
3688,989114,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011009",Other,,
3689,989115,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S011009",Other,,
3690,989116,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S011009",Other,,
3691,989117,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S011009",Other,,
3692,996824,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011204",Other,,
3693,996825,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S011204",Other,,
3694,996826,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S011204",Other,,
3695,996827,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S011204",Other,,
3696,999270,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011204",Other,,
3697,999271,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011204",Other,,
3698,999272,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S011204,Other,,
3699,999273,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S011204",Other,,
3700,999274,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S011204,Other,,
3701,999275,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S011204",Other,,
3702,999276,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S011204",Other,,
3703,999277,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S011204",Other,,
3704,999278,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S011204",Other,,
3705,999279,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S011204",Other,,
3706,999280,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S011204",Other,,
3707,999281,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S011204",Other,,
3708,999282,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S011204",Other,,
3709,999283,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S011204",Other,,
3710,999284,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011204",Other,,
3711,999285,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S011204",Other,,
3712,999286,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S011204",Other,,
3713,999287,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011204",Other,,
3714,999288,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S011204",Other,,
3715,999289,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S011204",Other,,
3716,999290,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S011204",Other,,
3717,999291,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S011204",Other,,
3718,999292,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S011204",Other,,
3719,999293,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S011204",Other,,
3720,999294,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S011204",Other,,
3721,999295,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Spleen; Assay: Extramedullary Hematopoiesis Increased; Study_ID: S011204,Other,,
3722,999296,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S011204,Other,,
3723,999297,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S011204,Other,,
3724,999298,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S011204",Other,,
3725,999299,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011204",Other,,
3726,999300,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011204",Other,,
3727,999301,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S011204",Other,,
3728,999302,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S011204,Other,,
3729,999303,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011204",Other,,
3730,999886,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S011204",Other,,
3731,999887,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S011204",Other,,
3732,999888,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S011204",Other,,
3733,999889,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S011204",Other,,
3734,999890,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S011204,Other,,
3735,1001751,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011204",Other,,
3736,1001752,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S011204",Other,,
3737,1001753,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S011204",Other,,
3738,1001754,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S011204",Other,,
3739,1001755,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S011204",Other,,
3740,1001756,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S011204",Other,,
3741,1001757,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Spleen; Assay: Lymphoid Depletion; Study_ID: S011204,Other,,
3742,1001758,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S011204",Other,,
3743,1001759,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S011204,Other,,
3744,1001760,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S011204",Other,,
3745,1001761,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S011204",Other,,
3746,1001762,1,3,,104234176,36462,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S011204,Other,,
3747,1001763,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S011204",Other,,
3748,1001764,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S011204",Other,,
3749,1001765,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S011204",Other,,
3750,1001766,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S011204",Other,,
3751,1001767,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S011204",Other,,
3752,1001768,1,3,,104234176,36462,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S011204",Other,,
3753,1039926,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 554/5,Other,,
3754,1040592,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 554/5,Other,,
3755,1040593,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 554/5,Other,,
3756,1040594,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 554/5,Other,,
3757,1040595,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 554/5,Other,,
3758,1040596,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 554/6,Other,,
3759,1040597,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 554/6,Other,,
3760,1040598,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 554/6,Other,,
3761,1040599,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 554/6,Other,,
3762,1040600,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 554/6,Other,,
3763,1040601,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 554/7,Other,,
3764,1040602,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 554/7,Other,,
3765,1040603,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 554/7,Other,,
3766,1040604,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 554/7,Other,,
3767,1040605,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 554/7,Other,,
3768,1040606,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 554/8,Other,,
3769,1040607,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 554/8,Other,,
3770,1040608,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 554/8,Other,,
3771,1040609,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 554/8,Other,,
3772,1040610,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 554/8,Other,,
3773,1040611,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 554/9,Other,,
3774,1040612,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 554/9,Other,,
3775,1040613,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 554/9,Other,,
3776,1040614,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 554/9,Other,,
3777,1040615,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 554/9,Other,,
3778,1040616,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 554/10,Other,,
3779,1040617,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 554/10,Other,,
3780,1040618,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 554/10,Other,,
3781,1040619,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 554/10,Other,,
3782,1040620,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 554/10,Other,,
3783,1040621,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 554/11,Other,,
3784,1040622,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 554/11,Other,,
3785,1040623,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 554/11,Other,,
3786,1040624,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 554/11,Other,,
3787,1040625,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 554/11,Other,,
3788,1040626,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 554/12,Other,,
3789,1040627,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 554/12,Other,,
3790,1040628,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 554/12,Other,,
3791,1040629,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 554/12,Other,,
3792,1040630,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 554/12,Other,,
3793,1040631,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 554/13,Other,,
3794,1040632,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 554/13,Other,,
3795,1040633,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 554/13,Other,,
3796,1043448,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 554/13,Other,,
3797,1043449,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 554/13,Other,,
3798,1043450,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 554/14,Other,,
3799,1043451,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 554/14,Other,,
3800,1043452,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 554/14,Other,,
3801,1043453,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 554/14,Other,,
3802,1043454,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 554/14,Other,,
3803,1043455,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 554/15,Other,,
3804,1043456,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 554/15,Other,,
3805,1043457,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 554/15,Other,,
3806,1043458,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 554/15,Other,,
3807,1043459,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 554/15,Other,,
3808,1043460,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 554/16,Other,,
3809,1043461,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 554/16,Other,,
3810,1043462,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 554/16,Other,,
3811,1043463,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 554/16,Other,,
3812,1043464,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 554/16,Other,,
3813,1043465,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 555/5,Other,,
3814,1043466,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 555/5,Other,,
3815,1043467,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 555/5,Other,,
3816,1043468,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 555/5,Other,,
3817,1043469,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 555/5,Other,,
3818,1043470,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 555/6,Other,,
3819,1043471,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 555/6,Other,,
3820,1043472,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 555/6,Other,,
3821,1043473,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 555/6,Other,,
3822,1043474,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 555/6,Other,,
3823,1043475,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 555/7,Other,,
3824,1043476,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 555/7,Other,,
3825,1043477,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 555/7,Other,,
3826,1043478,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 555/7,Other,,
3827,1043479,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 555/7,Other,,
3828,1043480,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 555/8,Other,,
3829,1043481,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 555/8,Other,,
3830,1043482,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 555/8,Other,,
3831,1043483,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 555/8,Other,,
3832,1043484,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 555/8,Other,,
3833,1043485,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 555/9,Other,,
3834,1043486,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 555/9,Other,,
3835,1043487,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 555/9,Other,,
3836,1043488,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 555/9,Other,,
3837,1043489,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 555/9,Other,,
3838,1044155,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 555/10,Other,,
3839,1044156,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 555/10,Other,,
3840,1044157,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 555/10,Other,,
3841,1044158,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 555/10,Other,,
3842,1044159,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 555/10,Other,,
3843,1046303,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 555/11,Other,,
3844,1046304,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 555/11,Other,,
3845,1046305,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 555/11,Other,,
3846,1046306,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 555/11,Other,,
3847,1046307,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 555/11,Other,,
3848,1046308,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 555/12,Other,,
3849,1046309,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 555/12,Other,,
3850,1046310,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 555/12,Other,,
3851,1046311,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 555/12,Other,,
3852,1046312,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 555/12,Other,,
3853,1046313,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 555/13,Other,,
3854,1046314,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 555/13,Other,,
3855,1046315,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 555/13,Other,,
3856,1046316,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 555/13,Other,,
3857,1046317,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 555/13,Other,,
3858,1046318,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 555/14,Other,,
3859,1046319,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 555/14,Other,,
3860,1046320,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 555/14,Other,,
3861,1046321,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 555/14,Other,,
3862,1046322,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 555/14,Other,,
3863,1046323,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 555/15,Other,,
3864,1046324,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 555/15,Other,,
3865,1046325,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 555/15,Other,,
3866,1046326,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 555/15,Other,,
3867,1046327,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 555/15,Other,,
3868,1046328,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 555/16,Other,,
3869,1046329,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 555/16,Other,,
3870,1046330,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 555/16,Other,,
3871,1046331,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 555/16,Other,,
3872,1046332,1,2,,104234176,36462,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 555/16,Other,,
3873,1053197,1,1,,56463308,36462,Inactive,74734243.0,54414.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of sialic acid acetylesterase (SIAE),Screening,,
3874,1055608,1,2,,104234176,36462,Active,,,2.0,IC50,Growth inhibition of human A549 cells after 72 hrs by MTT assay,Confirmatory,24180210.0,
3875,1055609,1,2,,104234176,36462,Active,,,4.0,IC50,Growth inhibition of human MCF7 cells after 72 hrs by MTT assay,Confirmatory,24180210.0,
3876,1055610,1,1,,104234176,36462,Unspecified,,,100.0,IC50,Growth inhibition of human PC3 cells after 72 hrs by MTT assay,Confirmatory,24180210.0,
3877,1055611,1,1,,104234176,36462,Active,,,2.0,IC50,Growth inhibition of human Hs683 cells after 72 hrs by MTT assay,Confirmatory,24180210.0,
3878,1055612,1,1,,104234176,36462,Active,,,25.0,IC50,Growth inhibition of human U373 cells after 72 hrs by MTT assay,Confirmatory,24180210.0,
3879,1055613,1,2,,104234176,36462,Active,,,3.0,IC50,Growth inhibition of human SK-MEL-28 cells after 72 hrs by MTT assay,Confirmatory,24180210.0,
3880,1055819,1,2,,104234176,36462,Active,,,23.0,GI50,Growth inhibition of human WiDr cells after 48 hrs by SRB assay,Confirmatory,24211632.0,
3881,1055820,1,2,,104234176,36462,Active,,,22.0,GI50,Growth inhibition of human T47D cells after 48 hrs by SRB assay,Confirmatory,24211632.0,
3882,1055821,1,2,,104234176,36462,Active,,,15.0,GI50,Growth inhibition of human SW1573 cells after 48 hrs by SRB assay,Confirmatory,24211632.0,
3883,1055822,1,2,,104234176,36462,Active,,,3.3,GI50,Growth inhibition of human HeLa cells after 48 hrs by SRB assay,Confirmatory,24211632.0,
3884,1055823,1,1,,104234176,36462,Active,,,1.4,GI50,Growth inhibition of human HBL100 cells after 48 hrs by SRB assay,Confirmatory,24211632.0,
3885,1055910,1,2,,104234176,36462,Unspecified,,,,,Induction of apoptosis in human MCF7 cells assessed as early apoptotic cells at IC50 using annexin V-PE/7-AAD double staining by flow cytometry (Rvb = 4.88%),Other,24219991.0,
3886,1055911,1,2,,104234176,36462,Unspecified,,,,,Induction of apoptosis in human MCF7 cells assessed as late apoptotic cells at IC50 using annexin V-PE/7-AAD double staining by flow cytometry (Rvb = 0.12%),Other,24219991.0,
3887,1055912,1,2,,104234176,36462,Unspecified,,,,,Induction of apoptosis in human MCF7 cells assessed as viable cells at IC50 using annexin V-PE/7-AAD double staining by flow cytometry (Rvb = 95%),Other,24219991.0,
3888,1055913,1,2,,104234176,36462,Unspecified,,,,,Induction of apoptosis in human MCF7 cells assessed as necrotic cells at IC50 using annexin V-PE/7-AAD double staining by flow cytometry (Rvb = 0%),Other,24219991.0,
3889,1055921,1,2,,104234176,36462,Unspecified,,,,,Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay,Other,24219991.0,
3890,1055922,1,2,,104234176,36462,Unspecified,,,,,Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay,Other,24219991.0,
3891,1055923,1,2,,104234176,36462,Unspecified,,,,,Cytotoxicity against human T47D cells after 48 hrs by MTT assay,Other,24219991.0,
3892,1057169,1,1,,104234176,36462,Active,,,7.06,IC50,Cytotoxicity against human HCT8 cells after 48 hrs by MTT assay,Confirmatory,24140948.0,
3893,1057170,1,2,,104234176,36462,Active,,,3.2,IC50,Cytotoxicity against human A549 cells after 48 hrs by MTT assay,Confirmatory,24140948.0,
3894,1057171,1,2,,104234176,36462,Active,,,2.91,IC50,Cytotoxicity against human HeLa cells after 48 hrs by MTT assay,Confirmatory,24140948.0,
3895,1057172,1,1,,104234176,36462,Active,,,1.15,IC50,Cytotoxicity against human HL60 cells after 48 hrs by cell counting kit-8 assay,Confirmatory,24140948.0,
3896,1059390,1,1,,104234176,36462,Unspecified,,,,,Inhibition of human DNA topoisomerase-2 at 100 uM after 30 mins by agarose gel electrophoresis,Other,24262885.0,
3897,1061259,1,4,,104234176,36462,Inconclusive,12644118.0,7150.0,,,Inhibition of topoisomerase 1 (unknown origin)-mediated relaxation of supercoiled plasmid DNA assessed as intensity of supercoiled DNA after 30 mins by agarose gel electrophoresis relative to camptothecin,Other,24326278.0,
3898,1061262,1,4,,104234176,36462,Active,13959709.0,7153.0,,,Inhibition of topoisomerase 2 (unknown origin)-mediated kinetoplast DNA decatenation at 100 uM after 30 mins by agarose gel electrophoresis,Other,24326278.0,
3899,1063024,1,1,,104234176,36462,Active,,,1.0,IC50,Antiproliferative activity against human HCT116 cells assessed as cell viability after 72 hrs by MTS assay,Confirmatory,24328269.0,
3900,1063190,1,2,,104234176,36462,Unspecified,,,20.0,IC50,Cytotoxicity against multidrug-resistant human KBVIN cells after 72 hrs by sulforhodamine B assay,Confirmatory,24332656.0,
3901,1063191,1,1,,104234176,36462,Active,,,2.03,IC50,Cytotoxicity against human DU145 cells after 72 hrs by sulforhodamine B assay,Confirmatory,24332656.0,
3902,1063192,1,1,,104234176,36462,Active,,,3.88,IC50,Cytotoxicity against human KB cells after 72 hrs by sulforhodamine B assay,Confirmatory,24332656.0,
3903,1063193,1,2,,104234176,36462,Active,,,2.58,IC50,Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay,Confirmatory,24332656.0,
3904,1063327,1,4,,104234176,36462,Active,13959709.0,7153.0,,,Inhibition of DNA topoisomerase 2 (unknown origin)-mediated DNA cleavage assessed as linear band at 20 to 50 uM by agarose gel electrophoresis,Other,24334150.0,
3905,1064784,3,1,,104234176,36462,Active,,,0.0057,IC50,Cytotoxicity against human HeLa cells by MTT assay,Confirmatory,24422592.0,
3906,1067061,1,2,,104234176,36462,Active,,,21.45,IC50,Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay,Confirmatory,24487188.0,
3907,1067062,1,2,,104234176,36462,Active,,,24.22,IC50,Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay,Confirmatory,24487188.0,
3908,1067063,1,1,,104234176,36462,Active,,,14.4,IC50,Cytotoxicity against human PC3 cells after 48 hrs by MTT assay,Confirmatory,24487188.0,
3909,1067064,1,2,,104234176,36462,Active,,,4.71,IC50,Cytotoxicity against human HeLa cells after 48 hrs by MTT assay,Confirmatory,24487188.0,
3910,1067065,1,2,,104234176,36462,Inconclusive,,,,IC50,Cytotoxicity against human MDA-MB-453 cells after 48 hrs by MTT assay,Confirmatory,24487188.0,
3911,1067066,1,2,,104234176,36462,Active,,,23.9,IC50,Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay,Confirmatory,24487188.0,
3912,1067067,1,1,,104234176,36462,Active,,,8.9,IC50,Cytotoxicity against human ME180 cells after 48 hrs by MTT assay,Confirmatory,24487188.0,
3913,1069343,1,1,,104234176,36462,Unspecified,,,,,Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 24 hrs by MTT assay,Other,24424132.0,
3914,1069344,1,1,,104234176,36462,Unspecified,,,,,Cytotoxicity against mouse B16F10 cells assessed as reduction in cell viability after 24 hrs by MTT assay,Other,24424132.0,
3915,1069345,1,1,,104234176,36462,Unspecified,,,,,Cytotoxicity against human U937 cells assessed as reduction in cell viability after 24 hrs by MTT assay,Other,24424132.0,
3916,1069346,1,1,,104234176,36462,Unspecified,,,,,Cytotoxicity against human THP1 cells assessed as reduction in cell viability after 24 hrs by MTT assay,Other,24424132.0,
3917,1071368,1,1,,104234176,36462,Unspecified,,,,,"Selectivity index, ratio of GI50 for human RWPE1 cells to GI50 for human PC3 cells",Other,24389510.0,
3918,1071369,1,2,,104234176,36462,Unspecified,,,,GI50,Cytotoxicity against human A549 cells after 72 hrs by MTT assay relative to untreated control,Confirmatory,24389510.0,
3919,1071370,1,2,,104234176,36462,Unspecified,,,,GI50,Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay relative to untreated control,Confirmatory,24389510.0,
3920,1071371,1,1,,104234176,36462,Unspecified,,,,GI50,Cytotoxicity against human RWPE1 cells after 72 hrs by MTT assay relative to untreated control,Confirmatory,24389510.0,
3921,1071372,1,2,,104234176,36462,Unspecified,,,,GI50,Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay relative to untreated control,Confirmatory,24389510.0,
3922,1071373,1,1,,104234176,36462,Unspecified,,,,GI50,Cytotoxicity against human PC3 cells after 72 hrs by MTT assay relative to untreated control,Confirmatory,24389510.0,
3923,1072534,1,1,,104234176,36462,Active,,,3.88,IC50,Cytotoxicity against human KB cells after 72 hrs by SRB assay,Confirmatory,24553146.0,
3924,1072535,1,2,,104234176,36462,Unspecified,,,20.0,IC50,Cytotoxicity against human KBVIN cells after 72 hrs by SRB assay,Confirmatory,24553146.0,
3925,1072536,1,1,,104234176,36462,Active,,,2.03,IC50,Cytotoxicity against human DU145 cells after 72 hrs by SRB assay,Confirmatory,24553146.0,
3926,1072537,1,2,,104234176,36462,Active,,,2.58,IC50,Cytotoxicity against human A549 cells after 72 hrs by SRB assay,Confirmatory,24553146.0,
3927,1073046,1,1,,104234176,36462,Active,,,20.0,IC50,Growth inhibition of human DLD1 cells assessed as inhibition of cell viability after 72 hrs by MTT assay,Confirmatory,24527835.0,
3928,1073047,1,2,,104234176,36462,Active,,,16.0,IC50,Growth inhibition of human HeLa cells assessed as inhibition of cell viability after 72 hrs by MTT assay,Confirmatory,24527835.0,
3929,1075850,1,4,,104234176,36462,Active,13959709.0,7153.0,,,Inhibition of recombinant human top2 alpha-mediated kDNA decatenation compound added post enzyme-DNA incubation by agarose gel electrophoresis in presence of DTT,Other,24507920.0,
3930,1075851,1,4,,104234176,36462,Active,13959709.0,7153.0,,,Inhibition of recombinant human top2 alpha-mediated kDNA decatenation compound added post enzyme-DNA incubation by agarose gel electrophoresis,Other,24507920.0,
3931,1075852,1,4,,104234176,36462,Active,13959709.0,7153.0,,,Inhibition of recombinant human top2 alpha-mediated kDNA decatenation at 100 uM after 30 mins by agarose gel electrophoresis,Other,24507920.0,
3932,1077756,1,2,,104234176,36462,Inconclusive,,,,IC50,Cytotoxicity against human HuCCa1 cells by MTT assay,Confirmatory,,
3933,1077757,1,2,,104234176,36462,Inconclusive,,,,IC50,Cytotoxicity against human A549 cells by MTT assay,Confirmatory,,
3934,1077758,1,2,,104234176,36462,Active,,,22.11,IC50,Cytotoxicity against human HepG2 cells by MTT assay,Confirmatory,,
3935,1077759,1,2,,104234176,36462,Active,,,0.03,IC50,Cytotoxicity against human MOLT3 cells by XTT assay,Confirmatory,,
3936,1079931,1,1,,104234176,36462,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
3937,1079932,1,1,,104234176,36462,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
3938,1079933,1,1,,104234176,36462,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
3939,1079934,1,1,,104234176,36462,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
3940,1079935,1,1,,104234176,36462,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
3941,1079936,1,1,,104234176,36462,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
3942,1079937,1,1,,104234176,36462,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
3943,1079938,1,1,,104234176,36462,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
3944,1079939,1,1,,104234176,36462,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
3945,1079940,1,1,,104234176,36462,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
3946,1079941,1,1,,104234176,36462,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
3947,1079942,1,1,,104234176,36462,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
3948,1079943,1,1,,104234176,36462,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
3949,1079944,1,1,,104234176,36462,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
3950,1079945,1,1,,104234176,36462,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
3951,1079946,1,1,,104234176,36462,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
3952,1079947,1,1,,104234176,36462,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
3953,1079948,1,1,,104234176,36462,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
3954,1079949,1,1,,104234176,36462,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
3955,1086934,1,2,,104234176,36462,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) HepG2 cells after 3 days by MTT assay,Other,,
3956,1086937,1,2,,104234176,36462,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) MOLT3 cells after 3 days by crystal violet staining,Other,,
3957,1087139,1,2,,104234176,36462,Unspecified,,,702.8,IC50,Cytotoxicity against Homo sapiens (human) HEK293 cells after 72 hr by MTT assay,Confirmatory,,
3958,1087140,1,2,,104234176,36462,Active,,,8.3,IC50,Cytotoxicity against Homo sapiens (human) KB cells after 72 hr by MTT assay,Confirmatory,,
3959,1087141,1,2,,104234176,36462,Active,,,6.4,IC50,Cytotoxicity against Homo sapiens (human) SW480 cells after 72 hr by MTT assay,Confirmatory,,
3960,1087142,1,2,,104234176,36462,Active,,,3.9,IC50,Cytotoxicity against Homo sapiens (human) A549 cells after 72 hr by MTT assay,Confirmatory,,
3961,1093815,1,2,,104234176,36462,Unspecified,,,,,Growth inhibition of Homo sapiens (human) A549 cells at 10'-7 mol/l after 72 hr by MTT assay,Other,,
3962,1093816,1,2,,104234176,36462,Unspecified,,,,,Growth inhibition of Homo sapiens (human) A549 cells at 10'-8 mol/l after 72 hr by MTT assay,Other,,
3963,1093817,1,2,,104234176,36462,Unspecified,,,,,Growth inhibition of Homo sapiens (human) A549 cells at 10'-5 mol/l after 72 hr by MTT assay,Other,,
3964,1093818,1,2,,104234176,36462,Unspecified,,,,,Growth inhibition of Homo sapiens (human) A549 cells at 10'-6 mol/l after 72 hr by MTT assay,Other,,
3965,1093819,1,2,,104234176,36462,Unspecified,,,,,Growth inhibition of Homo sapiens (human) A549 cells at 10'-4 mol/l after 72 hr by MTT assay,Other,,
3966,1093820,1,2,,104234176,36462,Unspecified,,,,,Growth inhibition of Mus musculus (mouse) P388 cells at 10'-7 mol/l after 72 hr by MTT assay,Other,,
3967,1093821,1,2,,104234176,36462,Unspecified,,,,,Growth inhibition of Mus musculus (mouse) P388 cells at 10'-8 mol/l after 72 hr by MTT assay,Other,,
3968,1093822,1,2,,104234176,36462,Unspecified,,,,,Growth inhibition of Mus musculus (mouse) P388 cells at 10'-5 mol/l after 72 hr by MTT assay,Other,,
3969,1093823,1,2,,104234176,36462,Unspecified,,,,,Growth inhibition of Mus musculus (mouse) P388 cells at 10'-6 mol/l after 72 hr by MTT assay,Other,,
3970,1093824,1,2,,104234176,36462,Unspecified,,,,,Growth inhibition of Mus musculus (mouse) P388 cells at 10'-4 mol/l after 72 hr by MTT assay,Other,,
3971,1094748,1,2,,104234176,36462,Unspecified,,,427.0,IC50,Cytotoxicity against Homo sapiens (human) HepG2 cells after 3 days by MTT assay,Confirmatory,,
3972,1105826,1,2,,104234176,36462,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) MOLT3 cells assessed as survival after 3 days by crystal violet staining,Other,,
3973,1105827,1,2,,104234176,36462,Inconclusive,,,,,Cytotoxicity against Homo sapiens (human) A549 cells assessed as survival after 3 days by crystal violet staining,Other,,
3974,1105828,1,2,,104234176,36462,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) HepG2 cells assessed as survival after 3 days by crystal violet staining,Other,,
3975,1105829,1,2,,104234176,36462,Inconclusive,,,,,Cytotoxicity against Homo sapiens (human) HuCCa1 cells assessed as survival after 3 days by crystal violet staining,Other,,
3976,1107317,1,2,,104234176,36462,Unspecified,,,100.0,IC50,Cytotoxicity against Homo sapiens (human) HEK293 cells assessed as decrease in cell growth after 3 days by MTT assay,Confirmatory,,
3977,1107318,1,2,,104234176,36462,Active,,,8.3,IC50,Anticancer activity against Homo sapiens (human) KB cells assessed as decrease in cell growth after 3 days by MTT assay,Confirmatory,,
3978,1107319,1,2,,104234176,36462,Active,,,13.5,IC50,Anticancer activity against Homo sapiens (human) HCT116 cells assessed as decrease in cell growth after 3 days by MTT assay,Confirmatory,,
3979,1107320,1,2,,104234176,36462,Active,,,3.9,IC50,Anticancer activity against Homo sapiens (human) A549 cells assessed as decrease in cell growth after 3 days by MTT assay,Confirmatory,,
3980,1107321,1,2,,104234176,36462,Active,,,6.4,IC50,Anticancer activity against Homo sapiens (human) SW480 cells assessed as decrease in cell growth after 3 days by MTT assay,Confirmatory,,
3981,1115799,1,2,,104234176,36462,Active,,,0.040999999999999995,IC50,Cytotoxicity against Homo sapiens (human) MOLT3 cells assessed as inhibition of cell growth after 3 days by crystal violet staining,Confirmatory,,
3982,1115800,1,2,,104234176,36462,Active,,,27.18,IC50,Cytotoxicity against Homo sapiens (human) HepG2 cells assessed as inhibition of cell growth after 3 days by MTT assay,Confirmatory,,
3983,1115801,1,2,,104234176,36462,Inconclusive,,,,IC50,Cytotoxicity against Homo sapiens (human) A549 cells assessed as inhibition of cell growth after 3 days by MTT assay,Confirmatory,,
3984,1115802,1,2,,104234176,36462,Inconclusive,,,,IC50,Cytotoxicity against Homo sapiens (human) HuCCa1 cells assessed as inhibition of cell growth after 3 days by crystal violet staining,Confirmatory,,
3985,1120900,1,1,,104234176,36462,Active,,,0.61,IC50,Cytotoxicity against human HL60 cells,Confirmatory,,
3986,1120901,1,1,,104234176,36462,Active,,,0.02,IC50,Cytotoxicity against human MOLT3 cells,Confirmatory,,
3987,1121881,1,1,,104234176,36462,Active,,,7.5,LC50,Cytotoxicity against human PC3 cells assessed as cell survival after 48 hrs by MTT assay,Confirmatory,,
3988,1121882,1,2,,104234176,36462,Inactive,,,,,Binding affinity to Escherichia coli plasmid DNA assessed as intercalation at 100 uM after 20 mins by agarose gel electrophoresis,Other,,
3989,1121884,1,3,,104234176,36462,Active,13959709.0,7153.0,,,Inhibition of human topoisomerase-2alpha-mediated supercoiled pRYG DNA relaxation at 100 uM after 30 mins by agarose gel electrophoresis,Other,,
3990,1121885,1,3,,104234176,36462,Active,13959709.0,7153.0,,,Inhibition of human topoisomerase-2alpha-mediated kDNA decatenation at 100 uM after 30 mins by agarose gel electrophoresis,Other,,
3991,1122128,1,1,,104234176,36462,Inactive,,,,,Induction of DNA damage in human A549 cells assessed as inhibition of EGFP translation at 50 uM after 1 hr by fluorescence assay,Other,,
3992,1125803,1,2,,104234176,36462,Active,,,1.5,IC50,Cytotoxicity against human KB cells after 72 hrs by methylene blue assay,Confirmatory,24657567.0,
3993,1125806,1,1,,104234176,36462,Active,,,26.4,IC50,Cytotoxicity against human vincristine/paclitaxel-resistant KB-VIN10 cells overexpressing P-gp170 after 72 hrs by methylene blue assay,Confirmatory,24657567.0,
3994,1125807,1,1,,104234176,36462,Active,,,3.5,IC50,Cytotoxicity against human vincristine/paclitaxel-resistant KB-S15 cells overexpressing P-gp170 after 72 hrs by methylene blue assay,Confirmatory,24657567.0,
3995,1125808,1,1,,104234176,36462,Active,,,46.1,IC50,Cytotoxicity against human VP16-resistant KB-7d cells overexpressing MRP after 72 hrs by methylene blue assay,Confirmatory,24657567.0,
3996,1140297,1,1,,104234176,36462,Active,,,2.45,IC50,Anticancer activity against human A549 cells after 48 hrs by MTT assay,Confirmatory,24721832.0,
3997,1140298,1,1,,104234176,36462,Active,,,1.47,IC50,Anticancer activity against human HT-29 cells after 48 hrs by MTT assay,Confirmatory,24721832.0,
3998,1140299,1,1,,104234176,36462,Active,,,2.04,IC50,Anticancer activity against human ACHN cells after 48 hrs by MTT assay,Confirmatory,24721832.0,
3999,1140300,1,2,,104234176,36462,Active,,,3.17,IC50,Anticancer activity against human DU145 cells after 48 hrs by MTT assay,Confirmatory,24721832.0,
4000,1140301,1,1,,104234176,36462,Active,,,2.75,IC50,Anticancer activity against human HeLa cells after 48 hrs by MTT assay,Confirmatory,24721832.0,
4001,1140302,1,1,,104234176,36462,Unspecified,,,,,Cell cycle arrest in human A549 cells assessed as accumulation at sub-G1 phase at 0.5 uM after 48 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 6.47%),Other,24721832.0,
4002,1140303,1,1,,104234176,36462,Unspecified,,,,,Cell cycle arrest in human A549 cells assessed as accumulation at sub-G1 phase at 1 uM after 48 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 6.47%),Other,24721832.0,
4003,1140304,1,1,,104234176,36462,Unspecified,,,,,Cell cycle arrest in human A549 cells assessed as accumulation at G0/G1 phase at 0.5 uM after 48 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 78.23%),Other,24721832.0,
4004,1140305,1,1,,104234176,36462,Unspecified,,,,,Cell cycle arrest in human A549 cells assessed as accumulation at G0/G1 phase at 1 uM after 48 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 78.23%),Other,24721832.0,
4005,1140306,1,1,,104234176,36462,Unspecified,,,,,Cell cycle arrest in human A549 cells assessed as accumulation at S phase at 0.5 uM after 48 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 3.57%),Other,24721832.0,
4006,1140307,1,1,,104234176,36462,Unspecified,,,,,Cell cycle arrest in human A549 cells assessed as accumulation at S phase at 1 uM after 48 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 3.57%),Other,24721832.0,
4007,1140308,1,1,,104234176,36462,Unspecified,,,,,Cell cycle arrest in human A549 cells assessed as accumulation at G2/M phase at 0.5 uM after 48 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 11.73%),Other,24721832.0,
4008,1140309,1,1,,104234176,36462,Unspecified,,,,,Cell cycle arrest in human A549 cells assessed as accumulation at G2/M phase at 1 uM after 48 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 11.73%),Other,24721832.0,
4009,1142267,1,1,,104234176,36462,Active,,,25.72,IC50,Cytotoxicity against human BGC823 cells,Confirmatory,24775914.0,
4010,1142268,1,1,,104234176,36462,Unspecified,,,167.97,IC50,Cytotoxicity against human A549 cells,Confirmatory,24775914.0,
4011,1142269,1,1,,104234176,36462,Active,,,1.15,IC50,Cytotoxicity against human HepG2 cells,Confirmatory,24775914.0,
4012,1142273,1,1,,104234176,36462,Unspecified,,,,IC50,Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay,Confirmatory,24775914.0,
4013,1142274,1,1,,104234176,36462,Unspecified,,,,IC50,Cytotoxicity against human HeLa cells after 48 hrs by MTT assay,Confirmatory,24775914.0,
4014,1142275,1,1,,104234176,36462,Unspecified,,,,IC50,Cytotoxicity against human A549 cells after 48 hrs by MTT assay,Confirmatory,24775914.0,
4015,1142276,1,1,,104234176,36462,Unspecified,,,,IC50,Cytotoxicity against human BGC823 cells after 48 hrs by MTT assay,Confirmatory,24775914.0,
4016,1142277,1,1,,104234176,36462,Unspecified,,,,IC50,Cytotoxicity against human HL-7702 cells after 48 hrs by MTT assay,Confirmatory,24775914.0,
4017,1142283,2,1,,104234176,36462,Unspecified,,,,,"Octanol-water partition coefficient, log P of the compound",Other,24775914.0,
4018,1142284,1,3,,104234176,36462,Active,13959709.0,7153.0,,,Inhibition of human DNA topoisomerase-2 using kDNA as substrate assessed as inhibition of DNA relaxation at 1 to 10 uM after 10 mins by agarose gel electrophoresis,Other,24775914.0,
4019,1142513,1,1,,104234176,36462,Active,,,5.0,IC50,Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay,Confirmatory,24780599.0,
4020,1142514,1,1,,104234176,36462,Active,,,1.0,IC50,Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay,Confirmatory,24780599.0,
4021,1142515,1,1,,104234176,36462,Active,,,0.1,IC50,Antiproliferative activity against human H460 cells after 72 hrs by MTT assay,Confirmatory,24780599.0,
4022,1143516,3,1,,104234176,36462,Inconclusive,,,,IC50,Cytotoxicity against human HuCCa1 cells after 48 hrs by MTT assay,Confirmatory,24836071.0,
4023,1143517,3,1,,104234176,36462,Active,,,30.16,IC50,Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay,Confirmatory,24836071.0,
4024,1143518,3,1,,104234176,36462,Inconclusive,,,,IC50,Cytotoxicity against human A549 cells after 48 hrs by MTT assay,Confirmatory,24836071.0,
4025,1143519,3,1,,104234176,36462,Active,,,0.051,IC50,Cytotoxicity against human MOLT3 cells after 48 hrs by MTT assay,Confirmatory,24836071.0,
4026,1143520,3,1,,104234176,36462,Inconclusive,,,,IC50,Cytotoxicity against african green monkey Vero cells after 4 days by GFP detection method,Confirmatory,24836071.0,
4027,1155281,1,3,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of human DNA topoisomerase-2a-mediated relaxation of supercoiled DNA pBR322 at 100 uM after 4 hrs using ethidium bromide staining by agarose gel electrophoresis analysis,Other,24904965.0,
4028,1155284,1,3,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of human DNA topoisomerase-2a-mediated relaxation of supercoiled DNA pBR322 at 20 uM after 4 hrs using ethidium bromide staining by agarose gel electrophoresis analysis,Other,24904965.0,
4029,1155285,1,1,,104234176,36462,Active,,,12.23,IC50,Cytotoxicity against human MCF10A cells after 2 days,Confirmatory,24904965.0,
4030,1155286,1,1,,104234176,36462,Active,,,2.57,IC50,Cytotoxicity against human T47D cells after 2 days,Confirmatory,24904965.0,
4031,1155287,1,2,,104234176,36462,Active,,,13.85,IC50,Cytotoxicity against human DU145 cells after 2 days,Confirmatory,24904965.0,
4032,1155288,1,1,,104234176,36462,Active,,,9.45,IC50,Cytotoxicity against human HCT15 cells after 2 days,Confirmatory,24904965.0,
4033,1156516,1,1,,104234176,36462,Active,,,8.9,IC50,Cytotoxicity against human ME180 cells assessed as inhibition of cell viability after 48 hrs by MTT assay,Confirmatory,24953027.0,
4034,1156517,1,1,,104234176,36462,Active,,,23.9,IC50,Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability after 48 hrs by MTT assay,Confirmatory,24953027.0,
4035,1156518,1,1,,104234176,36462,Active,,,4.71,IC50,Cytotoxicity against human HeLa cells assessed as inhibition of cell viability after 48 hrs by MTT assay,Confirmatory,24953027.0,
4036,1156519,1,1,,104234176,36462,Active,,,12.5,IC50,Cytotoxicity against human MDA-MB-453 cells assessed as inhibition of cell viability after 48 hrs by MTT assay,Confirmatory,24953027.0,
4037,1156520,1,1,,104234176,36462,Active,,,24.22,IC50,Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell viability after 48 hrs by MTT assay,Confirmatory,24953027.0,
4038,1156521,1,1,,104234176,36462,Active,,,14.4,IC50,Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 48 hrs by MTT assay,Confirmatory,24953027.0,
4039,1156522,1,1,,104234176,36462,Active,,,21.45,IC50,Cytotoxicity against human HT-29 cells assessed as inhibition of cell viability after 48 hrs by MTT assay,Confirmatory,24953027.0,
4040,1156932,1,1,,104234176,36462,Active,,,13.65,IC50,Antiproliferative against human HepG2 cells after 48 hrs by MTT assay,Confirmatory,24996136.0,
4041,1156933,1,1,,104234176,36462,Unspecified,,,241.9,IC50,Antiproliferative against human A549 cells after 48 hrs by MTT assay,Confirmatory,24996136.0,
4042,1156934,1,1,,104234176,36462,Unspecified,,,81.09,IC50,Antiproliferative against human MCF7 cells after 48 hrs by MTT assay,Confirmatory,24996136.0,
4043,1158061,1,1,,104234176,36462,Active,,,0.105,IC50,Antiproliferative activity against human EPG85-257P cells after 5 days by sulforhodamine B assay,Confirmatory,24864039.0,
4044,1158062,1,1,,104234176,36462,Active,,,1.55,IC50,Antiproliferative activity against human EPG85-257RN cells after 5 days by sulforhodamine B assay,Confirmatory,24864039.0,
4045,1158063,1,1,,104234176,36462,Unspecified,,,,,Resistance ratio of IC50 for human EPG85-257RN cells to IC50 for human EPG85-257P cells,Other,24864039.0,
4046,1158064,1,1,,104234176,36462,Active,,,6.2,IC50,Antiproliferative activity against human EPG85-257RD cells after 5 days by sulforhodamine B assay,Confirmatory,24864039.0,
4047,1158065,1,1,,104234176,36462,Unspecified,,,,,Resistance ratio of IC50 for human EPG85-257RD cells to IC50 for human EPG85-257P cells,Other,24864039.0,
4048,1158066,1,1,,104234176,36462,Active,,,0.58,IC50,Antiproliferative activity against human EPP85-181P cells after 5 days by sulforhodamine B assay,Confirmatory,24864039.0,
4049,1158067,1,1,,104234176,36462,Active,,,4.5,IC50,Antiproliferative activity against human EPP85-181RN cells after 5 days by sulforhodamine B assay,Confirmatory,24864039.0,
4050,1158068,1,1,,104234176,36462,Unspecified,,,,,Resistance ratio of IC50 for human EPP85-181RN cells to IC50 for human EPP85-181P cells,Other,24864039.0,
4051,1158069,1,1,,104234176,36462,Unspecified,,,62.0,IC50,Antiproliferative activity against human EPP85-181RD cells after 5 days by sulforhodamine B assay,Confirmatory,24864039.0,
4052,1158070,1,1,,104234176,36462,Unspecified,,,,,Resistance ratio of IC50 for human EPP85-181RD cells to IC50 for human EPP85-181P cells,Other,24864039.0,
4053,1158071,1,1,,104234176,36462,Active,,,2.3,IC50,Antiproliferative activity against human HT-29 cells after 5 days by sulforhodamine B assay,Confirmatory,24864039.0,
4054,1158072,1,1,,104234176,36462,Active,,,35.0,IC50,Antiproliferative activity against human HT-29RN cells after 5 days by sulforhodamine B assay,Confirmatory,24864039.0,
4055,1158073,1,1,,104234176,36462,Unspecified,,,,,Resistance ratio of IC50 for human HT-29RN cells to IC50 for human HT-29 cells,Other,24864039.0,
4056,1158074,1,1,,104234176,36462,Active,,,26.0,IC50,Antiproliferative activity against human HT-29RD cells after 5 days by sulforhodamine B assay,Confirmatory,24864039.0,
4057,1158075,1,1,,104234176,36462,Unspecified,,,,,Resistance ratio of IC50 for human HT-29RD cells to IC50 for human HT-29 cells,Other,24864039.0,
4058,1159524,1,1,,56463308,36462,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
4059,1159606,1,1,,56463308,36462,Inactive,,,,,"uHTS identification of small molecule inhibitors of TWEAK-Fn14 interactions, using a cell-based reporter assay",Other,,
4060,1159607,2,1,,312309833,36462,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
4061,1159620,1,1,,104234176,36462,Active,,,,,Summary of drug indications.,Other,,
4062,1165123,1,1,,104234176,36462,Active,,,3.67,IC50,Cytotoxicity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay,Confirmatory,25240702.0,
4063,1165124,1,1,,104234176,36462,Active,,,13.78,IC50,Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay,Confirmatory,25240702.0,
4064,1165125,1,1,,104234176,36462,Active,,,4.36,IC50,Cytotoxicity against human HeLa cells after 72 hrs by sulforhodamine B assay,Confirmatory,25240702.0,
4065,1165127,1,2,,104234176,36462,Active,13959709.0,7153.0,,,Inhibition of human recombinant topoisomerase 2alpha assessed as reduction in pBR322 DNA relaxation at 100 uM incubated for 30 mins by DNA gel electrophoresis,Other,25240702.0,
4066,1165132,1,2,,104234176,36462,Active,13959709.0,7153.0,,,Inhibition of human recombinant topoisomerase 2alpha assessed as increase in linear DNA using circular supercoiled plasmid DNA substrate at 100 uM incubated for 30 mins by ethidium bromide staining based DNA gel electrophoresis,Other,25240702.0,
4067,1165139,1,1,,104234176,36462,Inactive,,,,,Increase in histone H3 Ser10 phosphorylation in human MDA-MB-231 cells at 10 uM after 24 hrs by Western blot method,Other,25240702.0,
4068,1165149,1,1,,104234176,36462,Active,,,,,Induction of DNA damage in human MDA-MB-231 cells assessed as increase in ATM S1981 phosphorylation at 10 uM after 24 hrs by Western blot method,Other,25240702.0,
4069,1165150,1,1,,104234176,36462,Unspecified,,,,,"Antitumor activity against human MDA-MB-231 cells xenografted in BALB/c-nu mouse assessed as reduction in tumor weight at 20 mg/kg, iv dosed every other day for 15 days",Other,25240702.0,
4070,1165151,1,1,,104234176,36462,Unspecified,,,,,"Toxicity in nude BALB/c mouse xenografted with human MDA-MB-231 cells assessed as reduction in body weight at 20 mg/kg, iv dosed every other day for 15 days (Rvb = 24.2 g)",Other,25240702.0,
4071,1171231,1,1,,104234176,36462,Active,,,9.3,IC50,Cytotoxicity against human A549 cells after 72 hrs by MTT assay,Confirmatory,25402632.0,
4072,1171232,1,1,,104234176,36462,Active,,,3.4,IC50,Cytotoxicity against human HeLa cells after 72 hrs by MTT assay,Confirmatory,25402632.0,
4073,1171233,1,1,,104234176,36462,Active,,,2.5,IC50,Cytotoxicity against human ZR-7530 cells after 72 hrs by MTT assay,Confirmatory,25402632.0,
4074,1171234,1,1,,104234176,36462,Active,,,4.6,IC50,Cytotoxicity against human HCT15 cells after 72 hrs by MTT assay,Confirmatory,25402632.0,
4075,1171235,1,1,,104234176,36462,Active,,,8.5,IC50,Cytotoxicity against human U373 cells after 72 hrs by MTT assay,Confirmatory,25402632.0,
4076,1171236,1,1,,104234176,36462,Active,,,3.6,IC50,Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay,Confirmatory,25402632.0,
4077,1172538,1,1,,104234176,36462,Active,,,1.83,IC50,Cytotoxicity against human SKMES1 cells,Confirmatory,25440884.0,
4078,1172994,1,1,,104234176,36462,Unspecified,,,50.0,IC50,Cytotoxicity against human A549 cells after 72 hrs by MTT assay,Confirmatory,25453799.0,
4079,1172995,1,1,,104234176,36462,Active,,,8.9,IC50,Cytotoxicity against human ME180 cells after 72 hrs by MTT assay,Confirmatory,25453799.0,
4080,1172996,1,1,,104234176,36462,Active,,,4.71,IC50,Cytotoxicity against human HeLa cells after 72 hrs by MTT assay,Confirmatory,25453799.0,
4081,1172997,1,1,,104234176,36462,Active,,,14.4,IC50,Cytotoxicity against human PC3 cells after 72 hrs by MTT assay,Confirmatory,25453799.0,
4082,1172998,1,1,,104234176,36462,Active,,,23.9,IC50,Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay,Confirmatory,25453799.0,
4083,1172999,1,1,,104234176,36462,Unspecified,,,,,"Selectivity index, ratio of IC50 for human RWPE cells to IC50 for human PC3 cells",Other,25453799.0,
4084,1173395,1,2,,104234176,36462,Active,13959709.0,7153.0,33.8,IC50,Inhibition of human DNA topoisomerase 2alpha using plasmid pNO1 substrate incubated at 37 degC for 30 mins by fluorimetry,Confirmatory,25453816.0,
4085,1174229,1,1,,104234176,36462,Active,,,10.12,IC50,Cytotoxicity against human A549 cells after 48 hrs by MTT assay,Confirmatory,25462233.0,
4086,1174230,1,2,,104234176,36462,Unspecified,,,64.26,IC50,Cytotoxicity against human DU145 cells after 48 hrs by MTT assay,Confirmatory,25462233.0,
4087,1174231,1,1,,104234176,36462,Active,,,5.48,IC50,Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay,Confirmatory,25462233.0,
4088,1174232,1,1,,104234176,36462,Unspecified,,,96.26,IC50,Cytotoxicity against human HeLa cells after 48 hrs by MTT assay,Confirmatory,25462233.0,
4089,1175275,1,2,,104234176,36462,Active,13959709.0,7153.0,,,Inhibition of human topoisomerase-2 alpha assessed as Escherichia coli pBR322 DNA cleavage at 100 uM after 30 mins by agarose electrophoresis,Other,25466187.0,
4090,1175276,1,1,,104234176,36462,Active,,,2.87,IC50,Cytotoxicity against human A549 cells after 48 hrs by Alamar Blue assay,Confirmatory,25466187.0,
4091,1175277,1,1,,104234176,36462,Active,,,18.99,IC50,Cytotoxicity against rat L6 cells after 71.5 hrs by Presto Blue assay,Confirmatory,25466187.0,
4092,1175278,1,1,,104234176,36462,Unspecified,,,,,Selectivity ratio of IC50 for rat L6 cells to IC50 for human A549 cells,Other,25466187.0,
4093,1175673,1,1,,104234176,36462,Active,,,0.73,IC50,Cytotoxicity against human MCF7 cells after 2 days by CCK-8 assay,Confirmatory,25481396.0,
4094,1175674,1,1,,104234176,36462,Active,,,1.26,IC50,Cytotoxicity against human HeLa cells after 2 days by CCK-8 assay,Confirmatory,25481396.0,
4095,1175675,1,2,,104234176,36462,Active,,,0.5,IC50,Cytotoxicity against human DU145 cells after 2 days by CCK-8 assay,Confirmatory,25481396.0,
4096,1175676,1,1,,104234176,36462,Active,,,1.1,IC50,Cytotoxicity against human HCT15 cells after 2 days by CCK-8 assay,Confirmatory,25481396.0,
4097,1179936,1,2,,104234176,36462,Active,13959709.0,7153.0,,,Inhibition of DNA topoisomerase-2 (unknown origin) assessed as inhibition of supercoiled pBR322 relaxation at 100 uM after 15 mins by gel electrophoresis,Other,24931277.0,
4098,1180233,1,1,,104234176,36462,Active,,,0.1,IC50,Growth inhibition of human A549 cells after 72 hrs by MTT assay,Confirmatory,24950030.0,
4099,1180234,1,1,,104234176,36462,Active,,,17.0,IC50,Growth inhibition of human MCF7 cells after 72 hrs by MTT assay,Confirmatory,24950030.0,
4100,1180235,1,1,,104234176,36462,Active,,,2.0,IC50,Growth inhibition of human PC3 cells after 72 hrs by MTT assay,Confirmatory,24950030.0,
4101,1180236,1,1,,104234176,36462,Active,,,1.0,IC50,Growth inhibition of human Hs683 cells after 72 hrs by MTT assay,Confirmatory,24950030.0,
4102,1180237,1,1,,104234176,36462,Active,,,7.0,IC50,Growth inhibition of human U373 cells after 72 hrs by MTT assay,Confirmatory,24950030.0,
4103,1180238,1,1,,104234176,36462,Active,,,1.0,IC50,Growth inhibition of human SK-MEL-28 cells after 72 hrs by MTT assay,Confirmatory,24950030.0,
4104,1180381,1,1,,104234176,36462,Active,,,1.3,GI50,Antiproliferative activity against human MiaPaCa cells after 48 hrs by SRB assay,Confirmatory,24953821.0,
4105,1180382,1,1,,104234176,36462,Active,,,0.25,GI50,Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay,Confirmatory,24953821.0,
4106,1180383,1,1,,104234176,36462,Active,,,0.64,GI50,Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay,Confirmatory,24953821.0,
4107,1182004,1,1,,104234176,36462,Unspecified,,,,,Induction of cell death in serum starved human MDA-MB-231 cells at 50 uM after 16 hrs by trypan blue dye exclusion assay,Other,24986663.0,
4108,1182006,1,1,,104234176,36462,Active,,,,,Induction of apoptosis in serum starved human MDA-MB-231 cells assessed as caspase-3 activation at 50 uM after 16 hrs by Western blotting method,Other,24986663.0,
4109,1182008,1,1,,104234176,36462,Inactive,,,,,Induction of apoptosis in serum starved human MDA-MB-231 cells assessed as caspase-9 activation at 50 uM after 16 hrs by Western blotting method,Other,24986663.0,
4110,1182609,1,2,,104234176,36462,Active,13959709.0,7153.0,,,Inhibition of topoisomerase 2 in human A549 cells assessed as reduction in decatenation of kinetoplast DNA at 30 nM incubated for 60 mins by ethidium bromide staining based gel electrophoresis,Other,25003995.0,
4111,1183093,1,1,,104234176,36462,Active,,,0.6,IC50,Cytotoxicity against human HL60 cells after 72 hrs by MTT assay,Confirmatory,25014747.0,
4112,1183317,1,1,,104234176,36462,Unspecified,,,,,Cytotoxicity against human U937 cells assessed as growth inhibition after 48 hrs by MTT assay,Other,25016373.0,
4113,1183318,1,2,,104234176,36462,Unspecified,,,,,Cytotoxicity against human THP1 cells assessed as growth inhibition after 48 hrs by MTT assay,Other,25016373.0,
4114,1183319,1,1,,104234176,36462,Unspecified,,,,,Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay,Other,25016373.0,
4115,1183320,1,1,,104234176,36462,Unspecified,,,,,Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay,Other,25016373.0,
4116,1183563,1,1,,104234176,36462,Active,,,20.389,IC50,Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay,Confirmatory,25019480.0,
4117,1183564,1,1,,104234176,36462,Inconclusive,,,,IC50,Cytotoxicity against human HuCCa1 cells after 48 hrs by MTT assay,Confirmatory,25019480.0,
4118,1183565,1,1,,104234176,36462,Inconclusive,,,,IC50,Cytotoxicity against human A549 cells after 48 hrs by MTT assay,Confirmatory,25019480.0,
4119,1183566,1,1,,104234176,36462,Active,,,0.051,IC50,Cytotoxicity against human MOLT3 cells after 48 hrs by MTT assay,Confirmatory,25019480.0,
4120,1183567,1,1,,104234176,36462,Inconclusive,,,,IC50,Cytotoxicity against human MRC5 cells after 48 hrs by MTT assay,Confirmatory,25019480.0,
4121,1185437,1,2,,104234176,36462,Active,,,1.1,IC50,Antiproliferative activity against human KB cells,Confirmatory,25059503.0,
4122,1185440,1,1,,104234176,36462,Active,,,23.0,IC50,Antiproliferative activity against human KB-VIN10 cells,Confirmatory,25059503.0,
4123,1185441,1,1,,104234176,36462,Active,,,3.5,IC50,Antiproliferative activity against human KB-S15 cells,Confirmatory,25059503.0,
4124,1185442,1,1,,104234176,36462,Unspecified,,,54.0,IC50,Antiproliferative activity against human KB-7d cells,Confirmatory,25059503.0,
4125,1185512,1,2,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of recombinant human DNA topoisomerase 2alpha assessed as relaxation of supercoiled DNA pBR322 at 100 uM after 30 mins using ethidium bromide staining by agarose gel electrophoresis,Other,25062006.0,
4126,1185513,1,2,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of recombinant human DNA topoisomerase 2alpha assessed as relaxation of supercoiled DNA pBR322 at 20 uM after 30 mins using ethidium bromide staining by agarose gel electrophoresis,Other,25062006.0,
4127,1185514,1,1,,104234176,36462,Active,,,1.04,IC50,Cytotoxicity against HEK293 cells after 4 days by CCK-8 assay,Confirmatory,25062006.0,
4128,1185515,1,2,,104234176,36462,Active,,,0.001,IC50,Cytotoxicity against human DU145 cells after 4 days by CCK-8 assay,Confirmatory,25062006.0,
4129,1185516,1,1,,104234176,36462,Active,,,7.74,IC50,Cytotoxicity against human HCT15 cells after 4 days by CCK-8 assay,Confirmatory,25062006.0,
4130,1185517,1,1,,104234176,36462,Active,,,8.74,IC50,Cytotoxicity against human T47D cells after 4 days by CCK-8 assay,Confirmatory,25062006.0,
4131,1186145,1,1,,104234176,36462,Inconclusive,,,,IC50,Cytotoxicity against human HuCCa1 cells assessed as reduction in cell viability after 48 hrs by MTT assay,Confirmatory,25078311.0,
4132,1186146,1,1,,104234176,36462,Active,,,30.16,IC50,Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay,Confirmatory,25078311.0,
4133,1186147,1,1,,104234176,36462,Inconclusive,,,,IC50,Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay,Confirmatory,25078311.0,
4134,1186148,1,1,,104234176,36462,Active,,,0.051,IC50,Cytotoxicity against human MOLT3 cells assessed as reduction in cell viability after 48 hrs by XTT assay,Confirmatory,25078311.0,
4135,1186149,1,1,,104234176,36462,Inconclusive,,,,IC50,Antimalarial activity against multidrug-resistant Plasmodium falciparum K1 after 24 hrs by [3H]hypoxanthine incorporation assay,Confirmatory,25078311.0,
4136,1186150,1,1,,104234176,36462,Inconclusive,,,,IC50,Cytotoxicity against african green monkey Vero cells assessed as reduction in cell viability after 4 days by green fluorescent protein detection method,Confirmatory,25078311.0,
4137,1186152,1,1,,104234176,36462,Active,,,18.0,LC50,Cytotoxicity against HEK293 cells after 48 hrs by MTT assay,Confirmatory,25078313.0,
4138,1186153,1,1,,104234176,36462,Active,,,28.0,LC50,Cytotoxicity against african green monkey Vero cells after 48 hrs by MTT assay,Confirmatory,25078313.0,
4139,1187288,1,1,,104234176,36462,Active,,,6.27,IC50,Cytotoxicity against human HeLa cells after 48 hrs by MTT assay,Confirmatory,25113878.0,
4140,1187289,1,1,,104234176,36462,Active,,,3.39,IC50,Cytotoxicity against human K562 cells after 48 hrs by MTT assay,Confirmatory,25113878.0,
4141,1187290,1,1,,104234176,36462,Unspecified,,,234.7,IC50,Cytotoxicity against human K562/A02 cells after 48 hrs by MTT assay,Confirmatory,25113878.0,
4142,1187291,1,1,,104234176,36462,Unspecified,,,,,"Resistance index, ratio of IC50 for human K562/A02 cells to IC50 for human K562 cells",Other,25113878.0,
4143,1187300,1,1,,104234176,36462,Unspecified,,,,,Induction of apoptosis in human K562/A02 cells assessed as viable cells level at 6 uM after 48 hrs by Annexin V-FITC and propidium iodide double staining based flow cytometry (Rvb = 90.7%),Other,25113878.0,
4144,1187301,1,1,,104234176,36462,Unspecified,,,,,Induction of apoptosis in human K562/A02 cells assessed as early apoptotic cells level at 6 uM after 48 hrs by Annexin V-FITC and propidium iodide double staining based flow cytometry (Rvb = 6.23%),Other,25113878.0,
4145,1187302,1,1,,104234176,36462,Unspecified,,,,,Induction of apoptosis in human K562/A02 cells assessed as late apoptotic cells level at 6 uM after 48 hrs by Annexin V-FITC and propidium iodide double staining based flow cytometry (Rvb = 1.58%),Other,25113878.0,
4146,1187303,1,1,,104234176,36462,Unspecified,,,,,Induction of apoptosis in human K562/A02 cells assessed as necrotic cells level at 6 uM after 48 hrs by Annexin V-FITC and propidium iodide double staining based flow cytometry (Rvb = 1.53%),Other,25113878.0,
4147,1187314,1,1,,104234176,36462,Active,,,,,Reduction in MDR1 mRNA expression in human K562/A02 cells at 6 uM incubated for 48 hrs by RT-PCR method,Other,25113878.0,
4148,1187763,1,1,,104234176,36462,Unspecified,,,,,Genotoxicity against human HTLA-230 cells assessed as phosphorylation of histone H2AX at 100 uM after 24 hrs by Western blot analysis,Other,25126889.0,
4149,1188220,1,1,,104234176,36462,Active,,,1.1,GI50,Antiproliferative activity against human MIAPaCa2 cells assessed as growth inhibition after 48 hrs by SRB assay,Confirmatory,25131956.0,
4150,1188221,1,1,,104234176,36462,Active,,,0.25,GI50,Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 48 hrs by SRB assay,Confirmatory,25131956.0,
4151,1188222,1,1,,104234176,36462,Active,,,0.62,GI50,Antiproliferative activity against human HeLa cells assessed as growth inhibition after 48 hrs by SRB assay,Confirmatory,25131956.0,
4152,1192316,1,1,,104234176,36462,Active,,,0.31,IC50,Anticancer activity against human HL60 cells after 48 hrs by MTT assay,Confirmatory,25744190.0,
4153,1192317,1,1,,104234176,36462,Active,,,8.12,IC50,Anticancer activity against human SMMC7721 cells after 48 hrs by MTT assay,Confirmatory,25744190.0,
4154,1192318,1,1,,104234176,36462,Active,,,11.92,IC50,Anticancer activity against human A549 cells after 48 hrs by MTT assay,Confirmatory,25744190.0,
4155,1192319,1,1,,104234176,36462,Active,,,32.82,IC50,Anticancer activity against human MCF7 cells after 48 hrs by MTT assay,Confirmatory,25744190.0,
4156,1192320,1,1,,104234176,36462,Active,,,17.11,IC50,Anticancer activity against human SW480 cells after 48 hrs by MTT assay,Confirmatory,25744190.0,
4157,1194195,1,1,,104234176,36462,Unspecified,,,,GI50,Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay,Confirmatory,25792142.0,
4158,1194196,1,1,,104234176,36462,Unspecified,,,,GI50,Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay,Confirmatory,25792142.0,
4159,1194197,1,1,,104234176,36462,Unspecified,,,,GI50,Cytotoxicity against human CCRF-CEM cells after 72 hrs by MTT assay,Confirmatory,25792142.0,
4160,1194198,1,1,,104234176,36462,Unspecified,,,,GI50,Cytotoxicity against human PC3 cells after 72 hrs by MTT assay,Confirmatory,25792142.0,
4161,1194199,1,1,,104234176,36462,Inconclusive,,,,GI50,Cytotoxicity against human HTB-54 cells after 72 hrs by MTT assay,Confirmatory,25792142.0,
4162,1194299,1,1,,104234176,36462,Active,,,1.5,IC50,Cytotoxicity against human U937 cells after 24 hrs by MTT assay,Confirmatory,25800433.0,
4163,1194300,1,1,,104234176,36462,Unspecified,,,,,Induction of apoptosis in human U937 cells assessed as condensed/fragmented nuclei at 10 ug/ml after 24 hrs using Hoechst 33342 staining by microscopy relative to solvent control,Other,25800433.0,
4164,1194303,1,1,,104234176,36462,Unspecified,,,,,Induction of apoptosis in human U937 cells assessed as condensed/fragmented nuclei at 5 ug/ml after 24 hrs using Hoechst 33342 staining by microscopy relative to solvent control,Other,25800433.0,
4165,1194305,1,1,,104234176,36462,Unspecified,,,,,Induction of apoptosis in human U937 cells assessed as caspase 3/7 level at 10 ug/ml after 24 hrs by Caspase-Glo 3/7 assay relative to solvent control,Other,25800433.0,
4166,1194308,1,1,,104234176,36462,Unspecified,,,,,Induction of apoptosis in human U937 cells assessed as caspase 3/7 level at 5 ug/ml after 24 hrs by Caspase-Glo 3/7 assay relative to solvent control,Other,25800433.0,
4167,1194312,1,1,,104234176,36462,Active,,,,,Induction of apoptosis in human U937 cells assessed as DNA fragmentation measured as DNA laddering at 5 ug/ml after 24 hrs by agarose gel electophoresis relative to solvent control,Other,25800433.0,
4168,1197370,1,1,,104234176,36462,Active,,,0.06,IC50,Cytotoxicity against human HL60 cells after 48 hrs by MTT assay,Confirmatory,25599951.0,
4169,1197371,1,1,,104234176,36462,Active,,,1.64,IC50,Cytotoxicity against human K562 cells after 48 hrs by MTT assay,Confirmatory,25599951.0,
4170,1197372,1,1,,104234176,36462,Active,,,0.54,IC50,Cytotoxicity against human HeLa cells after 48 hrs by MTT assay,Confirmatory,25599951.0,
4171,1197373,1,1,,104234176,36462,Active,,,8.91,IC50,Cytotoxicity against human A549 cells after 48 hrs by MTT assay,Confirmatory,25599951.0,
4172,1197577,1,1,,104234176,36462,Active,,,2.69,IC50,Anticancer activity against human MCF7 cells after 48 hrs by MTT assay,Confirmatory,25615796.0,
4173,1197578,1,1,,104234176,36462,Active,,,3.01,IC50,Anticancer activity against human A549 cells after 48 hrs by MTT assay,Confirmatory,25615796.0,
4174,1197579,1,2,,104234176,36462,Active,,,1.98,IC50,Anticancer activity against human DU145 cells after 48 hrs by MTT assay,Confirmatory,25615796.0,
4175,1197580,1,1,,104234176,36462,Active,,,3.23,IC50,Anticancer activity against human HeLa cells after 48 hrs by MTT assay,Confirmatory,25615796.0,
4176,1197581,1,1,,104234176,36462,Active,,,2.45,IC50,Anticancer activity against human HepG2 cells after 48 hrs by MTT assay,Confirmatory,25615796.0,
4177,1197582,1,2,,104234176,36462,Unspecified,,,,,Cell cycle arrest in human DU145 cells assessed as subG1 phase at 1 uM after 48 hrs by propidium iodide based flow cytometry (Rvb = 9.36 %),Other,25615796.0,
4178,1197583,1,2,,104234176,36462,Unspecified,,,,,Cell cycle arrest in human DU145 cells assessed as G0/G1 phase at 1 uM after 48 hrs by propidium iodide based flow cytometry (Rvb = 79.15 %),Other,25615796.0,
4179,1197584,1,2,,104234176,36462,Unspecified,,,,,Cell cycle arrest in human DU145 cells assessed as S phase at 1 uM after 48 hrs by propidium iodide based flow cytometry (Rvb = 1.65 %),Other,25615796.0,
4180,1197585,1,2,,104234176,36462,Unspecified,,,,,Cell cycle arrest in human DU145 cells assessed as G2/M phase at 1 uM after 48 hrs by propidium iodide based flow cytometry (Rvb = 6.75 %),Other,25615796.0,
4181,1197745,1,2,,104234176,36462,Unspecified,27734563.0,28234.0,,,Inhibition of human OATP1B3-mediated [3H]CCK-8 at 100 uM after 5 mins relative to control,Other,25618019.0,
4182,1197747,1,2,,104234176,36462,Active,27734563.0,28234.0,,IC50,Inhibition of human OATP1B3-mediated [3H]CCK-8 after 5 mins by Dixon plot method,Confirmatory,25618019.0,
4183,1198036,1,1,,104234176,36462,Active,,,1.4,IC50,Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT colorimetric assay,Confirmatory,25644672.0,
4184,1198037,1,1,,104234176,36462,Active,,,6.69,IC50,Cytotoxicity against human MDA-MB-468 cells assessed as reduction in cell viability after 72 hrs by MTT colorimetric assay,Confirmatory,25644672.0,
4185,1198038,1,1,,104234176,36462,Active,,,0.82,IC50,Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability after 72 hrs by MTT colorimetric assay,Confirmatory,25644672.0,
4186,1198039,1,2,,104234176,36462,Active,,,1.82,IC50,Cytotoxicity against human THP1 cells assessed as reduction in cell viability after 72 hrs by MTT colorimetric assay,Confirmatory,25644672.0,
4187,1198040,1,1,,104234176,36462,Active,,,4.9,IC50,Cytotoxicity against mouse EL4 cells assessed as reduction in cell viability after 72 hrs by MTT colorimetric assay,Confirmatory,25644672.0,
4188,1198041,1,1,,104234176,36462,Active,,,1.1,IC50,Cytotoxicity against human U937 cells assessed as reduction in cell viability after 72 hrs by MTT colorimetric assay,Confirmatory,25644672.0,
4189,1198042,1,1,,104234176,36462,Active,,,10.4,IC50,Cytotoxicity against mouse S17 cells assessed as reduction in cell viability after 72 hrs by MTT colorimetric assay,Confirmatory,25644672.0,
4190,1198043,1,1,,104234176,36462,Active,,,1.95,IC50,Cytotoxicity against mouse N9 cells assessed as reduction in cell viability after 72 hrs by MTT colorimetric assay,Confirmatory,25644672.0,
4191,1198044,1,1,,104234176,36462,Unspecified,,,,,"Selectivity index, ratio of IC50 for human HepG2 cells to IC50 for mouse S17 cells",Other,25644672.0,
4192,1198045,1,1,,104234176,36462,Unspecified,,,,,"Selectivity index, ratio of IC50 for human MDA-MB-468 cells to IC50 for mouse S17 cells",Other,25644672.0,
4193,1198046,1,1,,104234176,36462,Unspecified,,,,,"Selectivity index, ratio of IC50 for mouse RAW264.7 cells to IC50 for mouse S17 cells",Other,25644672.0,
4194,1198047,1,1,,104234176,36462,Unspecified,,,,,"Selectivity index, ratio of IC50 for human THP1 cells to IC50 for mouse S17 cells",Other,25644672.0,
4195,1198048,1,1,,104234176,36462,Unspecified,,,,,"Selectivity index, ratio of IC50 for mouse EL4 cells to IC50 for mouse S17 cells",Other,25644672.0,
4196,1198049,1,1,,104234176,36462,Unspecified,,,,,"Selectivity index, ratio of IC50 for human U937 cells to IC50 for mouse S17 cells",Other,25644672.0,
4197,1198050,1,1,,104234176,36462,Unspecified,,,,,"Selectivity index, ratio of IC50 for human HepG2 cells to IC50 for mouse N9 cells",Other,25644672.0,
4198,1198051,1,1,,104234176,36462,Unspecified,,,,,"Selectivity index, ratio of IC50 for human MDA-MB-468 cells to IC50 for mouse N9 cells",Other,25644672.0,
4199,1198052,1,1,,104234176,36462,Unspecified,,,,,"Selectivity index, ratio of IC50 for mouse RAW264.7 cells to IC50 for mouse N9 cells",Other,25644672.0,
4200,1198053,1,1,,104234176,36462,Unspecified,,,,,"Selectivity index, ratio of IC50 for human THP1 cells to IC50 for mouse N9 cells",Other,25644672.0,
4201,1198054,1,1,,104234176,36462,Unspecified,,,,,"Selectivity index, ratio of IC50 for mouse EL4 cells to IC50 for mouse N9 cells",Other,25644672.0,
4202,1198055,1,1,,104234176,36462,Unspecified,,,,,"Selectivity index, ratio of IC50 for human U937 cells to IC50 for mouse N9 cells",Other,25644672.0,
4203,1198275,1,2,,104234176,36462,Unspecified,,,,,Cell cycle arrest in human KB cells assessed as accumulation at S phase at 5 uM after 96 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 13.6%),Other,25668494.0,
4204,1198276,1,2,,104234176,36462,Unspecified,,,,,Cell cycle arrest in human KB cells assessed as accumulation at G2 phase at 5 uM after 96 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 34%),Other,25668494.0,
4205,1198277,1,2,,104234176,36462,Unspecified,,,,,Cell cycle arrest in human KB cells assessed as accumulation at G1 phase at 5 uM after 96 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 52.4%),Other,25668494.0,
4206,1201071,1,1,,104234176,36462,Active,,,40.47,IC50,Cytotoxicity against human HepG2 cells by MTT assay,Confirmatory,25747499.0,
4207,1201072,1,1,,104234176,36462,Inconclusive,,,,IC50,Cytotoxicity against human HuCCa1 cells by MTT assay,Confirmatory,25747499.0,
4208,1201073,1,1,,104234176,36462,Active,,,0.11,IC50,Cytotoxicity against human MOLT3 cells by XTT assay,Confirmatory,25747499.0,
4209,1201074,1,1,,104234176,36462,Inconclusive,,,,IC50,Cytotoxicity against human A549 cells by MTT assay,Confirmatory,25747499.0,
4210,1201075,1,1,,104234176,36462,Inconclusive,,,,,"Selectivity index, ratio of IC50 for human MRC5 cells to IC50 for human HepG2 cells",Other,25747499.0,
4211,1201076,1,1,,104234176,36462,Inconclusive,,,,,"Selectivity index, ratio of IC50 for human MRC5 cells to IC50 for human HuCCa1 cells",Other,25747499.0,
4212,1201077,1,1,,104234176,36462,Inconclusive,,,,,"Selectivity index, ratio of IC50 for human MRC5 cells to IC50 for human MOLT3 cells",Other,25747499.0,
4213,1201078,1,1,,104234176,36462,Inconclusive,,,,,"Selectivity index, ratio of IC50 for human MRC5 cells to IC50 for human A549 cells",Other,25747499.0,
4214,1202170,1,1,,104234176,36462,Active,,,7.6,IC50,Cytotoxicity against human MCF7 cells by MTT assay,Confirmatory,25847767.0,
4215,1202171,1,1,,104234176,36462,Active,,,10.3,IC50,Cytotoxicity against human MDA-MB-231 cells by MTT assay,Confirmatory,25847767.0,
4216,1202172,1,1,,104234176,36462,Active,,,8.9,IC50,Cytotoxicity against human T47D cells by MTT assay,Confirmatory,25847767.0,
4217,1202178,1,1,,104234176,36462,Unspecified,,,,,Induction of apoptosis in human MDA-MB-231 cells assessed as early apoptotic cells at IC50 after 12 hrs by annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 3.82%),Other,25847767.0,
4218,1202179,1,1,,104234176,36462,Unspecified,,,,,Induction of apoptosis in human MDA-MB-231 cells assessed as late apoptotic cells at IC50 after 12 hrs by annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 0.01%),Other,25847767.0,
4219,1202180,1,1,,104234176,36462,Unspecified,,,,,Induction of apoptosis in human MDA-MB-231 cells assessed as necrotic cells at IC50 after 12 hrs by annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 0.97%),Other,25847767.0,
4220,1202181,1,1,,104234176,36462,Unspecified,,,,,Induction of apoptosis in human MDA-MB-231 cells assessed as viable cells at IC50 after 12 hrs by annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 95.2%),Other,25847767.0,
4221,1202182,1,1,,104234176,36462,Unspecified,,,,,Induction of apoptosis in human MCF7 cells assessed as early apoptotic cells at IC50 after 12 hrs by annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 2.49%),Other,25847767.0,
4222,1202183,1,1,,104234176,36462,Unspecified,,,,,Induction of apoptosis in human MCF7 cells assessed as late apoptotic cells at IC50 after 12 hrs by annexin V-FITC/propidium iodide staining-based flow cytometric analysis relative to control,Other,25847767.0,
4223,1202184,1,1,,104234176,36462,Unspecified,,,,,Induction of apoptosis in human MCF7 cells assessed as necrotic cells at IC50 after 12 hrs by annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 0.29%),Other,25847767.0,
4224,1202185,1,1,,104234176,36462,Unspecified,,,,,Induction of apoptosis in human MCF7 cells assessed as viable cells at IC50 after 12 hrs by annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 97.23%),Other,25847767.0,
4225,1202305,1,1,,104234176,36462,Active,,,0.4,GI50,Cytotoxicity against human HL60 cells assessed as growth inhibition after 48 hrs by trypan blue staining-based hemocytometric analysis,Confirmatory,25874335.0,
4226,1202306,1,1,,104234176,36462,Inconclusive,,,,AC50,Induction of apoptosis in human HL60 cells after 48 hrs by acridine orange/ethidium bromide staining-based fluorescence microscopic analysis,Confirmatory,25874335.0,
4227,1202307,1,1,,104234176,36462,Unspecified,,,400.0,GI50,Cytotoxicity against human HL60R cells expressing p-glycoprotein assessed as growth inhibition after 48 hrs by trypan blue staining-based hemocytometric analysis,Confirmatory,25874335.0,
4228,1202308,1,1,,104234176,36462,Inconclusive,,,,AC50,Induction of apoptosis in human HL60R cells expressing p-glycoprotein after 48 hrs by acridine orange/ethidium bromide staining-based fluorescence microscopic analysis,Confirmatory,25874335.0,
4229,1202309,1,1,,104234176,36462,Inconclusive,,,,GI50,Cytotoxicity against human K562 cells expressing Bcr-Abl assessed as growth inhibition after 48 hrs by trypan blue staining-based hemocytometric analysis,Confirmatory,25874335.0,
4230,1202310,1,1,,104234176,36462,Inconclusive,,,,AC50,Induction of apoptosis in human K562 cells expressing Bcr-Abl after 48 hrs by acridine orange/ethidium bromide staining-based fluorescence microscopic analysis,Confirmatory,25874335.0,
4231,1202311,1,1,,104234176,36462,Inconclusive,,,,GI50,Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by trypan blue staining-based hemocytometric analysis,Confirmatory,25874335.0,
4232,1202312,1,1,,104234176,36462,Inconclusive,,,,AC50,Induction of apoptosis in human HepG2 cells after 48 hrs by acridine orange/ethidium bromide staining-based fluorescence microscopic analysis,Confirmatory,25874335.0,
4233,1204006,1,1,,104234176,36462,Active,,,1.9,GI50,Antiproliferative activity against human HBL100 cells after 48 hrs incubation by SRB assay,Confirmatory,25899335.0,
4234,1204007,1,1,,104234176,36462,Active,,,2.0,GI50,Antiproliferative activity against human HeLa cells after 48 hrs incubation by SRB assay,Confirmatory,25899335.0,
4235,1204008,1,1,,104234176,36462,Active,,,3.0,GI50,Antiproliferative activity against human SW1573 cells after 48 hrs incubation by SRB assay,Confirmatory,25899335.0,
4236,1204009,1,1,,104234176,36462,Active,,,15.0,GI50,Antiproliferative activity against human T47D cells after 48 hrs incubation by SRB assay,Confirmatory,25899335.0,
4237,1204010,1,1,,104234176,36462,Active,,,26.0,GI50,Antiproliferative activity against human WiDr cells after 48 hrs incubation by SRB assay,Confirmatory,25899335.0,
4238,1204662,1,2,,104234176,36462,Unspecified,,,,,Cytotoxicity against human THP1 cells assessed as decrease in cell number after 24 hrs by MTT assay,Other,25978960.0,
4239,1204663,1,1,,104234176,36462,Unspecified,,,,,Cytotoxicity against human U937 cells assessed as decrease in cell number after 24 hrs by MTT assay,Other,25978960.0,
4240,1204664,1,1,,104234176,36462,Unspecified,,,,,Cytotoxicity against mouse B16F10 cells assessed as decrease in cell number after 24 hrs by MTT assay,Other,25978960.0,
4241,1204665,1,2,,104234176,36462,Unspecified,,,,,Cytotoxicity against human COLO205 cells assessed as decrease in cell number after 24 hrs by MTT assay,Other,25978960.0,
4242,1204666,1,1,,104234176,36462,Unspecified,,,,,Cytotoxicity against human HL60 cells assessed as decrease in cell number after 24 hrs by MTT assay,Other,25978960.0,
4243,1205605,1,1,,104234176,36462,Active,,,2.81,IC50,Cytotoxicity against human MDA-MB-435 cells assessed as cell growth inhibition after 72 hrs by MTT assay,Confirmatory,25800514.0,
4244,1205607,1,2,,104234176,36462,Active,13959709.0,7153.0,,,Inhibition of human recombinant topoisomerase-2 alpha assessed as conversion of negatively supercoiled plasmid DNA pBR322 to relaxed DNA at 100 uM after 30 mins by agarose gel electrophoresis,Other,25800514.0,
4245,1221956,1,1,,104234176,36462,Unspecified,,,,,Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis,Other,21051535.0,
4246,1221957,1,1,,104234176,36462,Unspecified,,,,,Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis,Other,21051535.0,
4247,1221958,1,1,,104234176,36462,Unspecified,,,,,Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis,Other,21051535.0,
4248,1221959,1,1,,104234176,36462,Unspecified,,,,,Efflux ratio of permeability from apical to basolateral over basolateral to apical side of MDCK cells expressing MDR1,Other,21051535.0,
4249,1221960,1,1,,104234176,36462,Unspecified,,,,,Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979,Other,21051535.0,
4250,1221961,1,1,,104234176,36462,Unspecified,,,,,Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979,Other,21051535.0,
4251,1221962,1,1,,104234176,36462,Unspecified,,,,,Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979,Other,21051535.0,
4252,1221963,1,1,,104234176,36462,Unspecified,,,,,Transporter substrate index ratio of permeability from apical to basolateral side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979,Other,21051535.0,
4253,1221964,1,1,,104234176,36462,Unspecified,,,,,Transporter substrate index ratio of permeability from basolateral to apical side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979,Other,21051535.0,
4254,1221965,1,1,,104234176,36462,Unspecified,,,,,Transporter substrate index of efflux ratio in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979,Other,21051535.0,
4255,1221967,1,1,,104234176,36462,Unspecified,,,,,Ratio of intestine AUC in po dosed mdr1 knock out mouse to intestine AUC in po dosed wild type mouse,Other,21051535.0,
4256,1221968,1,1,,104234176,36462,Unspecified,,,,,Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of BCRP inhibitor Ko143,Other,21051535.0,
4257,1221969,1,1,,104234176,36462,Unspecified,,,,,Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of BCRP inhibitor Ko143,Other,21051535.0,
4258,1221970,1,1,,104234176,36462,Unspecified,,,,,Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of BCRP inhibitor Ko143,Other,21051535.0,
4259,1221971,1,1,,104234176,36462,Unspecified,,,,,Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK571,Other,21051535.0,
4260,1221972,1,1,,104234176,36462,Unspecified,,,,,Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK571,Other,21051535.0,
4261,1221973,1,1,,104234176,36462,Unspecified,,,,,Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK571,Other,21051535.0,
4262,1221975,1,1,,104234176,36462,Unspecified,,,,,Transporter substrate index ratio of permeability from apical to basolateral side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of BCRP inhibitor Ko143,Other,21051535.0,
4263,1221976,1,1,,104234176,36462,Unspecified,,,,,Transporter substrate index ratio of permeability from basolateral to apical side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of BCRP inhibitor Ko143,Other,21051535.0,
4264,1221977,1,1,,104234176,36462,Unspecified,,,,,Transporter substrate index of efflux ratio in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of BCRP inhibitor Ko143,Other,21051535.0,
4265,1221978,1,1,,104234176,36462,Unspecified,,,,,Transporter substrate index ratio of permeability from apical to basolateral side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK571,Other,21051535.0,
4266,1221979,1,1,,104234176,36462,Unspecified,,,,,Transporter substrate index ratio of permeability from basolateral to apical side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK571,Other,21051535.0,
4267,1221980,1,1,,104234176,36462,Unspecified,,,,,Transporter substrate index of efflux ratio in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK571,Other,21051535.0,
4268,1221981,1,1,,104234176,36462,Unspecified,,,,,Efflux ratio of permeability from apical to basolateral over basolateral to apical side of MDCK cells expressing BCRP,Other,21051535.0,
4269,1221982,1,1,,104234176,36462,Unspecified,,,,,Fraction absorbed in human,Other,21051535.0,
4270,1224611,1,1,,104234176,36462,Unspecified,,,,,Induction of apoptosis in human HT-29 cells assessed as early apoptotic cells at 1 uM after 72 hrs by flow cytometry (Rvb = 3.93%),Other,24937209.0,
4271,1224614,1,2,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of topoisomerase 2-alpha (unknown origin)-mediated pBR322 DNA cleavage assessed as linear configuration of plasmid DNA formation at 100 uM by ethidium bromide staining based agarose gel electrophoresis (Rvb = 3.7%),Other,24937209.0,
4272,1224616,1,1,,104234176,36462,Unspecified,,,,,Induction of apoptosis in human HT-29 cells assessed as viable cells at 1 uM after 72 hrs by flow cytometry (Rvb = 77.6%),Other,24937209.0,
4273,1224617,1,1,,104234176,36462,Unspecified,,,,,Induction of apoptosis in human HT-29 cells assessed as late apoptotic cells at 1 uM after 72 hrs by flow cytometry (Rvb = 8.60%),Other,24937209.0,
4274,1224618,1,1,,104234176,36462,Unspecified,,,,,Induction of apoptosis in human HT-29 cells assessed as necrotic cells at 1 uM after 72 hrs by flow cytometry (Rvb = 9.83%),Other,24937209.0,
4275,1224619,1,1,,104234176,36462,Unspecified,,,,,Induction of apoptosis in human HT-29 cells assessed as viable cells at 5 uM after 72 hrs by flow cytometry (Rvb = 77.6%),Other,24937209.0,
4276,1224620,1,1,,104234176,36462,Unspecified,,,,,Induction of apoptosis in human HT-29 cells assessed as early apoptotic cells at 5 uM after 72 hrs by flow cytometry (Rvb = 3.93%),Other,24937209.0,
4277,1224621,1,1,,104234176,36462,Unspecified,,,,,Induction of apoptosis in human HT-29 cells assessed as late apoptotic cells at 5 uM after 72 hrs by flow cytometry (Rvb = 8.60%),Other,24937209.0,
4278,1224622,1,1,,104234176,36462,Unspecified,,,,,Induction of apoptosis in human HT-29 cells assessed as necrotic cells at 5 uM after 72 hrs by flow cytometry (Rvb = 9.83%),Other,24937209.0,
4279,1224623,1,1,,104234176,36462,Inactive,,,,,Induction of apoptosis in human HT-29 cells assessed as caspase-3 activation by measuring cleaved caspase-3 level at 1 to 10 uM after 24 hrs by western blot analysis,Other,24937209.0,
4280,1224863,1,1,,176484190,36462,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
4281,1224863,1,1,,176484950,36462,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
4282,1224865,1,2,,56463308,36462,Inactive,578162.0,,,,Identify inhibitors of HNF4 alpha protein binding to DNA,Screening,,
4283,1224905,2,1,,92308790,36462,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
4284,1224905,2,1,,92308790,36462,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
4285,1225281,1,1,,104234176,36462,Active,,,0.8,IC50,Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay,Confirmatory,25495422.0,
4286,1225282,1,1,,104234176,36462,Active,,,1.9,IC50,Cytotoxicity against human HCT116 cells after 72 hrs by sulforhodamine B assay,Confirmatory,25495422.0,
4287,1225283,1,1,,104234176,36462,Active,,,0.5,IC50,Cytotoxicity against human SNU638 cells after 72 hrs by sulforhodamine B assay,Confirmatory,25495422.0,
4288,1225284,1,1,,104234176,36462,Active,,,3.1,IC50,Cytotoxicity against human K562 cells after 72 hrs by sulforhodamine B assay,Confirmatory,25495422.0,
4289,1225285,1,1,,104234176,36462,Active,,,1.1,IC50,Cytotoxicity against human SKHEP1 cells after 72 hrs by sulforhodamine B assay,Confirmatory,25495422.0,
4290,1225286,1,1,,104234176,36462,Active,,,10.6,IC50,Cytotoxicity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay,Confirmatory,25495422.0,
4291,1225980,1,1,,104234176,36462,Active,13959709.0,7153.0,,,Inhibition of topoisomerase-2alpha (unknown origin)-mediated pBR322 DNA relaxation at 50 uM after 30 mins by agarose gel electrophoresis,Other,25815139.0,
4292,1226760,1,1,,104234176,36462,Active,13959709.0,7153.0,,,Poisoning activity against human topoisomerase 2alpha assessed as induction of linear DNA formation at 100 uM incubated for 20 mins using small circular supercoiled pHOT DNA substrate by ethidium bromide staining based gel electrophoresis method,Other,25941559.0,
4293,1226761,1,1,,104234176,36462,Unspecified,,,55.0,LC50,Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 48 hrs by MTT assay,Confirmatory,25941559.0,
4294,1226763,1,1,,104234176,36462,Unspecified,,,75.0,LC50,Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 48 hrs by MTT assay,Confirmatory,25941559.0,
4295,1226765,1,1,,104234176,36462,Active,13959709.0,7153.0,,,Inhibition of topoisomerase 2alpha in HEK293 cells at 45 uM incubated for 48 hrs using TOP-FLASH plasmid substrate by ethidium bromide staining based agarose gel electrophoresis method,Other,25941559.0,
4296,1226773,1,1,,104234176,36462,Active,13959709.0,7153.0,,,Activity of TOP2A in human K562 cells assessed as poisoning activity at 100 uM after 1 hr by TARDIS assay,Other,25945730.0,
4297,1226774,1,1,,104234176,36462,Active,20141946.0,7155.0,,,Activity of TOP2B in human K562 cells assessed as poisoning activity at 100 uM after 1 hr by TARDIS assay,Other,25945730.0,
4298,1226775,1,1,,104234176,36462,Active,,,,,Activity of TOP2 in human K562 cells assessed as poisoning activity by measuring phosphorylation of gamma-H2AX at Ser139 at 100 uM after 1 hr by DAPI staining-based epifluorescence microscopic analysis,Other,25945730.0,
4299,1226776,1,1,,104234176,36462,Active,,,0.134,IC50,Cytotoxicity against wild type human NALM6 cells assessed as growth inhibition after 5 days by XTT assay,Confirmatory,25945730.0,
4300,1226777,1,1,,104234176,36462,Active,,,0.23399999999999999,IC50,Cytotoxicity against human NALM6 cells expressing 50% TOP2A assessed as growth inhibition after 5 days by XTT assay,Confirmatory,25945730.0,
4301,1226778,1,1,,104234176,36462,Active,,,0.182,IC50,Cytotoxicity against TOP2B double knockout human NALM6 cells assessed as growth inhibition after 5 days by XTT assay,Confirmatory,25945730.0,
4302,1226779,1,1,,104234176,36462,Unspecified,,,,,Selectivity ratio of IC50 for human NALM6 cells expressing 50% TOP2A to IC50 for wild type human NALM6 cells,Other,25945730.0,
4303,1226780,1,1,,104234176,36462,Unspecified,,,,,Selectivity ratio of IC50 for TOP2B double knockout human NALM6 cells to IC50 for wild type human NALM6 cells,Other,25945730.0,
4304,1227971,1,1,,104234176,36462,Active,,,0.8,IC50,Antiproliferative activity against human A549 cells after 3 days by sulforhodamine B assay,Confirmatory,25700232.0,
4305,1227972,1,1,,104234176,36462,Active,,,1.9,IC50,Antiproliferative activity against human HCT116 cells after 3 days by sulforhodamine B assay,Confirmatory,25700232.0,
4306,1227973,1,1,,104234176,36462,Active,,,0.5,IC50,Antiproliferative activity against human SNU638 cells after 3 days by sulforhodamine B assay,Confirmatory,25700232.0,
4307,1227974,1,1,,104234176,36462,Active,,,3.1,IC50,Antiproliferative activity against human K562 cells after 3 days by sulforhodamine B assay,Confirmatory,25700232.0,
4308,1227975,1,1,,104234176,36462,Active,,,1.1,IC50,Antiproliferative activity against human SKHEP1 cells after 3 days by sulforhodamine B assay,Confirmatory,25700232.0,
4309,1227976,1,1,,104234176,36462,Active,,,11.0,IC50,Antiproliferative activity against human MDA-MB-231 cells after 3 days by sulforhodamine B assay,Confirmatory,25700232.0,
4310,1229555,1,1,,104234176,36462,Active,,,0.4,IC50,Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay,Confirmatory,26010585.0,
4311,1229556,1,1,,104234176,36462,Active,,,1.9,IC50,Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay,Confirmatory,26010585.0,
4312,1229557,1,1,,104234176,36462,Active,,,7.7,IC50,Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay,Confirmatory,26010585.0,
4313,1229558,1,1,,104234176,36462,Inconclusive,,,,IC50,Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay,Confirmatory,26010585.0,
4314,1229559,1,1,,104234176,36462,Active,,,2.8,IC50,Cytotoxicity against human SKHEP1 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay,Confirmatory,26010585.0,
4315,1229560,1,1,,104234176,36462,Active,,,0.3,IC50,Cytotoxicity against human SNU638 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay,Confirmatory,26010585.0,
4316,1230334,1,1,,104234176,36462,Active,,,,,Antimitotic activity against sea urichin L embryo model assessed as cleavage alteration after 2.5 to 5.5 hrs of fertilization by sea urichin embryo assay,Other,26042548.0,
4317,1230335,1,1,,104234176,36462,Unspecified,,,,,Antimitotic activity against sea urichin L embryo model assessed as full mitotic arrest by sea urichin embryo assay,Other,26042548.0,
4318,1230336,1,1,,104234176,36462,Unspecified,,,,,Antimitotic activity against sea urichin L embryo model assessed as embryo spinning by sea urichin embryo assay,Other,26042548.0,
4319,1230337,1,1,,104234176,36462,Active,,,,,Antimitotic activity against sea urichin L embryo model assessed as death of embryo at hatched blastula stage by sea urichin embryo assay,Other,26042548.0,
4320,1230338,1,1,,104234176,36462,Active,,,,,Antimitotic activity against sea urichin L embryo model assessed as inhibition of skeletal spiculae growth by sea urichin embryo assay,Other,26042548.0,
4321,1231634,1,1,,104234176,36462,Unspecified,,,,,Genotoxicity in human HTLA-230 cells assessed as gamma-H2AX production at 100 uM after 24 hrs by Western blot analysis,Other,25936260.0,
4322,1231677,1,1,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of recombinant human DNA topoisomerase-2alpha using supercoiled pBR322 plasmid DNA as substrate at 100 uM after 30 mins by agarose gel electrophoresis relative to control,Other,25936262.0,
4323,1231678,1,1,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of recombinant human DNA topoisomerase-2alpha using supercoiled pBR322 plasmid DNA as substrate at 20 uM after 30 mins by agarose gel electrophoresis relative to control,Other,25936262.0,
4324,1231679,1,1,,104234176,36462,Active,,,2.09,IC50,Cytotoxicity against human DU145 cells measured on day 4 by CCK8 assay,Confirmatory,25936262.0,
4325,1231680,1,1,,104234176,36462,Active,,,18.87,IC50,Cytotoxicity against human HCT15 cells measured on day 4 by CCK8 assay,Confirmatory,25936262.0,
4326,1231681,1,1,,104234176,36462,Active,,,13.7,IC50,Cytotoxicity against human T47D cells measured on day 4 by CCK8 assay,Confirmatory,25936262.0,
4327,1231682,1,1,,104234176,36462,Active,,,7.32,IC50,Cytotoxicity against human HeLa cells measured on day 4 by CCK8 assay,Confirmatory,25936262.0,
4328,1232164,1,1,,104234176,36462,Unspecified,,,,,Fraction unbound in human plasma at pH 7.4 after 18 hrs by equilibrium dialysis,Other,,
4329,1232165,1,1,,104234176,36462,Unspecified,,,,,Fraction unbound in dog plasma at pH 7.4 after 18 hrs by equilibrium dialysis,Other,,
4330,1232166,1,1,,104234176,36462,Unspecified,,,,,Fraction unbound in rat plasma at pH 7.4 after 18 hrs by equilibrium dialysis,Other,,
4331,1232432,1,1,,104234176,36462,Active,,,0.163,IC50,Cytotoxicity against human K562 cells assessed as cell growth inhibition after 72 hrs by MTS assay,Confirmatory,25922181.0,
4332,1232433,1,1,,104234176,36462,Active,,,2.5,IC50,Cytotoxicity against etoposide-resistant human K/VP.5 cells assessed as cell growth inhibition after 72 hrs by MTS assay,Confirmatory,25922181.0,
4333,1232434,1,1,,104234176,36462,Unspecified,,,,,"Relative resistance, ratio of IC50 for etoposide-resistant human K/VP.5 cells to IC50 for human K562 cells",Other,25922181.0,
4334,1232435,1,1,,104234176,36462,Active,13959709.0,7153.0,,,Inhibition of full-length human recombinant topoisomerase 2-alpha-mediated decatenation activity of kDNA at >10 uM by ethidium bromide based gel-assay,Other,25922181.0,
4335,1232436,1,1,,104234176,36462,Active,13959709.0,7153.0,,,Inhibition of full-length human recombinant topoisomerase 2-alpha assessed as conversion of decatenated kDNA into open circular DNA at 100 uM by ethidium bromide based gel-assay,Other,25922181.0,
4336,1232438,1,1,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of full-length human recombinant topoisomerase 2-alpha mediated relaxation and cleavage of supercoiled pBR322 plasmid DNA to linear DNA by ethidium bromide staining based gel electrophoresis assay,Other,25922181.0,
4337,1232439,1,1,,104234176,36462,Active,,,,,Induction of DNA double strand breaks in human K562 cells assessed as increase in gamma-H2AX level at 25 uM after 4 hrs by chemiluminescence analysis,Other,25922181.0,
4338,1232441,1,1,,104234176,36462,Unspecified,,,,,Induction of apoptosis in CHO cells assessed as increase in sub-G0/G1 cell population at 10 uM after 49 hrs by propidium iodide staining based flow cytometry (Rvb <2%),Other,25922181.0,
4339,1232442,1,1,,104234176,36462,Active,,,,,Induction of cell cycle arrest in CHO cells assessed as accumulation at G2/M phase at 10 uM after 21 hrs by propidium iodide staining based flow cytometry,Other,25922181.0,
4340,1232446,1,1,,104234176,36462,Active,,,,,Induction of apoptosis in human K562 cells assessed as decrease in proportion of viable cells at 10 uM after 24 to 48 hrs by annexin V-FITC/propidium iodide staining based two-color fluorescence flow cytometry,Other,25922181.0,
4341,1232447,1,1,,104234176,36462,Active,,,,,Induction of apoptosis in human K562 cells assessed as increase in proportion of apoptotic and apoptotic/necrotic cells at 10 uM after 24 to 48 hrs by annexin V-FITC/propidium iodide staining based two-color fluorescence flow cytometry,Other,25922181.0,
4342,1235358,1,1,,104234176,36462,Active,,,26.4,IC50,Antiproliferative activity against human KB-VIN10 cells expressing P-gp170/MDR after 72 hrs by methylene blue assay,Confirmatory,26160020.0,
4343,1235359,1,1,,104234176,36462,Active,,,1.5,IC50,Antiproliferative activity against human KB cells after 72 hrs by methylene blue assay,Confirmatory,26160020.0,
4344,1235361,1,1,,104234176,36462,Active,,,3.5,IC50,Antiproliferative activity against human KB-S15 cells expressing P-gp170/MDR after 72 hrs by methylene blue assay,Confirmatory,26160020.0,
4345,1235362,1,1,,104234176,36462,Active,,,46.1,IC50,Antiproliferative activity against human KB-7d cells expressing MRP after 72 hrs by methylene blue assay,Confirmatory,26160020.0,
4346,1235612,1,1,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of human DNA topoisomerase IIalpha assessed as decatenation of kDNA at 500 uM after 90 mins by ethidium bromide staining,Other,26183545.0,
4347,1235613,1,1,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of human DNA topoisomerase IIalpha assessed as decatenation of kDNA at 125 uM after 90 mins by ethidium bromide staining,Other,26183545.0,
4348,1235614,1,1,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of human DNA topoisomerase IIalpha assessed as decatenation of kDNA at 31.5 uM after 90 mins by ethidium bromide staining,Other,26183545.0,
4349,1235615,1,1,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of human DNA topoisomerase IIalpha assessed as decatenation of kDNA at 3.9 uM after 90 mins by ethidium bromide staining,Other,26183545.0,
4350,1235617,1,1,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of human DNA topoisomerase IIalpha assessed as reduction in enzyme-catalyzed supercoiling of relaxed circular pBR322 DNA by measuring linear DNA level at 3.9 uM after 60 mins by agarose gel electrophoresis,Other,26183545.0,
4351,1235618,1,1,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of human DNA topoisomerase IIalpha assessed as reduction in enzyme-catalyzed supercoiling of relaxed circular pBR322 DNA by measuring linear DNA level at 31.5 uM after 60 mins by agarose gel electrophoresis,Other,26183545.0,
4352,1235619,1,1,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of human DNA topoisomerase IIalpha assessed as reduction in enzyme-catalyzed supercoiling of relaxed circular pBR322 DNA by measuring linear DNA level at 125 uM after 60 mins by agarose gel electrophoresis,Other,26183545.0,
4353,1235620,1,1,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of human DNA topoisomerase IIalpha assessed as reduction in enzyme-catalyzed supercoiling of relaxed circular pBR322 DNA by measuring linear DNA level at 500 uM after 60 mins by agarose gel electrophoresis,Other,26183545.0,
4354,1235622,1,1,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of human DNA topoisomerase IIalpha assessed as reduction in enzyme-catalyzed supercoiling of relaxed circular pBR322 DNA by measuring linear DNA level at 62.5 uM after 60 mins by agarose gel electrophoresis,Other,26183545.0,
4355,1235623,1,1,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of human DNA topoisomerase IIalpha assessed as reduction in enzyme-catalyzed supercoiling of relaxed circular pBR322 DNA by measuring linear DNA level at 50 uM after 60 mins by agarose gel electrophoresis,Other,26183545.0,
4356,1235633,1,1,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of human DNA topoisomerase IIalpha ATPase activity assessed as residual ATP hydrolysis at 3.9 uM measured up to 60 mins,Other,26183545.0,
4357,1235634,1,1,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of human DNA topoisomerase IIalpha ATPase activity assessed as residual ATP hydrolysis at 31.5 uM measured up to 60 mins,Other,26183545.0,
4358,1235635,1,1,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of human DNA topoisomerase IIalpha ATPase activity assessed as residual ATP hydrolysis at 125 uM measured up to 60 mins,Other,26183545.0,
4359,1235636,1,1,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of human DNA topoisomerase IIalpha ATPase activity assessed as residual ATP hydrolysis at 500 uM measured up to 60 mins,Other,26183545.0,
4360,1235889,1,1,,104234176,36462,Active,,,0.48,IC50,Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by Hoechst assay,Confirmatory,26225905.0,
4361,1235890,1,1,,104234176,36462,Active,,,3.3,IC50,Cytotoxicity against human DLD1 cells assessed as inhibition of cell growth incubated for 48 hrs by Hoechst assay,Confirmatory,26225905.0,
4362,1235891,1,1,,104234176,36462,Unspecified,,,10.0,IC50,Cytotoxicity against human WS1 cells assessed as inhibition of cell growth incubated for 48 hrs by Hoechst assay,Confirmatory,26225905.0,
4363,1236353,1,1,,104234176,36462,Active,,,2.13,IC50,Cytotoxicity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay,Confirmatory,,
4364,1236354,1,1,,104234176,36462,Active,,,2.97,IC50,Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay,Confirmatory,,
4365,1236355,1,1,,104234176,36462,Active,,,6.56,IC50,Cytotoxicity against human SGC7901 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay,Confirmatory,,
4366,1236368,1,1,,104234176,36462,Active,,,,,Induction of apoptosis in human HeLa cells assessed as increase in cleaved caspase-3 levels at 3 uM incubated for 48 hrs by Western blotting method,Other,,
4367,1236892,1,1,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of human recombinant DNA topoisomerse 2 alpha using pBR322 as substrate assessed as inhibition of conversion of supercoiled pBR322 to relaxed form at 100 uM after 30 mins by ethidium bromide staining-based electrophoresis analysis,Other,26022080.0,
4368,1236893,1,1,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of human recombinant DNA topoisomerse 2 alpha using pBR322 as substrate assessed as inhibition of conversion of supercoiled pBR322 to relaxed form at 20 uM after 30 mins by ethidium bromide staining-based electrophoresis analysis,Other,26022080.0,
4369,1236894,1,1,,104234176,36462,Active,,,1.1,IC50,Cytotoxicity against human HCT15 cells incubated from day 2 to day 4 by CCK8 assay,Confirmatory,26022080.0,
4370,1236895,1,1,,104234176,36462,Active,,,0.7,IC50,Cytotoxicity against human T47D cells incubated from day 2 to day 4 by CCK8 assay,Confirmatory,26022080.0,
4371,1236896,1,1,,104234176,36462,Active,,,0.5,IC50,Cytotoxicity against human DU145 cells incubated from day 2 to day 4 by CCK8 assay,Confirmatory,26022080.0,
4372,1236897,1,1,,104234176,36462,Active,,,1.41,IC50,Cytotoxicity against human HeLa cells incubated from day 2 to day 4 by CCK8 assay,Confirmatory,26022080.0,
4373,1240557,1,1,,104234176,36462,Active,,,18.2,IC50,Antiproliferative activity against human A549 cells by MTT assay,Confirmatory,26216018.0,
4374,1240558,1,1,,104234176,36462,Active,,,20.9,IC50,Antiproliferative activity against human HepG2 cells by MTT assay,Confirmatory,26216018.0,
4375,1240559,1,1,,104234176,36462,Unspecified,,,30.0,IC50,Antiproliferative activity against human H460 cells by MTT assay,Confirmatory,26216018.0,
4376,1240560,1,1,,104234176,36462,Unspecified,,,,,Cytotoxic activity against human PBMC by MTT assay,Other,26216018.0,
4377,1240567,1,1,,104234176,36462,Active,13959709.0,7153.0,,,Inhibition of human topoisomerase-2 alpha assessed as reduction in enzyme-mediated kinetoplast DNA decatenation at 100 uM incubated for 30 mins by ethidium bromide staining based agarose gel electrophoresis method,Other,26216018.0,
4378,1240568,1,1,,104234176,36462,Unspecified,13959709.0,7153.0,78.4,IC50,Inhibition of human topoisomerase-2 alpha assessed as reduction in enzyme-mediated kinetoplast DNA decatenation incubated for 30 mins by ethidium bromide staining based agarose gel electrophoresis method,Confirmatory,26216018.0,
4379,1241173,1,1,,104234176,36462,Active,13959709.0,7153.0,,,Interfacial poisoning activity at DNA-topoisomerase 2 (unknown origin) using catenated kDNA as substrate assessed as linear DNA formation at 1 to 100 uM after 30 mins by agarose gel electrophoresis,Other,26264845.0,
4380,1241173,1,1,,104234176,36462,Active,20141946.0,7155.0,,,Interfacial poisoning activity at DNA-topoisomerase 2 (unknown origin) using catenated kDNA as substrate assessed as linear DNA formation at 1 to 100 uM after 30 mins by agarose gel electrophoresis,Other,26264845.0,
4381,1245881,1,1,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of human DNA topoisomerase 2alpha assessed as relaxation of supercoiled pBR322 DNA at 100 uM after 30 mins using ethidium bromide staining by agarose gel electrophoresis,Other,26361737.0,
4382,1245882,1,1,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of human DNA topoisomerase 2alpha assessed as relaxation of supercoiled pBR322 DNA at 20 uM after 30 mins using ethidium bromide staining by agarose gel electrophoresis,Other,26361737.0,
4383,1245885,1,1,,104234176,36462,Active,,,13.1,IC50,Cytotoxicity against human DU145 cells after 2 days by CCK8 assay,Confirmatory,26361737.0,
4384,1245886,1,1,,104234176,36462,Active,,,2.6,IC50,Cytotoxicity against human HCT15 cells after 2 days by CCK8 assay,Confirmatory,26361737.0,
4385,1245887,1,1,,104234176,36462,Active,,,0.94,IC50,Cytotoxicity against human T47D cells after 2 days by CCK8 assay,Confirmatory,26361737.0,
4386,1245888,1,1,,104234176,36462,Active,,,10.14,IC50,Cytotoxicity against human MCF10A cells after 2 days by CCK8 assay,Confirmatory,26361737.0,
4387,1246960,1,1,,104234176,36462,Active,,,38.5,IC50,Cytotoxicity against human A549 cells after 48 hrs by MTT assay,Confirmatory,26292628.0,
4388,1246961,1,1,,104234176,36462,Active,,,5.21,IC50,Cytotoxicity against human DU145 cells after 48 hrs by MTT assay,Confirmatory,26292628.0,
4389,1246962,1,1,,104234176,36462,Active,,,27.64,IC50,Cytotoxicity against human RWPE1 cells after 48 hrs by MTT assay,Confirmatory,26292628.0,
4390,1246963,1,1,,104234176,36462,Unspecified,,,50.33,IC50,Cytotoxicity against human LNCAP cells after 48 hrs by MTT assay,Confirmatory,26292628.0,
4391,1246964,1,1,,104234176,36462,Active,,,10.9,IC50,Cytotoxicity against human HGC cells after 48 hrs by MTT assay,Confirmatory,26292628.0,
4392,1246965,1,1,,104234176,36462,Active,,,49.35,IC50,Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay,Confirmatory,26292628.0,
4393,1246966,1,1,,104234176,36462,Unspecified,,,,,"Therapeutic index, ratio of IC50 for human RWPE1 cells to IC50 for human DU145 cells",Other,26292628.0,
4394,1246967,1,1,,104234176,36462,Unspecified,,,,,"Therapeutic index, ratio of IC50 for human RWPE1 cells to IC50 for human LNCAP cells",Other,26292628.0,
4395,1247002,1,1,,104234176,36462,Active,13959709.0,7153.0,,,Inhibition of topoisomerase-2 (unknown origin) using kDNA assessed as increase of catenated kDNA level at 100 uM after 10 mins using ethidium bromide staining by agarose gel electrophoresis,Other,26292628.0,
4396,1248958,1,1,,104234176,36462,Active,,,0.47,IC50,Anticancer activity against human COLO205 cells by MTT assay,Confirmatory,,
4397,1248959,1,1,,104234176,36462,Active,,,10.1,IC50,Anticancer activity against human U937 cells by MTT assay,Confirmatory,,
4398,1248960,1,1,,104234176,36462,Active,,,0.008,IC50,Anticancer activity against human MCF7 cells by MTT assay,Confirmatory,,
4399,1248961,1,1,,104234176,36462,Active,,,4.7,IC50,Anticancer activity against human A549 cells by MTT assay,Confirmatory,,
4400,1248962,1,1,,104234176,36462,Unspecified,,,,,Induction of DNA damage in human COLO205 cells assessed as tail DNA formation by alkaline comet assay (Rvb = 0%),Other,,
4401,1248963,1,1,,104234176,36462,Active,,,,,Induction of cell cycle arrest in human COLO205 cells assessed as accumulation at G2/M phase after 24 hrs by flow cytometry,Other,,
4402,1248971,1,1,,104234176,36462,Active,,,,,Decrease in Bcl2 expression in human COLO205 cells after 24 hrs by western blot analysis,Other,,
4403,1248972,1,1,,104234176,36462,Active,,,,,Increase in Bax expression in human COLO205 cells after 24 hrs by western blot analysis,Other,,
4404,1249166,1,1,,104234176,36462,Active,,,13.24,IC50,Cytotoxicity against human SW620 cells assessed as growth inhibition after 48 hrs by SRB assay,Confirmatory,,
4405,1249167,1,1,,104234176,36462,Active,,,16.43,IC50,Cytotoxicity against human DU145 cells assessed as growth inhibition after 48 hrs by SRB assay,Confirmatory,,
4406,1249168,1,1,,104234176,36462,Active,,,9.03,IC50,Cytotoxicity against human SK-N-SH cells assessed as growth inhibition after 48 hrs by SRB assay,Confirmatory,,
4407,1249169,1,1,,104234176,36462,Active,,,12.23,IC50,Cytotoxicity against human HCT15 cells assessed as growth inhibition after 48 hrs by SRB assay,Confirmatory,,
4408,1249170,1,1,,104234176,36462,Active,,,14.23,IC50,Cytotoxicity against human COLO205 cells assessed as growth inhibition after 48 hrs by SRB assay,Confirmatory,,
4409,1249171,1,1,,104234176,36462,Active,,,10.4,IC50,Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by SRB assay,Confirmatory,,
4410,1250175,1,1,,104234176,36462,Unspecified,,,,,Antiproliferative activity against human MDA-MB-231 cells assessed as growth inhibition at 10 uM after 72 hrs by SRB assay,Other,26291037.0,
4411,1250176,1,1,,104234176,36462,Unspecified,,,,,Antiproliferative activity against human MDA-MB-435 cells assessed as growth inhibition at 10 uM after 72 hrs by SRB assay,Other,26291037.0,
4412,1250177,1,1,,104234176,36462,Active,,,3.6,IC50,Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay,Confirmatory,26291037.0,
4413,1250178,1,1,,104234176,36462,Active,,,1.7,IC50,Antiproliferative activity against human MDA-MB-435 cells after 72 hrs by SRB assay,Confirmatory,26291037.0,
4414,1250179,1,1,,104234176,36462,Active,,,30.0,IC50,Antiproliferative activity against human HepG2 cells after 72 hrs by SRB assay,Confirmatory,26291037.0,
4415,1250180,1,1,,104234176,36462,Active,,,1.0,IC50,Antiproliferative activity against human PC3 cells after 72 hrs by SRB assay,Confirmatory,26291037.0,
4416,1250181,1,1,,104234176,36462,Active,13959709.0,7153.0,,,Inhibition of human recombinant topoisomerase 2alpha assessed as relaxation of pBR322 DNA at 100 uM after 30 mins by agarose gel electrophoresis,Other,26291037.0,
4417,1250185,1,1,,104234176,36462,Active,13959709.0,7153.0,,,Inhibition of human recombinant topoisomerase 2 alpha assessed as topoisomerase poison activity by measuring generation of linear DNA using circular supercoiled DNA at 100 uM by agarose gel electrophoresis,Other,26291037.0,
4418,1250200,1,1,,104234176,36462,Active,,,,,Inhibition of topoisomerase in human MDA-MB-231 cells assessed as ATM phosphorylation at Ser1981 residue at 10 uM after 24 hrs by western blot analysis,Other,26291037.0,
4419,1252043,1,1,,104234176,36462,Active,,,0.4,IC50,Antiproliferative activity against human DU145 cells assessed as cell viability incubated for 72 hrs by MTT assay,Confirmatory,25799376.0,
4420,1252044,1,1,,104234176,36462,Active,,,4.33,IC50,Antiproliferative activity against human PC3 cells assessed as cell viability incubated for 72 hrs by MTT assay,Confirmatory,25799376.0,
4421,1252047,1,1,,104234176,36462,Active,13959709.0,7153.0,,,Inhibition of human recombinant topoisomerase 2 alpha assessed as blocking of supercoiled pHOT DNA relaxation at 50 uM incubated for 45 mins at 37 degC by ethidium bromide staining based agarose gel electrophoresis,Other,25799376.0,
4422,1252950,1,1,,104234176,36462,Inconclusive,,,,IC50,Cytotoxicity against HuCCa1 cells after 48 hrs by MTT assay,Confirmatory,26397393.0,
4423,1252951,1,1,,104234176,36462,Active,,,33.98,IC50,Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay,Confirmatory,26397393.0,
4424,1252952,1,1,,104234176,36462,Inconclusive,,,,IC50,Cytotoxicity against human A549 cells after 48 hrs by MTT assay,Confirmatory,26397393.0,
4425,1252953,1,1,,104234176,36462,Active,,,0.040999999999999995,IC50,Cytotoxicity against human MOLT3 cells after 48 hrs by XTT assay,Confirmatory,26397393.0,
4426,1252954,1,1,,104234176,36462,Inconclusive,,,,IC50,Cytotoxicity against African green monkey Vero cells after 4 days by GFP detection method,Confirmatory,26397393.0,
4427,1252955,1,1,,104234176,36462,Inconclusive,,,,IC50,Antimalarial activity against multidrug-resistant Plasmodium falciparum K1 infected in human erythrocytes after 48 hrs by [3H]hypoxanthine incorporation assay,Confirmatory,26397393.0,
4428,1254808,1,1,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of recombinant human topoisomerase 2alpha assessed as relaxation of supercoiled plasmid DNA pBR322 at 100 uM incubated for 30 mins by agarose gel electrophoresis,Other,26334499.0,
4429,1254809,1,1,,104234176,36462,Unspecified,13959709.0,7153.0,,,Inhibition of recombinant human topoisomerase 2alpha assessed as relaxation of supercoiled plasmid DNA pBR322 at 20 uM incubated for 30 mins by agarose gel electrophoresis,Other,26334499.0,
4430,1254815,1,1,,104234176,36462,Active,,,5.54,IC50,Cytotoxicity against human HCT15 cells measured after 2 days by MTT assay,Confirmatory,26334499.0,
4431,1254816,1,1,,104234176,36462,Active,,,9.28,IC50,Cytotoxicity against human T47D cells measured after 2 days by MTT assay,Confirmatory,26334499.0,
4432,1254817,1,1,,104234176,36462,Active,,,7.6,IC50,Cytotoxicity against human HeLa cells measured after 2 days by MTT assay,Confirmatory,26334499.0,
4433,1254838,1,1,,104234176,36462,Unspecified,,,,,Antiproliferative activity against human GBM1 cells assessed as reduction in cell viability at 10 uM incubated for 72 hrs by WST-1 method,Other,26355532.0,
4434,1254839,1,1,,104234176,36462,Unspecified,,,,,Antiproliferative activity against human GBM2 cells assessed as reduction in cell viability at 10 uM incubated for 72 hrs by WST-1 method,Other,26355532.0,
4435,1254840,1,1,,104234176,36462,Unspecified,,,10.0,IC50,Antiproliferative activity against human GBM1 cells assessed as reduction in cell viability incubated for 72 hrs by WST-1 method,Confirmatory,26355532.0,
4436,1254841,1,1,,104234176,36462,Active,,,1.1,IC50,Antiproliferative activity against human GBM2 cells assessed as reduction in cell viability incubated for 72 hrs by WST-1 method,Confirmatory,26355532.0,
4437,1254842,1,1,,104234176,36462,Unspecified,,,10.0,IC50,Cytotoxicity against normal human astrocytes assessed as cell viability incubated for 72 hrs by WST-1 method,Confirmatory,26355532.0,
4438,1254843,1,1,,104234176,36462,Inconclusive,,,,,"Selectivity index, ratio of IC50 for normal human astrocytes to IC50 for human GBM1 cells",Other,26355532.0,
4439,1254844,1,1,,104234176,36462,Inconclusive,,,,,"Selectivity index, ratio of IC50 for normal human astrocytes to IC50 for human GBM2 cells",Other,26355532.0,
4440,1254845,1,1,,104234176,36462,Unspecified,,,,,Antiproliferative activity against human GBM3 cells assessed as reduction in cell viability at 10 uM incubated for 72 hrs by WST-1 method,Other,26355532.0,
4441,1254846,1,1,,104234176,36462,Unspecified,,,10.0,IC50,Antiproliferative activity against human GBM3 cells assessed as reduction in cell viability incubated for 72 hrs by WST-1 method,Confirmatory,26355532.0,
4442,1254847,1,1,,104234176,36462,Inconclusive,,,,,"Selectivity index, ratio of IC50 for normal human astrocytes to IC50 for human GBM3 cells",Other,26355532.0,
4443,1259310,1,1,,46386954,36462,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
4444,1259310,1,1,,333473198,36462,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
4445,1259313,1,1,,56463308,36462,Inactive,,,,,uHTS identification of small molecule modulators of NR3A,Screening,,
4446,1259318,1,1,,56463308,36462,Inactive,,,,,uHTS identification of small molecule modulators of Rev-erb Alpha.,Screening,,
4447,1259325,1,2,,336955424,36462,Inactive,4504843.0,3763.0,,,Discovering small molecule activators of G protein-gated inwardly-rectifying potassium subunit 2 (GIRK2) containing channels utilizing methyl-2 4-pentanediol (MPD) for partial channel activation during screening,Screening,,
4448,1259389,1,1,,124659141,36462,Inactive,,,,,HIV1_TAR : FRET assay measuring displacement of FAM and TAMRA-labeled Tat peptide from HIV-1 TAR RNA.,Screening,,
4449,1259407,1,1,,363900342,36462,Active,,,,,CCRIS mutagenicity studies,Other,,
4450,1259408,1,1,,363897223,36462,Active,,,,,GENE-TOX mutagenicity studies,Other,,
4451,1259413,1,2,,46386954,36462,Inactive,47605623.0,173990.0,,,Modulators of fzo-1,Other,,
4452,1259415,1,1,,56463308,36462,Active,,,,,qHTS Assay for inhibitors of the human cytomegalovirus (HCMV),Screening,,
4453,1259416,1,2,,375172101,36462,Active,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
4454,1259416,1,2,,375178226,36462,Active,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
4455,1259416,1,2,,375192664,36462,Active,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
4456,1259421,1,1,,375172101,36462,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
4457,1259421,1,1,,375178226,36462,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
4458,1259421,1,1,,375192664,36462,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
4459,1259423,1,2,,354921962,36462,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
4460,1259423,1,2,,354965360,36462,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
